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ABSTRACT 
The orphan nuclear receptor 4A1 (NR4A1) and specificity protein (Sp) 
transcription factors (TFs) are both overexpressed in the majority of solid tumors.  
Our laboratory has researched the molecular mechanisms of a novel class of 1,1-
bis(3'-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) as NR4A1 antagonists 
and Sp proteins as non-oncogene addiction genes (NOA) that are targets of 
reactive oxygen species (ROS) inducing agents.  Nr4A1 antagonists (DIM-C-
pPhOH) (C-DIM 8) and (DIM-C-pPhCO2Me) (C-DIM 14) inhibited cancer cell 
proliferation, induced apoptosis, and inhibited migration.  The NR4A1 antagonists 
inhibited constitutive and TGFβ-induced migration in Triple Negative Breast 
Cancer (TNBC) cells. We also demonstrate that p38α is necessary and sufficient 
for TGFβ-mediated migration and NR4A1 nuclear export in triple negative breast 
cancer (TNBC) which was attenuated with NR4A1 antagonists (C-DIMs), 
leptomycin B, and the p38 inhibitor SB202190.  We also demonstrate that NR4A1 
is essential for TGFβ-induced EMT and NR4A1 antagonists promoted cytosolic 
sequestration of the transcription factor β-catenin and its proteasome-dependent 
degradation in a time dependent manner.  β-catenin, along with TCF-3, TCF-4, 
and LEF-1 binds to TCF/LEF response elements in the NR4A1 promoter, 
regulating its expression. 
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RNA interference (RNAi) demonstrates that Sp1, 3, and 4 TFs individually 
play a role in cancer cell growth, survival and migration/invasion in cancer cell 
lines.  Individual knockdown of Sp1, Sp3, or Sp4, resulted in inhibition of cell 
growth, migration, and induction of apoptosis, with no compensation.  Moreover, 
tumor growth in athymic nude mice bearing pancreatic cancer xenografts was 
significantly attenuated in cells depleted of Sp1, Sp3, and Sp4 in combination or 
Sp1 alone.  Ingenuity Pathway Analysis (IPA) of changes in gene expression in 
Panc1 pancreatic cancer cells after individual knockdown of Sp TFs demonstrates 
that Sp1-, Sp3- and Sp4-regulated genes were associated with pro-oncogenic 
activity. 
C-DIMs are promising anticancer agents in NR4A1-overexpressing solid 
tumors and represent a novel class of mechanistic-based drugs that target 
TGFβ/NR4A1-dependent inducible migration in TNBC. The functional and 
genomic results coupled with overexpression of Sp transcription factors in tumor 
vs. non-tumor tissues and decreased Sp1 expression with age indicate that Sp1, 
Sp3 and Sp4 are non-oncogene addiction (NOA) genes and are attractive drug 
targets for individual and combined cancer chemotherapies. 
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CHAPTER I 
INTRODUCTION 
 
Cancer 
Cancer is a complex disease that is a result of normal cells becoming 
transformed into a cancerous cell that displays uncontrolled cell growth, 
proliferation, survival, altered metabolism, and evading apoptosis (1).  Cancer 
cells begin as a benign neoplasm that may proliferate uncontrollably but still retain 
normal cell physiology and phenotype (1). These cells subsequently obtain 
mutations, resulting in a more malignant and aggressive phenotype; this is 
accompanied by changes in their morphology, invasion of the surrounding tissues, 
intravasation of blood vessels, and then colonization of distal organs through a 
process that is called metastasis (2). Cancer cell metastasis results in the majority 
of cancer cell deaths.  Cancers are broadly classified into two major types: solid 
tumors and non-solid malignancies.  Solid tumors consist of carcinomas (cancers 
which arise from cells derived from cells that are endodermal in origin) sarcomas 
(cancers that arise from mesodermal cells and are mesenchymal in origin) and 
neuroendocrine tumors which arise from cells of the neuroendocrine system.  
Non-solid tumors encompass cancers that arise from hematological or lymphatic 
system malignancies, which include leukemias and lymphomas respectively (3,4).  
These can arise from fluid filled cystic lesions commonly associated with glands, 
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with proliferation of immature poorly differentiated leukocytes, granulocytes and 
lymphocytes and these cancer cells are dispersed and circulate throughout the 
body (4,5). These cancers are usually treated with ionizing radiation, 
chemotherapies that contain arabinoside-based nucleotide analogs and 
specialized chemotherapies that target cancer specific epitopes (6).  For instance, 
non-Hodgkin’s lymphoma (NHL) is normally treated with the CHOP 
(cyclophosphamide, hydroxydaunorubicin, oncovirin, and prednisone) 
chemotherapeutic regimen along with the monoclonal antibody rituximab, which 
specifically targets CD20 a common marker expressed on the surface of NHL 
cells (6,7).  Other leukemias, such as chronic myelogenous leukemia (CML), are 
generated by chromosomal translocations (8).  CML is caused by the Philadelphia 
chromosome which is a result of a reciprocal translocation between chromosome 
9 and 22, designated t(9;22)(q34;q11) (8).  This gives rise to the BCR-ABL1 fusion 
gene and promotes the ABL1 kinase proto-oncogene to an oncogene and driving 
CML progression (8,9).  This cancer is treated with Gleevec (imatinib) which is a 
tyrosine kinase inhibitor specifically developed to treat this cancer.  Solid tumors 
can be surgically removed if localized to specific tissue, treated with ionizing 
radiation, or treated with available chemotherapeutic regimens (9).  Estrogen 
receptor positive (ER+) breast cancer can be treated with an ER antagonists such 
as tamoxifen, aromatase (the enzyme which converts androgens into estrogens, 
such as estradiol (E2)) inhibitors like anastrazole, along with other drugs including 
the thymidylate synthase inhibitor 5-fluoruracil (5-FU) and Adriamycin 
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(doxorubicin) (10).  Other cancers such as glioblastoma multiforme (GBM), are 
very difficult to treat not only because of their location, but also the blood brain 
barrier (BBB) makes drug delivery very challenging (11).  Drugs such as 
temozolomide (TMZ, a DNA alkylating agent), EGFR inhibitors (gefitinib, erlotinib, 
specifically targeting EGFRvii) (classical GBM), PDGF inhibitors (i.e. crenolanib) 
(proneuronal GBM), carmustine (bis-chloroethylnitrosourea or BCNU, another 
alkylating agent), and bevacizumab (a VEGF inhibitor) (11,12).  GBM is also a 
disease with a strong genetic component.  Along with EGFR, these tumors exhibit 
aberrant expression of other genes, which designate their type.  Classical GBM is 
associated with EGFR, proneuronal (platelet derived growth factor receptor α 
(PDGFA) isocitrate dehydrogenase-1 (IDH1)), the mesenchymal subtype 
(neurofibromin 1 (NF1)), and the nueral type (gamma-aminobutyric acid type A 
receptor alpha1 (GABARA1), Neurofilament light polypeptide (NEFL), 
Synaptotagmin-1 (SYT1), and solute carrier family 12 member 5 (SLC12A5).  
DNA methylation is also of interest in GBM and hypomethylation is associated 
with enhanced malignancy (13).  The enzyme O-6-methylguanine-DNA 
methyltransferase (MGMT) is involved in repair of DNA alkylation and is a so 
called suicide DNA repair enzyme since the reaction is irreversible and the active 
site of the enzyme cannot be regenerated (14).  In GBM hypermethylation of this 
promoter leads to decreased activity (i.e. TMZ) which enhances the response to 
TMZ treatment (15).  Other genetically linked diseases such as Li Fraumeni 
syndrome (TP53) (16), Tuberous sclerosis (TSC1/2) (17), Von Hippel-Lindau 
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syndrome (pVHL-1) (18), Neurofibromatosis (NF-1) (18), and Turcott syndrome 
(MutL homologue 1 and 2 (MLH1 and MLH2) and MutS homolog 6 (MSH6), and 
endonuclease PMS2 (19), all of which are critical in the DNA mismatch repair 
(MMR) system). 
Cancer mortality figures 
Cancers are among the leading causes of morbidity and mortality 
worldwide, with approximately 14 million new cases and 8.2 million cancer related 
deaths in 2016 (20). Cancer related deaths have continued to rise over the past 
decades and this emphasizes the necessity for development of more innovative, 
efficacious, less cytotoxic, and targeted chemotherapeutic agents, especially for 
late stage/ metastatic tumors (20).  In 1990, 5.8 million people died of cancer in 
the worldwide and in 2010, this number has increased to 7.8 million (21).  Lung, 
colorectal, breast, and prostate cancers are the most commonly diagnosed 
cancers (21).  In 2012, lung cancer has the highest mortality rate associated with 
all cancer related deaths (1.59 million, 20.2% of all cancer deaths), followed by 
liver (745,000 9.7%), stomach (723,000, 9.2%), breast (521,000, 6.4%) and 
esophageal (400,000 5.0%) cancers (21). Liver, esophageal and pancreatic 
cancers have the highest mortality rates, and for pancreatic there is a 95% 
likelihood of mortality within a year (21).  This is due in part to the lack of reliable 
biomarkers to diagnose the disease in its early stages.  Approximately 70% of 
cancer related deaths occur in less developed countries and many of these are 
caused by viral infections, including Hepatitis B/C virus (HCC) human papilloma 
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virus (HPV) (cervical cancer), accounting for 20% of cancer deaths (21,22,23,24).  
In the United States, cancer is the second leading cause of mortality behind heart 
disease.  Men and women are both highly susceptible to cancer with a 43.9 and 
38.0% chance of developing cancer respectively and 22.9% and 19.3% of these 
resulting in mortality respectively (21).  It is estimated that 1,658,370 Americans 
will be diagnosed with cancer and 589,430 of these will result in cancer related 
deaths (21).  
Cancer demographic statistics and risk factors 
The incidence of different types of cancers is summarized in Figure 1.  
Breast cancer occurs most frequently in females whereas prostate cancer is most 
common in males (21). As people age the likelihood for developing cancer 
increases, with some cancer probabilities increasing exponentially (21).  Indeed, 
nearly 80% of all diagnosed cancers occur in persons of greater than 55 yrs. of 
age, for both sexes.   Prostate cancer has less than 1% likelihood in males from 
age 35-44; however, at 55-64 years of age the number of new cases increases 
nearly 66 fold and the likelihood increases to 33% (25).  Some cancers also have 
higher predispositions with regard to race, for example prostate cancer is more 
frequently diagnosed in African American males as opposed to Caucasians or 
men of other races (25).  Despite the ostensible evidence that cancer is age 
related, at least one third of all cancers are preventable (25). The incidence of 
these cancers are dependent on lifestyle, including diet, smoking/nonsmoking, 
alcohol and drug use, working environment, and a sedentary life style (25,26).  
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Many cancers can be prevented or at the very least delayed by regular 
screenings, healthy diet, which includes high fiber and cruciferous green leafy 
vegetables, fruits, low consumption of fried food and processed sugars), and 
regular physical activity (27). Chronic infections and infections inducing pro-
inflammatory cytokines (i.e. high fat diet), some environmental contaminants 
(polycyclic aromatic hydrocarbons (PAHs), nitrosamines) including carcinogens 
(benzo [a] pyrene, acridine dyes, nitrous acid asbestos, etc.) also contribute to the 
increased risk of cancer (27,28).  These risk factors can be mitigated by deliberate 
lifestyle changes and increased awareness of their presence in the everyday 
environment (28).  Being proactive in reducing cancer risk and advocating a 
cancer preventive lifestyle is the best defense against cancer and has more 
favorable outcomes than some cancer treatments (28). Genetically-related and 
other unavoidable cancers are insidious and require development of improved 
treatment regimens that are less toxic and more patient specific (28,29).  This can 
only be accomplished by a greater and more comprehensive knowledge of the 
molecular biology of cancer and individual tumors with increasing reliance on a 
personalized medicine approach (29). 
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Multistep carcinogenesis 
 
 
Initiation 
Carcinogenesis (or tumorigenesis) refers to the multistep transformation of 
normal cells and tissue into a benign neoplasm and then into a malignant 
aggressive mass known as cancer (Figure 1).  Tumor transformation is a 
multifactorial process and in many models, it can be generalized into three stages: 
cancer initiation, cancer promotion, and cancer progression (30).  Cancer initiation 
is the first step of carcinogenesis and entails a genetic change induced by a 
Figure 1:  Model of carcinogenesis.  Initiation is started by a carcinogen such as DMBA or benzo[a]pyrene.  
This damage if unrepaired leads to initiated cells which can be promoted by agents like PKC induced TPA.  
This leads to proliferation of these initated cell population forming benign neoplasms.  Cells then become 
invasive by loss of heterozygosity (LOH) of key tumor suppressor genes and/or undergoing EMT and 
overexpressing proteases to digest extracellular matrix (ECM).  This is the final stage which is progression 
and ultimately metastasis. 
Reprinted with permission from: Surh YJ, Nat Rev Cancer 2003 Oct;3(10):768-80. (30) 
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carcinogen (30).  A carcinogen is a type of mutagen, which can be any chemical, 
or ionizing radiation that induce genetic mutations, which can ultimately lead to 
tumor formation (27).  These species can induce genetic mutations by directly 
binding, intercalating to or covalently reacting with DNA, preventing the DNA from 
being properly transcribed into mRNA by RNA polymerase II (RNA pol II) and/or 
preventing proper replication of DNA (31).  It is a generally accepted by regulatory 
agencies carcinogens that such as benzo [a] pyrene and high energy ionizing 
radiation, may have no thresholds in their ability to initiate tumors (32).  Some 
chemicals are not carcinogenic at low concentrations by themselves but can 
initiate or promote carcinogenesis when their exposure is combinatorial with other 
chemicals or radiation.  An example of this is sodium arsenite, which by itself does 
not cause tumors but does exacerbate tumor size and formation rate of UV-
induced tumor formation in mice.  Oncoviruses (i.e. retroviruses) can initiate 
carcinogenesis by integrating their viral oncogenes into the host genome (33).  
They can also make proto-oncogenes become oncogenes within the host genome 
by enhancing their expression (i.e. c-Myc, HCV-induced liver cancer) or they can 
attenuate tumor suppressors (i.e. HPV induced cervical cancer interfering with 
p53) (33,34).  Carcinogens cause mutations and epimutations and these can 
accumulate as normal cells become transformed malignant cells (35).  
Carcinogens induce cellular and DNA damage, which provides certain cells with 
a selective advantage to override mechanisms that have evolved to suppress 
tumor cell formation (36).  In carcinogenesis, there is an aberration in the fine-
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tuned balance between cell proliferation and programmed cell death (apoptosis) 
which results in aberrant cell proliferation and growth.  These involve mechanisms 
that hyperactivate oncogenes and/or inactivate/attenuate tumor suppressor gene 
function or expression and these are integral components of carcinogen induced 
initiation.  There are many in vivo cancer initiation models including one in mouse 
skin where multiple papillomas form.   Topical administration of a carcinogen [i.e. 
dimethylbenzanthracene (DMBA)] results in the formation of covalent DMBA-DNA 
adducts (i.e. N7 methyl guanine adducts) which can results in mutations of 
oncogenes such as H-Ras leading to formation of benign papillomas and 
eventually squamous cell carcinoma (SCC) (37).  However, in this model 
exposure to carcinogens does not directly result in cancer since most DNA 
damage is efficiently repaired by DNA repair systems, such as nucleotide excision 
repair (NER), mismatch repair (MMR), and base excision repair (BER).  The 
former two systems deal with repairing DNA adducts. NER deals with smaller 
bulky lesions on DNA and uses enzymes such as excision repair cross-
complementation group (ERCC 1, 4) Cockayne syndrome type A (CSA, ERCC6), 
Cockayne syndrome type B (CSB,ERCC8) and DNA repair protein Xeroderma 
Pigmentosum complementing (XPA, XPB, XPC, XPD, XPE, XPF, and XPG), 
which remove the lesion and through DNA polymeraseβ resynthesize the excised 
DNA. BER removes less bulky non helix-distorting lesions, which result in 
generation of apurinic or apyrimidinic (AP) sites (38).   Bulkier lesions require the 
MMR system and use the enzymes human MutL homolog 1 (hMlh1) and two 
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(human postmeiotic segregation increased 1and 2 (hPms1and 2)), human MutS 
homolog 2/6/3 (hMsh2/6/3), and other repair proteins (38,39).  These repair 
systems are very critical to DNA replication and normal cell proliferation.  If the 
damage to the DNA is too great then mechanisms within the cell (p53) can initiate 
cell death through apoptosis.  This can be initiated either extrinsically (i.e. TNFR 
trimerization and formation of the DISC) or intrinsically (Bax/Bak homo-
oligomerization leading to mitochondrial out membrane permeabilization 
(MOMP)) followed by activation of cysteine-aspartic acid proteases (caspases) 
that cleave proteins (i.e. PARP, ICAD) and induce cell death (40).  These 
pathways are crucial for normal physiology and it is believed that defects in genes 
involved in DNA synthesis and DNA damage assessment and repair (during cell 
cycle checkpoints or apoptosis) can amplify the mutation rate of these initiated 
cells and therefore enhance tumor formation.  These topics will be covered in 
depth in the “Hallmarks of Cancer” section.  
Promotion 
Cancer promotion is the second stage of carcinogenesis and is 
characterized by the clonal expansion of initiated cells.  Initiated cells often 
express aberrant tumor suppressor genes or genes that exhibit decreased 
expression or are epigenetically silenced.  Retinoblastoma (Rb) the heralded 
guardian of the genome p53, phosphatase tensin homologue deleted on 
chromosome 10 (PTEN), adenamatosis polyposis coli (APC) are examples of key 
tumor suppressor genes which are important for cell cycle arrest after DNA 
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damage (41).  Initiated cells, which are refractory to growth inhibitory signals or 
apoptosis, have increased likelihood to survive allowing them to proliferate and 
expand.  Although carcinogens are no longer required at the promotion stage of 
carcinogenesis, chronic inflammatory conditions are important for stimulating 
clonal expansion of precancerous cells (42).  Inflammation triggers cells to 
produce growth factors such as the epidermal growth factor (EGF) which activates 
mitotic pathways and kinases such as mitogen activated protein kinases (MAPKs) 
(43).  Inflammation also enhances the secretion of the proliferative cytokines such 
as tumor necrosis factor alpha (TNFα) and chemokines, which attract pro-
inflammatory cells such as neutrophils (44).  TNFα has a dichotomous role with 
respect to cell physiology since it stimulates both cell death (hence its namesake) 
and also cell proliferation (40).   
Cell death is triggered by TNFα binding to TNFR (tumor necrosis factor 
receptor), which trimerizes and recruits TRADD (Tumor necrosis factor receptor 
associated death domain) by binding to its respective death domains on their 
cytosolic tails and this complex recruits FADD (Fas associated death domain) 
(40,45).  Fas (CD95) is another death receptor involved in extrinsic apoptosis and 
through association with its respective ligand, FasL can stimulate apoptosis (45). 
This will be further discussed in the “hallmarks of Cancer” section under “resisting 
cell death”. TNFRs recruit TRAFs (TNF receptor associated factor), specifically 
TRAF2 which also associates with kinase RIPK1, phosphorylating MAP3K14 (NIK 
NFκB inducing kinase), and this is essential for NFκB activation.  NIK 
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phosphorylates NEMO, which is the regulatory subunit of Inhibitor of κB kinase 
(46).   
These promoted cells can also release reactive oxygen species (ROS) that 
exacerbate inflammation that can cause DNA damage (47).  Hormones can also 
promote initiated cancer cells to expand by activating hormone receptors.  17β-
Estradiol (E2) binds to the estrogen receptor (ERα is the isoform most implicated 
in carcinogenesis) and upregulate genes required for cell proliferation (48).  E2 
can also stimulate genes required for angiogenesis inducing expression of 
vascular endothelial growth factor (VEGF) (49).  Moreover, some non or weakly 
carcinogenic compounds such as phorbol esters (i.e. TPA through PKC), 
phenobarbital (a classic cytochrome P450 (CYP) inducer) and chlorinated 
biphenyls (PCBs) can serve as tumor promoters by activating proliferative 
pathways and stimulating inflammation (50).  Inflammation, hormones, and tumor 
promoters all enhance cell proliferation and contribute to an increase in genetic 
instability, which drives promoted cells to a malignant state. 
Progression 
Cancer progression is the third stage of carcinogenesis in which benign 
neoplastic cells are transformed into malignant cells that exhibit several 
phenotypic changes including increased growth, dysplasia to anaplasia, loss of 
polarity, refractory to inhibitory signals from the outside whether exocrine or 
paracrine, morphological changes, induction of angiogenesis, and invasiveness 
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(Figure 2).  The phenotypic changes in cancer cells are due to irreversible 
genomic alterations, which include mutations and genetic polymorphisms that 
accumulate and are amplified in the first two stages of carcinogenesis as well as 
acquired chromosomal abnormalities such as aneuploidy (51).  Aneuploidy 
includes the acquisition, loss, truncation, or imbalance of chromosomes, which 
are common karyotypic observations in many advanced cancer cells, especially 
in cancers of the skin and the colon.  The degree of aneuploidy, which may include 
the loss of either chromosome 8p or 18q or both, is negatively correlated with the 
5-year disease-free survival rate in colon cancer patients without metastasis.  All 
these genetic changes in cancer progression advance cells towards a malignant 
phenotype in which cells are able to invade adjacent tissues and metastasize to 
non-adjacent organs.   
Epithelial to mesenchymal transition 
A crucial stage in cancer cell malignancy and invasive propensity is the 
acquisition of a mesenchymal phenotype by undergoing what is called an 
epithelial to mesenchymal transition (EMT). EMT constitutes a series of 
physiological and molecular changes that occur in order for a cell to become a 
motile, less differentiated, depolarized cell that can detach from the basement 
membrane and adjacent epithelial cells so they can intravasate neighboring blood 
vessels and colonize at sites on distal organs (52).  These changes all arise by 
molecular changes in transcriptional machinery and molecular biological 
composition.  Potent transcription factors of EMT such as Snail, Slug, ZEB, Twist, 
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and Goosecoid upregulate genes associated with a mesenchymal state such as 
N-cadherin and vimentin and downregulate epithelial associated genes such as 
E-cadherin.  Cadherins are a class of calcium-dependent adhesion molecules that 
play a role in cell adhesion, polarity and motility (53).  In an epithelial cell, E-
cadherin associates with tight junctions along with spectrins and α-catenin.  In a 
mesenchymal state, E-cadherin expression is robustly downregulated and N-
cadherin expression becomes elevated.  Cells also lose sense of apical-basal or 
up-down polarity and junctions associated with the basement membrane and 
adjacent cells are lost (54).  Epithelial cells that do not undergo EMT can also co-
migrate with these transformed mesenchymal cells and have a higher likelihood 
of establishing a metastatic site in distal organs.  This is due to the fact epithelial 
cells have a greater probability of attaching to the endothelial layer of blood 
vessels and extravasating into a secondary site (55).  Mesenchymal cells that are 
able to extravasate into a secondary tissue also need to revert from the 
mesenchymal state back into the epithelial state by undergoing mesenchymal to 
epithelial transition or MET.    
Cancer cell invasion 
EMT increases the propensity for cancer cell invasion; moreover, cells 
acquiring the ability to intravasate blood vessels to colonize at distal tissues, or 
metastasize is important components and risk factors for decreased patient 
survival.  Indeed, the primary tumor rarely leads to patient mortality but the 
metastases are frequently lethal (56).  Another fundamental characteristic of 
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malignant cancer cells is their ability to invade the surrounding tissue by 
upregulation of matrix metalloproteinases (MMPs), motility by formation of 
invasive lamellipodia and intravasation of blood vessels to colonize to distal 
tissues.  Tumor metastasis represents a highly advanced phase of the disease.  
Malignant tumor cells can proteolytically degrade the encapsulated boundary, the 
basement membrane and the extracellular matrix surrounding the primary organ 
by using proteolytic enzymes such as MMPs, A disintegrin and matrix 
metalloproteinases (ADAMs), and other proteases, which proteolytically digest the 
matrix and basal membrane and enable the cells to intravasate a nearby blood 
vessel or infiltrate a surrounding tissue (56).  Proteases such as urokinase also 
participate in intravasation and lymphatic vessel infiltration.   
The process of invasion and metastasis results in tumor formation at a 
secondary site with tumors that originate from one organ preferentially 
metastasizing to other organs.  For example, tumors that originate from the colon 
have a higher preference to metastasize in the liver by intravasating the portal 
vein and extravasating in the liver (57).  These primary colon tumor cells can also 
metastasize to the lung. Indeed, Stephen Paget was the first person to discover 
the non-random metastatic pattern of tumors after examining over 700 
postmortem breast cancer cases, which lead to him proposing the “seed and soil” 
theory, which suggested that the dynamic interaction between metastatic cancer 
cells and its respective microenvironment determines the organ preference 
patterns of cancer metastases.  The most frequently targeted organs are the liver, 
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lung and bone.  This directional dissemination is orchestrated by distinctive 
chemokines in cancer cell chemotaxis, which is an integral component of cancer 
cell invasion, intravasation, and subsequent colonization at distal organs and 
tissues (58).   
Normal cells undergo extensive changes and acquire distinctive genetic 
and epigenetic changes, as well as alterations in post-translational regulation and 
machinery, that are required for the transformed, and the malignant cancer cell 
phenotype (59).  As stated in a famous paper by Weinberg and Hanahan, 
describes distinctive changes, or hallmarks, of cancer, namely: sustained 
proliferative signaling, evading growth suppressors, evading cell death, enabling 
replicative immortality, evasion of immunosurveilance, genomic instability, tumor 
promoting inflammation, aberrant and deregulated metabolism, inducing 
angiogenesis, and activating invasion and metastasis (60).  Not all of these traits 
are present in the transformed phenotype or required for cancer cell initiation, 
promotion, progression and metastasis.  However, more often than not many of 
these hallmarks are acquired sequentially and selected for transformed cells in 
the most aggressive cancers and the ones most refractory to available 
chemotherapy, surgery, and treatment. 
Hallmarks of cancer: preview 
Weinberg and Hanahan published a famous and highly cited paper in 2000 
that delineated the complex nature of cancer into tangible underlying principles or 
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“hallmarks”, which has been updated to include new hallmarks in 2011 (Figure 2) 
(60). Virtually all cancers possess many, if not all, these hallmarks and this has 
significantly enhanced the way we perceive cancer.  Perhaps the most common 
and rudimentary characteristic of cancer is uncontrolled cell proliferation.  Normal 
cells divide under strict regulation by highly sophisticated and evolutionarily 
conserved machinery that makes cells pass certain checkpoints within the cell 
cycle before they can be cleared to proceed into successive steps. The first step 
in the transformation of normal cells into becoming cancerous is usually a gain of 
function mutation that involves mutation of a proto-oncogene into an oncogene 
(60).  
  
Reprinted with permission from: Hanahan D., Weinberg RA, Cell 2011 Mar 4;144(5):646-74. 
(60) 
 
 
 
 
Figure 2:  Hallmarks of cancer.  Cancers acquires some, if not all, of these characteristics in 
a sequential fashion during their progression into a transformed state.   
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This mutation can make the protein constitutively active and not require the 
normal activating posttranslational modifications such as kinase-dependent 
phosphorylations which activate many a receptor tyrosine kinases (RTK) (e.g. 
Epidermal Growth Factor Receptor (EGFR)) (60).  K-ras is an excellent example 
of such a mutation and is present in at least 33% of all cancers.  K-ras mutations 
are often required in colorectal cancer (CRC) and is listed on the “vogelgram” of 
CRC progression (61).  A missense mutation of K-ras is acquired in amino acid 
positions 12, 13, or 61 where the corresponding glycine is replaced with a valine, 
cysteine, or aspartate, resulting in constitutively active K-ras (61).  Ras is a small 
monomeric GTPase and a member of the eponymous Ras superfamily.  Its 
association with guanosine triphosphate (GTP) or guanosine diphosphate (GDP) 
respectively determines the activation or deactivation of Ras (62,63).  Two effector 
proteins regulate Ras: a GAP (GTPase activating protein) and a GEF (guanine 
nucleotide exchange factor).  Ras has intrinsic, yet very weak GTPase activity, 
which requires its GAP to fully activate its own GTPase activity (62).  When Ras 
is associated with GAP it hydrolyzes the bound GTP into GDP, making Ras 
inactive.  However, in order to activate Ras the GDP can be exchanged with a 
GTP by GEF, therefore activating Ras.  However, when Ras is mutated at the 
above-mentioned codons, Ras becomes insensitive to this level of regulation and 
remains constitutively activated (62,63).  Mutation of many other genes such as 
c-Myc can also lead to uncontrolled cell proliferation.  The other hallmarks of 
cancer include evading growth suppressors and sustained growth/proliferative 
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signaling (autocrine signaling), deregulated cellular energetics, resisting cell 
death/evading apoptosis, immunoevasion, inducing angiogenesis, genomic 
instability (mutations/ translocations, acquiring replicative immortality 
(telomerase), pro-inflammatory signaling, and acquiring invasion/migratory and 
ultimately metastatic propensity (60). These hallmarks are acquired through a 
series of mutations that accumulate over a lifetime and is the result of one’s 
environment, spontaneous mutations, and internal factors pertaining to hormones 
and other metabolites.  In normal cells, there is a balance of factors that are 
competing with one another to influence the fate of the cell, which can broadly be 
classified into tumor suppressor genes and oncogenes (64).  As mentioned 
earlier, oncogenes are mutated proto-oncogenes that gain aberrant activity and 
lose sensitivity to regulation.  These kind of mutations are gain of function 
mutations and lead to aberrant and excessive cell proliferation, growth, migration, 
invasion and ultimately metastasis (65).  Even though cancer is normally 
associated with these type of mutations and excessive activating of these kind of 
genes, cancer is largely a “loss of function” disease where critical tumor 
suppressor gene function is mitigated or completely lost.  This can be due to 
mutations that hinder or abrogate the tumor suppressor function of the gene 
(hypomorphic, amorphic, or antimorphic (dominant negative) mutations) or loss of 
gene function due to epigenetic changes that silence expression of the gene [(e.g. 
hypermethylation of the promoter, histone deacetylase (HDAC)] (65,66,67).   
Perhaps the most famous tumor suppressor gene is p53, which is heralded as the 
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guardian of the genome and is often mutated in cancer.  Other common tumor 
suppressor genes that are mutated or epigenetically silenced are APC (CRC), 
BRCA1/2 (breast), Smad4 (pancreatic, CRC), TGFBRII (CRC), Rb, VHL (kidney), 
and PTEN (68-71).  The alterations in both oncogenes and tumor suppressor 
genes leads to the transformation of normal cells into cancerous cells in a 
multifactorial and multivalent successive process called carcinogenesis.  This will 
be described in further detail in the succeeding sections. 
 
The Hallmarks of Cancer 
Sustained proliferative signaling 
RTKs and MAPKs 
The most fundamental and rudimentary characteristic of all cancer cells is 
their ability to acquire sustained cell proliferation.  This is almost universally the 
first step in becoming a transformed cell and involves contiguous signaling 
through one or multiple signaling pathways such as mitogen activate protein 
kinase (MAPK) pathways (72).  This represents a vast superfamily of kinases that 
activate proliferation in response to receptor tyrosine kinase (RTKs) such as 
epidermal growth factor receptor (EGFR), insulin receptor (IR), and insulin-like 
growth factor receptor type I (IGF1R) (73).  These RTKs are activated by ligand 
binding on the extracellular side of the membrane, which promotes dimerization 
of the receptor.  Dimerization (either homo- or heterodimerization) promotes 
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autophosphorylation or “phosphorylation in trans” of the cytoplasmic tails of these 
receptors on multiple tyrosine residues (hence the name RTK) (74).  These 
phosphorylations create multiple docking sites for proteins that contain src 
homology domains, specifically SH2 (src homology 2 domain) which recognizes 
and binds to phosphotyrosine residues (75).  Proteins such as Grb2 (growth 
receptor binding 2) and Shc (src homology collagen) can bind by virtues of these 
domains and serve as docking proteins for protein kinase cascades (75). 
Ras and PI3K/Akt pathway  
 The Ras protein as stated earlier is a small monomeric GTPase that is 
activated and repressed by guanine nucleotide exchange factors (GEF) and 
GTPase activating proteins (GAP) respectively.  The known GEF son of sevenless 
(Sos) binds to Grb2 and activates farnesylation tethered Ras by exchanging GDP 
for GTP (76).  This activates the Ras-Raf-MEK-ERK signaling cascade. These 
RTKs can also activate the phosphatidylinositol 3, 4, 5-triphosphate kinase (PI3K) 
pathway.  This kinase can bind to RTKs by virtue of Shc/Grb2/GAB interaction or 
by binding to insulin receptor substrates (IRS1 and 2) (77).   Constitutively active 
Ras is found overexpressed in 30% of all cancers (predominantly K-ras mutations) 
especially in pancreatic and colorectal cancers.  Ras downstream effectors 
include the pathway of Raf-MEK-ERK.  Raf contains three isoforms Raf-1 B-Raf 
and C-Raf.  B-Raf is often mutated to become constitutively active especially in 
melanoma and drugs that target B-raf such as vemurafinib and dabrafinib can 
attenuate progression of these B-Raf mutated cancers (78).   
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Figure 3: The three classes of PI3K.  They share a high degree of homology and also have significant differences.  
Class I PI3K family members contain regulatory domains whereas class II lack these.  Regulatory domains contain 
SH3 and SH2 domains (with exception of p87 andp101) which bind to poly-proline and phosphotyrosine domains 
respectively.  Class III has only two members Vps34 and Vps15 (vacuole protein sorting 34 and 15 respectively), 
which are critical to autophagy.  Vps contains a HEAT (Huntington, elongation factor 3 (EF3), phosphatase 2A, 
and yeast kinase TOR1) and WD domains that are critical for protein-protein interaction.  The former motif is found 
in the mammalian homolog of TOR1, mTOR (mechanistic target of rapamycin), a negative regulator of autophagy.  
WD repeats (which end in tryptophan (W)-aspartate (D) dipeptides) form solenoid structure domains which 
facilitate protein-protein interactions 
 
PI3K has three classes: Class I, ClassII, and ClassIII (Figure 3) (79).   The 
first class is the canonical class most implicated in cancer and is composed of two 
subunits a p110 catalytic subunit and a p85 catalytic subunit (79,80).  The catalytic 
subunit consists of three isoforms: α, β, γ with the first two being ubiquitously 
expressed and the latter being expressed exclusively in leukocytes, playing a 
crucial role in regulating the cytotoxicity in natural killer (NK) lymphocytes (80).  
The p85 regulatory subunit contains five isoforms: p85α, p85β, p50α, p55α, p55γ.  
The p85 regulatory subunit regulates the catalytic subunit, masking its kinase 
Reprinted with permission from: Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges 
B., Nat Rev Mol Cell Biol 2010 May;11(5):329-41. (79) 
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domain and inhibiting its ability to phosphorylate its respective substrate 
phosphatidyl inositol 3, 4 bisphosphate (PIP2).   
 
 
Figure 4: The PI3K/Akt signaling pathways.  Upon receptor activation by ligand binding, PI3K binds to 
phosphorylated docking proteins (like IRS-1 and IRS-2) and phosphorylates PIP2 (phosphatidyl inositol 3,4 
bisphosphate) to PIP3 (phosphatidyl inositol 3,4,5 triphosphate).  This phosphorylation is reversible and is 
catalyzed by the phosphatase PTEN (phosphatase tensin homolog).  Formation of PIP3 provides a docking site 
for Akt by virtue of Akt’s Pleckstrin Homology (PH) domain within its N-terminus.  Akt is then phosphorylated by 
PDK1 at T308 and S473 by mTORC2 (or PDK2).  Akt promotes cell proliferation and survival by activating MDM2, 
NFκB, and mTOR (mechanistic target of rapamycin).  Akt also inhibits apoptosis by inhibiting caspase cascade, 
GSK3β (glycogen synthase kinase 3β), and promoting the cytosolic sequestration of FOXO1 (FKHR, Forkhead 
box protein O1) and Bad bcl2-associated death promoter).  The PI3K/Akt pathway is often aberrantly regulated in 
cancer.  This constitutes constitutively active forms of the PI3K catalytic subunit, mutations or epigenetic 
silencing of PTEN (i.e. Cowden’s syndrome), or overexpression of RTKs (such as EGFR or HER2). 
 
Upon receptor activation and association of adaptor proteins, p85 
regulatory subunit binds to Grb2/GAB or IRS1/2 and this relieves the catalytic 
subunit, enabling it to phosphorylate PIP2 to PIP3 (phosphatidyl inositol 3,4,5 
triphosphate) (Figure 4).  PIP3 serves as a docking site for many proteins and 
kinases that contain a Pleckstrin Homology (PH) domain (81).  One of these 
Reprinted with permission from: Engelman JA, Nat Rev Cancer 2009 Aug;9(8):550-62. (81) 
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kinases is AKT kinase (also known as PKB) (82).  AKT kinase has three known 
isoforms (AKT 1, 2 and 3 respectively) that are expressed from three different loci 
on three different chromosomes (82).  Upon binding by virtue of its pleckstrin 
homology domain KT can be phosphorylated and therefore activated on two 
critical residues: T308 by phosphatidyl inositol dependent kinase 1 (PDK1) and 
S473 by mechanistic target of rapamycin complex 2 (mTORC2) or PDK2 (82,83).  
T308 is located within the AGC kinase loop of the protein (83).  This motif is shared 
by other protein kinases such as Protein Kinase A (PKA), Protein Kinase G (PKG) 
and Protein kinase C (PKC) (hence the name of the loop and the acronym of PKB 
for Akt) (84).  The other phosphorylation site, S473 is located within the 
hydrophobic pocket of Akt (83).  Both phosphorylation sites are associated with 
activation of AKT; however, phosphorylation of S473 is indispensable for 
complete activation as it causes a conformational change within the hydrophobic 
cleft of AKT and consummately activates its kinase activity (85).  Akt has multiple 
downstream targets, activating Tpl2 (86), IKKα (NFκB signaling) (87), PFKB2 (88) 
glycogen synthase kinase β (inhibitory) (activating glycolysis) (89), AS160 (90), 
PIP5K (glucose transport) (91), Wee kinase (92), Myt1 (93), p21 (inactivating cell 
cycle suppressors therefore upregulating cell cycle progression) (92,94).  PI3K is 
often mutated in many cancers, including multiple myeloma, CML, colorectal 
cancer (95), NHL (96), and breast cancer (metastatic and endocrine resistant and 
inhibitors such as Idelalisib and duvelisib (PI3Kδ inhibitor, for hematological 
malignancies) (97), copanlisib (NHL) (96), perifosine (colorectal cancer, although 
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discontinued since 2013) (95,98), buparlisib (breast cancer) (99), and alpelisib 
(metastatic breast cancer) (100,101).  Akt is associated with multiple cancers, 
such as colorectal cancer (102), neuroblastoma (103), renal cell carcinoma (RCC) 
(104), and melanoma (105).  Proteus syndrome is associated with a mosaic 
mutation (E17K), which produces overgrowth of skin, brain, and connective 
tissues (106).  Akt inhibitors such as MK2206 (colorectal cancer) and VQD-002 
(neuroblastoma) (107).   
mTOR 
 
 
Figure 5:  Mechanistic target of rapamycin (mTOR) signaling pathway.  mTOR is positively regulated by rhedb 
(ras homology enhanced in brain), which is negatively regulated by TSC1/2.   mTOR can form two complexes, 
mTORC1 and mTORC2, which have different components as shown above.  mTORC1 regulates protein 
synthesis by phosphorylating 4EBP1 (4E eukaryotic initiatior factor binding protein) and p70S6K (p70 S6 
ribosomal subunit kiase), both of which are critical for ptoein translation.   
Reprinted with permission from: Hoeffer CA, Klann E., Trends Neurosci 2010 Feb;33(2):67-75. (83) 
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One of Akt’s most integral targets with regards to cell proliferation is mTOR 
(Figure 5) (82,83,85).  The protein mTOR (mechanistic target of rapamycin) is a 
potent downstream effector of PI3K/AkT signaling and the mammalian/human 
homolog of the protein TOR found in the yeast saccharomyces cerevisiae 
(82,83,85,108).  It is a member of the PI3K-related kinase (PIKK) family, which 
includes ATM, ATR, DNA dependent protein kinase, SMG1 (nonsense mediated 
mRNA decay PI3K related kinase), and TRRAP (transformation/transcription 
domain associated protein) (109,110).  These members, along with mTOR have 
distinct features, which include N-terminal HEAT domains, a FAT (FRAP-ATM-
TRAP) domain, a PIKK regulatory domain (which in the case of mTOR is the FRB 
or FKB12/rapamycin binding domain) a kinase domain, and a C-terminal FATC 
(FAT at C-terminus) domain (109,110).  There are 20 HEAT domains (Huntington, 
elongation factor 3, subunit of protein phosphatase 2A, and TOR1), each 
composed of α-helices that mediate protein-protein interactions (109,110).  The 
FAT and FATC domains associate with other factors and aid in activation of 
mTOR kinase and mutations in either the FAT or FATC inhibits catalytic activity 
of mTOR (110).  The protein mTOR can be a component of two signaling 
complexes: mTORC1 and mTORC2.   
The complex mTORC1 is composed of mTOR, mLST8 (mammalian lethal 
with Sec-13 protein 8), RAPTOR (regulatory associated protein of mTOR), Deptor 
(DEP domain TOR binding protein), and PRAS40 (proline rich AkT substrate 40 
kDa) (109-111).  The components of mTORC2 are mTOR, RICTOR (rapamycin 
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insensitive component of TOR), mSin1 (mammalian stress activated protein 
kinase-interacting protein 1), Deptor, and Protor (protein observed with RICTOR) 
(Figure 5) (109-111).    Each of these complexes has its own unique composition 
and physiological functions.  The complex mTORC1 regulates protein translation, 
ribosomal biogenesis, and promotes an anabolic environment whereas mTORC2 
is involved in the regulation of cell survival, proliferation, metabolism, and is a 
potent activator of AkT (111-113).  In cancer, especially RCC mTOR signaling is 
often dysregulated and has therefore garnered a great deal of interest as a 
chemotherapeutic target (114-118). The complex mTORC is potently inhibit by the 
compound rapamycin, an immunosuppressant compound produced by the 
bacterium Streptomyces hygroscopicus on the island of Rapa Nui (Easter Island), 
where it was first isolated (119).  Ever since its discovery a myriad of chemical 
compounds called rapalogs have been developed in the treatment of cancer, 
autism, and coronary artery diseases such as atherosclerosis (120-125).  
Rapamycin and other rapalogs inhibit mTOR by binding to FK506-binding protein 
(FKB12), which is complexed with rapamycin, then binds with raptor to inhibit its 
association with mTOR (112,115,120,126).  This inhibits mTOR activity; however, 
it is known to require association with mTOR in order to be catalytically active as 
knockout of the raptor subunit attenuates mTOR kinase activity, making the entire 
role of raptor in mTOR equivocal (120,126,127).  Raptor is a 150 kDa non-
enzymatic component that is essential for mTOR activity and brings mTOR 
substrates in close proximity (120,126,127).  It consists of a highly conserve N-
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terminal region with three HEAT repeats and seven WD40 domain containing 
repeats (domains approximately 40 amino acids in length conserved tryptophan 
and aspartic acid residues that form anti-parallel beta strands) that mediate 
protein -protein interacts with mTOR and mTOR substrates (126-128).  Raptor is 
also essential for the formation of the mTORC1 complex itself and mTOR is 
believed to be complexed with raptor in states of nutrient stress and activation 
(126-128). Thus, raptor serves as a molecular rheostat of mTOR catalytic activity, 
and phosphorylation of raptor is an important factor on the dichotomous role raptor 
plays on mTOR function (127,128).  For example, in a nutrient deprived state, 
AMPK is activated and it phosphorylates raptor on S722/792, and inhibits mTOR 
activity.  Downstream from mTOR, the phosphorylation of raptor by p90 ribosomal 
S6 kinase (RSKs) on S719, S721, and S863 leads to activation of mTORC1, 
which is stimulated by EGFR, IR/IGF1R, and other RTK signaling (129,130), 
which is outlined in figure 5.  
PRAS40  
PRAS40 (proline-rich Akt substrate of 40kD) is an Akt-substrate and a 
negative regulator of mTOR (131).  Phosphorylation of PRAS on T246 by Akt near 
its C-terminus leads to dissociation of PRAS40 from mTOR and relieves mTOR 
of its inhibition (131).  PRAS40 contains a putative mTOR signaling motif FVMDE, 
which is required for the interaction with raptor (131,132).  Raptor serves as a 
scaffold to bring mTOR and PRAS40 in close proximity to promote PRAS binding 
to mTOR (Figure 5).  PRAS40 has also been demonstrated to be a substrate of 
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mTORC1 at S221 and this phosphorylation seems to be a necessary 
phosphorylation for the full activation of mTORC1 and in the presence of 
rapamycin this phosphorylation is abrogated (133).  mLSt8 is composed of seven 
WD40 repeats, which enable binding to the catalytic domain of mTOR and it is 
hypothesized mLST8 stimulates mTORC1 kinase activity (133,134).  Deptor binds 
to the FAT domain of mTOR and is a component of both the mTORC1 and 
mTORC2 complexes, with unknown activators or function (132,133,134).  AKT 
also phosphorylates a negative regulator of mTORC1 PRAS40 which inhibits 
mTOR from associating with raptor which is critical for mTOR kinase activity. 
MTOR induces cell growth, protein translation, ribosomal biogenesis and 
proliferation by its two main substrates p70S6 kinase and 4EBP1 (eukaryotic 
initiation factor 4E binding protein) (134,135).  P70S6K phosphorylates S6RP (S6 
ribosomal protein) which is a crucial step in the hierarchical assembly of 
ribosomes (136,137).  This also leads to an increase in ribosomal RNA 
transcription within the nucleolus and its subsequent translocation into the cytosol.  
Translation is a multistep process that requires the ribosome to recognize specific 
motifs within the mature mRNA in order to initiate translation (134,135,138).  Along 
with the Kozak sequence, recognition of the 5’ 7-methyl guanosine cap is vital for 
translation initiation (139).  Of the many factors involved in translation, initiation 
eIF4E is vital to recognize the methyl cap; however, when it is in complex with 
4EBP1 it is inactivated and translation is substantially halted.  Phosphorylation of 
4EBP1 by mTOR relieves this association therefore promoting protein translation 
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(139).  Aberrant mTOR activity is associated with many cancers, including breast, 
prostate, lung, melanoma, bladder, pancreatic, neuroblastoma, glioblastoma, and 
RCC cancers (140-145).  Drugs such as sirolimus (rapamycin), everolimus, 
temsirolimus, ridaforolimus, and other “rapalogs” are drugs currently in clinical 
trials (143-146).  The drug Tesmirolimus is FDA approved for treatment of RCC 
(147).  mTOR is a critical target for RCC chemotherapy as it is associated with 
increased HIF1α expression, especially in those patients that have Von Hippel-
Lindau syndrome, who are highly susceptible to RCC development (148). 
 Although mTOR is not a direct substrate for Akt, it is activated by virtue of 
Akt phosphorylation of Tuberous Sclerosis complex TSC1/2 (149). TSC1 
(hamartin) and TSC2 (tuberin) form a heterodimer and serve as a GAP for the 
monomeric GTPase and one of the activators of mTOR Rheb (Ras homology 
enhanced in brain) (149).  TSC1 and 2 share very little homology with one another 
and TSC2 GAP domain is activated by association with TSC1, which promotes 
the hydrolysis of GTP within Rheb to promote its inactive state (150).  AKT 
phosphorylation inactivates this complex by promoting dissociation of TSC1/2 and 
from Rheb (149,150).  There is evidence that Akt phosphorylation also promotes 
subcellular relocalization of TSC1/2 to the cytosol (as opposed to rough 
endoplasmic reticulum membrane and/or lysosomal membrane) by promoting 
association of TSC1 with the sequestration protein 14-3-3 (151).  Indeed, many 
targets of Akt that are negatively regulated by AKT phosphorylation gain affinity 
for 14-3-3 and are sequestered within the cytosol (149,150).  Phosphorylation of 
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the BH3 only proapoptotic protein Bad inhibits its ability to form pores on the 
mitochondrial out membrane as it becomes sequestered in the cytosol by this 14-
3-3 association event (152).   Another proapoptotic protein Bim is regulated in a 
similar way as well as the potent transcription factor FOXO1 (153).   
LKB1 and AMPKα 
MTOR can also be negatively regulated by LKB1-AMPKα pathway (154).  
LKB1 (liver kinase B1; STK11) is a kinase that is part of a trimer that forms AMPKK 
(AMPK kinase), which includes the pseudokinase activator of LKB1 STRAD 
(LYK5) and MO25 (CAB39) (155).  Endogenous STRAD and LKB1 form a 
complex in which STRAD activates LKB, which results in a phosphorylation of 
both partners.  MO25 enhances the interaction between STRAD and LKB1 and 
stimulates LKB1 catalytic activity, serving as a scaffold and regulating the 
subcellular localization of LKB1 (155).  Upon nutrient stress, LKB1 is activated 
and this leads to phosphorylation of AMPKα (on T172) (156,157).  AMPK consists 
of three subunits (α,β,γ).  Each of these subunits plays a role in the stability and 
activity of AMPK (156,157).  The gamma subunit responds to high levels of AMPK 
(hence the name AMPK) and accomplishes this by binding to AMPK through its 
CBS (cystathionine beta synthetase) domain and can therefore directly sense the 
ATP: AMP ratio (158).  The gamma subunit contains four CBS domains, which 
create two binding pockets for AMPK.  The binding of AMP to two CBS domains 
(Bateman domain) causes a conformational change and AMPKγ exhibits 
cooperative binding activity kinetics.  Although AMPK can be activated by AMP 
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binding, it is relatively weak compared to the phosphorylation of AMPKα (1000 
fold) which is a true marker of complete AMPK activation (159).  Cancer cells can 
epigenetically silence AMPK and or suppress its kinase activities by having no 
expression of LKB1, as seen in HeLa cells (160).  However, AMPKα can be 
activated by p53 or in response to ROS, both which activate sestrin2, which in 
turn activates AMPK (161,162).  This demonstrates a novel way mTOR can be 
inhibited in both a LKB1 and p53 mutant cancer cell and is chemotherapeutically 
valuable since ROS inducing anticancer agents can inhibit mTOR in these 
cancers.  Compounds such as doxorubicin, ifosfamide, arsenic trioxide, 
isothiocyanates, and natural phytochemicals can indirectly inhibit mTOR through 
this ROS-sestrin 2 mechanism (163-168).  
These proliferation pathways are also activated in a ligand independent 
manner by secreting growth factors that serve as paracrine and autocrine 
activators of RTKs like EGFR (165).  TGFα rests on the outside surface of cancer 
cells and can be cleaved by intracellular proteases and then activate its receptor 
EGFR (167,168).  These cancer cells can also stimulate and acquire growth 
factors from adjacent non-tumorigenic cells such as stromal fibroblasts or 
transformed cancer associated fibroblasts (167,168).  Many growth factor 
receptors are overexpressed or become aberrantly regulated or mutated 
(hypersensitive to growth stimuli, constitutively active or recalcitrant to growth 
inhibitory signals).  A classic example of receptor overamplification is the HER2 
(EGFR2, Erbb2, Neu) receptor in breast cancer (169).  This receptor is a member 
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of the EGFR family and although it has no known endogenous ligand it can 
heterodimerize rapidly with other EGFR receptors that have bound ligand and 
overamplify growth signals (169,170).  This is an example of oncogene addiction 
and drugs such as trastuzumab and lapatinib can target such receptors (169,170).  
Mutated receptors can also amplify a very strong signal in response to very low 
ligand binding or concentration.  In other cases, mutations give rise to hyperactive 
forms of receptors or downstream effectors of kinase cascades.  PI3K can also 
become constitutively active (i.e. p110αCA) and drugs such as wortmannin, 
LY294002, 3-methyladenine can inhibit these PI3K driven cancers; however, 
these drugs are too toxic to be considered for any chemotherapeutic value and 
are exclusively used in a research based context (171-173).  This is because most 
of these inhibitors are non-specific and inhibit all isoforms and classes of PI3K.  
Some of these inhibitors are also dual specificity inhibitors and also inhibit proteins 
such as mTOR.  However clinical trials for isoform specific PI3K inhibitors (i.e. 
p110γ) are being developed (174).  In addition, negative feedback mechanisms 
that normally regulate or counterbalance proliferative are often compromised in 
cancer cells.  The negative regulator of PI3K and its respective phosphatase 
PTEN becomes epigenetically silenced by promoter hypermethylation in many 
breast and lung cancer cell tumors (175,176).  Excessive proliferative signals also 
trigger cell senescence, which is a definitive feature or premalignant tumor cells.  
As cells become more malignant this machinery becomes incapacitated.   
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Evading growth suppressive signaling 
Retinoblastoma (Rb)  
Cancer cells must also become refractory to potent growth suppressors 
that counterbalance the effects of the proliferative signaling. Indeed, late stage 
cancers frequently represent a loss of function disease as advanced cancers have 
significantly attenuated, or completely silenced, growth suppressor function. Many 
growth suppressors are products of tumor suppressor genes, such as Rb and 
TP53, which negatively regulate cell proliferation by arresting cell cycle 
progression, activating cell quiescence or senescence, and inducing apoptosis/ 
cell death (177,178).  Functional tumor suppressors are gatekeepers of cell cycle 
progression and they integrate extra- and intracellular signals.  For example, Rb 
protein transduces inhibitory signals originating extracellularly, whereas p53 
integrates intracellular signals that detect cellular stress, nutrient deficiency, 
malfunctional proteins, and DNA damage (177,178).   The primary functions of 
p53 and Rb are to inhibit G to S phase and serve as sentinels at the G1/S 
checkpoint.  These proteins also regulate the metabolism of dNTPs, glutamine, 
and glucose, which are necessary for cell growth.  Rb is a member of the DREAM 
complex (dimerization partner, Rb-like, E2F, and multivulval class B) which are 
genes that participate in cell cycle regulation and repress gene expression (E2F, 
c-Myc) during quiescence (179,180). Rb normally forms a complex with E2F, a 
transcription factor that is required for the transcription of proteins known as 
cyclins (specifically Cyclin E and A) (177,181).  Cyclins are vital proteins involved 
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in the cell cycle and associate with cyclin dependent kinases (CDKs) that fully 
activate the kinase and participate in the specific stages of cell cycle progression 
(181,182).  The expression of cyclins is very ephemeral (30 mins or less) and as 
robustly as a specific cyclin expression is induced it is then swiftly degraded and 
followed by expression of another cyclin (182).  The flow of cyclins in cell cycle 
progression is Cyclin D, Cyclin E, Cyclin A, then Cyclin B, with each having waxing 
and waning waves of expression (183).  As cyclin D expression wanes there is a 
sequential increase in Cyclin E, then Cyclin A, then Cyclin B (184).  When cells 
are progressing through the cell cycle and CDK4/6 is activated by complexing with 
Cyclin D, it hyperphosphorylates Rb and this makes RB inactive and unable to 
bind to E2F.  E2F can then activate transcription of Cyclins E and A (185).  E2F 
can also activate PCNA (proliferating cell nuclear antigen) which is the eukaryotic 
processivity factor required for DNA replication during S phase.   
TP53 
TP53 (encodes the p53 protein) is the most commonly mutated gene in 
cancer and due to its very complicated and multivalent role in cell homeostasis, 
DNA repair, genomic stability, metabolism, and apoptosis (177, 186).  This 
illustrates why p53 is heralded as “the guardian of the genome”.  Including the full-
length protein p53 encodes 15 different isoforms (186,187).  The structure of p53 
is modular and it contains an N-terminal acidic transcription-activation domain 
(TAD) which activates transcription factors such as those involved in proapoptotic 
activity and a second activation domain (AD2) (187).  There is also proline rich 
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domain that is integral for nuclear exportation by MAPKs and therefore critical for 
its apoptotic activity, a DNA binding domain (DBD) that binds zinc and contains 
several arginines, nuclear localization signals, an oligomerization domain (OD) 
where tetramerization of p53 is required for full activity, and a C-terminal inhibitory 
domain that suppresses the transcriptional activity of p53 (187).   This protein has 
many cancer inhibitory functions including activation of DNA repair mechanisms.  
Upon DNA damage, kinases ATM (ataxia telangiectasia mutated) and ATR 
(ataxia telangiectasia and Rad3 related) are activated and phosphorylate 
checkpoint kinases (CHK) 1 and 2.  CHK2 is activated by ATM, stabilizes p53, 
and promotes its activity (188,189).  P53 is also a downstream target of ATM and 
is further activated by decreasing association of p53 with its negative regulator 
mdm2 (murine double minute 2) which is an ubiquitin ligase that ubiquitinates p53 
and promotes its proteasome-dependent degradation (189).  P53 activates 
several genes involved with cell cycle arrest, including p21 (WAF/CIP1), and 
microRNA (miR) miR34a (190,191).   
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The pro-apoptotic proteins PUMA and BAX are also upregulated, the latter 
being a potent apoptotic factor that oligomerizes and forms pores on the 
mitochondrial outer membrane inducing apoptosis (192).  p53 upregulates 
expression of these genes, and p21 binds CDK to inhibit its ability to promote cell 
cycle progression (Figure 6).  In contrast mutated p53 cannot effectively bind to 
DNA and induce p53-dependent expression of p21 mRNA (193). Many p53 
polymorphisms have been observed and there are mutational “hotspots”  
 
associated with carcinogenesis: these include R175, G245, R248, R249, R273, 
and R282 (193,194).  These mutations are located within the DNA-binding domain 
Figure 6:  Rb and p53 pathway.  E2F-1 remains in complex with Rb and is inhibited.  Upon oncogene activation, 
such as ras or c-Myc, Rb is hyperphosphorylated, which leads to its dissociated from E2F-1, and degradation 
of Rb.  E2F-1 can then complex with cyclin D1 and transactivate other cyclins such as Cyclin E and other cell 
cycle genes.  The guardian of the genome, p53, negatively regulates the cell cycle, regulates DNA repair, and 
promotes cell survival.  However, under very stressful conditions, p53 promotes apoptosis by upregulating 
pro-apoptotic proteins such as Bax, NOXA, and Apaf-1.  The E3 ubiquitin ligase mdm2 negatively regulates 
p53 by proteasome-dependent degradation and p53 participates in a feedback inhibition loop by upregulating 
its own repressor in a metastable state.  Mdm2 mediated ubiquitination can be reversed by the ubiquin-specific 
protease HAUSP (herpesvirus-associated ubiquitin-specific protease). 
Reprinted with permission from: Van Maerken T., Vandesompele J., Rihani A., De Paepe A., Speleman 
F., Cell Death Differ 2009 Dec;16(12):1563-72. (192) 
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of p53 and disrupt its conformation and inhibits transcription of p53-dependent 
tumor suppressor genes.  Furthermore, this mutant p53 is a dominant negative 
protein, squelching WT p53 monomers forming defective tetramers (194).  This 
not only inhibits the tumor suppressor activity of WT p53 but mutant p53 displays 
some oncogenic functions and transactivates genes such as multiple drug 
resistance 1 (MDR1), c-Myc, PCNA, interleukin-6 (IL-6), insulin-like growth factor 
(IGF-1), EGFR, and telomerase reverse transcriptase that are potent pro-
oncogenic genes (194-197).  MDR-1 is involved in chemotherapeutic resistance, 
as it is a member of the ATP-binding cassette (ABC) superfamily of pumps 
involved in pumping out cytotoxic drugs from the intracellular milieu (198).  As 
stated earlier EGFR as well as IGF-1 are involved in excessive cell proliferation 
and activation of PI3K, Ras/MAPK pathways.  PCNA and c-Myc are also drivers 
of excessive cell growth and proliferation and so is IL-6, the canonical activator of 
Janus kinases (JAK), which activate STATS (signal transducers and activators of 
transcription) (199,200).  Some STATs are oncogenic transcription factors that 
upregulate oncogenic genes such as HIF-1α, COX-2, and others (200).  
Telomerase reverse transcriptase is an enzyme critical for replicative immortality, 
a hallmark of cancer, which will be discussed later.  p53 is negatively regulated 
by E3 RING (Really Interesting New Gene) finger ubiquitin ligase mdm2 (murine 
double minute 2) (200,201).  The RING finger domain of mdm2 is unique in the 
fact that it contains a Walker A or P-loop, which confers nucleotide binding and 
nucleolar localization Mdm2 binds to and blocks the N-terminal trans-activation 
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domain of p53 and ubiquitinates several lysine residues within the C-terminal 
domain of p53, leading to proteasome-dependent degradation (201,202).  Mdm2 
is also a p53-responsive gene that serves as a negative-feedback loop for 
regulation of p53.  P53 protein can undergo proteasome-dependent degradation 
in an mdm2-independent manner by E3 ubiquitin ligases pirh2 (p53 induced ring 
H2 domain protein) and COP1 (constitutive photomorphic 1) (203,204).  Aberrant 
regulation and overexpression of mdm2 are associated with cancer and 
imadazoline drugs, like nutlin, are being investigated as anticancer agents (205).   
CDKN2A 
CDKN2A is a tumor suppressor gene encoding two proteins that participate 
in cell cycle arrest and growth suppression: namely, the protein p16 (p16INK4A) 
and p14 (p14ARF) (206).  Both of these gene products function as tumor 
suppressors in different ways.  The p16 protein binds with CDK4/6 to inhibit 
hyperphophorylation of Rb, therefore leading to the hypophosphorylated active 
Rb protein (Figure 6) (206).  The p14ARF (alternate reading frame) is a shorter 
gene product because of translation from an alternate reading frame of the 
CDKN2A locus (206,207).  P14 is induced in response to elevated mitogenic 
stimuli (i.e. c-Myc, RAS/MAPK pathway) and accumulates in the nucleolus 
forming a stable complex with the p53 suppressor mdm2 (206,208).  Upon 
activation by p16 and p14 mdm2 is phosphorylated by these kinases which not 
only destabilizes mdm2/p53 protein interaction but also induces association with 
p14 and mdm2, leading to nucleolar sequestration of mdm2 (209).  
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Desensitisation and inactivation of these growth suppressive signals can also 
directly lead to loss of apoptotic mechanisms which will be discussed in the next 
section 
Resisting cell death 
 Perpetual cell proliferation and resistance to growth suppressive signals 
are characteristics of cells acquiring a more malignant phenotype (210). Normal 
cells are in equilibrium with multiple signals from the intracellular and extracellular 
environment that affect cell proliferation and quiescence, survival, and apoptosis 
(211).  Apoptosis is crucial not only for normal tissue homeostasis but also for 
embryological and limb development.  Cancer cells are resistant to apoptosis and 
other cell death pathways and acquiring these capabilities is a fundamental step 
in cancer malignancy (212).  Apoptosis is a tightly regulated process, which 
involves activation of proteins known as caspases (cysteine-aspartic acid 
proteases) that cleave and degrade proteins.  This leads to deliberate DNA 
cleaving, nuclear fragmentation (pyknosis or nuclear shrinkage) followed by 
karyorrhexis or DNA rupturing, cell blebbing and global mRNA decay (213).  This 
is in sharp contrast to necrosis, which is unregulated, leads to cell swelling, 
lysosomal swelling, lysosomal and cell leakage, and tissue damage to 
surrounding cells (214).  Not only does this cause damage to tissues but also it is 
pro-inflammatory and promotes carcinogenesis (214).   Apoptosis is activated via 
intrinsic or extrinsic pathways that are induced within cells by excessive oncogenic 
signaling, DNA damage, oxidative or nutrient stress and these are all 
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consequences of hyperproliferation and increased malignant metabolism (aerobic 
glycolysis) (215).  Cancer cells can find loopholes to evade these mechanisms, 
alter metabolism, increase the flux of glucose, increase expression of antioxidant 
enzymes (GSTs, glutathione S-transferases) to reduce oxidative stress, and 
therefore evade apoptotic induction.  The two apoptotic pathways are distinct but 
also converge and lead to caspase cleavage (216).   
Extrinsic pathway 
Figure 7: The extrinsic pathway. This is mediated by TNFα-mediated binding to TNFR (tumor necrosis factor 
receptor), which trimerize and associate with TRADD (TNFR associated death domain) and enables formation of 
the DISC (death induced signaling complex). The DISC can also form at Fas/CD95/ FADD (Fas associated death 
domain) interactions 
 
Reprinted with permission from: Vucic D., Dixit VM, Wertz IE, Nat Rev Mol Cell Biol 2011 Jun 23;12(7):439-52. 
(217) 
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The extrinsic pathway involves extracellular signaling with Fas ligand 
binding to Fas (CD95) or TNFα binding to TNFR (tumor necrosis factor receptor) 
(Figure 7).  With TNFα binding to TNFR, the receptor trimerizes and recruits 
TRADD (Tumor necrosis factor receptor associated death domain) by binding to 
its respective death domains on their cytosolic tails (217).  This kinase exists as a 
trimer with IKKα and IKKβ serving as the catalytic subunits of the complex where 
IKKγ (NEMO) serves as the regulatory subunit. TRADD also activates the p38 
and c-JNK regulatory cascades.  
Likewise, Fas can recruit FADD (Fas associated death domain), which 
associates with TRADD through their respective death domains and this enables 
procaspase8 (as well as pocaspase10) to bind by virtue of the caspases DED 
(death effector domain).  This complex is known as the DISC (death induced 
signaling complex) (Figure 7A) (217). All caspases exist in an inactive state in 
which the inactive protein needs to be cleaved in order for the caspase to 
tetramerize and form the active caspase (217).  FADD like interleukin β1 
converting enzyme (FLICE) induces cleavage of caspase 8 by the DISC and this 
action is inhibited by cFLIP (cellular FLICE Inhibitory Protein) also known as 
CFLAR.  Caspase 8 (as well as caspase 10 and 9) are initiator caspases (218).  
When active they cleave effector caspases which cleave proteins (including ICAD 
or inhibitor of caspase activated DNase) (217,218).  Caspases can be divided into 
two groups: the initiator caspases (2, 8, 9, and 10) and the effector caspases (3, 
6, and 7) (218,219).  There is also another group of caspases; however, they are 
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involved in inflammation (caspase 1, 4, 5, 12, 13, 14) (219). These caspases exist 
in an inactive state and the two families differ with respect to the length of their 
pro-domains.  Initiator caspase contain two domains called a DED (death effector 
domain) and a caspase recruitment domain (CARD) (220).  These domains were 
initially identified in the ced-3 and ced-4 genes in Caenorhabditis elegans where 
many of the component of the apoptotic machinery were first characterized (221).  
The DED and CARD facilitate association with other proteins that have these 
domains (221).  THE DED is required for assembly with the DISC and other 
proapoptoic machinery (221).  The CARD can bind with proteins that possess a 
CARD domain including the family of proteins called IAPs (inhibitor of apoptosis 
protein) (222).  Only the initiator caspases contain these CARD and DED domains 
(222).  The caspases contain both a large and small subunit and once the 
procaspases are cleaved they can tetramerizes in a 2:2 stoichiometry of small to 
large subunit and become active (222,223).  The initiator caspase once activated 
cleave the effector caspases and irreversibly induce apoptosis.  This leads to 
destruction of ICAD and cleavage of DNA between histones, phosphorylation of 
the protein H2AXγ and cleavage of the DNA repair enzyme PARP (poly ADP-
ribose polymerase) (223,224).   
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Intrinsic pathway 
 
Reprinted with permission from: Tait SW, Green DR, Nat Rev Mol Cell Biol 2010 
Sep;11(9):621-32. (225) 
Figure 8: The intrinsic pathway.  Bcl-Xl and bcl-2 form plugs on the mitochondrial outermembrane 
(MOM) whereas the pro-apoptotic members such as Bax and Bak oligomerizes and form pores, 
inducing MOM permeabilization (MOMP).  The extrinsic pathway can also feed into the intrinsic 
pathway as the pro-apoptotic member Bid is cleaved (forming truncated or t-bid) and promotes MOMP.  
Cytochrome c is then released and associates with Apaf1.  The inactiave form of caspase 9, 
procaspase 9, binds with Apaf1 in a 1;1 rato via their CARD domains, forming the apoptosome.  This 
activates effector caspases 3/7 and induces apoptosis. 
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Along with the extrinsic pathway, apoptosis can also be activated 
intrinsically.  In cancer cells, the extrinsic pathway plays practically no role and is 
non-functional, and this facilitates the ability to evade immune surveillance. CD95 
negative tumors can overexpress FasL, which induces apoptosis in infiltrating T 
lymphocytes (225). Stimulation of the TNFR by TNFα also promotes NFκB 
signaling as well as inflammation and release of cancer growth factors (226).  The 
intrinsic pathway is dependent on molecules that interact with and regulate the 
integrity of the mitochondrial out membrane (MOM) (Figure 8). 
Figure 9:  Bcl-2 family. These members are distinguished by possessing bcl-2 homology (BH) domains.  BH1 
and BH2 domains are associated with membrane insertion and interaction with the MOM.  Pro-apoptitc 
proteins contain a BH3 domain and lack a BH4 domain.  Certain members such as Bim (bcl2-like protein 11), 
Bik (bcl2-interacting killer) and PUMA (p53 upregulated mediator of apoptosis) possess only a BH3 domain 
and interact with other bcl-2 family members through their respective BH3 domains.  The presence of a BH4 
domain confers anti-apoptotic activity. 
Reprinted with permission from: Strasser A., Nat Rev Immunol 2005 Mar;5(3):189-200. (227) 
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A large superfamily of bcl-2 homology (BH) proteins that can contain up to 
four different BH domains (1, 2, 3, and 4 respectively) regulate this pathway (227-
229) (Figure 8 and Figure 9).  There are also three major classes in this 
superfamily: antiapoptotic proteins, the pro-apoptotic proteins, and the BH3-only 
pro-apoptotic proteins (Figure 9) (227-229).  The anti-apoptotic proteins are 
distinguished by possessing a BH4 domain, which confers antiapoptotic activity 
and this includes bcl-2, bcl-Xl, and Mcl-1 (227-229). These proteins are positioned 
on the MOM and serve as plugs (forming homo- and heterodimers), preventing 
mitochondrial outer membrane permeabilization (MOMP), a hallmark feature of 
apoptosis (227). These proteins interact with one another by associating through 
the BH regions 1,2, and 3 which is mediated by αhelices 2, 7-8, and 4-6 
respectively (229).  When bound to pro-apoptotic members, their BH4 domains 
undergo conformational changes and theses “plugs” become disrupted (227,228).  
Anti-apoptotic proteins also prevent oligomerization of the pro-apoptotic members 
and inhibit the activity of VDAC (voltage gated anion channel), a critical member 
of the mitochondrial permeability transition pore complex (MPTP), required for the 
release of cytochrome c and Ca2+, which are steps in apoptosis (Figure 8) 
(228,230-232).   The pro-apoptotic members include Bax (Bcl-2 associated 
member X) and Bak (Bcl-2 homologous antagonist killer). Bax was originally 
identified by coimmunoprecipitation studies with bcl-2 and Bak was identified and 
cloned by multiple groups.  Both proteins are composed of nine α helices, with a 
C-terminal transmembrane domain, and an αhelix 9, which is essential for 
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tethering to the MOM.  Bax has high affinity for bcl-2 whereas Bak has higher 
affinity for Mcl-1, and both have equal affinity for bcl-XL.  Bak is constitutively 
bound to the MOM, whereas Bax is cytosolic and upon apoptotic stimuli, such as 
p53 activation, Bax localizes to the MOM.  Helix 9 of Bak is always exposed 
whereas helix 9 of Bax in a resting state interacts with its hydrophobic core and 
needs to be exposed by conformational changes within the protein after apoptotic 
stimuli.  As stated earlier p53 upregulates Bax and activates it.  Bax is normally in 
the cytosol but under apoptotic stimuli it is translocated to the MOM and can 
interact with and stimulate the opening of VDAC (192,227,228).  Bax along with 
Bak can also form oligomeric pores known as mitochondrial apoptotic channels 
(MAC) on the MOM (192,226,227,228).  This leads to the release of cytochrome 
c from the mitochondria along with other apoptotic factors (i.e. AIF, SMAC/Diablo) 
(228,229).  Bcl-2, bcl-xL, and also VDAC2 can prevent formation of the MAC by 
binding to Bak (227-229).  The BH3 family members are also pro-apoptotic and 
are induced by a number of stimuli including heat, mechanical stress, peroxide, 
and increased acidity (227,228,230).  These members have only a BH3 domain 
as well as a transmembrane domain and include Bad, Bid, Bim, Bix, Blk, and Bnip 
(227-230).  One of these proteins, Bid, can be cleaved by caspase 8, which is 
activated by the extrinsic apoptotic pathway, and become truncated Bid (tBid), 
which binds MOM and induces MOMP (230).  These proteins along with the other 
pro-apoptotic bcl-2 family members decrease mitochondrial membrane potential 
(MMP), leading to cytochrome c release.  The release of Apaf1 and cytochrome c 
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leads to the formation of the apoptosome, a heptameric structure consisting of a 
1:1 stoichiometric ratio of cytochrome c, apaf1, active caspase 9 and dATP, which 
leads to the activation of caspase 3 (230-232). 
Bcl-2 family proteins and cancer 
 Cancers can evade apoptosis by overexpressing antiapoptotic members 
such as bcl-2 and bcl-xL.  Indeed in follicular lymphoma a chromosomal 
translocation occurs between chromosomes 14 and 18 (t (14:18)) (233).   This 
places the bcl-2 protein-coding region next to the immunoglobulin heavy chain 
locus on chromosome 14, leading to very high expression levels of bcl-2 (232).  
The p53 tumor suppressor is also critical for induction of apoptosis, including BAX 
and transcription of the lincRNA (lincRNA-p21, the antisense transcript of the p21 
mRNA) with the latter being required for hnRNP-K induced apoptosis 
(192,193,227,233).  Exploiting the fact that BH3 confers pro-apoptotic propensity, 
the development and innovation of BH3-mimetics and Bcl-2 inhibitors are being 
extensively investigated (234).  These include drugs like ABT-737, which 
selectively targets Bcl-2, bcl-xL, and bcl-W and has delivered desirable results in 
patients with B-cell malignancies and patients with small lung cell carcinoma 
(SCLC) (235,236).  A similar drug ABT-263 has also demonstrated efficacy in 
SCLC as well as the drug obatoclax (GX15-070) (237).  Another drug that has 
shown promise as a BH3 mimetic is venetoclax (ABT-199) which blocks bcl-2 and 
favorable responses have been reported (238). 
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Inhibitors of apoptosis proteins 
 
  
Cancers also upregulate the class of proteins known as inhibitors of 
apoptosis (IAP) proteins (239).  These proteins were originally identified in the 
baculovirus, and are important for its reproductive cycle in lepidopteran cells (239, 
240). IAP proteins contain eight members (NAIP, cIAP1, cIAP2, XIAP, survivin, 
Bruce, ML-IAP, and ILP2) which are encoded from the genes BIRC1-8 
respectively (Figure 10) (239).  The proteins are so named because they possess 
baculoviral IAP repeats (BIR) domains, which are involved in anti-apoptotic 
activity, and the two most well studied and implicated in cancer members, are 
surivivin and XIAP (241,242).  Survivin is the smallest IAP member (being 16-17 
Figure 10: Inhibitors of apoptosis (IAP) family. They are identified by the presence of BIR (bacuolviral IAP 
repeats).  These proteins inhibit apoptosis by inhibiting the activitaion of procaspases (like surivin), or can 
directly bind to effector caspases (XIAP).  Surivin and XIAP are the two most studied IAP proteins and have the 
best-documented roles in cancer.  These IAPS can also possess RING fingers and can serve as E3 ubiquitin 
ligases, which can ubiquitinate substrates for proteasome-dependent degradation or auto-ubiquitinate (XIAP).  
The proteins c-IAP1 andc-IAP2 have a more equivocal role in apoptotis and also participate in cell survival and 
necroptotsis via TRAF2 and TRAF6. 
Reprinted with permission from: Riedl SJ, Shi Y., Nat Rev Mol Cell Biol 2004 Nov;5(11):897-907. (239) 
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kDa) and has only one BIR domain and a coiled coil domain (241).  Survivin 
inhibits activation of procaspase 9 and 10 by virtue of its BIR domain and in many 
cancers, including colorectal and pancreatic cancers survivin expression is 
elevated (241,243).  Survivin has been a therapeutic target of much interest and 
its expression is often a negative prognostic factor for cancer patients 
(241,243,244).  Strategies for targeting survivin include drugs that inhibit promoter 
activity (such as YM155), decrease stability of the mRNA (antisense oligos), inhibit 
upstream activators (RTK inhibitors, Raf inhibitors, MEK/ERK inhibitors), protein 
stability and folding [HSP90 inhibitors geldamycin (17-AAG), shepherdin] and its 
epigenetic regulation (HDAC inhibitors like belinostat), Aurora kinase B/PLK-1 
inhibitors) (245-259).  The drug YM155 has exhibited therapeutic potential in 
colorectal cancer, prostate cancer, melanoma as an adjuvant to docetaxel 
treatment, and in cisplatin-resistant HNSCC (245-248).  Other compounds used 
to inhibit survivin transcription are M4N (Tetra-O-methyl nordihydroguaiaretic 
acid) by targeting Sp1, a transcription factor important for surviving expression 
(260).  Cotreatment of M4N plus temozolomide (TMZ) enhanced cell death and 
inhibited proliferation of glioblastoma cells (261).  Mithramycin has also been of 
use as an agent to target survivin by virtue of its inhibition of Sp1 interactions with 
the survivin promotor (262,263). 
  XIAP is also a negative prognostic factor for colorectal, pancreatic, 
prostate, ovarian, lymphomas, AML (acute myelogenous leukemia), and ALL 
(acute lymphoblastic leukemia) patients (242,264-270).  XIAP is the only IAP 
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member that directly inhibits effector caspases 3 and 7 by binding with the BIR2 
domain of XIAP through their IBM (IAP binding motif) (242,264,265).  XIAP also 
inhibits caspase 9 directly by its BIR3 domain (Figure 10) (264,265,269).  XIAP 
also contains an UBA (ubiquitin association domain) as well as cIAP1, cIAP2 and 
RING finger domains, which is one of two type of domains associated with E3 
ubiquitin ligases (the other being HECT type E3 ligases, which are found in 
proteins such as SMURF) (264-266).  There is evidence that in normal or 
apoptotic conditions, XIAP through its E3 ligase activity can auto-ubiquitinate and 
promote its own proteasome-dependent degradation (271).  In a survival context 
however, Akt can phosphorylate XIAP on S87, to promote association with 
survivin and this stabilizes XIAP (271).  In apoptotic cells, SMAC (secondary 
mitochondrial activator of caspases) is released from the mitochondria and 
through its IBM can bind with XIAP leading to its proteolytic degradation (263-
265,272).  XIAP is overexpressed in many cancers, and is a negative prognostic 
factor, and also a potential therapeutic target (264-270).  These strategies include 
antisense morpholinos and oligos that target XIAP mRNA to reduce its expression 
such as the antisense oligonucleotide AEG35156 developed for treating AML 
(271).  However, success with this strategy has been limited  and phase I/II clinical 
studies have shown severe neurotoxicity (271).  A much more viable strategy has 
been the development of compounds that bind to the BIR3 domain of XIAP, 
namely mimetics of the protein SMAC/Diablo, and the SMAC mimetic TL32711 
exhibited anti-tumor activity in solid tumors and lymphomas (272).  SMAC 
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mimetics GDC-0917 and HGS1029 have also shown promise in Phase 1 studies 
and antitumorigenic activity in solid tumors and lymphomas, and the mimetic 
LCL161 from Novartis was effective in TNBC (triple negative breast cancer) (273-
275). 
Necroptosis   
 
In addition to apoptosis, another cellular program that results in death is a 
process called programmed necrosis or necroptosis.  This is a mode of 
programmed cell death that is independent of caspase activation and involves 
proteins called RIP (receptor-associated protein) kinases (Figure 11) (276).  It was 
originally thought that apoptosis was always favored over necrosis, however in 
Figure 11: Necroptosis.  Necroptosis is programmed apoptosis that involves the activity of RIP kinases 1 and 
3.  RP1 binds to FADD and TRADD in response to TNFα which facilitates binding of RIP3.  TRAF2,5, and 6 are 
recruited to the necroptotic complex and their cytosolic tails are ubiquitinated (K63) by cIAP 1 and 2 (cellular 
IAP proteins 1 and 2).  This complex forms along with MLKL, PGAM5L, PGAM55, and DRP1 and induces 
apoptosis.  This pathway is very prevealent in cells where caspases are intactvated even in response to 
apoptotic stimuli. Caspase inhibitors, like zVAD-fmk also promote this pathway 
Reprinted with permission from: Long JS, Ryan KM, Oncogene 2012 Dec 6;31(49):5045-60. (276) 
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certain cases, especially with the immune system and pathogen infiltration, a form 
of regulated necrosis is favorable.  This involves RIP1 binding to FADD and 
TRADD in response to TNFα which facilitates binding of RIP3.  RIP1 and 3 recruit 
TRAF 2, 5 and 6 as well as cIAP 1 and 2 which can ubiquitinate the TRAF tails 
(on K63) and stimulate downstream necroptotic signaling (277-280).  RIP1, RIP3 
along with MLKL phosphoglycerol mutase family member 5L (PGAM5L), 
PGAM55, and dynamin related protein 1 (DRP1) can form the necroptosome, 
which binds mitochondria to induce mitochondrial fission and necroptosis (276-
280).  This pathway is especially favored in response to caspase 8 inhibition, 
which is another evolutionary adaptation for normal cells where caspases are 
inhibited or mutated.  In cancer cells apoptosis is blocked and cells have another 
way to undergo cell death to prevent tumor formation (280).   
Autophagy 
 
Figure 12:  Classical autophagy pathway.  The phagosome forms and elongated by beclin1, ATG14L, Vps15, and 
Vps34.  The contents of the autophagosome then fuse with the lysosme where the contents are degraded.  
Chloroquine, baflomycin A, and Azithromycin inhibit this interaction.  Cancer cells become resistant to many 
drugs and chemotherapeutic regimens by exploiting this pathway. 
Reprinted with permission from: Kirkegaard K., Taylor MP, Jackson WT, Nat Rev Microbiol 2004 Apr;2(4):301-
14. (281) 
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 Cancer cells can also exploit autophagy as a way to survive in times of 
nutrient stress, protein instability, and cytotoxicity derived from chemotherapeutic 
agents (Figure 12) (281).  ULK1 is required for the formation of the 
preautophagosomal structure along with other autophagy related genes (ATGs) 
13, 101 and FIP200 (281).  After induction and initiation, there is nucleation and 
elongation of the phagophore until it becomes a phagosome and these steps are 
regulated by beclin1, ATG14L, Vps15, and Vps34 (vacuole protein sorting 
proteins, class III PI3K kinases) (282,283).  The full closure of the autophagosome 
requires ATGs 5, 12, and 16 along with insertion of phosphatidyl ethanolamine 
conjugated LC3 into the autophagosome membrane (281-283).  ATG5 and 
ATG12 are linked together by ATG7 (an E1-like protein) and ATG 10 (E2-like 
protein) whereas phosphatidyl ethanolamine conjugation of LC3 (LC3-I to LC3-II, 
which is necessary for autophagasome maturation and fusion of a lysosome) is 
associate with ATG7 and ATG3 (an E2-like protein) and both these ubiquitination 
pathways are critical for autophagy (281-283).  ATG5 and ATG12 linkage 
promotes interaction with E3-ligase protein ATG16L promotes LC3I PE 
(phosphatidylethanolamine) conjugation fusion with a lysosome (forming an 
autophagolysosome) where the contents are degraded by pH sensitive autosome 
hydrolases, and recycled for other metabolic processes within the cell (ATG4 
removes the phosphatidyl ethanolamine and recycles LC3) (281-284).  Proteins 
such as ESCRTS (endosomal complexes required for transport), SNARES (N-
ethylmaleimide sensitivity factor associated receptor proteins) and Rab 7 also 
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promote this interaction.   Other SNARE complexes that are implicated in 
autophagosome maturation include syntaxin 17 and VAMP 8 (vesicle associated 
membrane protein 8) by SNAP 29 (synaptosome-associated protein 29) (281-
284).   This process is negatively regulated by mTOR and positively regulated by 
AMPK (AMP kinase) (282-285).  MTOR phosphorylates ULK1, therefore inhibiting 
its activity and activation of the PAS (phagophore assembly site).  When mTOR 
is inhibited by AMPK, ULK1 kinase is active and phosphorylates FIP200, ATG13 
and itself (282-285).  This leads to the maturation of the phagophore, which 
includes the acquisition of Beclin-1, ATG14L, vps15 and vps34 (284,285).  Other 
positive regulators of phagophore elongation that are independent of mTOR 
activation include AMBRA1 (autophagy and beclin 1 regulator 1), Bif1 (bax 
interacting factor 1), and UVRAG (UV radiation resistance-associated gene 
protein) and negative regulators include Rubicon, Bcl-2, Bcl-xL, and Bim (284-
285).   
This mechanism is similar to how cancer cells also use the ubiquitin 
proteasome-dependent pathway to remove potentially toxic, nonfunctional 
proteins to prevent further protein misfolding, formation of aggregates further 
oxidative damage, and recycle proteins for amino acids.  This has made both 
autophagy and the proteasome attractive targets for treating some cancers and 
their roles might not necessarily be mutually exclusive.  Indeed, research has 
shown that in ovarian cancer resistant to cisplatin/carboplatin treatment rely 
heavily on autophagy to overcome the high amounts of DNA-crosslinking and 
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oxidative stress and damage.  Bortezomib (Velcade) is a well-known 26S 
proteasome inhibitor that binds to the catalytic site of the proteasome. Bortezomib 
induces early stage autophagy in carboplatin-resistant ovarian cancer yet inhibits 
late stage autophagy (286,287).  Treatment with bortezomib increased formation 
of several lysosomal-autophagic vacuoles that accumulated throughout the cell 
(286,287).  This was due to decreased activity of the lysosomal hydrolases 
cathepsins, and the inability of the cell to break down the contents of the 
autophagolysosome (286,287).  It is known that autophagy can induce apoptosis 
by the excessive accumulation of autophagic vacuoles (286,287). Cancer cells 
rely heavily on autophagy in later stages due to the increased demand for building 
blocks for cell membranes and energy through aerobic glycolysis and the Warburg 
Effect.  Cancer cells are also prone to excessive oxidative damage and autophagy 
is implemented in order to break down damaged proteins and prevent further 
damage.  There are several stages of apoptosis that can be inhibited and likewise 
certain stages of autophagy inhibition can result in differential effects. 
Mechanistically, autophagy and apoptosis are linked and have some interrelated 
pathways (288).  One of the proteins critical for autophagosome maturation is p62, 
which is also important for activation of NF-κB (by association with TRAF6) and 
activation of caspase 8. Caspase 8 and p62 share a mutual regulatory role and 
one can degrade the other (281-285,288).  With formation of the death induced 
signaling complex (DISC), caspase 8 degrades p62, which inhibit later stages of 
autophagy.  On the other hand, in later stages of autophagy it has been shown 
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that caspase 8 can be degrades by p62-mediated autophagy (281,284.  However, 
p62 needs to be degraded for proper autophagosomal-lysosomal fusion. If 
caspase 8 is degraded before degrading p62, then formation of autophagosomal 
vacuoles and puncta can aggregate, inhibit cell function, and promote apoptosis 
by oxidative damage, excessive aggregation of misfolded proteins, and induce 
mitochondrial outer membrane permeablization.    
When operating at low levels, autophagy is a survival strategy for cancer 
cells, however when overly exploited cancer cells can become irreversibly 
dormant and this leads to apoptosis.  Drugs such as chloroquine and bafilomycin 
A have similar effects and inhibit formation of the autophagolysosome (289).  
Vps34, which is required for nucleation and elongation of the autophagosome, is 
a PI3K family member and can be blocked by PI3K inhibitors such as wortmannin, 
3-methyladenine, LY-294002 (79-81, 283-285).  Class 1 PI3K is necessary for 
activation of AKT, which is vital for mTOR activation and inhibiting PI3K can 
indirectly induce apoptosis due to a drastic reduction in protein synthesis.  
Activation of ERK and MEK is also important for autophagy and inhibitors of these 
respective proteins can have the same effects as PI3K inhibitors.   Currently there 
are Vps34-specific inhibitors available, such as SAR405, which binds to the ATP 
binding cleft of the protein (79-81, 290).  Evidence suggests that this type of 
inhibitor could serve as a potential anticancer agent when used as an adjuvant in 
RCC treatment with FDA approved everolimus (291).  Excessive self-
consumption can lead to cell death as expression of beclin1 in many tumors is 
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lost.  Therefore, autophagy has a dichotomous role in cancer and certain 
molecules and mechanisms serve as rheostats for regulating the activation and 
duration of autophagy. 
Enabling replicative immortality 
Telomerase 
Cancer cells can proliferate continuously, however they also face another 
hurdle: namely, the problem of telomere shortening with each successive cell 
cycle.  DNA is replicated in S phase of the cell cycle and the mechanisms of high 
fidelity DNA replication and processivity have evolved to pass on the genetic 
information from one cell to daughter progeny cells effectively and with high 
fidelity. DNA is replicated by enzymes known as DNA polymerases, which require 
an RNA primer, since they cannot synthesize DNA de novo.  In humans, this RNA 
template is made by the primase DNA polymerase α and then the strand is 
synthesized by DNA polymerases δ and ε (292-294).  RNases then remove the 
RNA template and DNA polymerase δ resynthesizes the remaining gap, using the 
DNA 3’ as a “primer” to resynthesize the gap (292-294).  This is performed on 
both the leading stand, which is continuous, and the lagging strand, which is 
discontinuous and has multiple RNA primers and Okazaki fragments (292-294).  
DNA replication is always in the 5’ to 3’ direction and the lagging strand is halted 
at the replication fork, hence the punctuated periods of replication.  Eukaryotic 
DNA is linear and exists within structures called chromosomes.  Chromosomes 
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contain a long q arm and a p short arm, one centromere and two identical pairs of 
chromatids (294).  At the ends of these chromatids are structures called telomeres 
that are dynamic structures, which constantly interchange between a closed 
confirmation to block recognition by DNA repair enzymes to an open confirmation 
during S phase in the cell cycle.  During S phase in cell division these telomeres 
are continuously shortened because when the RNA primer is removed, DNA 
polymerases have no primer to use to resynthesize the removed RNA primer 
(292-294).  This results in shortened telomeres, leading to chromosome instability, 
which triggers cellular senescence and death (293-295).  In order for cells to 
become malignant and progress they must acquire replicative immortality and 
gain unlimited proliferative capacity (296).  In 1961, Leonard Hayflick observed 
that cultured human fetal cells divide only 40 to 60 times and this phenomenon 
was termed the Hayflick limit (297).  A good example of this is the HeLa cell line 
(cervical cancer cells derived from patient HenriettaLacks) established in 1961 
and still used today as a cancer cell model.  The molecular basis of this Hayflick 
limit is the shortening of the telomeres after every successive cell  
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division.  Telomeres are composed of thousands of hexanucleotide repeats 
(TTAGGG) which end in a G-rich 3’ overhang of 30-300 nucleotides long 
(298,299).  These defend against nucleotide loss during DNA replication and 
prevention of end-to-end fusion during chromosome segregation in late 
metaphase and anaphase.  These repeats are associated with a complex of six 
proteins called shelterin, which prevents the chromosomal ends from being 
recognized as DNA double-stranded breaks by DNA repair machinery (300).   
Figure 13:  Telomeric complex and telomerase. A) The structure of telomeric complexes that form to protect 
telomeres from degradation by DNA repair mechanisms.  This includes shelterin (composed of TRF1, TRF2, 
POT1, tankyrase, TIN2, and TPP1.  Tankyrase is a member of the poly-ADP-ribosyltransferase (PAR) family of 
proteins and mediates length and stability of telomeres by PARsylating TRF1.  The proteins RAD50 , 3’-5’ 
endonuclease MRE11, NBS1, and KU70/80 mediate homolgous recombination during telomeric repair. B) 
Components of telomerase: telomerase reverse transcriptase (TERT), human telomerase RNA component 
(hTRC or HTR) and dyskerin (which contains ribonucleoproteins NOP10 , GAR1, and H/ACA ribonucleoprotein 
complex subunit 2 (NHP2)).   Telomerase carries its own unique RNA template, which is hTRC, and is 
approximately 451 nucleotides in length.  TERT uses the template region of TERC (3’CAAUCCCAAUC-5’) to 
add TTAGGG repeats to the 3’ end of chromosomes multiple times by constantly realigning the new 3’ end 
after each successful telomeric repeat addition.  Diseases associated with TERT and hTRC include pulmonary 
fibrosis, bone marrow failure, and dyskeratinosis congentia ( which is also associated with mutations in 
NOP10, hTRC, and dyskerin). 
Reprinted with permission from: Verdun RE, 
Karlseder J., Nature 2007 Jun 21;447(7147):924-31. 
(298) 
Reprinted with permission from: Garcia CK, Wright 
WE, Shay JW, Nucleic Acids Res 2007;35(22):7406-
16. (299) 
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 Shelterin is composed of TTAGGG binding factors, telomeric repeat-
binding factors 1 and 2 (TRF1 and TRF2), protection of telomeres 1 (POT1), 
repressor/activator protein 1 (RAP1), TRF1-interacting nuclear factor 2 (TIN2) and 
TIN2 interacting protein 1 (TPP1) (Figure 13 A) (300,301).    The double stranded 
repeats are bound by TRF1 and 2 whereas the single stranded repeats are bound 
by POT1 which heterodimerizes with TPP1 (301,302).  TIN2 serves as an adaptor 
protein, which creates a link between the TRF1/TRF2 and TPP1/POT1 
heterodimers (300-302).  Each member is required since deletion studies of each 
protein decrease the function of sheltrin and increased susceptibility by the DNA 
damage response (300-302).  Telomeres can also form telomeric loops, with the 
3’ overhang displacing the upstream telomeric region, forming a so-called 
displaced loop (D-loop) (302,303).  Another capping structure is a four-stranded 
DNA structure called a G-quadraplex which is derived from the folding of single 
stranded DNA containing tandem repeats of 3-4 consecutive guanines to form 
stacked tetrads of guanines that are stabilized by Hoogsteen base pairing and 
cation coordination (303).    Both of these structures depend on the activity of the 
RTEL1 helicase (303).  The gradual erosion of telomeres generates genomic 
instability and this in turn activates ATM/ATR kinases that promote p53 dependent 
apoptosis and cellular senescence (188,189,303).     
When cells become senescent, they become very large, flat, and express 
high levels of β-galactosidase (302,303).  Telomere longevity and renewal is 
crucial and cancer cells achieve this by primarily activating the enzyme 
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telomerase.  Initially discovered by Elizabeth Blackburn, this enzyme is highly 
expressed in germ line cells but is repressed in somatic and differentiated cells.  
Cancer cells upregulate telomerase in order to stabilize telomeric longevity and 
acquire replicative immortality (304).  Telomerase is composed of two molecules 
each of telomerase reverse transcriptase (hTERT) telomerase RNA component 
(hTERC), and dyskerin (Figure 13 B) (304).  HTERT is a reverse transcriptase, 
which allows DNA to be transcribed from an RNA template (304).  Telomerase 
carries its own unique RNA template, which is hTERC, and is approximately 451 
nucleotides in length (304).  TERT uses the template region of TERC 
(3’CAAUCCCAAUC-5’) to add TTAGGG repeats to the 3’ end of chromosomes 
multiple times by constantly realigning the new 3’ end after each successful 
telomeric repeat addition (304).  Telomerase is often inactivated in premalignant 
cancer cells and activated in malignant cells and the rationale behind this is that 
cancer cells need to acquire mutations that are favorable for malignancy and then 
activate telomerase to stabilize and perpetuate the mutated malignant phenotype 
(304,305).  Telomerase activation has been observed in about 90% of human 
tumors and other pathways such as alternative lengthening of telomeres (ALT) 
exist in tumor and therefore bypassing the need for of telomerase (305).  Along 
with telomere elongation, TERT participates in other cellular activities such as 
gene expression, DNA repair and apoptosis that can enhance cancer progression 
(305).  Although telomerase overexpression is often associated with a 
transformed and malignant phenotype, telomerase overexpression itself does not 
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confer the transformed phenotype as many “normal” immortalized cells also 
overexpress telomerase.  For example, MCF10A mammary epithelial cell line and 
the pancreatic ductal epithelium cell line HDPE (human ductal pancreatic 
epithelium) have been immortalized by telomerase and are used as models for 
“normal” cells (306,307).  In some instances, impaired TERT function can 
enhance carcinogenesis in a certain biological context, such as when coupled with 
defective p53 (188,189,305).  Although TERT does not confer the transformed 
phenotype and its role in cancer is somewhat paradoxical, it is more often than 
not a critical component in cancer cell progression and it expression can enhance 
malignancy by conferring replicative immortality. 
Inducing angiogenesis 
Vascular endothelial growth factor (VEGF) 
 Rapidly growing tumors have a very high demand for nutrients, oxygen, 
and other biological resources to promote an anabolic environment and avoid 
becoming excessively stressed to induced necrotic cell death (308).  Cancer cells 
in the center of a tumor mass will become hypoxic and necrotic and another crucial 
hallmark of cancer is the acquisition by a cancer cell to have sustained blood flow 
that delivers nutrients and oxygen, and removes wastes and CO2 (308).  This is 
accomplished by inducing angiogenesis, which is the formation of new blood 
vessels from the pre-existing vasculature and this process can also be transiently 
activated during wound healing (308). However, sustained and perpetual 
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induction of angiogenesis is required for tumors and suppression of angiogenesis 
leads to anoxic tumor necrosis as well as tumor dormancy, which is evidenced by 
asymptomatic microscopic tumors that are commonly observed in clinical settings.  
In 1971, Folkman first described the interaction between vascular endothelium 
and tumors and postulated the requirement of angiogenic growth factors (309).  
The most fundamental gene involved in angiogenesis is vascular endothelial 
growth factor (VEGF), which is also important in normal physiology and 
embryological development which also need the formation of new blood vessels 
(Figure 14) (310).  VEGF and angiogenesis are also required after vessel and 
ischemic injury during exercise and to bypass blocked vessels to prevent ischemic 
injury (310).  VEGF is a member of the platelet-derived growth factor (PDGF) 
family of cysteine-knot growth factors and was first identified in guinea pigs by Dr. 
Sanger in 1983 and originally labeled the “vascular permeability factor” (311).    
VEGF has five isoforms: VEGFA, B, C, D, and Placental growth factor (PIGF) 
(310).  VEGF-A is the most physiologically relevant isoform of VEGF in cancer 
and it induces angiogenesis, migration, and proliferation of endothelial cells; 
VEGF also upregulates MMPs, and increases expression of the vitronectin 
receptor (integrin αvβ3, the known receptor for vitronectin, a critical component of 
the ECM important for angiogenesis and metastasis) (312,313). VEGF also 
indirectly induces vasodilation because of nitric oxide (NO) production by 
stimulated eNOS (endothelial nitric oxide synthase) activity, which attracts 
macrophages, neutrophils and other granulocytes, and produces growth factors 
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that can be exploited by the tumor (314,315).  VEGF-C VEGF-D and PIGF also 
contribute to angiogenesis but to a lesser degree.  PIGF and VEGF-B are more 
involved in embryological development, VEGF-C in lymphangiogenesis, and 
VEGF-D in the vascularization of the lung bronchioles. VEGF protein activity 
requires initial binding to their cognate receptors, namely: VEGFR1 (Flt-1), 
VEGFR2 (KDR/Flk-1), and VEGFR3 (Flt-4) (315,316).  These receptors are RTKs 
and function in a very similar fashion; they autophosphorylate when activated by 
ligand and can stimulate downstream PI3K/Akt and Ras/Raf/MEK/Erk pathways.  
Of the three receptors, VEGFR2 seems to mediate all the downstream responses 
required for angiogenesis, with VEGFR1 being able to modulate VEGFR2 
signaling both positively and negatively (315,316).  VEGFR1 can in some contexts 
serve as a decoy and sequester VEGF, preventing it from binding to VEGFR2.  
VEGFR3 mediates lymphangiogenesis and its cognate ligand is VEGF-C 
(315,316).   
VEGF expression can be triggered by hypoxia, inflammation, and other 
factors associated with the tumor microenvironment (315-317).  Transcription 
factors such as NFκB and Sp1  activate transcription of VEGF in breast lung and 
pancreatic tumor cells and it was demonstrated that hormone activation of VEGF 
transcription was due to estrogen receptor α (ERα) interacting with Sp1 bound to 
GC rich regions within the VEGF promoter (317).  Tumors in vivo secrete VEGF 
ligands which bind to VEGFRs and initiate mitogenesis within the stromal cells by 
induction of PI3K/AKT, Ras, and PKC signaling, actin remodeling through MKK 
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3/6 signaling and Hsp27, and activation of FAK through the vitronectin receptor, 
and vascular permeability by production of IP3 (318).  IP3  
 
 
stimulates IP3 and ryanodine receptors on the surface of the endoplasmic 
reticulum (ER) which release calcium and stimulate eNOS and prostaglandins, 
resulting in increased vascular permeability (319).  However, release of 
endogenous angiogenesis inhibitors such as angiostatin, endostatin and 
thrombospondin-1 (TSP-1) and also transcriptional repressors of VEGF such as 
ZNF24, can counterbalance the effects of VEGF on endothelial cells.  VEGF can 
Figure 14:  Angiogenesis. Angiogenesis is a critical part of cancer progression as well as normal physiological 
function.  In cancer angiogenesis is induced to form new blood vessels to hypoxic tumors by VEGF (vascular 
endothelial growth factor) and its cognate receptors (VEGFR1, VEGFR2, and VEGFR3).  Angiogenesis is also 
mediated by platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) and their respective 
receptors PDGFR and FGFR respectively.  Other angiogeneic factors include IL-8, TGFα, and angiopoietin. 
Reprinted with permission from: Bellmunt J., Teh BT, Tortora G., Rosenberg JE, Nat Rev Clin Oncol 
2013 Oct;10(10):557-70. (318) 
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also be sequestered by proteoglycans within the ECM and are only released by 
the action of MMPs (320,321).  In 1990, Folkman and Hanahan proposed the 
“angiogenic switch” concept that described an equilibrium between an angiogenic 
inducing and an angiogenic-repressing environment, that explain how tumors 
proceed from a state of dormancy to malignancy and activation of angiogenesis 
is a critical component of the process (322).  The angiogenic switch can occur at 
any stage of tumorigenesis and development and it is dependent on the type of 
tumor and the communication within the tumor’s microenvironment, which 
includes many types of myeloid and inflammatory cells synergistically promoting 
angiogenesis with tumor cells (322).  Furthermore, certain bone marrow-derived 
cells can differentiate into endothelial cells and pericytes to form tumor 
vasculature.  Monoclonal antibodies such as bevacizumab and ranibizumab and 
drugs like afibercept are agents that target VEGF and show promise for treating 
retinoblastoma, breast cancer, and RCC (323-325).  
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HIF-1 and VHL 
  
 
As stated above, hypoxia is a potent driver of angiogenesis and hypoxia-
induced angiogenesis is orchestrated by the protein known as HIF (hypoxia 
inducible factor)-1α.  It is a subunit of a heterodimeric complex, the other member 
being HIF-1β (also known as ARNT or aryl hydrocarbon receptor nuclear 
translocator) (326). HIF-1β is a PAS basic helix-loop-helix (bHLH) containing 
Figure 15: HIF-1.  A) The structure of HIF-1 (HIF-1α and HIF-1β), which are members of the PAS (period, 
ARNT, and singleminded) family of transcription factors.  The basic helix-loop-helix (bHLH) and PAS domain 
confer DNA binding and dimerization.  The C-terminal region contains transactivational domains (TAD-N and 
TAD-C) which are necessary for transcriptional activation and contain sites for hydroxylation by prolyl 
hydroxylase domain-containing enxymes (PHDs), which included P402 and P564. B) These hydroxylations 
occur in normoxic, unstressed conditions and enable binding by the E3 ubiquitin ligase von-hippel lindau 
(VHL), which promotes proteasome-dependent degradation.  In hypoxic conditions, PHDs are not activated 
and HIF-1α translocates to the nucleus to induce hypoxia inducible genes. 
B 
A 
Reprinted with permission from: Denko NC, Nat Rev Cancer 2008 Sep;8(9):705-13. (326)
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protein (Figure 15A) and is the master regulator of the hypoxia inducible response 
(327).  Dysregulation of HIF-1α has serious consequences in a cancer context. 
One of the most important regulators of HIF-1α is the E3 ubiquitin ligase VHL (Von 
Hippel-Lindau) tumor suppressor, which is often mutated in cancers, especially 
RCC, and is the cause of the eponymous disease von Hippel-Lindau disease 
(328). This disease is characterized by the spontaneous generation of 
hemangioblastomas, angiomatosis, pheochromocytomas, pancreatic and 
glomerulic cysts, and RCC (renal cell carcinoma (328-330).  The VHL gene is 
found on the short arm of chromosome 3 and over 1500 germline and somatic 
mutations are associated with the disease, which is autosomal dominant (327). 
Many of the mutations (30-40%) in the VHL gene consist of 50-250 kb deletion 
mutations that produce a truncated protein, the remaining of mutations cause 
truncated proteins by nonsense, insertional/deletional, and splice site mutations 
(328-330).  Cells that express the normal copy in heterozygous individuals are 
healthy, however cells that express the mutated version have epistatic penetrance 
that results in formation of benign neoplasms within the kidney and pancreas 
(329,330).   In normal physiological conditions HIF-1α is hydroxylated by prolyl 
hydroxylase domain containing enzymes (PHDs) and this enables association 
and recognition of HIF-1α by the VHL protein (Figure 15B) (326-330). VHL is a 
component of an E3 ligase complex that includes ECV (elongins, Cul2, VHL) and 
RBX and this association results in proteasome-dependent degradation of HIF-1α 
(326-330).  However, when VHL is mutated and cannot recognize HIF-1α even 
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under normoxic conditions, this results in hyper-angiogenesis and increased 
carcinogenesis (326-330). 
HIF-1 and MITF 
 
 
Another protein called MITF (microphthalmia associated transcription 
factor) is bound by a SUMO (small ubiquitin like modifier) molecule, which has low 
affinity for HIF-1α (331).  Under hypoxic conditions, MITF promotes association of 
Figure 16:  The role of MITF on HIF-1α stability. A) Under hypoxic conditions, MITF promotes association of HIF-
1α with ARNT and the histone acetyl transferase (HAT) enzyme p300 after the reversible de-sumoylation of HIF-
1α by SENP1 (Sentrin specific protease 1).   B) Mutations of MITF also enhances carcinogenesis MITF also 
induces expression of the drug pumping protein ABCB5 (an ATP binding cassette protein drug that is implicated 
in chemotherapeutic resistance in melanoma and RCC), TRIM63 (an E3 ligase that is implicated in increased 
malignancy in RCC and breast cancer) and GADD45G (Growth Arrest and DNA Damage γ), which is important in 
DNA damage repair. 
 
A B 
Reprinted with permission from: Ohh M., Nature Medicine 2012;18:30–31 (331)  
  
71 
 
HIF-1α with ARNT and the histone acetyl transferase (HAT) enzyme p300 after 
the reversible de-sumoylation of HIF-1α by SENP1 (Sentrin specific protease 1) 
(Figure 16A) (331). Mutations of MITF also enhance carcinogenesis, for example 
a mutation of MITF that frequently occurs in RCC and melanoma is E318K, and 
this inhibits conjugation of SUMO to MITF, resulting in activation of HIF-1α and 
induction of angiogenesis, aerobic glycolysis, cell growth and metastasis (Figure 
16B) (331).  MITF also induces expression of the drug pumping protein ABCB5 
(an ATP binding cassette protein drug that is implicated in chemotherapeutic 
resistance in melanoma and RCC), TRIM63, an E3 ligase that is implicated in 
increased malignancy in RCC and breast cancer and GADD45G (Growth Arrest 
and DNA Damage γ), which is important in DNA damage repair (331). 
VEGF and NFκB are potent transcriptional activators of HIF-1α along with 
Stat3.  HIF-1α is also heavily regulated at the post transcriptional and 
posttranslational level.  RNA binding proteins such as PTB (polypyrimidine tract 
binding protein 1) and HuR (human antigen R) bind and stabilize HIF-1α mRNA 
(332,333).  HIF-1α is also regulated by miRNAs (micro RNAs) which are a class 
of non-coding small (~22nt long) RNAs that regulate mRNA stability by either 
inhibiting translation or promoting degradation by binding to the 3’UTR of a 
targeted mRNA (334).  MiRNAs can repress or stabilize HIF-1α transcript by either 
directly binding to its transcript or by repressing expression of HIF-1α repressors 
(334). The miRNA machinery reported to repress HIF-1α mRNA include miR-
519c, miR-107, miR-155, miR-20b, and miR-199, miR-17-92 (335-340).  Some 
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miRs including miR-424 and miR-210 target negative regulators of HIF-1, Cul2 
and GPD1L respectively (341,342).  HIF-1α also has IRES (internal ribosomal 
entry sites) and is sensitive to calcium signaling (by activation of calcineurin and 
RACK1) which increase stability of HIF-1α (343).  Along with PHDs and VHL, HIF-
1α is degraded by proteins OS-9 (osteosarcoma amplified 9) which promotes its 
proteasome-dependent degradation, and the protein SSAT2 
(spermidine/spermine N1-acetyltransferase 2), which stabilizes the interaction of 
HIF-1α and the E3 ubiquitin ligase complex (344,345).  SSAT can do this both in 
an oxygen dependent and independent manner (344).  Ubiquitination and 
sumoylation also plays a role in the stability of HIF-1α; sumoylation (catalyzed by 
RSUME), and de-sumoylation (SENP1, and the enzyme VDU2 de-ubiquitinating 
HIF-1α) all have stabilizing effects on HIF-1α during hypoxia and the proteins 
GSK3β and the transcription factor FOXO4 also promote degradation of HIF-1α 
(346-348). 
HIF-1 regulation 
During hypoxia in a cancer cell, HIF-1α regulates expression of VEGF and 
also enthryopoietin, which are both powerful drivers of not only angiogenesis but 
also erythropoiesis, and thus increases blood delivery to cancer cells (326,327).  
HIF-1α also upregulates the transcription of genes involved in cell proliferation 
and migration, as well as those involved in glucose and iron metabolism and these 
include hexokinase2, glucose transporter GLUT1, monocarboxylate transporter 4 
(MCT4), and REDD1 (a negative feedback loop protein that inhibits mTOR by 
73 
 
stimulating TSC1/2) and BNIP3 (326,327,334-340).    Thus, VEGF and HIF-1α 
represent attractive cancer therapeutic targets for inhibiting tumor angiogenesis 
at the primary site and also for cancer cell metastasis at distal sites.   
 
Activating invasion and metastasis 
 
 
The most definitive feature of a malignant tumor is the ability to separate 
from the primary tumor, migrate, invade the surrounding tissue, and metastasize 
Figure 17: Steps of metastasis.  Cancer cells that have sustained unregulated cell proliferation grow within 
an encapsulated barrier formin a carcinoma in situ.  As a tumor acquires a malignant phenotype it 
undergoes EMT and overexpresses proteases such as MMPs, which degrade the basement membrane.  
These cells then invade the ECM and intravasate into blood vessels and spread to lymphatic tissue and 
distal organs.  These cells then undergo MET and form metastatic lesions. 
 
Reprinted with permission from: Steeg PS, Nat Rev Cancer 2003 Jan;3(1):55-
63. (349)
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to distal sites.  Cells can be anaplastic or dysplastic or have all the above 
capabilities, but still be a benign tumor or a ductal carcinoma in situ (DCIS) and 
never become malignant until they acquire the ability to migrate invade and 
metastasize (Figure 17) (349).  Metastasis is the cause of 90% of cancer mortality 
and acquisition of this characteristic can occur early and it is estimated that 60-
70% of cancer patients have overt metastases at diagnosis (51,349,350).  
Malignant cancer cells undergo EMT and begin to invade by invading the 
surrounding tissues, degrading extracellular matrix by upregulation expression of 
MMPs, invade lymph nodes, and transcoelomically spread (55,349,350).  Tumor 
cells will invade the lymphatic networks and intravastate blood vessels in order to 
disseminate to distal tissues and colonize, and form metastatic lesions.  
Angiogenesis enables cancer cells to disseminate in blood circulation and some 
tumor cells accomplish this by secreting VEGF-C and VEGF-D, which bind to 
VEGFR3, induce lymphangiogenesis, and enhance metastasis (315,316,351).  
Metastasis to the lymph nodes is physiologically distinct than the type observed 
by homeostatic chemokines CXCL12-CXCR4), which challenges the common 
perception that cancer cells must first metastasize to the lymph nodes then to 
distant organs, as the homeostatic axis relies on the “seed and soil” hypothesis 
mentioned earlier (352,353).   Invasion and metastasis use many of the same 
gene expression cassettes to increase cell motility and cell migration.   
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Cadherins, β-catenin, and EMT 
 
 
 
The paramount phenotypic change in metastatic cancer cell is the loss of 
polarity and the loss of cellular and basement membrane attachment and this 
involves E-cadherin (Figure 18) (354).  E-cadherin is a calcium dependent 
adhesion molecule that forms vast networks that span the cell membrane and 
interact with extracellular domains of other e-cadherin molecules from adjacent 
cells.   Intracellularly, the E-cadherin networks are stabilized by vinculins and α-
Figure 18: Steps of EMT.  EMT is a critical process cancer cells must undergo in order to become 
metastatic and colonize distal organs.  This involves not only changes in morphology (fibroblast 
morphology, loss of apical to basal polarity, formation of invasipodia, and loss of cell to cell adhesion) 
but also decreased expression of epithelial markers (such as E-cadherin, occluding, and ZO-1) and 
upregulation of mesenchymal markers (N-cadherin, vimentin, T-cadhein, collagen 1.  The transcription 
factor β-catenin also becomes unbound from the membrane with E-cadherins and translocates to the 
nucleus to transcribe EMT associated genes such as slug and snail. 
 
Reprinted with permission from: Lamouille S., Xu J., Derynck R., u Nature Reviews Molecular Cell 
Biology Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96. (354) 
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actinin, and bind to p120-catenin (δ-catenin), plakoglobin (γ-catenin), β-catenin, 
and α-catenin (indirectly through plakoglobin and β-catenin) (354,355).  E-
cadherin is a natural repressor of migration and invasion and cancer cells must 
inhibit its expression in order to become invasive (354).  This is accomplished by 
upregulating expression of EMT transcription factors, such as Snail, Slug, ZEB, 
and Twist family members, which directly repress expression of E-cadherin and 
induce expression of mesenchymal proteins N-cadherin and vimentin (354,355).  
Cells also lose expression of cytokeratin and Zonula occludins (ZO) molecules 
and upregulate expression smooth muscle actin α (ACTA2), fibroblast specific 
protein (FSP1), Type 1 collagen, and fibronectin (354-356).   Mutations of E-
cadherin are quite rare in many cancers but it is present in 50% of all breast 
cancers.   The cytosolic location of β-catenin is also changed in a metastatic cell 
as it translocates to the nucleus and upregulates expression of pro-survival genes 
(including c-Myc, cyclinD1, ASCL2, ITF-2B, and pluripotency genes oct4, sox2, 
and nanog).  
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Dissociation of β-catenin from the adherens junction network promotes cell 
motility and loss of cellular attachments (357).  Free cytosolic β-catenin is also 
tightly regulated in the cytosol and it is a potent activator of Wnt signaling and this 
is particularily important in colorectal and prostate cancers (357).  In the absence 
of ligand, APC (adenomatosis polyposis coli), Axin, GSK3β, and CK1α sequester 
Figure 19: β-catenin subcellular localization and it stability.  The Wnt signaling pathway is a major mediator 
of β-catenin transcriptional activity and its stability.  In resting conditions, β-catenin is complexed with APC, 
Axin, and kinases GSK3-β (glycogen synthase kinase 3β) and CK1α (casein kinase 1), with the latter two 
phosphorylating β-catenin at S33 and S37 respectively.  This enables β-catenin to be recognized by βTrCP, 
and ubiquitinated for proteasome-depednet degradation.  In epithelial cells β-catenin is also associated at 
adherens junctions with E-cadherin.  Upon stimulation by Wnt, β-catenin dissociates from the complex and 
translocates to the nucleus to serve as a transcription factor for TCF-dependent genes. 
 
Reprinted with permission from: Valenta T., Hausmann G., Basler K., EMBO J 2012 Jun 13;31(12):2714-
36. (357) 
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β-catenin in the cytosol, where it is hyperphosphorylated and subsequently 
ubiquitinated by β-TrCP (which contains BRTC and SKP1-CUL1-F-box) and then 
degraded by the proteasome (Figure 19) (357,358).   However, when Wnt binds 
to Wnt receptor LRP-5/6 and frizzled, the phosphoprotein disheveled (dsh) is 
activated and it disrupts the destruction complex as CK1α (casein kinase 1α) 
phosphorylates the cytoplasmic tail of LRP-5/6 which promotes Axin binding 
(357,358).    This permits β-catenin to accumulate in the nucleus and subsequently 
induce a cellular response (EMT like responses and invasion) by interacting with 
other transcription factors TCF/LEF (T-cell factor/lymphoid enhancing factor) 
(359).  Mutations in β-catenin are common in prostate and colorectal cancers but 
rarer in other kinds of cancers.   
EMT transcription factors such as ZEB, snail, and slug are also important 
for wound healing and embryological morphogenesis (354,355).  There are three 
distinct forms of EMT, the first two being embryological development, and wound 
healing respectively, with the third type being related to malignant cancer 
(354,355).  EMT can be transiently or stably activated in both epithelial and non-
epithelial tumor types, promoting an invasive and metastatic phenotype in these 
tumors (354,355).  This is accompanied by a loss of cell polarity (which is 
accompanied by loss to attachment of the basement membrane by 
hemidesmosomes), loss of zonula and adherens junction and desmosomes, 
increased motility, increased expression of matrix degrading enzymes such as 
MMPs, and acquisition of a fibroblastic or amoeboid morphology (354,355).   
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Blood vessel intravasation and mesenchymal to epithelial transition 
 
 
Tumor cells also stimulate stromal cells such as mesenchymal stem cells 
(MSCs) and tumor associated macrophages, which foster the malignant behavior 
in these cancer cells by being a garrison for growth promoting factors and 
chemokines such as CCL5, IL-8, and MMPs (Figure 20) (360).  Another feature 
of EMT in tumors is that this process is reversible and this is critical for establishing 
metastatic sites (360).  Cancer cells must revert to their epithelial type by 
undergoing mesenchymal to epithelial transition (MET) (354,355,360).  The 
Figure 20: Blood vessel intravasation and MET. Model highlighting the key morphological and biological 
features of cancer cell invasion and metastasis.  A benign tumor progressesto a malignant state and then 
becomes invasive.  This is accompanied by expression of matrix metalloproteinases, ADAMs, and undergoin 
EMT.  The cells then migrate and intravaste blood vessels to become part of systemic circulation.  The cancer 
cells then extravasate the blood vessels into a distal tissue and then undergo MET (mesenchymal to epithelial 
transition) and form micrometastases and colonize distal tissues. 
 
Reprinted with permission from: Reymond N., d'Água BB, Ridley AJ, Nat Rev Cancer. 2013 Dec;13(12):858-
70. (360)  
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process of metastasis is very inefficient and cancer cells must adapt to harsh 
conditions and selective pressures in order to become an established metastatic 
lesion (361).  Indeed, it is estimated that millions of tumor cells enter the circulation 
daily and less than 0.01% of these circulating tumor cells successfully extravasate 
a distal tissue and initiate metastasis (361).  An ostensible impediment is that most 
cancer cells from a primary tumor poorly adapt to a foreign environment without 
the support of the stroma.  This is apparent by the prevalence of dormant 
micrometastases that never overcome the initial hurdle to become macroscopic 
secondary tumors (51,354,361).  Some primary tumors also release angiogenic 
inhibitors such as angiostatin and endostatin that suppress growth of metastatic 
lesions, which underscores the competitive and selective nature of metastasis and 
only a small fraction from a heterogeneous neoplastic population are selected to 
form secondary tumors (51,354,361).  However, depending on the origin of the 
primary tumor cells the secondary tissue site can be hospitable to the newly 
colonizing cells.  As stated earlier, colorectal cells preferentially metastasize to 
liver and lung.  In breast cancer, metastasis is observed in bones and lung, in 
malignant melanoma the brain, and in stomach cancer the ovaries (i.e. krukenberg 
tumor) (51-53,360,361).  This non-random organotropism of cancer metastasis is 
explained by Paget’s “seed and soil” theory as mentioned above (362).  This 
theory was not met uncontested since Ewing proposed that mechanical forces like 
blood flow and the diameter of blood vessels, and blood flow between the primary 
tumor and putative metastatic sites dictated the specificity of the metastatic site 
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(362,363).  For example, the lung is a favorable milieu for a metastasis due to its 
dense vascular surface area, whereas the liver attracts colorectal tumor cells due 
to the mesenteric circulation pattern.  Ewing’s hypothesis was dominant for over 
50 years until it was disproven by molecular evidence within the past 30 years 
(362,363).  Metastasis is regulated by communication between the seeding tumor 
cells and the tumor microenvironment that will sow and harvest that tumor cell into 
a metastasis (362,363).  For example, breast cancer cells express chemokine 
receptor CXCR4 and metastasize to bone marrow, which express its cognate 
ligand CXCL12 (364).  Colorectal cancer, exhibits high expression of TGF-α and 
metastases to the liver which express the EGFR (365).  Moreover, some of these 
molecular determinants are chemokines, which navigate cancer cell chemotaxis 
like the CXCL12-CXCR4 axis (364).  These chemokines are constitutively 
expressed in specific tissues and therefore called homeostatic chemokines.  The 
process of metastasis is very selective, complex and depends on an orchestration 
of multiple molecular components from the tumor microenvironment, the primary 
tumor, and the parenchyma itself and the molecular interplays of metastasis are 
still not consummately understood and are still being rigorously investigated. 
The extracellular matrix (ECM) and integrins 
Not all tumor cells undergo these EMT changes simultaneously and it is usually 
only observed in cells residing at the invasive front of the tumor that are adjacent 
to the ECM (51,52,366).  This suggests that the ECM plays a pivotal role in 
triggering these physiological and morphological changes associated with 
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invasiveness and motility.  The extracellular matrix (ECM) and the intracellular 
milieu are mutually dependent on one another and can send signals to change 
the shape, arrangement, chemical makeup, and the dynamics of the environment 
(Figure 21) (51,52).  The extracellular matrix includes the interstitial matrix and 
the basement membrane, which is composed of type IV collagen, entactin, 
nidogen, and fibronectin, and vitronectin (51,52).  The interstitial matrix is rich in 
fibrillary  
 
Figure 21: The extracellular matrix. The complex and integrative network of proteins called the extracellular 
matrix (ECM).  The ECM interacts with surface membrane proteins which include integrins, syndecans, 
glypicans, and collagen.  These surface membrane proteins serve as conduits which mediate “inside-out” 
and “outside-in” communication, meaning the intracellular and extracellular environment respond to simuli 
from the opposite side.  THE ECM is a diverse network of glycoproteins, proteoglycans, hyaluronic acid, 
perlecans, vitronectin, fibronectin, FACIT (Fibril Associated Collagens with Interrupted Triple helices) 
collagens (which include collagen type, IX, XII, XIV, XIX, and XXI, fibrallar collagen. 
 
Reprinted with permission from: Lau LW, Cua R., Keough MB, Haylock-Jacobs S., Yong VW,  Nat Rev 
Neurosci. 2013 Oct;14(10):722-9.  
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collagens (Type I, II, III, V, XI), tenasin C, highly charged, hydrated fibronectin 
(heparin sulfate and syndecans) Normal epithelial cells are attached to the 
basement membrane through hemidesmosomes and the ECM provides growth 
factors and growth signals from the outside (51,52,366).  The ECM is very 
dynamic and can have varying degrees of elasticity and stiffness, which correlate 
with the tumorigenic propensity of a transformed cell.  One of the factors that 
contributes to ECM stiffening is the enzyme lysyl oxidase (LOX) (367).  This 
enzyme induces crosslink within collagen fibers, which leads to increased ECM 
stiffening.  When the ECM stiffens, this mechanosignaling is transduced to the 
cell, which becomes more rigid and forms cortical actin tension fibers (366).  
Proteins known as integrins sense these mechanical signals and integrins form 
heterodimers on the cell surface and can communicate with the ECM by binding 
to specific components of the ECM.  Specifically, α5β1 integrin heterodimers bind 
to fibronectin at the FnIII 9-10 which contain the RGD motif recognized by β1 
integrin (366,368).  β1-Integrin and its role in tumorigenesis, migration, and 
malignancy is ostensible and well documented (368,369). β1-Integrin has multiple 
binding partners of the α-integrin family, which include 18 members and the β 
family contains eight isoforms. β and α chains form heterodimers with 24 different 
heterodimers that can form and promote focal adhesion complexes (FACs) (369). 
Along with fibronectin, the proteins type 1 collagen (binds to α2β1 integrin) 
vitronectin (binds αvβ3) and laminin (α6β4) are physiologically relevant, in 
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pancreatic, lung, colorectal, breast cancers, as well as temozolomide refractory 
glioblastoma multiforme (GBM) (type 1 collagen receptor and fibronectin receptor) 
(370-373). Different heterodimer combinations recognize different components of 
the ECM.  α1β5 heterodimers recognize a specific region within fibronectin 
domain Fn III that contains the RGD (arginine, glycine, aspartate motif), whereas 
the αVβ3 heterodimer recognizes vitronectin and vitronectin recognizes αVβ3 via 
its somatomedin domain (368,369,370-373).  Association of these heterodimers 
with the ECM promotes the formation of focal adhesions. β1-Integrin is an integral 
component of conveys signals between the ECM and the intracellular milieu (369). 
Specifically, β1-integrin can recruit focal adhesion kinase (FAK) which can 
autophosphorylate and cause recruitment of Src and Src kinase family members 
as well as p130cas (which is a substrate for Src (369-373).  Src can phosphorylate 
FAK and further recruit other protein and actin-associated proteins such as 
vinculin and talin. Upon β1-Integrin heterodimerization and binding to the ECM 
(i.e. fibronectin), there is association of Integrin binding proteins such as paxillin, 
which enables recruitment of the focal adhesion kinase (FAK) (369-373). 
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Focal adhesion complexes and cytoskeletal activation 
 
 
Upon association of FAK, FAK becomes autophosphorylated at tyrosine 
residue 397.  FAK contains two domains: A N-terminal FERM domain (4.1 protein, 
ezrin, radixin, moesin domain, which enables association with actin and actin 
binding proteins as well as actin like proteins) which serves as an auto inhibitory 
domain and a C-terminal kinase and FAT (focal adhesion targeting) domain 
Reprinted with permission from: Hannigan G., Troussard AA, Dedhar S., Nat Rev Cancer 2005 
Jan;5(1):51-63. (369)  
Figure 22: Focal adhesion complexes (FAC).  Integrins are in the inactive state until stimulation by binding to 
extracellular components (such as fibronectin and vitronectin). Upon ligand activation Paxillon binds to 
integrin cytoplasmic tails and recruits FAK (focal adhesion kinase).  FAK autophosphorylates at Y397 and this 
promotes binding of Src kinases (such as src, fyn, yes).  Talin and vinculin also bind to paxillin and promotes 
association of β-actin and formation of stress fibers.  Integrin-linked kinase (ILK) can also bind to the 
cytoplasmic tails of integrin and promote Parvin and PINCH.  These also activate PI3K/Akt and Ras pathways 
and promote cell proliferation and actin stress fiber promotion through PKC activated Rac, RhoA, and cdc42. 
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(Figure 22) (369-373).  These two regions are joined together by a flexible linker 
region that enables the FERM domain to inhibit the kinase domain of FAK by 
binding to it (369-373).  Autophosphorylation of FAK enables Src kinase to 
associate with FAK through its SH2 domain and phosphorylate FAK on other sites 
(369-373).  This opens up other docking sites for proteins that contain SH2 (which 
recognizes phosphotyrosine residues) and SH3 (which recognizes proline rich 
regions) domains within FAK, including Src substrate p130cas (which promotes 
migration and contains an SH3 domain) ZAP70, SOC3 (369-373).  FAK interacts 
with Talin and vinculin through its FERM domain and the resulting complex 
associates with actin to promote formation of actin stress fibers (369-373).   
TGF-β signaling and metastasis 
Tumor cell malignancy and invasion also go hand in hand with a 
physiological phenomenon known as epithelial to mesenchymal transition EMT 
(374).  A powerful driver of EMT is TGF- β (transforming growth factor β).  This 
includes induction of mesenchymal transcription factors (ZEB, Snail, Slug, Twist) 
that upregulate changes in cell-to cell contacts through differential expression of 
cadherins (i.e. decreased E-cadherin and increased N-cadherin (374,375).  In 
early stage cancer, TGF- β is a tumor suppressor and inhibits cancer cell growth 
and promotion through canonical TGF- β signaling pathways.  TGFβRII binds to 
TGFβRI, phosphorylates the GS loop, which activates its kinase activity 
(375,376).  Through association with SARA (SMAD anchor for receptor activation) 
phosphorylates Smads 2, 3, which associate with Smad 4, translocate into the 
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nucleus and induce transcription of tumor suppressor genes.  However, in later 
stage cancer, TGF- β signaling becomes aberrant, and can signal through non-
canonical TGF- β pathways.  TGF- β has also been shown to induce migration in 
late stage breast cancer cells (375,376).  It has been demonstrated that TGF- β 
can induce formation of a destructive complex that promote ubiquitination and 
proteasome-dependent degradation of inhibitory Smad 7.  Smad 7 inhibits TGF- 
β signaling by promotion the endocytic recycling of TGF- β. 
  All isoforms of TGF- β are dimers that are excreted and are associated 
with a protein called latency-associated peptide (LAP), which constitutes the small 
latent complex (SLC) (374,377,378).   This complex remains in the cell until it is 
bound by another protein called Latent TGF-β-Binding Protein (LTBP), forming a 
larger complex called Large Latent Complex (LLC). LLC is secreted to the ECM 
(377,378).  The LAP contains an RGD motif that is recognized by α5β1 
heterodimers that are a part of the focal adhesion complex that was described 
above (378,379).  Upon cell stiffening and actin stress fiber formation, the integrin 
complex pulls on the LAP, and through this mechanic opening of the LAP TGF-β 
is released (380).  There is an ostensible interplay and connection between 
ECM/cell stiffening and aberrant TGF- β signaling and their roles in promoting 
tumor malignancy, which emphasizes the therapeutic potential of drugs that target 
TGF- β (380,381).  The role of TGFβ in the research described in this thesis will 
be described later. β1-Integrin can also directly stimulate TGF- β signaling through 
the LAP as described above. β1-Integrin is a very promising drug target but it is 
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very hard to target due to compensatory mechanisms (i.e. β3-Integrin expression 
and so-called integrin switching in breast cancer) as well as other compensatory 
mechanisms (382).   
 
Genomic instability 
Epigenetic regulation 
 
Genomic instability refers to loss of DNA integrity, chromosomal 
aberrations (deletions, translocations, and insertions), epigenetic and genetic 
Figure 23:  Epigenetic regulation changes that occur in cancer cells.  This involves epigenetic upregulation of 
oncogenes and epigenetic silencing of tumor suppressor genes (such as CTBP1, p53, SMAD3, and TGFβRII).  
This is accomplished by direct DNA methylation, nucleosome postioning, histone acetylation (methylation, 
acetylation, and phosphorylation) on the same gene (in cis) or different genetic loci (in trans).   
 
Reprinted with permission from: Portela A., Esteller M., Nat Biotechnol. 2010 Oct;28(10):1057-68. (383) 
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aberrations, high mutations rates, unsustainable single nucleotide 
polymorphisms, and any other accumulative damage that impairs genomic 
integrity (383-385).  These can include mutation in the primary nucleic acid 
sequence itself, in the machinery that regulates its expression (DNA methyl 
transferases (DNMT), histone acetyl transferases (HATs), histone deacetylases 
(HDAC)) (Figure 24), chromosomal instability (i.e. Philadelphia chromosome 
observed in CML), microsatellite instability, transposon instability, and mutations 
observed from metabolic stress (8-oxo-guanine) (386-390).  Along with 
carcinogenesis, genomic instability is associated with diseases such as 
amyotrophic lateral sclerosis (AML or Lou Gherrig’s Disease) and myotonic 
dystrophy.  DNA damage is a factor that often leads to genomic instability and 
there are DNA repair mechanisms that handle DNA damage depending on the 
type and degree (386-390).  MMR or mismatch repair deals with very large bulky 
lesions and removes large amounts of DNA.  Smaller bulky adducts are removed 
by Nucleotide Excision Repair machinery (NER) (386-391).  Smaller aberrations, 
especially apurinic and apyrimidinic lesion, are ameliorated by base excision 
repair (BER) (388-391).  Some lesions cause DNA crosslinks and are so extensive 
that these repair mechanisms cannot remove the damage.  As observed in 
prokaryotes, eukaryotes, including humans, have error prone DNA polymerases 
(i.e. DNA polymerase ζ and DNA polymerase η) which can bypass the DNA 
damage (392).  Many lesions occur in noncoding regions and in some cases this 
bypass solves the issue and the mutations are silent, or ones that do not have any 
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genomic or phenotypic consequences.  Other mechanisms, such as observed 
with DNA double strand breaks can be repaired by homologous recombination 
(i.e. recombinase Rad51) or by non-homologous end joining (NHEJ i.e. holiday 
junctions) (392,393).  Not only can mutations occur directly within the DNA 
sequence but also epigenetic mutations can arise.  Epigenetic regulation refers to 
any kind of change in DNA gene expression, regulation, or status that is 
independent of the primary sequence.  These can include covalent changes to 
the DNA (.e. methylation of DNA promoters at CpG islands by DNMTs), changes 
in transcriptional accessibility (HATs (i.e. p300/CBP), HMTs (i.e. EZH), and 
HDACs (i.e. HDAC1, 6), or regulatory non-coding RNAs (i.e. lncRNAs) 
(383,384,394).  Endogenous DNA damage by metabolic and oxidative stress is a 
commonly encountered by cancer cells and many transformed cells bypass this 
issue by having reduced expression of DNA checkpoint enzymes (i.e. CHK 1,2), 
enhanced DNA repair machinery or translesional bypass enzymes, or 
upregulation of redox enzymes (i.e. glutathione S transferases (GSTs)) 
(188,189,395,396).   
DNA repair mechanisms and genomic instability: NER, BER, and   
MMR 
Exposure to carcinogens does not directly result in cancer as most DNA 
damage is efficiently repaired by DNA repair systems, which can induce cell cycle 
arrest (189,383,386).  DNA damage is efficiently repaired by DNA repair systems, 
such as nucleotide excision repair (NER), mismatch repair (MMR), and base 
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excision repair (BER) (Figure 25) (386-393).  The former two systems deal with 
repairing DNA adducts. NER deals with smaller bulky lesions on DNA and uses 
enzymes such as excision repair cross-complementation group (ERCC 1, 4) 
Cockayne syndrome type A (CSA, ERCC6), Cockayne syndrome type B 
(CSB,ERCC8) and DNA repair protein Xeroderma Pigmentosum complementing 
(XPA, XPB, XPC, XPD, XPE, XPF, and XPG), which remove the lesion and 
through DNA polymeraseβ resynthesize the excised DNA (397-400).   
 
 
Figure 24: DNA repair pathways.  Among these are Mismatch repair (MMR), Base excision repair (BER), and 
nucleotide excision repair (NER).  MMR repairs extensive bulky regions and resynthesizes large pieces of 
DNA.  The BER pathway involves removal of purines and pyrimidines, generating apurinic/apyrimidinic by 
uridine glycosylases (OGG1 and UNG).  These pathches are then resynthesized by short patch and long patch 
BER.  NER deals with smaller bulky lesions on DNA and uses enzymes such as excision repair cross-
complementation group (ERCC 1, 4) Cockayne syndrome type A (CSA, ERCC6), Cockayne syndrome type B 
(CSB,ERCC8) and DNA repair protein Xeroderma Pigmentosum complementing (XPA, XPB, XPC, XPD, XPE, 
XPF, and XPG), which remove the lesion and through DNA polymeraseβ resynthesize the excised DNA.  Other 
pathways include translesion synthesis (with DNA polymerase η and ζ).  Direct repair in is observed in bacteria 
such as E. coli. 
 
Reprinted with permission from: Davidsen T., Tønjum T., Nat Rev Microbiol 2006 Jan;4(1):11-22. (387) 
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Mutations in XP gene family members are related to the disease xeroderma 
pigmentosum (XP) whereas mutations in CSA and CSB are linked to Cockayne 
syndrome (399-401). XP is an autosomal recessive genetic disorder in which 
individuals are very sensitive to UV light from sunlight and are susceptible to basal 
cell carcinomas.  Cockayne syndrome is a fatal autosomal recessive linked 
disorder, where individuals are very sensitive to sunlight, exhibit growth 
retardation, neurodegenerative disorders, eye disorders, and premature aging. 
Squamous cell carcinoma, melanoma, and other skin related malignancies 
(401,402). BER removes less bulky non helix-distorting lesions which result in 
generation of apurinic or apyrimidinic (AP) sites (Figure 25) (387,403).  These 
sites are generated by DNA glycosylases such as 8-Oxoguanine glycosylase 
(Ogg1), 3-methyladenine glycosylase (Mag1) and Uracil-DNA glycosylase (UNG) 
(403).  The resulting AP sites are removed my AP endonucleases (403,404).  The 
resulting 5’ and 3’ ends are then processed by the end processing enzyme 
polynucleotide kinase phosphatase (PNKP) and DNA is synthesized by DNA 
polymerase β (DNA pol β) during short patch BER and DNA polymerase δ and 
polymerase ε during long stretch BER (403,404).  The resulting 5’ flap that is 
generated in long stretch BER is then removed by the flap endonuclease (FEN1) 
and the resulting nick is ligated by DNA ligase III and X-ray repair cross-
complementing protein (XRCC1) (405).  Mutations associated with cancer are 
less characterized in the BER pathway but include silencing of methyl-CpG-
binding domain protein 4 (MBD4) and Endonuclease VIII-like 1 (NEIL1) (406-409).  
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MBD4 recognized and binds methylated CpG islands and is important in 
preventing transition mutations (406,407)).  Specifically 5-methylcytosine can 
spontaneously deaminate and become thymine, which produce G:U and G:T base 
pairs.  This leads from a G:C to an A:T transition, which is a common mutation 
found in 50% of p53 mutations of the tumor suppressor p53 (406,407).  NEIL1 
recognizes ROS-induced oxidized pyrimidines, formamidopyrimidines, and 
methoxy-thymine and thymine glycol stereoisomers.  Hypermethylation and 
therefore epigenetic silencing of the NEIL1 promoter was found in 71% of HNSCC 
tumors and 42% of non-small cell lung cancer (NSCLC) (408).  Hypermethylation 
is also exhibited in gastric and colorectal cancers and mutations in mutY DNA 
glycosylase homolog (MUTYH) (409).  The gene XRCC is a rare case in which 
the gene is overexpressed in NSCLC and within the metastatic lymph nodes of 
these individuals (410). 
   Bulkier lesions require the MMR system and use the enzymes human 
MutL homolog 1 (hMlh1) and two (human postmeiotic segregation increased 1and 
2 (hPms1and 2)), and human MutS homolog 2/6/3 (hMsh2/6/3), exonuclease 1 
(Exo1), replication protein A (RPA), (proliferating cell nuclear antigen) PCNA, 
replication factor C (RFC) and DNA polymerase δ (Figure 25) (411,412).  
Mismatch implies that there is a non-Watson-Crick base pair present within the 
DNA (i.e. either not A:T nor G:C).   Msh2 forms a heterodimer with Msh3 or 6 (to 
form hMutSα or hMutSβ respectively) and hMlh1 heterodimerizes with hMlh3, 
HPms1, or hPms2 (forming hMlhα, hMlhβ, and hMlhγ respectively) (411-413).  
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HMutS is an ATPase critical for MMR recognition of mismatches and lesions 
within DNA, hMlh is required for termination of mismatch excision, and its 
endonuclease activity requires RFC (411-413).  EXO1 is an exonuclease that is 
involved in excision of DNA which is repaired by DNA polymerase δ and the 
eukaryotic version of the prokaryotic processivity β-clamp PCNA (411-413).  This 
molecule aids in DNA polymerase attachment to the DNA and enhances its 
processivity (number of nucleotides per initiation event before the polymerase 
dissociates from the DNA) (411-413).   Defects in the MMR pathway have been 
linked to cancer such as through microsatellite instability (414).  For example, the 
genes MSH2 and MLH1 are associated with the majority of hereditary 
nonpolyposis colorectal cancer (HNPCC, i.e. Muir-Torre Syndrome) (415,416).  
The MMR related syndrome Turcot syndrome, associates familial adenomatous 
polyposis (FAP) with brain tumors (417).  Epigenetic defects (i.e. promoter 
hypermethylation) in MSH2, MSH6, PMS2, and MLH1 are associated with cancer, 
with over 90% of these mutations in the promoter region of MLH1 (414,418).  
MLH1 is mutated in 73% of esophageal and stomach cancers (foveolar type), 33% 
of HNSCC, 69% of NSCLC, and 10% of colorectal cancer (411,415,416).  
Mutations in MLH1 are most often associated with loss of other DNA repair genes 
(1.e MLH3, OGG1, XRCC3, XRCC5) (419-422). 
Cell cycle deregulation and cancer 
Genomic stability can also arise from losses or dismantling of cell cycle 
checkpoints (423-425).  The cell cycle is a very tightly regulated process that  
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contains several sentinels that assure specific cellular and molecular 
criteria are met before a cell can successfully progress to another stage of the cell 
cycle (Figure 26) (423-425).  The cell cycle is developed into three major phases: 
interphase, mitosis, and cytokinesis.  Interphase has three major phases, which 
can be divided into G1, S, and G2/M (423-425).  There are cellular checkpoints 
that are installed between each border of these phases and certain criteria must 
be met in a normal cell in order to gain entry into the next phase of the cell cycle.  
In cancer cells these checkpoints are lost or dismantled, resulting in controlled cell 
Figure 25:  The cell cycle and cancer.  The cell cycle is composed of interphase and mitosis.  Interphase is 
composed of G1, S, G2, phases of cell cycle and mitosis id composed of the M phase.  At every phase of the 
cell cycle there are specific checkpoints which a cell must pass in order to go to the next phase of the cell 
cycle.   If the checkpoint is not passed then tumor suppressor proteins such as p16 and p27 inhibit 
progression of the cell cycle by disrupting cdk/cyclin complexes (such as cdk4/6 with cyclin D1).  Cancer cell 
will epigenetical suppress tumor suppressor proteins like p16 and p27. 
Reprinted with permission from: Asghar U., Witkiewicz AK, Turner NC, Knudsen ES, Nat Rev Drug Discov 2015 
Feb;14(2):130-46. (423) 
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cycle progression and initiation.  This is often associated with accumulated DNA 
damage and genomic instability (423-425).  G1 is the DNA replication preparatory 
stage, S phase involves DNA replication, and G2/M phase involves preparation 
into mitosis and is instigated by mitotic promoting factor (MPF) (424,425).   
Progression of the cell cycle is strictly regulated by proteins known as 
cyclins.  Originally discovered by Timothy Hunt (along with Paul Nurse and 
Leeland Hartwell), these proteins have cycles of expression to where they are 
induced and then subsequently degraded (423,426).  The cell cycle has gradual 
fluctuations in these cyclins, with an increase in one cyclin that is proceeded by 
waning expression of another cyclin.  Expression of cyclins flows as D, E, A and 
B cyclin respectively (426).  These cyclins are important for activation of cell cycle 
kinases that promote cell cycle progression known as cyclin dependent kinases 
(CDKs) (426).  They not only promote the cell cycle but also prevent precocious 
initiation of another cell cycle before the preceding cell cycle has been completed.  
CDKs are a family of serine/threonine protein kinases that are associated and 
activated at specific stages of the cell cycle (426).  By themselves, they have very 
low intrinsic catalytic activity and require association of their respective positive 
regulatory cyclin.  Whereas cyclin levels are ephemeral and have dynamic 
expression and stability, CDK expression is constant and stable (426,427).  Once 
a CDK is associated with a cyclin, it requires activation by a phosphorylation by 
the enzyme CAK (cdk activating protein).  Cells can initiate interphase and 
become quiescent, entering the so-called G0 phase and in certain cases stay 
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there indefinitely (423-425).  This is different from a senescent cell as unlike 
cellular senescence, quiescent cells can be stimulated by mitogenic signals and 
their replicative silence is reversible.  When these cells are stimulated by 
mitogens, CDK4 and CDK6 associate with D cyclins (cyclin D1, D2, and D3 and 
association of CDK4/6 with cyclin D is vital for progression through the G1 phase 
and is negatively regulated by Rb, p16, and p53/p21 signaling (423-427).   Rb the 
retinoblastoma protein and the first tumor suppressor characterized in the 
childhood cancer retinoblastoma is a negative regulator of the cell cycle and is a 
sentinel of the G1/S checkpoint (177,178,423-426).  Excessive DNA damage can 
lead to upregulation of p53, which can stimulate p21 and inhibit the cell cycle (188, 
427,428).  The cycle cycle can also be arrested by p16 and p14, with the former 
binding to CDK4/6 and inhibiting association with cyclin D.  With mitogenic stimuli, 
Rb is hyperphosphorylated, resulting in liberation of the transcription factor E2F, 
which induces expression of cyclin E and cyclin A (177,178,188,423-425).  The 
induction of these cyclins is associated with the subsequent activation of CDK 2 
and this promotes DNA replication.  After successful DNA replication, cyclin B is 
induced and this leads to activation of CDK1 and the entry into mitosis.  In G2 
phase, CDK1 is kept inactive until the end of G2 and entry into M phase by the 
inhibitory protein Wee1 kinase (423-426).  Wee1 phosphorylates T14 and Y15 of 
CDK1 and this is reversed by the cognate phosphatase CDC25, which stimulates 
CDK1 activity and entry into the M cycle (423-426).  The activation status of CDK 
is also negatively regulated by phosphorylation in the ATP binding pocket, which 
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is vital for providing the phosphate for phosphorylation because 
dephosphorylation of ATP is thermodynamically favorable and permits otherwise 
thermodynamically unfavorable phosphorylation reactions (426,427).  Specific 
residues within the DNA binding pocket can also be phosphorylated and this can 
be reversed by specific phosphatases.  Proteins known as cyclin dependent 
kinase inhibitors (CKI) include p16 and p14ARF as well as p15 p18, and p19 and 
these are mainly involved in G1/S regulation (187-190, 427,428).  This checkpoint 
has the highest level of regulatory involvement due to the fact this is a 
“commitment” checkpoint.  This means that as soon as a cell goes beyond this 
checkpoint it is committed to completing the cell cycle and if it fails to do so it will 
undergo apoptosis.  CDKs can also be regulated at the level of subcellular location 
since their nuclear import is critical to their function (429,430).  For example, the 
cdk1/cyclin B complex is sequestered in the cytosol to prevent premature 
phosphorylation events leading to entrance into mitosis (429).  Other proteins that 
are involved include the phosphatase cdc25, which is sequestered by 14-3-3 in 
the cytosol.  DNA replicative fidelity and proficiency are vital to prevent genetic 
instability (430).   
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Checkpoint kinases (CHK1 and CHK2), ATM, and ATR 
 
 
DNA damage can be detected resulting in activation of the kinases ATM 
and ATR, these can stimulate checkpoint kinase CHK1 and CHK2 (Figure 27) 
(187-189, 427,428,431).  CHK1 is one of the main components of the DNA 
damage checkpoint pathways and it preserves DNA integrity.  CHK1 is activated 
by ATM/ATR (at S317 and S345), activated CHK1 phosphorylates cdc25, and 
inactivates it (187-189, 431).   ATR also depends upon the action of claspin, 
BRCA1, and TOBP1. It has a dual role in this mode of phosphorylation at both the 
Figure 26: Checkpoint kinases. The cell cycle checkpoints are regulated by kinases known as checkpoint 
kinases..  Upon DNA damage, the kinases ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia 
Rad 3 related) phosphorylate checkpoint kinases (CHK) CHK 2 and 1 respectively.  CHK1 phosphorylates 
CDC25C phosphatase and inactivates it.  CDC25C reverses the phosphorylation of Wee1 kinase on cdc2 
(CDK1) on two phosphorylation sites T14 and Y15.  CHK2 phosphorylates p53 and activates p21.  This 
inactivataes CDK2 and promotes cell cell arrest, DNA repair, and apoptosis. 
 
Reprinted with permission from: Lapenna S., Giordano A., Nat Rev Drug Discov 2009 Jul;8(7):547-66. (427) 
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G1/S and the S phase checkpoints by phosphorylating CDC25A at the G1/S 
checkpoint and then CDC25A and CDC25C at S and G2/M checkpoints (187-189, 
431-433).  Phosphorylation of CDC25A leads to its proteasome-dependent 
degradation whereas phosphorylation of CDC25C at S216 leads to 14-3-3 
association and its cytoplasmic sequestration (187-189, 431-433).  DNA damage 
causes single strand breaks, which is bound by several units of RPA (replication 
protein A) which prevent its degradation by cellular exonucleases (387,390).   RPA 
recruits recombinase protein Rad17 and the ATR/ATRIP complex, which further 
activates CHK1 (391, 433,434).  ATM activates CHK2 and is recruited to double 
strand breaks by the MRN complex, which consists of Mre11, Rad50, and Nbs1.  
Along with assisting ATM mediated CHK2 activation it is involved in double strand 
break priming for homologous recombination and NHEJ (431-434).  CHK1 and 
wee kinase inhibitors have been considered as potential chemotherapeutic 
targets, as adjuvants in chemotherapies that contain DNA damaging agents such 
as doxorubicin, cyclophosphamide, and others.  For example, the pyeazolo-
pyrimidine compound MK-1775 has been used as an inhibitor of Wee1 and is in 
phase II clinical trials for ovarian cancer with combinatorial paclitaxel, carboplatin 
treatment (435).  The drug UCN 01 has been developed as a CHK1 inhibitor 
however has had limited success due to lack of efficacy, poor pharmacokinetics, 
and enzymatic promiscuity (436).   
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Maturation promoting factor (MPF) and anaphase promoting complex 
(APC) 
 
 
After successful completion of interphase, cells enter mitosis, which is 
promoted, by MPF or maturation promoting factor (Figure 27) (435-437).  Mitosis 
is the duplication of chromosomes and this duplication requires successful 
duplication that is followed by complete and successful segregation of 
chromosomes.  Mitosis is broken down into prophase, prometaphase, metaphase, 
Figure 27:  MPF and APC. The early stage of mitosis involves the kinase activity of mitotic promoting factor 
(MPF), which is a complex of CDK1 and cyclin B.  MPF is then phosphorylated at T161.  As the cell cycle 
progess towards metaphase and the chromosomes are aligned at the metaphase plate, anaphase promoting 
complex (APC) poly-ubiquitinates cyclin B and is then subsequently degraded via the proteasome. APC 
ubiquitinates securing and frees seperase, which is required for completing of anaphase.    APC is also 
regulated by MAD2 (mitotic arrest deficient 2), BUBR1 (BUB related protein 1), BUB3 (mitotic checkpoint 
protein BUB3), and EMI 1/2 (Emilin 1/2).  In late M phase, APC exchanges its activator CDC20 for CDH1, which 
is mediated by CDC14, a phosphatase.  Most of cell cycle cdc14 is sequestered in the nucleoulus and is freed 
by MEN (mitotic exchange network) and FEAR (fourteen early phase anaphase).  Once chromsomes 
arealigned at metaphase plate they are separted by active separase, and chromatids are pulled to opposite 
poles located at centrosomes by kinetochore microtubules. Aberrant APC leads to chromosomal instability 
in cancer 
 
 
Reprinted with permission from: Nakayama KI, Nakayama K., Nat Rev Cancer 2006 May;6(5):369-81. (437) 
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anaphase and telophase.  MPF promotes mitosis all the way up to metaphase 
where chromosomes that have been duplicated are aligned at the center of the 
metaphase plate (423-425, 430).  In order for successful segregation of the 
chromosomes MPF must be degraded and this is in part accomplished by a 
multisubunit protein complex known as the anaphase promoting complex (APC, 
cyclosome), and the other SCF (Skp1/CUL1/F-box protein) (437).  These are two 
E3-ligase complexes that promote entry of cells into anaphase by targeting MPF 
for proteasome-dependent degradation.  APC consists of 11 subunits that contain 
WD-40 containing adaptor proteins, cdc20, and Hct1 to recognize and bind to its 
substrates. There are also two different forms of APC: APCcdc20 and APCcdh1, with 
the latter being essential for exiting metaphase and the other form playing more 
of a role at G1/s transition. APC recognizes potential substrates by KEN box and 
destruction box motifs (RXXLXXXXN/D/E) (438).  APC also ubiquitinates cyclin B 
and securing, targeting them for proteasome-dependent degradation.  APC is 
tightly regulated and to prevent chromosomal instability and premature separation 
of chromosomes by negative regulation mediated by Mad2 and BubR1, which is 
part of the spindle assembly checkpoint (438,439).  When APC is activated it leads 
to dissociation of securin from seperase and its proteasome-dependent 
degradation (Figure 30) (438,439).  This is essential for separation of sister 
chromatids at the metaphase plate and completion of anaphase (423-430, 437-
439). 
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Microtubules and microtubule associated proteins (MAPs) and 
cancer 
When cells undergo mitosis, they have not only duplication of 
chromosomes but also microtubule organizers and mitotic spindle machinery, and 
complexes known as centrosomes are at the focal point of these structures (423-
425, 440).  Microtubules are one of the three main types of cytoskeleton proteins 
(the others being microfilaments and intermediate filaments, and the lesser-known 
septin proteins) (440,441).  Microtubules are approximately 25 nm in diameter and 
consist of 13 protofilaments that arrange into a hollow tube.  These protofilaments 
are composed of alternating αβ tubulin heterodimers.  They assemble through 
association with GTP, which promotes microtubule polymerization.  Hydrolysis of 
GTP leads to rapid depolymerization and this is a critical feature in regulation of 
microtubules through dynamic instability (440-442).   
In cells undergoing mitosis there are two centrosomes, each with pair of 
centrioles that are arranged orthogonally with respect to one another.  These 
contain a multitude of proteins that are important for centrosomal assembly and 
function.  Its activity is also dependent on the action of kinases, namely polo like 
kinases such as PLK-4, which is indispensable for centrosomal activity and its 
inactivation leads to cell cycle arrest at metaphase.  Centrosomes have 
microtubule organizing centers (MOCs), which have microtubules organizing and 
emanating from γ-tubulin ring complexes (γ-TURCs) (440-443).  These 
microtubules emanate and form astral microtubules and kineticore microtubules, 
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with the latter extending and making direct contacts with chromosomes at their 
kineticore structures.  Microtubules can move chromosomes through kinetochore 
structures to the metaphase plates and subsequently segregate them through 
anaphase (423-425, 440-443).   
Upon segregation of chromosomes the microtubules depolymerize and pull 
apart sister chromatids. There are also motors associated with microtubules, such 
as minus end (towards the cell center) dyneins and plus end (toward the cell 
leading edge) kinesins (with kinesin 11 being an exception) (443,444).  These 
proteins transport protein and cargo along microtubules and are involved in cell 
cycle progression (443,444).  Other microtubule associated proteins such as Tau, 
XMAP215, Lis1, EB1, EB2, and Dynamatin, stabilize microtubules through 
phosphorylation (443-445).  As a result, microtubules are a target for cancer 
chemotherapy.  Drugs such as vinca alkaloids vincristine, vinblastine and 
colchicine drugs like colchicine, and combrestin destabilize microtubules and 
prevent polymerization (440-445).  Dynamic instability is crucial for cell cycle 
progression and drugs that have the opposite effect such as taxane-derived drugs 
like Taxol and docetaxel prevent microtubule depolymerization 
Aurora A kinase 
Another group of proteins involved in chromosome segregation are the 
aurora kinase family.  This consists of aurora kinase A and aurora kinase B (446).  
Aurora A functions during prophase and is required for centrosomal function 
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(Figure 28) (446).  Aurora B is involved in mitotic spindle interaction with the 
centromere of chromosomes through their kinetochores (446,447).  Aurora A 
localizes by centrosomes during G1/S transition and then associates with mitotic 
spindles during later phases of mitosis (446,447).  It is critical for the formation of 
the mitotic spindle and phosphorylates many proteins involved in its formation, 
including TACC and kinesin-5 and it also promotes the formations of γ-TURCs 
(448).  Aurora A ensures proper chromosomal alignment along the metaphase 
plate during prometaphase, and exit of mitosis during telophase.  Aurora A kinase 
is often implicated in cancer progression and has been shown to be instrumental 
in EMT in neuroendocrine tumors and prostate cancer (449).  Overexpression of 
Aurora A can lead to aneuploidy, especially in cells that are deficient of p53 
activity, which regulates Aurora A.   
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Aurora B kinase 
Aurora B kinase expression is maximal at G2/M transition and associates 
with chromosomes during prophase and is involved in the chromosomal 
passenger complex, a critical complex involved in cell cycle progression, which 
consists of itself, survivin, Borealin, HBX, and INCENP.  Surivin is an IAP protein 
discussed previously and INCENP is an inner centromere protein (446,447,450).  
CENPs (or centromere proteins) describes a class of proteins which are divided 
Figure 28:  Aurora kinases. Aurora kinases and their substrates during various stages of the cell cycle.  The 
colored circles denote known substrates of Aurora A and B across the cell cycle.  Aurora A negatively 
regulates BRCA1, p53 and Lats, while positively regulating TACC, CENPA, and Eg5.  Tpx is also 
phosphorylated by aurora A, and is a critical component requires for associating aurora A to spindle 
microtubules and its autophosphorylation.  GOLGA2 interacts with importin α, the negative regulator of tpx2, 
and enables Tpx2 to associate with aurora A and promotes microtubule nucleation. Aurora B phosphorylates 
MCAK (microtubule centrome associated kinesin), MRLC (myosin regulatory light chain), MKLP-1 (mitotic 
kinesin-like protein 1), all of which are essential for microtubule activity and increased paclitaxel resistance 
in cancer.  Ask1 (apoptotic signaling kinase 1), Spc34p, and Ndc10p (centromere binding factor) are substrates 
of phospholipase LPL1.  Borealin interacts with INCENP, survivin, and aurora B kinase to promote the cell 
cycle as members of the chromosome passenger complex. 
 
Reprinted with permission from: Gautschi O., Heighway J., Mack PC, Purnell PR, Lara PN Jr., 
Gandara DR, Clinical Cancer Res 2008 Mar 15;14(6):1639-48. (446) 
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into constitutively binding and passively (or passenger) chromosomal binding 
proteins (Figure 28) (446,447,450).  Passenger proteins are those that localize to 
centromeres during metaphase to anaphase transition and include CENP 
(centromere protein E), Kinesin-like protein KIF2c, kinesin family member 22, 
Dynein DYNC1H1, CLIP1 (CAP-GLY domain containing linker protein), and 
CENPF (450-452).  These localize to centromeres during metaphase-anaphase 
and promote chromosomal passenger complex activity.  INCENP regulates the 
catalytic activity of Aurora B along with survivin and Borealin (450-452).  In order 
for Aurora B to localize to the centromeres during metaphase the protein CENP-
A needs to be phosphorylated and promotes assembly of the kinetochore (450-
452).  This phosphorylation occurs at S7 on CENP-A and is mediated by Aurora 
A.   
Aurora B also associates with MAP EB1 during anaphase and its 
overexpression increases Aurora B catalytic activity and blocks the catalytic 
activity of the negative counterpart of Aurora B protein phosphatase 2A (450-452).  
Aurora B is also important in the orientation of the chromosomes and ensures 
interaction with chromosome kinetochores and kinetochore microtubules (450-
452).  Aurora B mediates phosphorylation of Histone H3 on S10 and promotes 
chromosomal condensation and adhesion (452,453).    The spindle assembly 
checkpoint inhibits the progression of mitosis from metaphase to anaphase and 
one of the criterion is the proper biorientation of sister chromatids and deficiency 
of Aurora B leads to aberrant progression of the cell cycle and has implications in 
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cancer (452-454).  Aurora B also localizes the negative regulators of APC/C, 
MAD2 (mitotic arrest deficient 2) and BubR1 (454).  When misaligned 
chromosomes are presented at the metaphase plate this protein is involved in 
preventing sister chromatid segregation.  It binds to Mad1, which binds to cdc20 
and inhibits APC.  Abnormal levels of Aurora B lead to aneuploidy and this has 
led to the development of drugs that target this kinase (452-454).  The drug 
BI811283 developed by Boehringer Ingelheim for patients with AML is an Aurora 
B kinase inhibitor that binds to the ATP binding pocket of Aurora B (455).  This 
leads to polyploidy that is eventually too unstable to maintain and leads to cell 
death.  The drug is also in phase I and 2 clinical trials for NSCLC, brain cancer, 
head and neck squamous cell cancer, CRC, and ovarian cancer. BI811283 has 
also met with issues that limit its use as a chemotherapeutic agent due to 
development of leucopenia and neutropenia (456).   
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 Chromosomal translocations, HPV, and genomic instability 
 
Chromosomal instability is also associated with chromosomal 
translocations.  This can be spontaneous (as seen in CML) or a result of 
oncoviruses (33,34,457).  As stated previously CML is the result of the 
Philadelphia chromosome, which results in the BCR-ABL fusion gene products, 
which can be inhibited by Gleevec (imatinib) (31,32).  Retroviruses can cause 
cancer in mammals, although this is not as prevalent in primates, including 
Reprinted with permission from: Banks L., Pim D., Thomas M., Nat Rev Cancer 2012 
Dec;12(12):877-86. (457) 
Figure 29: Human papilloma virus (HPV). Lifecycle and stages of HPV (human papilloma virus) 
and how HPV induces cancer, such as cervical cancer. 
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humans.  This however does not preclude the existence of virus-derived 
malignancies.  One example is the development of Burkett’s Lymphoma from the 
Epstein - Barr virus (EBV), Kaposi’s sarcoma from HIV, and HCC from HBV 
(33,34,457).  Another virally induced cancer is cervical cancer from the human 
papilloma virus (HPV) (Figure 29).   
 HPV is a double stranded DNA virus with 100 different subtypes, however, 
only high-risk mucosotropic (HPV-16 and HPV-18) are causative agents of 
cancer.  Low risk type HPV only results in benign lesions such as genital warts 
(457,458).  High-risk HPV has a long latency period and encodes two oncogenes, 
E6 and E7, which facilitate immortalization and transformation of cervical 
epithelium by a series of steps.  Alone the proteins do not confer a transformed 
phenotype and just induce replicative immortality(stimulate telomerase) and 
promote other hallmarks of cancer such as unstained proliferation, evasion of 
tumor suppressors and apoptotic signals, and most importantly induce 
chromosomal abnormalities (457,458).  This can confer a replicative advantage 
and produce clonally selected transformed cells.  E6 and E7 degrade the RB 
protein, as well as inactivate p21 and p27 to promote sustained E2F signaling and 
activation of CDK2 through cyclins A and E.  This can activate a negative feedback 
loops as sustained E2F activates p14ARF, which in normal cells serves as an 
autoregulatory loop on E2F and CDK activity, as this activates p53 (457,458).  To 
circumvent this E6 activates E6-AP (a HECT-type E3 ubiquitin ligase) which 
targets p53 for proteasome-dependent degradation.  HPV E7 can also promote 
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the supernumerary of centrosomes and mitotic spindles, causing asymmetric 
chromosomal segregation and result in aneuploidal cells, which seems to be 
dependent on aberrant CDK2 activity induced by E7.  E6 can induce polynuclear 
or multilobulated nuclei as the result of inhibition of cytokinesis after persistent 
mitotic rounds (457,458).  High-risk HPV induced cervical cancers frequently have 
abnormal chromosomal structures and aneuploidy.  E6 and E7 can induce 
anaphase bridges as the result of the generation of unprotected chromosomal 
ends as the result of DNA damage or telomere erosion (457,458).  HPV positive 
cells are susceptible to this type damage as p53-induced DNA repair mechanisms 
are abolished to promote HPV induced carcinogenesis.  High-risk HPV-16 cells 
have higher levels of phosphorylated H2AX, which is a marker for DNA damage, 
and recruits the DNA repair machinery (457,458).    HPV is a major cause of 
cancer-induced mortality in females and much research has gone into elucidating 
HPV mechanisms of carcinogenesis.  Currently there are three different FDA 
approved vaccines for HPV, Gardasil, Gardasil 9, and Cervarix, which are all 
efficacious against HPV-16 and HPV-18 (457,458). 
Tumor promoting inflammation 
Cancer and inflammation  
Chronic inflammation has been linked to enhanced tumorigenesis and this 
idea was initially postulated in 1863 by Rudolf Virchow (459).  Virchow contributed 
much of the early knowledge of cancer and first described the origination of cancer 
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from previously normal cells.  He observed that there was a correlation between 
certain cancers and an increase in leukocyte number that produced chronic 
inflammation (458).  He was the first to characterize leukemia, chordoma (a 
cancer associated with remnants of the rudimentary notochord) and make the 
case for a specific link between inflammation and cancer (458).  Indeed many 
cancers are associated with inflammation such as mesothelioma (inflammation 
associated with asbestos exposure), prostate (chronic benign prostatic 
hyperplasia) bladder cancer (sustained urinary tract infections), pancreatic 
(pancreatitis), cervical cancer, CRC (colitis, IBD), melanoma (excessive UV 
exposure, exposure to irritants), and esophageal (acid-reflux diseases) (459-465).  
The experimental evidence that demonstrates how steroidal drugs (i.e. 
prednisone, dexamethasone) and non-steroidal anti-inflammatory drugs 
(NSAIDS) such as aspirin, sulindac sulfide, and ibuprofen attenuate cancer cell 
proliferation and progression also corroborates this concept (459-465).  During 
injury, immunological activation, or pathogenic infection produces inflammatory 
cells such as macrophages release inflammatory cytokines such as TNF-α and 
proliferative chemicals that potentiate neoplastic propensity (466).   
Inflammation is the body’s response to injury and it is mediated by 
leukocytes, consisting of neutrophils, monocytes (which extravasate into wounded 
tissue and differentiate into macrophages, and eosinophils, which trigger mast 
cells to release histamine and promote and inflammatory/allergic response (466).  
Neutrophils use a four-step mechanism that involves “a rolling stop” that 
113 
 
coordinates recruitment of other inflammatory cells to the provisional ECM, 
enabling fibroblast and endothelial cells to proliferate and migrate (467).  Steps 
include activation of the selectin family of adhesion molecules (L-selectin, P-
selectin, and E-selectin), which facilitate the “rolling” along the vascular 
endothelium (466,467).  Neutrophils upregulate integrins (α4β1 α4β7) which 
enable binding to vascular cell-adhesion molecule-1 (VCAM-1) and MadCAM-1 
respectively.  MMPs are then activated to create a route of entry for the neutrophil 
to the site of injury (466,467).  Platelet aggregation which is followed by the 
multistep coagulation cascade with the aid of phylloquinone and menaquinone 
(vitamins K1 and Vitamins K2 respectively), provide proteins that promote 
inflammation, including heparin, thrombin, serotonin, fibronectin and von 
Willebrand factor, PDGF, TGFα, and arachidonic acid (466-468).   
Cyclooxygenases (COX) and chemokines 
Arachidonic acid is the precursor to a group of lipid signaling molecules 
called prostaglandins (466).  Cyclooxygenases (COX) enzymes, which convert 
arachidonic acid into PGE (COX-2), and other pro-inflammatory and pain 
mediators synthesize these molecules.  Aspirin and NSAIDS inhibit these 
enzymes (459-465).  Formation of granulation tissue is mediated by chemotaxis 
of neutrophils, monocytes and fibroblasts.  Neutrophils produce early response 
inflammatory cytokines such as TNF-α, IL-1α and IL-1β (466,467).  Monocytes, 
which become macrophages within the injured tissue, are recruited by PDGF, PF-
4, chemoattractant protein-1, -2, CCl2, CCl8, CCl7, CCL3, CCl4, and the above-
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mentioned cytokines (466-469).  These macrophages produce a profuse amount 
of growth factors (TGFα, TGF-β, PDGF, bFGF) that promote tissue repair and 
promote inflammation (466-469). Chemokines attract specific leukocyte 
populations, which produce many inflammatory and wound healing cytokines, 
such as TNFα and TGFβ1 respectively, with the latter promoting type II EMT that 
is associated with wound healing.  TGFβ1 can negatively regulate the 
inflammatory response in cancer cells and this mode of regulation is abrogated 
(466-469).  Neutrophils and eosinophils are first recruited to an injured site and 
this leads to recruitment of mast cells, which release histamine and highly 
sulphated proteoglycans and proteases, and resulting in recruitment and 
differentiation of monocytes into macrophages.  Macrophages often promote 
inflammation as a normal response to pathogenic infection, allergy, or other 
foreign insults (467,469).    
Cancer and the immune system 
Tumor cells take advantage of this leukocyte attraction mechanism and 
produce their own chemokines to attract leukocytes, which may be composed of 
a heterogeneous population of neutrophils, eosinophils, mast cells, dendritic cells 
and macrophage, and lymphocytes (i.e. NK cells, T-cells, and B-cells) (465-469).  
This population can produce a concoction of cytokines, ROS inducing species and 
mediators, serines and cysteine proteases, MMPs, membrane perforating agents 
(i.e. granzyme from neutrophils), interleukins, and interferons (470).   
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Monocytes differentiate into immature dendritic cells in the presence of IL-
4 and granulocyte-macrophage colony stimulating factor (GM-CSF) (465-470).  
Dendritic cells are antigen-presenting cells (APCs) which collect antigens from 
sites of injury and infection, present them to T-cells, and stimulate their clonal 
proliferation within lymph nodes.  Tumor cells produce IL-6 and CSF-1 to promote 
monocyte differentiation into macrophages (470).  Tumor associated 
macrophages (TAMs) are highly implicated in inflammation induced 
Figure 30: Tumor associated macrophages. Tumor associated macrophages are associated with enhanced 
carcinogenesis.  Monocytes are recruited and extravasate tissue by chemokines CCL2, M-CSF (macrophage- 
conlony stimulating factor), and VEGF.  These monocytes differentiate into macrophages by IL-3 and M-CSF.  
These macrophages then become M2-polarized by other CSFs, IL-4, IL-10, and, TGFβ.  These TAMS not only 
promote tumor growth (by production of MMPs, VEGF, PDGF, FGF, and TGFβ) and metastasis (IL-1β, MMPs, 
and TNFα) but suppress cytotoxic T-cell responses by production of IL-10, and stimulate production of T 
regulatory cells (CCL17, CCL22).  T cells also become anergic by secretion of CCL 18.  TAMS have a profound 
effect on the tumor microenvironment and serve as garrisons for tumor growth. 
 
Reprinted with permission from: Biswas SK, Mantovani A., Nat Immunol. 2010 
Oct;11(10):889-96. (470) 
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carcinogenesis and are recruited by monocyte chemotactic protein (MCP) 
chemokines (Figure 30) (470,471).  TAMs produce angiogenic and 
lymphangiogeneic growth factors and proteases, which potentiate 
carcinogenesis.  Moreover TAMs produce anti-cytotoxic T-cell interleukin, IL-10, 
which attenuates CD8+ T cell mediated response, even when TAMs are 
eradicating tumor cells (470-472).  Several types of cancer take advantage of this.  
For example, melanoma, a very aggressive type of cancer, in response to 
macrophage activation express IL-8 and VEGF-A and induce angiogenesis (470-
472).  These TAMs express VEGF-C and VEGF-D, which as discussed previously 
are potent cognate ligands for VEGFR-3, which stimulates lymphangiogenesis, 
and potentiates lymph node infiltration and metastasis. 
Ulcerative colitis and irritable bowel disease (IBD) 
 As stated earlier many infectious diseases are associated with chronic 
inflammation and cancer.  Ulcerative colitis and IBD have demonstrated one of 
the strongest cases for such as relationship (473).  As discussed in the genomic 
instability section, HPV is associated with cervical cancer, HBV with liver 
carcinoma, and prolonged schistosomiasis from the trematodes Schistosoma are 
associated with CRC (473,474).  Stomach cancer (second most common cancer 
worldwide), and ulcers which increases the propensity for gastric cancer are 
caused by Helicobacter pylori infection.  Infected individuals will have 
macrophages that express migration inhibitory factor (MIF), which suppresses 
p53 activity and enhances tumorigenesis (475). With persistent infections and 
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inflammatory conditions, leukocytes induce DNA damage in these proliferating 
cells by generation of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS).  Repeated tissue damage and repair by the tumor results in the 
generation of cells with genomic alterations that can lead to genomic instability 
(473-475). This along with expanding the lifespan of macrophages and other 
immune cells creates a very opportunistic environment for tumor cells to exploit; 
this is in conjunction with cells that already have acquired successive DNA 
damage and gain of function cell proliferative mutations (476).  Tumor cells can 
use autocrine production of cytokines and chemokines to perpetuate their growth 
and progression.  Melanoma cells produce CXCL1, CXCL2, CXCL3, and CXCL8 
promote autocrine-stimulated cell proliferation (477).  Ligands to CXCR2 have 
also been linked to the autocrine growth of pancreatic, head and neck cancer, and 
NSCLC.  Macrophage inflammatory chemokine-3α (MIP-3α) is overexpressed in 
pancreatic carcinoma cells and tumor infiltrating macrophages (TIMs).  This 
protein enhances TAM migration and the growth of neoplastic cells 
simultaneously.  Certain chemokines can also induce angiogenesis, such as 
those with the ELR amino acid sequence N-terminal with respect to the CXC motif 
have potent angiogenic stimulating potential by stimulating endothelial cell 
migration in a chemotactic manner.  Lack of this ELR motif has antagonistic 
activity and inhibits angiogenesis (476).  ELR+ chemokines bind to CXCR2 and 
CXCR1, whereas those that lack the ELR sequence bind to CXCR3, CXCR4, and 
CXCR5.  Stromal cell-derived factor (also known as CXCL12) induces angiogenic 
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expression of VEGF-A which upregulates CXCR4 on endothelial cells. CXCL12 
has also been linked to metastasis and triggers chemotaxis of malignant 
mammary carcinoma cells (476). This demonstrates the direct role inflammation 
can have on tumor physiology by enhancing angiogenesis by chemokine 
production as well as metastasis.   
NSAIDS as anticancer agents 
NSAIDs exhibit anticancer activity in colorectal, lung, esophageal, and 
gastric cancer.  NSAIDs (like aspirin, ibuprofen) inhibit cyclooxygenases (i.e. 
COX-1 and COX-2) and prevent conversion of arachidonic acid into 
prostaglandins, which mediate pain and inflammatory responses (459-465).  
Aspirin (acetylsalicylic acid) acetylates and inactivates COX-1 and COX-2, and 
inhibits the synthesis of PGE, endoperoxides, and thromboxane A2.  Some 
NSAIDs have anti-inflammatory/antitumorigenic activities that are independent of 
COX inactivation (459-465).  Tolfenamic acid induces the downregulation of Sp 
proteins which attenuate cancer growth (478).  Some NSAIDS may induce 
apoptosis by directly targeting mitochondria to induce cytochrome c release and 
induction of caspase 3 (459-465,478).   
Cancer and the inflammasome 
Another complex that has been implicated in tumor progression, though in 
a somewhat equivocal way, is the inflammasome (Figure 31) (479).  The 
inflammasome is a component of the innate immune system and consists of 
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caspase 1, caspase 5, PYCARD (PYD and CARD containing domain), and NALP 
(Nod-like receptor) (479,480).  PYCARD consists of two protein domains, a pyrin 
domain (PYD) and a CARD domain.  The pyrin domain is a class of death fold 
proteins that enable interaction with proteins that have the same domain and 
CARD domains enable caspase recruitment (see evasion of apoptosis section) 
(479,480).   
 
 
Figure 31: The inflammasome. The inflammasome is a component of the innate immune system and consists 
of caspase 1, caspase 5, PYCARD (PYD and CARD containing domain), and NALP (Nod-like receptor).  
PYCARD consists of two protein domains, a pyrin domain (PYD) and a CARD domain.  The pyrin domain is a 
class of death fold proteins that enable interaction with proteins that have the same domain and CARD 
domains enable caspase recruitment (see evasion of apoptosis section).  NALP proteins detect pathogenic 
epitopes such as peptidoglycans that stimulate potassium efflux and activate caspase 1.  NOD-like receptors 
are part of a large family of receptors known as pattern recognition receptors (PRRs).   NLRP1 can stimulate 
the formation of the inflammasome and activate caspase 1, which leads to the formation of IL-1β and IL-18.  
This stimulates production of IFN-γ, NK cell activation, and proteolytic inactivation of IL-33 (Th2 responsive 
cytokine).    Production of IL-1β and IL-18 has also been implicated in the proliferation and metastasis of 
neoplastic cells.  Particular SNPs in seven inflammasome genes (NLRP1, 3, 6, CARD8, IL18, IL1β, and 
TNFAIP3) were linked with increased protection against HPV-induced cervical carcinoma.  The inflammasome 
is also implicated in promoting asbestos-induced mesothelioma. 
 
Reprinted with permission from: Davis BK, Ting JP, Nat Immunol 2010 Feb;11(2):105-6. (479) 
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NALP proteins detect pathogenic epitopes such as peptidoglycans that 
stimulate potassium efflux and activate caspase 1 (481).  NOD-like receptors are 
part of a large family of receptors known as pattern recognition receptors (PRRs) 
(481,482).   NLRP1 can stimulate the formation of the inflammasome and activate 
caspase 1, which leads to the formation of IL-1β and IL-18 (481,482).  This 
stimulates production of IFN-γ, NK cell activation, and proteolytic inactivation of 
IL-33 (Th2 responsive cytokine).    Production of IL-1β and IL-18 has also been 
implicated in the proliferation and metastasis of neoplastic cells (466,467).  
Specific SNPs in seven inflammasome genes (NLRP1, 3, 6, CARD8, IL18, IL1β, 
and TNFAIP3) were linked with increased protection against HPV-induced 
cervical carcinoma (480-482).  The inflammasome is also implicated in promoting 
asbestos-induced mesothelioma (483).  Dietary components such as cholesterol 
can serve as a promoter in colorectal cancer when used in azoxymethane treated 
mice and this was shown to be through an inflammasome-dependent pathway 
(484).  Though not all the details are explicitly clear, inflammation plays a role in 
tumor promotion, angiogenesis, and metastasis, through leukocyte infiltration, 
innate immune responses, or autocrine signaling and targeting these pathways 
can be of chemotherapeutic benefit. 
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Aberrant and deregulated metabolism 
Warburg effect 
Dr. Otto Heinrich Warburg is credited with discovering the phenomenon 
that cancer cells switch to a glycolytically active environment with lactic acid 
fermentation occurring within the cytosol (485).  This is the opposite to what is 
observed in normal cells as normal cells have low  rates of glycolysis and rely on 
oxidative phosphorylation in the mitochondria for energy (485). He also postulated 
that this change is not a passive consequence of tumorigenesis, but a potent 
tumorigenic driver and this is called the Warburg hypothesis (Figure 32) (485).  
Cancer cell metabolism is indisputably due to aberrant regulation and expression 
of tumor suppressor genes and oncogenes.   Glycolysis and oxidative 
phosphorylation are two vastly different forms of producing energy with differing 
cellular locations, enzymes, energy yielding rates, and kinetics (485,486).  
Glycolysis is a very rapid, normally anaerobic, cytosolic, method of producing 
instant energy and is a very evolutionarily ancient pathway, being conserved from 
humans to the most primitive prokaryotic species (485,486).  This process is very 
inefficient and yields only two ATP molecules per molecule of glucose.   
Oxidative phosphorylation produces 32-33 molecules of ATP per glucose, 
is aerobic, takes place in the mitochondrial matrix/mitochondrial intermembrane, 
and is not as expedient as glycolysis (487).  Depending on the cell type, many 
cells are very energetically demanding (i.e. muscle, pancreatic, brain) and require 
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large amounts of energy in the form of adenosine triphosphate (ATP), which is the 
major energy source of most organisms, including human cells.  ATP is an 
excellent energy source, which is released via ATP hydrolysis, to either ADP or 
AMP.   
 
The ATP/AMP ratio is a metabolic indicator and is directly proportional to 
the energy state of the cell (486,487).  When ATP/AMP ratio is high, anabolic 
pathways are activated, such as the mTOR pathway, PI3K/AKT, FAS (fatty acid 
synthase), protein synthesis through ribosomal biogenesis, and other pathways 
(487,488).  AMP kinase (AMPK) is a mediator of a low energy state and inhibits 
Figure 32: Warburg effect.  The Warburg effect is a metabolic shift that occurs within cancer cells.  In normal 
cells, the majority of energy is derivd by oxidative phosphorylation and very little glycolysis.  This is also 
emphasized by the low expression of HIF-1α and c-Myc, which upregulate glycolytic genes.  Cancer cells 
undergo the Warburg effect and upregulate glycolytic genes by overexpression of HIF-1α and c-Myc and 
decreased oxidative phosphorylation.  There is also increased glucose influx by upregulation of GLUT 
Transporters, increased pentose phosphate pathway metabolism, and upregulation of glutaminases.  These 
cancer cells also lose expression of sirtuins SIRT6 SIRT3 and SIRT 4. 
Reprinted with permission from: Guarente L., Nat Med 2014 Jan;20(1):24-5. (485) 
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anabolic pathways regulated by mTOR.  AMPK can be activated by AMP 
allosterically activating AMPK by binding to its CBS domain within the γ-subunit, 
although phosphorylation by LKB1 (a component of the heterotrimer AMPK 
kinase) on T172.  When normal cells become transformed, they exhibit the 
characteristic of switching from aerobic oxidative phosphorylation to 
anaerobic/aerobic glycolysis (154,155,487).  This involves shunting a key 
metabolite that is critical to oxidative phosphorylation and the TCA cycle, namely 
pyruvate.   
Pyruvate dehydrogenase complex 
Pyruvate is the end byproduct of glycolysis and the result of the 
transamination reaction of alanine.  In normal cells the pyruvate dehydrogenase 
complex, includes: pyruvate dehydrogenase (E1), Dihydrolipoyl transacetylase 
(E2) and dihydrolioyl dehydrogenase (Figure 33).  E1 has a dual role by 
decarboxylating pyruvate and acetylating lipoic acid (which is covalently bound to 
E2) to lipoamide (489).  Like the majority of enzyme that decarboxylate substrates, 
E1 utilizes thiamine pyrophosphate (TPP) as a cofactor (489).  TPP is unique in 
the fact that within the thiazolium ring there is a resonance structure that 
generates a carbonium anion ylide, which is very reactive and nucleophilically 
attacks (SN2) the carboxylate of pyruvate.   
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PDH is very critical in the metabolism of pyruvate and shunting it into 
aerobic mitochondrially driven pathways, and its activity is regulated by 
phosphorylation and dephosphorylation, pyruvate dehydrogenase kinase (PDK) 
and pyruvate dehydrogenase  
 
 
phosphatase (PDP1) (489).  Phosphorylation of PDH is inhibitory and is stimulated 
allosterically by NADH, citrate and acetyl-CoA, and allosterically repressed by 
pyruvate, CoA, and NAD+.  PDP1 is inhibited by magnesium and calcium ions 
Figure 33: Pyruvate dehydronase complex. This complex consists of E1: pyruvate dehydrogenase, E2: 
Dihydrolipoyl transacetylase, and E3: dihydrolipoyl dehydrogenase.  It is negatively regulated by 
phosphorylation by pyruvate dehrydrogenase kiase (PDK) and positively regulated by pyruvate dehydrogenase 
phosphatase 1 (PDHP1). Phosphorylation of PDH is inhibitory and is stimulated allosterically by NADH, citrate 
and acetyl-CoA, and allosterically repressed by pyruvate, CoA, and NAD+.  PDP1 is inhibited by magnesium 
and calcium ions. PDK1 is a drug target in cancer and can be targeted by use of chemicals such as 
dichloroacetic acid (DCA).    In cancer mitochondrial DNA mutations are often reported for Coomplex 1-V of 
oxidative phosphorylation and pyruvate dehydrogenase. 
Reprinted with permission from: Guarente L., Nat Med 2014 Jan;20(1):24-5. (485) 
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(490). PDK1 is a drug target in cancer and can be targeted by use of chemicals 
such as dichloroacetic acid (DCA) (491).     
Pyruvate/Lactate ratio and oxidative phosphorylation vs. aerobic 
glycolysis 
Cancer cells shunt pyruvate from aerobic metabolism by increasing the 
expression of lactate dehydrogenase (489).  This enzyme is responsible for the 
reversible interconversion of pyruvate to lactate.  With increases glycolytic flux, 
there is increased production of NADH, which pushes the equilibrium of 
pyruvate/lactate to the production of lactate, which is shuttled out of cancer cells 
by the protein symporter MCT4 (monocarboxylate transporter 4) (492).  This efflux 
of lactate is accompanied by efflux of H+, making the cell less acidic and 
preventing ketoacidosis in the cell.  Another protein transporter that is upregulated 
in cancer cells is the NA+/H exporter 1 (NHE1) (493).  This is an antiporter that 
cooperates with MCT4 by increasing the efflux of H+ by increasing the influx of 
Na+, which is energetically favorable and goes with the Na+ concentration 
gradient (492). In normal cells after pyruvate is shuttled to the mitochondria and 
acted upon by TCA cycle enzymes, generating 3 NADH molecules, a GTP 
(guanosine triphosphate) and a QH2 (the reduced form of ubiquinone, ubiquinol) 
(489).  NADH and ubiquinol participate in the electron transport chain (ETC) which 
generates a proton gradient used by ATP synthase to generate 32-36 ATP 
molecules per glucose molecule.  
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These enzymes are present in the mitochondrial inner membrane on the 
side facing the mitochondrial matrix and include complex I (NADH:Ubiquinone 
oxidoreductase), complex II (succinate dehydrogenase, which also participates in 
the TCA cycle), complex III (cytochrome c oxidoreductase), and complex IV 
(cytochrome c oxidase) (489,490).  These enzymes transfer electrons from NADH 
to ubiquinone, to FADH and then finally to oxygen, generating water as a final 
byproduct.  NADH as stated is generated from the TCA cycle as a result from the 
TCA cycle (489,490).  The acetyl-CoA generated by the PDH complex is used by 
citrate synthase to generate oxaloacetate, which is the start and finish of the cycle 
(489,490).  This metabolic hub ensures complete oxidation of pyruvate and 
requires only a catalytic amount of oxaloacetate, as radiolabeling has 
demonstrated that the two carbons given by acetyl-CoA are completely oxidized 
by this cycle into carbon dioxide.  However, cancer cells switch from oxidative 
phosphorylation to glycolysis, which is used in anaerobic, hypoxic/anoxic 
environments (489,490).  This has long been a paradox in cancer biology however 
there are some observations that can explain this switch.   
Along with providing ATP, glucose provides constituents for other 
metabolic pathways.  Glucose can also undergo the pentose phosphate pathway 
(PPP), which is utilized to generate ribose 5 phosphate for nucleotide synthesis 
(ribose-5-pyrophosphate in the purine de novo synthesis pathways) and the 
anabolic counterpart to NADH, NADPH (489,490).  NAPDH participates in fatty 
acid synthesis as well as steroidogenic pathways.  NADPH also participates in 
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GSH-mediated antioxidant pathways and therefore increased glucose uptake 
increases the concentration of GSH and the cancer cells ability to neutralize 
deleterious ROS and this makes the cancer cell more stable in hypoxic 
environments (494).    
TLK1/pentose phosphate pathway and GLUT transporters/glycolysis 
The pentose phosphate pathway has two stages, the oxidizing stage 
(which includes glucose 6-phosphate dehydrogenase) and the non-oxidative 
phase, which involves transaldolases and transketolases (495).  Transaldolase 
combines sedoheptulose 7-phosphate with glyceraldehyde-3-phosphate to 
generate fructose-6-phosphate and erythrose-4-phosphate (495).  
Transketolases participate in the first and last step on the non-oxidative phase of 
the PPP, generating sedoheptulose-7-phosphate and glyceraldehyde-3-
phosphate from ribose-5-phosphate and xylulose-5-phsphate in the first step and 
then glyceraldehyde-3-phosphate and fructose-6-phosphate in the third step 
(495).  These resulting molecules are substrates for glycolysis and serve as 
anaplerotic flux and the enzyme transketolase 1 (TLK1) is a cancer biomarker and 
a therapeutic target (Figure 33) (496).   
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Ectopic expression of TLK1 induces the Warburg effect in melanoma cells 
and enhances malignancy by DNA-hypomethylation (497). Cancer cells also 
Figure 34: Transketolases and the pentose phosphate pathway.  There is an increase in the pentose phosphate 
pathway (PPP) in cancer cells and this involves upregulation of transketolase 1 (TLK1), which is nvolved in 
the non-oxidative phase of PPP. Transketolases participate in the first and last step on the non-oxidative 
phase of the PPP, generating sedoheptulose-7-phosphate and glyceraldehyde-3-phosphate from ribose-5-
phosphate and xylulose-5-phsphate in the first step and then glyceraldehyd3-3-phosphate and fructose-6-
phosphate in the third step.  These resulting molecules are substrates for glycolysis and serve as anaplerotic 
flux  Glucose uptake is also increased by upregulation of GLUT 1,3, and 4, which is upregulated by c-Myc and 
HIF-1α.  HIF-1α also serves as a transcription factor that upregulates many glycolytic enzymes (including 
hexokinase 1 and 2 near VDACs situated at the mitochondrial outer membrane), phosphofructokinase 1 and 
2, and pyruvate kinase, which are key “commitment steps” of glycolysis. Compounds such as 2-DG 
(deoxyglucose), which inhibits hexokinase and 3-BP (3-bromopyruvate), which potently inhibits 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a vital enzyme in glycolysis that generates ATP using 
NADH.  3-BP is currently in Phase 1 clinical trials for liver cancer and should show promise in other 
metabolically overactive cancers such as pancreatic cancer and RMS (rhabdomyosarcoma). HIF1-α also 
upregulates PDK1, which dismantles pyruvate from entering the TCA cycle by virtue of its ability to inhibit 
PDH, LDHA, MCT4, NHE1, and carbonic anhydrases 9 and 12, which couples protons exported by NHE1 and 
MCT4 to bicarbonate, generating carbonic acid which breaks down into water and CO2.  These genes have 
consensus sequences within their promoters that contain HIF-1α and c-Myc binding motifs.   
 
Reprinted with permission from: Galluzzi L., Kepp O., Vander Heiden MG, Kroemer G., Nat Rev Drug 
Discov 2013 Nov;12(11):829-46. (498) 
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handle the energy demand predicament by upregulating glucose transporter 
proteins, namely GLUT1, GLUT2, GLUT3, and GLUT4 (Figure 34) and this is a 
major distinguishing feature between transformed and normal (498,499).  Drugs 
such as WZB117, ribonavir, phloretin, and STF-31 inhibit these transporters (500-
504).  With an increase in the influx of glucose, there is an accompanying 
upregulation of enzymes involved in glycolysis.  Cancer cells become very hypoxic 
and this increases expression is HIF-1α and both HIF-1α and c-Myc (326,327) 
serve as transcription factors that upregulate many glycolytic enzymes (including 
hexokinase 1 and 2 near VDACs situated at the mitochondrial outer membrane), 
phosphofructokinase 1 and 2, and pyruvate kinase (505).   
 Aldolase [which cleaves fructose 2, 6 bisphosphate into glyceraldehyde-
3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP)], triose phosphate 
isomerase and phosphoglycerate mutase are also upregulated, but these 
enzymes also participate in gluconeogenesis (489, 490). Compounds such as 2-
DG (deoxyglucose), which inhibits hexokinase and 3-BP (3-bromopyruvate), 
which potently inhibits glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a 
vital enzyme in glycolysis that generates ATP using NADH are drugs that have 
and are currently being investigated as anticancer agents (506,507).  3-BP is 
currently in Phase 1 clinical trials for treating liver cancer and should show promise 
in other metabolically overactive cancers such as pancreatic cancer and RMS 
(rhabdomyosarcoma) (507). HIF1-α also upregulates PDK1, LDHA, MCT4, 
NHE1, and carbonic anhydrases 9 and 12 (326,327).  These genes have 
130 
 
consensus sequences within their promoters that contain HIF-1α and c-Myc 
binding motifs (326,327, 508).   
In cancer cells, there is also decreased expression and function of 
glycolytic repressors.  Along with regulating DNA damage responses, apoptosis, 
and the cell cycle, p53 also has a substantial role in metabolism and suppresses 
the uptake and metabolism of glucose.  The GLUT1 and GLUT 4 genes are 
directly repressed by p53 and GLUT 4 is indirectly inhibited by p53’s negative 
regulation of NFκB (188,509,510).  P53 also represses expression of PGM and 
induces expression of SCO2 (SCO2 cytochrome c oxidase assembly member), 
TIGAR (TP53 induced glycolytic and apoptotic regulator), and GLS2 (glutaminase 
2) (509,510).   SCO2 and GLS2 potently enhance oxidative phosphorylation 
pathways, with the former being directly involved in the assembly and stimulation 
of Complex IV in the ETC.  TIGAR is the negative counterpart of the enzyme 
PFK2, which converts fructose-1-phosphate to fructose 2,6-bisphosphate (509).  
Fructose 2,6 bisphosphate potently allosterically activates PFK1, therefore TIGAR 
serves as a potent negative regulator of PFK1, which is an enzyme involved in an 
indispensable step in glycolysis (509,510).  All these enzymes are repressed in 
cancer cells, some in part due to loss of p53 activity. 
Glutaminases 
In addition to increased glycolytic flux in cancer cells, there is also 
increased protein translation, due to enhanced mTOR activity, and increased 
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glutaminase activity, which converts glutamine into glutamate, and then which is 
metabolized to glutarate. Glutarate is the ketogenic counterpart of aspartate, and 
can be shuttled into the mitochondria as α-keto glutarate (511).  In cancer cells 
there is increased expression of glutaminase and drugs such as BPTES (Bis-2-
(5-phenylacetoamido-1,3,4-thiadiazol-2-yl)ethyl sulfide and CB-839 are potent 
glutaminase inhibitors that are in Phase 1 clinical trials (512).  Inhibition of 
glutaminases (i.e. by BPTES) is effective in treating many solid cancers, such as 
glioblastoma and CB-839 has also shown promising results in TNBC (triple 
negative breast cancer) (512).  CB-839 is also in Phase 1 clinical trials for other 
solid tumors such as NSCLC (513).  Derivatives of CB-839 (i.e. Pac-CB, CBE, 
CB-Erl, and CBD) are in Phase 1 trials for NSCLC, renal cell carcinoma (RCC) 
mesothelioma, fumarate-hydratase (FH) and/or succinate dehydrogenase (SDH) 
tumors of the gastrointestinal tract and stroma, and tumors haring c-Myc 
amplifications or mutations in isocitrate dehydrogenase (IDH1 and IDH2) (514-
516).  Drugs are also used to target ASC amino acid transporter 2 and LATS1, 
which import glutamine into the cancer cells (517).  Drugs such as α-MT and 
SERMs inhibit these channels (518). 
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ATP citrate lyase, and carnitine palmitoyl transferase 1a (CPT1a)  
 
 
           Fatty acid synthesis and lipogenesis are critical pathways upregulated in 
cancer, with increased cell cycle activity and mitosis there is an increased need 
for membrane synthesis and cancer cells express high levels of the enzyme ATP 
citrate lyase and fatty acid synthase (FAS) (519).   There is also a concomitant 
Figure 35: ATP citrate lyase, SREBP1, and CPT1a. Cancer cells increase mTOR activity and have an increase 
in amino acid metabolism.  This is accompanied by not only the activatation of Rag A/B and C/D but the 
overexpression of glutaminases.  In normal cells glutaminases convert glutamine to -keto-glutarate and then 
glutarate, which is shunted to the malate/asparte shuttle within the mitochondria.  However in cancer cells 
this pathway is attenuated and the resulting glutarates are used for amino acid synthesis.  There is also an 
upregulation of faty acid synthase (FAS), ATP citrate lyase and a concomitant decrease in carnitine palmitoyl 
transferase 1 (CPT1) and uncoupling proteins (UCP) such as UCP2 and UCP3.  Along with increase lip 
synthesis there is also an increase in the anepleurotic flux into the mevalonate pathway.  This is important for 
cancer cells for membrane synthesis (cholesterol) and prenylation (farnesylation and geranylgeranylation) of 
oncogene like ras.  Drugs like metformin inhibit these pathways and have potential as anticancer agents. 
Cantoria MJ,  Patel H., Boros LG , Meuille EJt,  http://www.intechopen.com/books/pancreatic-cancer-insights-
into-molecular-mechanisms-and-novel-approaches-to-early-detection-and-treatment/metformin-and-
pancreatic-cancer-metabolism. 2014 (520) 
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decrease in the enzyme carnitine palmitoyl transferase 1A (CPT1A), a transporter 
protein that transports fatty acids into the mitochondria (Figure 35) (520).   
Carnitine serves as a shuttling intermediate for MCTs (medium chain triglycerides) 
and other fatty acids (520).  The mitochondria are the location where fatty acids 
are oxidized to yield energy by the process of β-oxidation.  In many tumors, the 
expression of β-oxidation enzymes is decreased as well as the expression of 
CPT1 (520).  However, there is evidence that the role of CPT1 in carcinogenesis 
is necessary and therefore the absolute role of this protein and fatty acid oxidation 
is equivocal.  Cancer cells have a high-energy demand for ATP, and ABC 
transport proteins such as MDR1, are important in cancer and confer 
chemotherapeutic resistance (521).  ATP production inhibits anoikis, which is 
cellular death induced by lack of cellular attachment to the ECM or some other 
substratum.  Mitochondria require CPT1 for fatty acid oxidation and this protein 
also confers mTOR inhibitor resistance and suppresses Bax/Bak induced 
apoptosis (520).  Increased β-oxidation can increase reactive oxygen species 
production, and is inhibited by drugs such as metformin (Figure 35).  Tumors with 
increased CPT1 production there is also accompanied increased expression of 
uncoupling proteins (UPC2, UPC3), which dissipate the proton gradient generated 
by ETC as heat (Figure 35) and drugs such as dinitrophenol have similar effects 
and are very mitotoxic (522,523).  These experimental findings suggest that the 
role of CPT1 in carcinogenesis is cancer and tumor cell specific (520,524).  
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Fatty acid synthase (FAS) 
FAS along with sterol response element binding protein-1 (SREBP-1) are 
involved in fatty acid synthesis, with SREBP-1 being a major transcription factor 
for genes involved in lipid and sterol synthesis that possess a sterol response 
element (SRE) (525).   FAS is not a single enzyme but a complex of enzymes that 
like β-oxidation perform stepwise reaction involving the addition rather than the 
lysis of two carbon atoms (520,521).  This reaction uses acetyl-CoA along with 
malonyl-CoA to generate the 16-carbon fatty acid palmitate.  Palmitate is involved 
in the post translation modification of many proteins, including sonic hedgehog 
(Shh), which is N-palmitoylated and is a potent oncogenic factor in breast cancer, 
glioblastoma, and other cancers (526).  There are two isoforms of FAS, FASI and 
FASII, with the former being the eukaryotic form and the latter being the 
prokaryotic form (520).   The first two reactions catalyzed by FAS involve the 
priming of acetyl CoA and malonyl CoA to the protein acyl carrier protein (ACP), 
which is also upregulated in tumor cells. Other FAS enzymes then form the 
product butyrl-COA by catalyzing reactions of these primed CoA intermediates. 
This is the beginning product of FAS, which is subsequently elongated to form 
palmitate (palmitic acid).  Palmitate and related fatty acid stearate (18-carbon fatty 
acid) also accumulate in cancer and can lead to fatty acid disease or steatosis of 
the liver, which can increases the likelihood of HCC.  SREBP1-c also regulated 
the transcription of ACC, and the active form SREBP1c is upregulated in cancer 
and leads to hyperactivation of ACC as well as FAS (520,521,525). 
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Mevalonate pathway: SREBP and HMGCoa reductase 
SREBP1 and SREBP2 are helix-loop-helix (HLH) transcription factor that 
remains inactive on the endoplasmic reticulum and require cleavage for activation 
(525,526).  AMPK, p53, and Rb negatively regulate SREBP in a normal cell 
(525,526).  The enzyme A citrate lyase (ACP) which is upregulated in cancer can 
cleave citrate to generate acetyl CoA, which feeds into the mevalonate pathway 
(Figure 35) (527).  Mevalonate is a critical intermediate for synthesis of 
cholesterol, which is an important membrane constituent that influences 
membrane fluidity of the membrane and this has a direct effect on lipid raft 
formation and activation of Ras and AKT (527,528).  Drugs called statins, which 
treat hypercholesterolemia by inhibiting the enzyme HMG-CoA reductase 
(HMGCR), target the mevalonate pathway that is involved in cholesterol synthesis 
and consequently exhibit antitumorigenic activity (527,528).  This enzyme 
catalyzes the reaction of HMG-CoA to mevalonate and is critical for all steroid 
synthesis. Mevalonate is an aneuplorotic intermediate not only for steroid 
synthesis but also for prenylation-dependent targeting of proteins (527,528). A 
biotin-dependent decarboxylase (as with many decarboxylases) generates the 
isopentyl pyrophosphate (IPP) intermediate that is in equilibrium with dimethylallyl 
pyrophosphate (DMAPP) by IPP isomerase activity, which are used for formation 
of farnesyl and geranyl groups that serve as tethers for proteins such as Ras.  The 
enzyme farnesyl diphosphate synthase (FPS) generates geranyl-PP then 
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farnesyl-PP sequentially, which is the key intermediate to cholesterol, 
ubiquinones, sterols, dolichols, and prenylated proteins (527,528).  The formation 
of squalene is required for all steroids, including cholesterol, which is itself an 
intermediate to all steroid synthesis and is formed into a pregnane (pregnenolone) 
by the cholesterol debranching enzymes (527,528).  This can lead to the formation 
of estradiol and testosterone (or dihydroxy testosterone formed by 5α-reductase), 
which can be deleterious and enhance breast cancer and androgen receptor 
positive prostate cancer respectively.  Farnesyl-PP and prenylation play a critical 
role in cancer as well (529).   
Farnesyl transferases as cancer drug targets 
Farnesylation of Ras is critical for its full activation and geranylgeranylation 
of Rac, Rho, cdc42 (monomeric GTPases involved in actin cytoskeletal stiffening 
and dynamics), Rab (vesicular trafficking proteins), and Rap (530).  These 
prenylation reactions are promoted by farnesyl transferases (FT) and 
geranylgeranyl transferase enzymes.   Farnesyl transferase adds a 15-carbon 
sesquiterpenoid group to Ras and other proteins bearing a CAAX motif within their 
carboxy terminus (530).  Ras has been deemed “undruggable” as many drugs 
that target Ras kinase activity are inefficacious or become obsolete due to tumor 
cell resistance.  However, FT inhibitors have garnered much attention and many 
are being used in research and clinical trials.  For example the drug tipifarnb, is 
being used or elderly patients with AML (531).   The drug lonafarnib is being used 
to treat breast cancer in conjunction with anastrazole and tamoxifen and their 
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efficacy in treating colorectal and pancreatic cancers is also being investigated 
(532).   These drugs are also being studied in thyroid, bladder, and kidney cancers 
as they also target H-ras, which is the driver of those cancers (533-536).   With 
the success of FT-inhibitors there also comes resistance to these drugs.  
Disappointingly, in many cases mutated Ras (both K- and H-) can become 
geranylgeranylated (530,537).  Many leukemias and also colon, pancreatic, 
kidney, thyroid, melanoma, and bladder cancers are also affected substantially by 
geranylgeranyl transferase (GGT) -inhibitors (538-543).  Many GGT inhibitors 
including GGTI-297, GGTI-298, and VHEMBL525185 are being investigated in 
multiple tumor types (538-543).  Recently it was shown that the turmeric 
anticancer compound curcumin, was able to bind with high affinity to both FT and 
GGT1 suggesting a potential anti-Ras activity for curcumin (544).  Statins inhibit 
not only geranylgeranylation by depleting levels of GGP, but also induce 
expression of p27Kip1 and p21Cip1 by inducing the degradation of Skp2, which 
is a subunit of the SCFSkp2 ubiquitin ligase that targets p27Kip1 and p21Cip1 for 
proteasome-dependent degradation (545,546).  FT-inhibitors and GGT1 inhibitors 
also have effects on Hippo signaling by negative regulation of Hippo signaling 
antagonists YAP and TAZ, which are overexpressed in some cancers, and exhibit 
antitumorigenic activity in Hippo mutated cancers (547). 
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Breast Cancer 
Breast cancer classification 
Breast cancer is any cancer that originates and develops in the mammary 
glands and breast tissue (9,10).  It is the most common cancer in women and the 
second most common cancer worldwide after lung cancer (20,21).  The global 
burden of breast cancer is greater than all other cancers and incidence rates are 
increasing (20,21). The beast tissue is made of adipose and connective tissue, 
lymph nodes and blood vessels.  Breasts have a series of glands called lobules 
that produce milk and thin tubes called ducts that carry the milk from the lobules 
to the nipples where they can feed young (20,21).   The most come types of cancer 
are ductal carcinomas, which can be broken down into the categories of non-
invasive and invasive cancers.  Non-invasive breast cancer consists of ductal 
carcinoma in situ (DCIS), which is a tumor that has grown to the boundaries of the 
ECM, has not become invasive, and originates in the milk ducts (548).  Invasive 
ductal carcinomas are those in which the cancer cells have invaded the basement 
membrane and can metastasize to distal tissues (548).  This kind of cancer is 
observed in about 80% of breast cancer patients and involves cancers that have 
originated in the milk ducts.  These can be further broken down into five 
subcategories:  Tubular carcinoma, medullary carcinoma, mucinous carcinoma, 
papillary carcinoma, and cribriform carcinoma.  Tubular carcinoma originates in 
the milk duct and spreads into healthy tissue; however, these tumors are usually 
low grade and are somewhat differentiated “normal” looking cells that grow very 
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slowly (548,549).  Medullary carcinoma is a very rare cancer that has superficial 
similarity to the medulla of the brain hence the name.  It effects women in their 
late 40-early 50s and more common in women that have a BRCA1 mutation (550).  
Although they appear aggressive, they grow slowly and have minimal invasive 
behavior.  Mucinous, or colloid, carcinomas are cells that are rich in the protein 
called mucin.  Mucins are proteins that are involved in carcinogenesis and are 
upregulated in advanced carcinomas (551).  This type of cancer is common in 
women who have gone through menopause and responds well to treatment (551).  
Papillary carcinomas affect 1-2% of invasive breast cancer patients and it is 
characterized by the presence of well-defined finger like projection that are 
moderate in tumor grade (552).  Cribriform carcinoma involves cancer cells that 
invade the stroma in nest like formations and have conspicuous holes within the 
tumor (553).  With both papillary and cribriform invasive ductal carcinomas, DCIS 
is also present concomitantly (548,549,552,553).   
Along with invasive ductal carcinoma, there is also invasive lobular 
carcinoma, which is the second most common type of breast cancer (~10% of 
breast cancer patients) (554).   This type of cancer originates in the breast lobules 
and has a 5-year survival rate of 85%.  These kind of cancer has multiple 
histological patterns, which include classical, alveolar, solid, tubulolobular, 
pleomorphic, and mixed (554).  The two most common patterns are classical and 
mixed.  Classical is composed of round cells that have very large nuclei and very 
little cytoplasm, having a single file infiltrating pattern (554,555).  Mixed simply 
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implies that the cells represent multiple histological patterns and/or ones that have 
no distinct or dominant pattern.  Pleomorphic pattern is like classical but the cells 
are pleomorphic (not uniform) in cell size, morphology, and cytoplasmic to nucleus 
ratios (554,555).  The next common type represents 10% of ILC and these are 
solid tumor cells, which are similar to classical cells except they are arranged in 
sheets that are intercalated by sheets of intervening stroma (554,555).  The least 
common histological patterns are alveolar and tubulolobular presentations the 
alveolar tumors form as aggregates of classical-like cells and have morphologies 
that are similar to alveolar cells of the lung (556).   
Breast cancer staging  
 
 
Breast cancer classification uses a staging system what is known as the 
TNM system (Tumor, Lymph Nodes, Metastases) (557).  This classification 
system takes into account the size of the tumor, its boundaries and whether it has 
infiltrated stroma and other components of the ECM, if it has invaded the lymph 
Figure 36: Breast cancer staging.  Stages for breast cancer malignancy. 
. 
Reprinted with permission from: Klein CA, Nat Rev Cancer. 2009 Apr;9(4):302-12. (557) 
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nodes, and if there are any metastases (Figure 36).  Tumor stages can be 
classified T0-T4 (557).   TO means that the tumor cannot be assessed for staging 
and the classification Tis is carcinoma in situ (either ductal or lobular).  There is 
also a special kind of Tis for Paget’s disease, which is associated with the nipple 
and the surrounding parenchyma.  T1 can be broken down into T1a, T1b, T1c, 
and Tic, and all of these subdivisions are contingent on the size of the tumor, with 
T1a: 1-5 cm, T1b: 5-10cm, T1c 10-20 cm (557).  T2 and T3 also are based on 
tumor sizes with 20-50 cm being T2 and sizes greater than 50cm belonging in the 
T3 category (557).   T4 is a category that is devised for tumors that have begun 
to invade into the chest wall through skin and muscle.  T4a there is extension into 
the pectoralis muscles and T4b tumors exhibit ulceration and edema (peau 
d’orange) with ipsilateral site nodules (557).  T4c is a combination of T4a and T4b 
and T4d is inflammatory carcinoma (557). 
The development of breast cancer involves a progression through a series 
of intermediate processes, which start with ductal or lobular cell proliferation, 
followed by carcinoma in situ, invasive carcinoma, and then metastatic cancer, 
which can metastasize preferentially to the lungs and bones (51-54).  Depending 
on the type and cancer and its stage there are varying degrees of survival, 
prognosis, and chemotherapeutic response and there are several diagnostic 
markers for breast cancer.  Diet, exercise, and family history also play a significant 
role in breast cancer onset (558). Breast Cancer was originally called “Nun’s 
disease” which was linked to abstinence from sex, a risk factor for breast cancer.  
142 
 
One of the most prominent markers of breast cancer is the estrogen receptor 
(ERα), which represents about 60% of breast cancer patients (559).  These 
cancers have good prognosis and can be treated with drugs such as tamoxifen 
and clomifene (559).  Cytotoxic drugs such as 5-FU (5-fluorouracil) and 
Adriamycin (doxorubicin) are also used to treat breast cancer (560).  In certain 
cases patients undergo a unilateral or bilateral mastectomy to remove the tumor 
(20,21).  ER negative breast cancers are much more difficult to treat and are 
refractory to chemotherapy (559).  The heterogeneity of breast cancer is 
emphasized in comparative genomic hybridization data demonstrating clear and 
somewhat ambiguous associations (559,561).  A more comprehensive approach 
integrating genomics, proteomics and potentially transcriptomics will lead to the 
innovation of better chemotherapeutic strategies that are more specialized to a 
specific cancer subtype (561). Breast cancer cell lines (as well as cancers) can 
be broken down into five basic categories based on their molecular infrastructures: 
Luminal A and B, Basal, Claudin-low, and HER-2 overexpressing.  Luminal A and 
B cancer types are usually very response to chemotherapy and have good 
prognosis in a clinical setting (562).  The expression of Ki67 (a proliferative 
marker) is variable as well as the expression of HER2.  They express both ER 
and PR.  Basal and claudin low are triple negative cell lines/tumors that are not 
endocrine response with variable chemotherapeutic responsiveness (562).   In 
the following sections, known biomarkers of cancer will be discussed as well as 
how they are targeted. 
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Nuclear receptors and breast cancer: estrogen receptor (ER) and    
progesterone receptor (PR) 
More than 700,000 of breast cancer patients are positive for elevated or 
aberrant expression of hormone receptors (20,21,558,563).  Hormone receptors 
are receptors, which dimerize (either in a hetero- or homo-dimeric fashion) and 
bind to their respect response elements activating expression of hormone 
response genes (563). Steroid hormone receptors are expressed in both the 
epithelium and the breast stroma and breast tumors are initially characterized by 
expression of ERα (558,563).  The PR (progesterone receptor) also plays a 
prominent role in breast cancer and both PR and ER can be tested for expression 
by immunohistochemistry analysis and their expression has important clinical and 
treatment implications (563,564).   
There two different estrogen receptors: ERα and ERβ (Figure 40).  The 
hormone estradiol (E2) binds with equal affinity to both ERα and ERβ.  There are 
other estrogenic steroid hormones, namely estrone and estriol, with affinities for 
ERα and ERβ respectively (558,564,565).  There are also drugs that can target 
these different ER isoforms and these are called selective estrogen receptor 
modulators (SERMs) and SERMs can be ER agonists or antagonists and their ER 
activity is dependent on tissue (558,565).  For example, the compound tamoxifen 
is an ER antagonist in breast cancer while it is an agonist in other tissues 
(558,565).  Another drug used to treat advanced stage metastatic cancer is the 
full ER antagonist fulvestrant.  Certain compounds such as genistein found in soy 
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bind preferentially bind to ERβ and exhibit tumor suppressive roles in colon cancer 
(558,565).  ERα and ERβ are encoded on two different chromosomes and have 
unique tissue distribution, with the alpha isoform predominantly found in breast, 
endometrium, ovarian stroma, hypothalamus, and the efferent ducts (males) and 
the beta isoform being expressed in the brain kidney, granulosa cells, bone, heart, 
prostate, endothelium, and colon (566-573).  
 Like other nuclear receptors, ER remain inactive in the cytosol and upon 
binding to ligand translocate as hormone dimers to the nucleus and bind to 
inverted repeats that compose estrogen response elements (558,564,565).  ER 
isoforms can are also involved in ligand independent regulation, which involves 
phosphorylation of its modular structure (558,564,565).  For example, Akt 
phosphorylates S255 in DNA binding domain of the beta isoform and cdk2 and 
ERK phosphorylate S106 and S118 respectively in AF1 domain of ERα, which 
expedites the cell cycle (574).  In breast cancers where ER expression is elevated 
the use of anti-estrogens (such as tamoxifen) and anti-aromatases (anastrazole) 
show the most chemotherapeutic benefit (558,565).  Tamoxifen itself is a prodrug, 
which is metabolized by the action of cytochromeP450 enzymes CYP2D6 and 
CYP3A4 into 4-OH tamoxifen (afimoxifene) and N-desmethyl-4-OH tamoxifen 
(endoxifene) (558,559).  These metabolites bind to the receptor and compete with 
estradiol.  These metabolites can also recruit corepressor proteins such as NCoR 
(nuclear receptor corepressor 1) and SMRT (silencing mediator for retinoid or 
thyroid hormone receptors), which is also known as NCoR2, which recruit histone 
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deacetylases (575).  However, upregulation of other receptors such as 
HER2/ErbB2, are associated with tamoxifen-resistant breast cancers and the 
upregulation of these growth factors must be suppressed and accounted for (576).  
In order for tamoxifen to suppress growth factor upregulation it requires the activity 
of PAX2 (paired box 2) transcription factor, which can promote a complex of 
tamoxifen bound ER with PAX2.  However, the level of PAX2 must surpass 
another protein, AIB1 (amplified in breast 1, also known as NCOA3, TRAM-1), 
which can actually transform tamoxifen bound ER into a transcriptional activator 
of EbB2, by recruiting histone acetyl transferases to the ErbB2 promoter (577).  
This illustrates the degree of sophistication and involvement the intracellular 
milieu has in certain chemotherapeutic drugs and their effects on breast cancer 
targets.  Anastrazole inhibits an enzyme known colloquially as aromatase 
(CYP19A1) (578).  This is the only known enzyme in humans, as well as other 
mammals, to convert testosterone (as well as other androgens) into estradiol and 
other estrogens.  Along with reversible inhibitors like anastrazole, there are also 
suicide inhibitors of aromatase such as exemestane (Aromasin), which forms a 
covalent bond in the active site of aromatase (578,579).  
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Progesterone is an ovarian steroid hormone that is required for breast 
development, pregnancy, and lactation during pregnancy (564,580).  This 
receptor is also has three different isoforms: hPR-A, hPR-B, and hPR-C and they 
are both dispersed in diverse tissues (Figure 37) (564,580).  They are encoded 
from a single gene on chromosome 11 at q22-23, which has two different distal 
and proximal promoter regions (580).  Using two internal translational start sites 
within a single mRNA encodes the full length protein (hPR-B), N-terminally 
truncated 9PR- A), and hPR-C (580).  Most cells concomitantly express hPR-A 
Figure 37: SThe estrogen receptor and the progesterone receptor. structure and homology between the 
estrogen receptors (ERα and ERβ) and progesterone receptors (PR-A and PR-B) 
. 
Reprinted with permission from: Shupnik MA, Oncogene 2004 Oct 18;23(48):7979-89. (564) 
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and hPR-B, which have different transcriptional effects with the same or distinct 
promoters (580).  In the brain PR and progesterone control mating and 
reproductive behaviors, and development of the reproductive organs (580,581).  
PR-C lacks any transcriptional activity but can enhance activity of the other 
isoforms in a breast cancer context (580,582).  Progesterone counterbalances the 
effects of estradiol, and progesterone like compounds (progestins) are frequently 
prescribed as contraceptives and for postmenopausal hormone replacement 
therapy to lower the risk of cancer associated with traditional hormone 
replacement therapy that had just estrogen (563,564,580-582).   
The role of the PR in breast cancer is not completely understood either as 
a bonafide tumor suppressor or oncogene.  The majority of breast cancer are 
positive for ER and PR (~60-70%) (558,563,564).  These cancers can undergo 
autocrine-signaling mechanisms that can sustain cell proliferation.  While many 
studies in breast cancer cell lines have established the role of PR and ER play in 
breast cancer cell proliferation, its physiological relevance in an organism (such 
as the human body) is ambiguous (558,559,563,564).  Steroid hormone receptor 
mediated activation of cytoplasmic signaling molecules could theoretically serve 
to potentiate the nuclear function of these receptors. For example, amplification 
of PR nuclear functions may occur through rapid direct phosphorylation of PR 
proteins and/or their coregulators in repose to activation of PR-induced 
cytoplasmic pathways that coincide with ligand binding (563,564).  Therefore 
appropriated phosphorylated and activated receptor complexes are orchestrated 
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for efficient and succinct regulation of selected genes, and this implicates a 
positive feedback loop for PR, which would explain the influence of activated 
signaling pathways on PR function (563,564).   
Many pathways of PR are Src and MAPK dependent and upregulate 
expression of cell cycle dependent genes such as cyclins D1, E, and activate 
CDK2.  Phosphorylation by both Src and MAPKs is required for PR to bind with 
Sp1 transcription factor to transactivate EGFR and p21 promoters (583,584).  
Activated oncogenes can also turn on PR pathways that are independent of ligand 
binding.  Therefore, perhaps PR can promote breast cancer growth by synergistic 
steroid hormone action and activation of MAPK pathways.  Similar mechanisms 
are seen with ligand activated ER which can induce a state of adaptive 
hypersensitivity, which is also an example of non-genomic signaling, where ER is 
membrane bound and not in the cytosol.  In this model ligand-bound ER interacts 
with the adaptor protein Shc, phosphorylates it, which leads to recruitment of other 
adaptor proteins and induction of MAPK pathways such as the Ra/Raf/MEK/ERK 
(585).  ERK then phosphorylates ETS factors and c-fos/c-jun (forming AP-1), 
which is independent of ER transcriptional activity (585,586).  The PR can 
therefore use a similar mechanism in concert with MAPK pathways to enhance 
breast cancer tumorigenesis.  Evidence to suggest this is in the fact that PR 
receptor expression is commonly associated with overexpression of cyclinD1, 
enhanced CDK2 activity and loss of tumor suppressor p21 (40%) (587).  The PR 
is also known to directly interact with CDK2, cyclins A and E and its activity is 
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highest during S phase of the cell cycle and when p27 activity is lost (40% of 
cancers), PR activity becomes independent of ligand and is driven by CDK2 
(587,588).  Progestins are also known to induce cyclin D1 expression and induce 
re-entry of antiestrogen-induced quiescent into the cell cycle.  Therefore, this 
suggests a role of PR in the cell cycle and its activity may become aberrant when 
cell cycle checkpoints are inactivated (563,585,587). Experiments where the 
BRCA-1 gene was knocked out showed increased activity of PR and cells where 
p53 and BRCA-1 protein expression is lost the growth of tumors was attenuated 
by anti-progestins (587,588).  These pieces of evidence definitely suggest a 
prominent role of PR in PR/ER positive breast cancer and further research must 
be done in order to fully elucidate mechanisms of PR in breast cancer. 
ErbB2 and breast cancer 
ErbB2 (also known as HER2, HER2/neu, EGFR2) is a member of the 
epidermal growth factor receptor family and is commonly amplified in breast 
cancers (51-51,562).  HER2 is a transmembrane tyrosine kinase receptor that is 
encoded by the ERBB2/HER2 gene on chromosome 17q21 and is amplified in 
30% of breast cancers and is a negative prognostic factor for patient survival (51-
54,562).  HER2 lacks any endogenous ligands, however, when overamplified in 
cancer it can homodimerize ligand-independently or heterodimerize with ligand 
bound EGFR receptors, triggering autophosphorylation of the cytoplasmic tails 
and downstream RTK signaling (i.e. PI3K/AkT, MAPK pathways) (51-
54,82,83,562).  Crystallographic evidence shows that HER2 exists in a 
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constitutive ligand-bound confirmation, which can activate other receptors (563).  
There are currently drugs that target HER2 such as lapatinib and monoclonal 
antibodies such as trastuzumab (Herceptin) (563).  Lapatinib is a kinase inhibitor, 
which inhibits the kinase domain of HER2 and EGFR and the trastuzumab 
antibody blocks receptor hetero-and homo-dimerization and may have other 
effects including attenuation of endocytosis of the receptor as well as cleavage of 
the extracellular domain, and activation of antibody-dependent cellular toxicity 
(ADCC) (563,564).  
 HER2 status is often assessed by IHC analysis or fluorescent in situ hybridization 
to determine the copy number of the gene (563-565).  HER2 extracellular domain 
can be proteolitically cleaved and released into circulation and can be used for 
detection of primary and metastatic breast cancer by use of ELISA.  Tumors that 
overexpress HER-2 develop a condition known as oncogene addiction (562).  
These types of cancer can be targeted in a receptor-dependent manner in even 
the most aggressive cancer types. 
Triple negative breast cancer 
Breast cancers can however become completely independent of the need 
for this receptor (as well as ER or PR) and become designated as triple negative 
breast cancer (TNBC) (51-514).  This name denotes the lack of expression of 
these three receptors and are refractory to conventional chemotherapy and more 
difficult to approach therapeutically.  There is currently fervent research being 
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conducted in order to develop new molecular based therapies towards this 
disease (51-54, 589).  Breast cancer cell lines have helped in such endeavors and 
multiple TNBC cell lines (such as MDA-MB-231, BT549) are being used.  Basal 
TNBC has high expression of cytokeratins 5/6 as well as EGFR and Ki67.  
Claudin-low express little to no expression of claudin-3, -4,and -7 proteins, which 
are required for cell attachment at tight junctions.  These cells also express the 
epithelial marker E-cadherin (561,562).  Both of these types are negative for 
mesenchymal marker N-cadherin (at resting conditions), although basal (MDA-
MB-231) has high expression of cadherin-11, a breast cancer marker (561,562).  
The development of innovative drugs for TNBC is of utmost urgency.  Below 
discussion of other novel breast cancer markers will be discussed. 
Carbohydrate 15-3 (CA 15-3) and carcinoembryonic antigens (CEA) 
Breast cancer that has metastasized becomes difficult to treat and Carbohydrate 
15-3 (CA 15-3) and carcinoembryonic antigen (CEA) are used as markers of 
metastatic breast cancer (590,591).  CEA is a glycosyl phosphatidyl inositol (GPI) 
cell surface anchored glycoprotein, which possess sialofucosylated selectin and 
E-selectin ligands, which is expressed in a vast majority of human colorectal, 
pancreatic, and breast carcinomas (590,592).  These can serve as mediators of 
metastasis and enable dissemination into distal sites (590,592).  The selectins are 
recognized by endothelial cells and facilitate cancer cell attachment to blood 
vessels and promote intravasation (590,592). Determination of CEA concentration 
is indicative of tumor size and nodal involvement and patients with levels >7.5 
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µg/L have a poorer prognosis than those within the normal range (<7.5ug/L) 
(590,592).   
CA 15-3 peptides are shed from soluble forms of a mucin, known as MUC1, 
which is a transmembrane protein that is implicated in immunoevasion and 
metastasis.  It has two subunits, which form a stable dimer (591).  Release of CA 
15-3 is mediated by 2 proteases ADMA17 and MT-MMP1 (591,593).  This is 
heterogeneously expressed on the apical surface of epithelial cells and is 
overexpressed in 90% of breast cancer (591).  There has been reports 
demonstrating a prognostic significance for CA 15-3 in patients that have HER2+ 
or HER2 overexpressing breast cancer (591,593).  CA 15-3 may be of value in 
predicting disease relapse after surgery or in patients resistant to conventional 
treatments for this disease subtype (591,593).  CA 15-3 seems to be a more 
reliable and reproducible marker of breast cancer compared to CEA, however the 
combination of CEA with CA 15-3 has been demonstrated to be a highly predictive 
marker of breast cancer (591,593).   
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BRCA1, BRCA2, and breast cancer  
 
 
Breast cancer also contains a direct hereditary component.  Approximately 
80% of the cases related to familial breast cancer are associated with the DNA 
repair tumor suppressor genes BRCA1 and BRCA2 (Figure 38) (594).  BRCA1 
and BRCA2 are important DNA repair enzymes that are stimulated by ATM (S988) 
and CHK2 (S187, S1423, S1524) by phosphorylation (594,595).  BRCA proteins 
play a major role in transcriptional regulation, DNA repair, inhibiting cell 
proliferation and cell cycle arrest.  BRCA1 combines with tumor suppressors and 
other signal transducers to form the BRCA1-associated genome surveillance 
complex (BASC) (594,595).  This associates with RNA polymerase II as well as 
histone deacetylases via BRCA1 C-terminal domain.  BRCA2 is also involved in 
the DNA damage response and involves BRCA2 directly interacting with RAD51 
Reprinted with permission from: Roy R., Chun J., Powell SN, Nature Rev Cancer 2011 Dec 23;12(1):68-78. (594) 
Figure 38: BRCA1 and BRCA2. Structure and homology between Breast Cancer Associated (BRCA) 1 and 2.  
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recombinase, through its BRC repeats, to promote strand invasion and 
subsequent recombination (594,595).  The recognition of RAD51 to double 
stranded DNA requires BRCA2-BRCA1 complex along with BRCA partner PALB2 
(partner and localizer of BRCA2) (594,595).    
The frequency, spectrum, and mutations within BRCA1 and BRCA2 genes 
show considerable variation between geographic, demographic, and ethnic 
background, which emphasizes the role that heredity and environment, play in 
mutational rates and locations (596).  Family history profiles can predict mutations 
in these genes mainly with characterizations of first-degree relatives with breast 
or ovarian cancer, along with young age of diagnosis, bilateral occurrence and 
increases number of affected relatives (596).  Genetic counseling to identify 
BRCA1 BRCA2 mutations is available and this may be able to serve as means for 
cancer prevention of at the very least prophylactic anticancer measures (594-
596).  
 
Kidney Cancer 
Kidney cancer classification 
Kidney cancer represents the seventh most common type of cancer in the 
United States and it is estimated that in 2016 there will be 62,700 new cases in 
2016 with over 14,000 of those resulting in cancer related death (20,21,597).   The 
two most common types of kidney cancer are RCC (renal cell carcinoma) and 
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TCC (transitional cell carcinoma), with the latter sometimes being called urothelial 
cell carcinoma (597).  RCC comprises approximately 80% of kidney cancer with 
the latter being mostly TCC.  The overall 5 year survival rate in the united states 
in 73%, however kidney cancer (especially RCC) presents itself without any overt 
symptoms and early diagnosis is very difficult due to lack of good early stage 
markers (597).  This 5 yr. survival rate also drops drastically if it spreads to the 
lymph nodes (65%) or metastasizes (i.e. pelvic abdominal cavity >12%) (597).   
Other less common types of kidney cancer include squamous cell carcinoma, 
juxtaglomerular cell tumor, angiomyolipoma, Bellini duct carcinoma, clear cell 
sarcoma, Wilm’s tumor, mesoblastic nephroma, and mixed epithelial stromal 
tumor (or cystic nephroma); Squamous cell carcinoma is kidney cancer of the 
squamous cells.  Juxtaglomerular cell tumors are tumors that arise from 
juxtaglomerular cells (597,598).  These tumors often secrete high levels of the 
enzyme renin, which causes extreme cases of hypertension.  Angiomyolipomas 
are tumors that have a high association rate with the disease tuberous sclerosis, 
which have a genetic component having mutant TSC ½, important tumor 
suppressors (597-599).  Bellini duct carcinoma is very rare (1-3% of kidney 
cancer) and it is a tumor that arise from the papillary duct of the kidney. Clear cell 
sarcoma of the kidney, mesoblastic nephroma and Wilm’s tumor are all pediatric 
associated malignancies, which occur very early in life (with mesoblastic 
nephromas being observed within the first 3 months of life) (599,600).  Wilm’s 
tumor is also referred to as a nephroblastoma and is quite heterogeneous, 
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containing blastemal cells (which have pluripotent propensity), mesenchymal 
cells, and epithelial cells (599,600).   Wilm’s tumors also have genetic 
components, which include mutations on Wilm’s tumor genes (WT1 and WTX) 
and β-catenin (601,602).   
Kidney cancer staging 
 
 
Figure 39: Kidney cancer staging. Staging of kidney cancer follows the TNM classification system.  
Infiltration into lymph nodes and growth either within or beyond Gerota’s fascia are assed to determine 
specific tumor stage and grade. 
 
https://pfizeroncology.com.au/understandingsomecancers/kidneycancer.aspx 
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Kidney cancer is staged using the TNM system (as seen in breast and other 
cancer types) and has four stages (Figure 39) (603).  At stage T1 there is a tumor 
that is between 4-7 cm within the kidney and it has not outgrown beyond the 
kidney (603).   If it is 4 cm, it is T1a; if larger than four, it is T1b.  At T2 stage, the 
tumor has grown beyond 7 cm but is still only within the kidney (603).  If it has 
grown larger than 10 cm then it is classified stage T2b (if less than 10 then T2a).  
When the kidney tumor has grown into a major vein or tissue of the kidney, but 
has not infiltrated the adrenal gland or beyond Gerotias fascia (fibrous layer that 
surrounds the kidney) then the tumor is classified T3 (603).  If the tumor is growing 
into the renal vein it is classified T3a (603).  If the tumor is growing into the vena 
cava, it is classified as T3b and if this growth is near your chest than it is T3c 
(603).  If the tumor has grown into the adrenal gland and/or beyond Gerotias fascia 
then it is labeled stage T4, and these type of tumors have a very high propensity 
for metastasis, especially to the pelvic and abdominal regions (603).   
As stated, RCC represents the majority of RCC cases and represents 5% 
of adult epithelial cancers (20,21,603).  RCC is a cancer that originates from the 
tubules of the kidney and clear cell carcinoma represents the most frequently 
observed subtype.  Detecting these tumors early has been a substantial 
challenge; increased detection has been a consequence of increased screening, 
and advances in technology as these cancers are most often asymptomatic (604).  
The most common symptoms are abdominal and lower back pain and hematuria 
and manifestations are variable (603,604).  RCC has also variable responses to 
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chemotherapy and radiation, and immunotherapies are promising (604,605).  
RCC responds the best to chemotherapies that target mTOR, angiogenesis 
(through VEGF and HIF-1α) and RTK inhibitors (i.e. EGFR inhibitors) such as the 
kinase inhibitor sorafenib and PDGFR and VEGFR inhibitor sunitinib (604,605).  
Other kinase inhibitors including pazopanib, axitinib, erlotinib, and cabozantinib 
(VEGFR) combined with mTOR inhibitors such as tesmirolimos and everolimous 
(analogs of rapamycin) and/or with bevacizumab (VEGF inhibitor) are among the 
most effective currently available chemotherapeutic regimens available for RCC 
today (606-610).  Risk factors associated with RCC include environmental factors 
such as exposure to petroleum products, smoking (direct or secondhand), 
chlorinated solvents (such as trichloroethylene (TCE)), cadmium, lead, and 
asbestos (611-615).  Diet and lifestyle also play a role as incidence is increased 
with obesity, insufficient water consumption, consume not enough water, high 
protein diets, high salt which leads to hypertension, and overuse of diuretic 
compounds (which can be drugs like clenbuterol, over the counter diuretics, or 
excessive caffeine consumption) (616-619).  Kidney transplantation, history of 
kidney issues or dialysis use in the family, and HIV infection also increase the risk 
of RCC (603,605,607,617). 
Certain genetic risk factors are associated with increased incidence of 
RCC, namely mutations in tumor suppressors VHL and TSC 1/2., which negatively 
regulate angiogenesis and mTOR signaling respectively (605).  Indeed people 
who have con Hippel-Lindau disease have a 40% likelihood of developing RCC 
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at an early age, and its frequency is bilateral (75%) or multifocal (87%), with males 
at high risk (5 times) than females and African Americans have a higher incidence 
than Caucasians (328-330).   
VHL and HIF-1 in RCC 
Identification of the Von Hippel-Lindau (VHL) gene and elucidating its 
functions has helped substantially in developing RCC specific chemotherapy and 
has substantially enhanced our knowledge of RCC parthenogenesis.  Loss of VHL 
is associated with VHL disease, which is a hereditary cancer syndrome that is 
characterized by the presentation of angiomatosis, phenochromocytoma, 
pancreatic and renal cysts, endolymphatic sac tumor, and hemangioblastomas 
(328-330).  VHL is a tumor suppressor gene that is found on chromosome 3p25.3 
and with affected families, the risk of RCC (and other cancers) is transmitted in an 
autosomal dominant manner (328-330).  The VHL gene is a textbook example of 
the two-hit hypothesis.  The two-hit (or Knudson hypothesis) states that cancer is 
caused by an accumulation of mutations, where two hits on a specific gene need 
to occur in order for a phenotype to emerge from these mutations (620).  He 
demonstrated this with children with retinoblastomas who had inherited a mutated 
Rb gene and would have to incur another mutation or “hit” on the wild type allele 
for development of retinoblastoma (620).  There are over 1500 germline and 
somatic mutations found in VHL disease, and individuals with VHL carry in their 
germline one wild type VHL allele, and one inactivated VHL allele (328-330).  VHL 
manifests with full penetrance when the remaining wild type allele is inactivated 
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in a susceptible cell type (328-330). It has been demonstrated that inactivation of 
VHL is an early step in the pathogenesis of RCC in those individuals who have 
VHL disease.  The VHL gene is mutated in approximately 50% of sporadic RCC 
and mutation is always observed in hereditary RCC (100%); therefore, the 
majority of RCC is linked by biallelic inactivation of VHL (328-330).   
The VHL protein (pVHL) which is an important regulator of HIF1-α and 
plays an important role in drug metabolism and pathogenic defense in the 
intestinal tract.  Under normoxic conditions, HIF1-α is hydroxylated by prolyl 
hydroxylases (PHD), and is recognized by pVHL (326-330). In hypoxic conditions, 
PHD is inactive, and HIF1-α accumulates, enabling it to translocate to the nucleus, 
associate with ARNT and express hypoxia inducible genes (326-330).  When 
pVHL is mutated however, it does not recognize HIF1-α even when it is 
hydroxylated, which leads to constitutive activation of HIF1-α.  This not only 
aberrantly upregulated genes involved in angiogenesis, but also glycolysis, 
glucose transport, pH regulation, cell cycle progression, and apoptosis (326-330).   
VEGFR pathway and RCC 
 Constitutively active HIF1-α enhances VEGF and PDGF expression, which 
both play a substantial role in angiogenic signaling (315-325). Cancer cells can 
either directly activate angiogenesis through HIF1-α regulated pathways or by 
recruiting immune cells and exploiting the growth factors they release (315-325).  
There are several therapeutic strategies that have been designed to target 
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angiogenic pathways and these include VEGFR inhibitors such as vandetanib, 
and VEGF-R inhibitors (vatalanib) (315-318). 
mTOR and RCC 
Along with regulation translation, cell growth and ribosomal biogenesis, 
mTOR also regulates HIF1-α expression and particularly increases levels in 
individuals who have mutant pVHL (328-330).  Patients who have RCC also have 
common mutations in the PTEN gene, which is a negative regulator of PI3K, 
further suggesting a link between mTOR necessity and angiogenesis (100,104).  
Inhibiting the mTOR pathway as well as PI3K/AkT pathway also inhibits growth 
and proliferation of endothelial cells and pericytes, which are crucial for 
angiogenesis (100,104).  Furthermore, under excessive hypoxic stress a p53 
upregulated gene REDD1 (Regulated in Development and DNA damage 
Response) (100,104).  Upon its expression, it links protein p63 to upregulation of 
proapoptotic genes (PUMA, Noxa) and REDD1 directly inhibits mTOR 
(100,104,192,218-285).  Together these three pathways converge on 
angiogenesis and excessive cell proliferation, which are hallmarks of cancer, and 
have a strong hereditary, as well as empirical and spontaneous component. 
 
 
 
162 
 
Rhabdomyosarcoma (RMS) 
Rhabdomyosarcoma classification 
Rhabdomyosarcoma (RMS) is the most prevalent soft tissue in children 
and adolescents, accounting for 5% of all pediatric cancers (621).  RMS is a 
relatively rare cancer effecting 4.3 per 1 million children, with 350 estimated new 
cases being diagnosed in children and adolescents, and extremely rare in adults 
and persons over the age of 20 (621).   The term rhabdomyosarcoma has a 
tripartite meaning: designating striated (rhabdo-) muscular tissue (myo-) and 
sarcoma, which is any cancer that is derived from mesenchymal stem cells and 
therefore mesenchymal in origin (621).  RMS can originate from anywhere in the 
body and its etiology is elusive, with only some association with genetic inherited 
diseases such as neurofibromatosis type 1 and Li-Fraumeni cancer syndrome 
(621).  RMS can occur either as a primary malignancy or as a component of a 
heterogeneous malignancy such as a teratoma, which is a tumor that contains 
cells that are derived from all three of the basic cell lineages: endoderm, 
mesoderm, and ectoderm (622).   
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There are two basic types of RMS: embryonal rhabdomyosarcoma (ERMS) 
and alveolar rhabdomyosarcoma (ARMS) (Figure 40) (621,622).  There are also 
two smaller categories of pleomorphic RMS (PRMS) and sclerosis/spindle cell 
RMS (SRMS).  ERMS however, has a much better prognosis and represents 60-
70% of RMS cases (622,623).  It has clear presentations with a characteristic 
pathology resembling “small round blue tumor cells” after H&E staining (623).  
Tumors are often present in the head and neck as well as the genitourinary track.  
ERMS can also be classified into small subdivisions based on cell morphology: 
Figure 40: Classification of rhabdomyosarcoma (RMS).  There are two basic types: embryonal RMS (ERMS) 
and alveolar RMS (ARMS), with the latter having a very poor prognosis.  Many animal models using genetic 
alterations (which both ARMS and ERMS have observed genetic components) can recapitulate the different 
types of RMS. 
 
Reprinted with permission from: Kashi VP, Hatley ME, Galindo RL, Nat Rev Cancer 2015 Jul;15(7):426-39. (621) 
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butyroid ERMS and spindle cell ERMS (622,623).  Butyroid ERMS originates from 
mucosal lined organs such as found in the bladder, nasopharynx, and vaginal 
cavity and is found in infants less than a year old (622,623).  It presents as a 
dense mass under an epithelial layer of tissue.  SRMS is very similar to another 
sarcoma types of smooth muscle cells, leiomyosarcoma presenting with a 
fascicular, spindled and leiomyomatous growth pattern with notable myoblastic 
differentiation (623).  
  It represents 3% of RMS cases and presents commonly in the 
paratesticular regions.  This type along with butyroid have very high survival rates 
with good prognoses (623,624).  ARMS is the most malignant form of these RMS 
types and has a very poor prognosis, with less than a 10% survival rate.  This type 
of RMS is characterized by densely packed, round cells that arrange is a fashion 
similar to pulmonary alveoli and forms in extremities, torso, and peritoneum (621-
624).  This type of cancer is very aggressive and most succumb to this disease 
(620-624).   
Rhabdomyosarcoma staging 
 Diagnosis of RMS is contingent on the size, physiology, morphology, and 
metastatic propensity of the cancer, with ERMS and ARMS having stark 
differences for these categories (621-624).  In order to stage RMS THE TNM 
stage and clinical group must be determined along with the type of RMS.  Along 
with TNM and clinical group staging there is a risk stratification system that has 
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been established by the Intergroup Rhabdomyosarcoma Study Group (IRSG), 
which is highly predictive of outcome (625).  TNM staging uses the classical tumor, 
lymph nodes and metastases characterization with other factors to determine the 
overall stage (625).  Stage 1 the tumor has originated in a favorable area, which 
include the orbit, head or neck (with exception to parameningeal sites), 
genitourinary track, or bile ducts (621-625).  Tumor size is not a factor in this 
staging and lymph node infiltration is possible, but metastatic lesions are not 
present.  Stage II on the other hand has a tumor that has originates in an 
unfavorable region of the body, which include arms or legs, prostate, bladder, a 
parameningeal site, or other regions not lists as stage I criterion (621-625).  
Tumors are less than 5 cm and there are no metastases or lymph node infiltration.  
Stage III is similar to Stage II, with the only distinction being a tumor larger than 5 
cm (with no lymph node infiltration or metastases) or the tumor is of similar size 
but has infiltrated adjacent lymph nodes.  Stage 4 tumors have metastasized to 
distal organs such as lungs, bones, or bone marrow and the size of tumor and site 
of origin are irrelevant in this stage (621-625). 
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Clinical group staging is based on the extent of the disease and the degree 
of efficacy in removal of the disease after initial surgery (Figure 41) (625).  Group 
I includes children with localized RMS (with no lymph node infiltration or 
metastases) and the cancer has been consummately removed after surgery 
(625).  This encompasses about 10-15% of children with RMS.  Group II children 
have had all the visible cancer removed by surgery but remnants of the tumor 
Figure 41: RMS staging. RMS is classified by the TNM classification system and by IRS clinical group 
classification.  TNM staging considers the size, location, and the presence of lymph node infiltration and 
metastases.  Clinical group classification considers the grade of the tumor after surgical resection. 
 
Reprinted with permission from: Dénes FT, Duarte RJ, Cristófani LM, Lopes RI, Front Pediatr. 2013 Dec 
16;1:48 (625) 
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remain and can reside in the periphery of the original tumor site, in the lymph 
nodes or both (625).  This comprises about 20% of RMS patients.  Group III 
children have tumors that could not be completely removed by surgery and 
conspicuous parts of the tumor were left behind (625).  Lymph node infiltration 
may be present but metastatic lesions are absent.  This group represents 
approximately 50% of RMS patients (625).  Group IV children the cancer has 
metastasized to the lung, bones, or bone marrow at the time of diagnosis and 15-
20% of RMS patients are in this group (621-625).   
 Risk group classification is determined by integrated information obtained 
from TNM and clinical group classification and is a determinant on the type and 
aggressiveness of the chemotherapeutic regimen (621-625).  About 1 in 3 children 
are in the low risk group which include children with TNM stage 1 embryonal RMS 
that are in clinical groups 1, II, or III or children with stage 2 or 3 ERMS in clinical 
groups I or II (621-625).  The intermediate risk group includes about 50% and is 
comprised of children with stage 2 or 3 ERMS or children with ARMS in stage 1, 
2, or 3 (with no metastases present).  The high-risk group includes children that 
have stage 4 RMS and metastases are present.  Age correlates with some degree 
of tumor histology and primary site physiology (621-625).  Patients who are over 
the age of 10 have a greater likelihood of ARMS whereas those younger than 10 
are more likely to have ERMS (621-625).   Treatment options available for RMS 
are very limited and include surgeries, radiation therapy, and a cocktail of very 
cytotoxic drugs (620-624).  There is the VAC chemotherapeutic regimen, which 
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includes vinca alkaloid microtubule disruptor vincristine, actinomycin-D, which is 
a potent pan inhibitor of transcription, and the nitrogen mustard alkylation agent 
cyclophosphamide (621-624).  Some drugs are replaced, such as ifosfamide, 
which is given concomitantly with mesna (sodium methane thiolate) to reduce the 
incidence of hemorrhagic cystitis and hematuria (621-624). A byproduct of 
cyclophosphamide metabolism is acrolein, which is toxic, and can be scavenged 
by mesna.  Type I and Type II topoisomerase inhibitors irinotecan and etoposide 
are also used in conjunction with cyclophosphamide and vincristine (621-624).  
These are cytotoxic drugs that target all rapidly dividing cells.   
Not only does RMS induce deleterious effects but the chemotherapies 
have detrimental effects later on in life (626).  Indeed, there is a high incidence of 
adverse health outcomes (pulmonary, endocrine, cardiac, cognitive etc.) in those 
individuals who have overcome RMS (626).  According to a St. Jude lifetime 
cohort study “at age 45 years, the estimated cumulative prevalence of any chronic 
health condition was 95.5% (95% CI, 94.8%-98.6%) and 80.5% (95%CI 73.0%-
86.6%) for a serious/disabling or life-threatening condition” (626).  Statistics, the 
ambiguous etiology, and paucity of efficacious chemotherapeutic regimens and 
procedures truly underscores the necessity to develop less cytotoxic drugs (621-
626). There has been a resurgence in the endeavors to develop novel RMS 
chemotherapy and treatment.  Recently two approaches involving lineage of origin 
and genetic studies which indicate that reactive oxygen species (ROS) inducing 
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drugs may be beneficial and this will be discussed in detail in the following 
sections (621-626). 
PAX3-FOXO1 and RMS 
 
 
Comparative Genomic Hybridization (CGH) analysis has revealed that all 
RMS types have specific acquisition or loss of chromosomes and exhibit 
chromosomal abnormalities (627,628).  ERMS frequently exhibits alterations is 
whole chromosomes, whereas ARMS is characterized by the presence of regions 
Figure 42: PAX3-FOXO1 and PAX7-FOXO1. ARMS is distinguished by the presence of the Pax 3-FOXO1 fusion 
gene product. This translocation is observed in 80% of ARMS cases and involves chromosomal translocation 
associated with t(2;13)(q35;q14) and t(1;13)(p36;q14), involving the 5’ DNA-binding region of PAX and the 
transactivation domain at the 3’ end of FKHR. The PAX7/FKHR fusion gene product t(1;3(q36;q14) is also 
observed but only in 25% of translocation-positive patients 
 
http://atlasgeneticsoncology.org/Genes/GC_FOXO1.html (627) 
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of genomic amplification.  The genes most of which have amplifications are CDK4, 
MYCN, GLI, MDM2, FGFR1, and FGFR4, which correspond to chromosomal 
regions 12q13.3-q14.1 (627-631).  Most genes that are aberrantly expressed due 
to chromosomal abnormalities are oncogenes, which increase cell proliferation or 
inhibit tumor suppressors.  ARMS tends to have less copy number variants than 
ERMS, and chromosomal amplification of gene TYROBP, LFRN3, and HCST 
were observed in ERMS but not ARMS (627-631).  Along with regional genomic 
amplification, chromosomal translocations are also frequently observed in ARMS.  
These involved the myogenic paired box transcription factor PAX3 and the 
transcription factor FOXO1 (FKHR), a member of the forkhead/HNF-3 
transcription factor family (632,633).  This translocation is observed in 80% of 
ARMS cases and involves chromosomal translocation associated with 
t(2;13)(q35;q14) and t(1;13)(p36;q14) (Figure 42) (632,633).  The chromosomal 
translocations involve the 5’ DNA-binding region of PAX and the transactivation 
domain at the 3’ end of FKHR (632,633).  It is estimated that 75% of these 
chromosomal rearrangements translocate the PAX3 (2q25) gene to FKHR 
(13q14) with the other 25% being associated with a PAX7/FKHR fusion gene 
product t(1;3(q36;q14) (632,633).   The other 20% of ARMS patients lack either 
translocation variant (designated PAX gene fusion negative or PFN) and these 
pose a challenge to detect (632,633). Risk stratification analysis has 
demonstrated that PAX3/FKHR status is a beneficial prognosis marker, whereas 
evidence for the PAX7 derivative is equivocal and inconclusive (632,633).          
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Recently a paper was published in Genes and Development, which 
addressed the lineage or origin concept in ARMS (634).  They used conditional 
genetic mouse models of ARMS to recapitulate the PAX3:FOXO1 fusion genes 
and inactivate p53 and demonstrated that lineage of origin had a substantial 
impact on the histopathology and morphology of the tumor and its sensitivity to 
chemotherapeutic agents (634).  They concluded that the p53 is often mutated in 
RMS and that these tumors that express the PAX3:FOXO1 fusion gene forms 
sarcoma for satellite cells that are distinctive from any other myogenic lineage and 
it was PAX3, not PAX7, fused with FOXO1 along with p53 mutation in these 
mouse models that congruently recapitulated the human ARMS phenotype (634).  
PAX3:FOXO1 was also demonstrated to be epigenetically regulated and that DNA 
methyltransferase inhibitor 5’Aza 2’deoxycytidine or etinostat (HDAC inhibitor) 
showed a significant decrease in PAX3:FOXO1 mRNA and protein expression, 
with a more pronounced effect with etinostat (634).  They also observed 
decreased tumor growth in these mouse models with etinostat treatment (634).  
They successfully demonstrated the therapeutic potential that HDAC inhibitors 
play in a human ARMS model; however, the exact mechanism was not elucidated.   
ROS (reactive oxygen species), sources of ROS, and ROS scavengers 
In humans, as well as mammals, the generation of reactive oxygen species 
(ROS) as well as reactive nitrogen species (RNS) is a natural consequence of 
aerobic metabolism (Figure 43) (635).  Cells have evolved mechanisms to reduce 
the concentration of these species as many can be deleterious to the cell.  These 
172 
 
include non-radical species and radical species.  Non radical species include 
hydrogen peroxide (H2O2) and organ peroxides (ROOH), superoxide (O2-˙) singlet 
Oxygen (O2)), ozone (O3), alkoxyl and peroxyl radicals (RO˙ ROO˙) hypochloride 
(HOCl), peroxynitrite (ONO--), nitrososperoxycarbpnate (O=NOOCO2-), 
nitrocarbonate (O2NOCO2-), nitrogen dioxide (N2O2), nitronium ions (NO2+) which 
can cause lipid peroxidation and modification to DNA (such as 8-oxo-guanine) 
that impair cellular homeostasis (635-637).  These enzymes include super oxide 
dismutases (SOD), catalases, glutathione synthesis pathways, glutathione-S-
transferase, and NRF2 (through antioxidant response elements) (635-637).   SOD 
uses a disproportionation reaction (a concomitant oxidation and reduction of a 
species to generate two products) to generate hydrogen peroxide which is 
subsequently neutralizes to water and oxygen by another round of SOD and 
catalase. 
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Cancer cells exploit the role of peroxide as a bonafide signaling molecule 
and whether this molecule signals survival or death pathways is determinant on 
the fine-tuned gradient of hydrogen peroxide that is generated in the cell (635-
637).    Hydrogen peroxide, as well as other peroxides and other peroxidase lipids 
can be neutralized by thioredoxins, peridoxins, and glutathione peroxidases.  The 
latter are unique in the fact that they contain a noncanonical encoding amino acid 
at its active center, selenocysteine (635-637).  The amino acid acts very similarly 
to a cysteine in that it generates a very reactive selenite just as cysteine can form 
reactive thiolates.  However, selenates are much more reactive and have very 
efficient enzyme kinetics (635-637).  The mitochondria are the main generator of 
ROS, which are byproducts of oxidative pathways such as oxidative 
Figure 43: Sources of reactive oxygen species (ROS). Mitochondiral respiration, NADPH oxidase, 5-
lipoxygenase ( are sources of ROS in normal and transformed cells.  Xanthine oxidase, eNOS (endothelial 
nitric oxide synthase) uncoupling and mitochondrial disfunction also increase ROS production. In muscle 
derived cancers ROS levels are substantially elevated and cancer cells upregulate expression of 
antioxidant enzymes including glutathione S-tranferase, thioredoxins, glutathione peroxidases, and 
peridoxins. 
 
Reprinted with permission from: Holmström KM, Finkel T, Nat Rev Mol Cell Biol 2014 
Jun;15(6):411-21. (635) 
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phosphorylation and β-oxidation (635-637).  Other enzymes such as NADPH 
oxidase (involved in pathogen defense and signaling mechanisms), xanthine 
oxidase (converts hypoxanthine into xanthine for purine salvage pathway), and 
heme oxygeneases generate ROS and these species are neutralized by 
antioxidant chemicals such as glutathione (gamma glutamylcysteinyl glycine), S-
adenosylmethionine, and N-acetyl cysteine (635-637).  ROS also plays an 
important role in innate immunity and signaling.  Another enzyme that deliberately 
generates ROS is nitric oxide synthase (NOS), which generates the reactive 
radical messenger nitric oxide (635-637).  Reactive thiyl species are generated by 
these reduced sulfhydryl groups reacting with ROS and RNS (638).  This 
stimulates guanylate cyclase, producing cyclic guanosine monophosphate.  This 
activates protein kinase G (PKG) that induces reuptake of calcium and activation 
of calcium activated potassium channels (638).  The fall in calcium disables 
myosin light-chain kinase (MLCK) from phosphorylating myosin.  This promotes 
vasodilation in endothelial cells and pathogenic defense in macrophages 
(470,471,481,482,638).   
Cancer and ROS 
ROS levels in cancer cells exceed normal physiological thresholds.  This 
is due to metabolic shifts to aerobic glycolysis, hypoxic stress, increased stress 
from increased anabolism, and stress from chemotherapeutic drugs (whether that 
be a direct or ancillary consequence of the drug).  Many cancers also arise from 
chronic inflammation, irritation or infection that induce ROS and tumor cells recruit 
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immune cells such as macrophages that secrete TNFα, which can generate ROS 
(470,471,481,482,638).  Some cancers derived from cells that undergo high levels 
of oxidative metabolism are especially prone to ROS.  Pancreatic cancer and RMS 
both have high levels of ROS that are just marginally under the critical threshold 
that induces ROS-dependent cell death in these cells.  Thus chemotherapeutic 
drugs that induce ROS are highly effective against these tumors (635-638).   ROS-
inducing anticancer agents include cytotoxic drugs that induce to excessive stress 
(such as DNA alkylating agents daunorubicin and doxorubicin, and microtubule 
disrupting agents like Taxol) and compounds that target mitochondria (635-638).  
Some compounds also indirectly induce ROS by inhibiting the synthesis or 
reducing the concentration of cellular antioxidants.  Buthionine sulphoximine 
inhibits glutathione (GSH) synthesis by inhibiting the enzyme gamma glutamyl 
cysteine synthase, Imexon and DEM (diethyl malonate) deplete intracellular levels 
of GSH, and 2-methoxyestradiol inhibit SOD directly and tertamethylmolybdate 
acts as copper sink, needed for SOD (639).  There are also natural products 
(phytochemicals) and analogs that have ROS-inducing anticancer activity. The 
compound piperlongumine (PL) from the Long pepper and nimbolide, a terpenoid 
lactone, are ROS-inducing agents (640,641).  Our laboratory investigated several 
ROS inducing compounds, including curcumin, triterpenoids (betulinic acid, 
CDDO-Me), celastrol, and the isothiocyanate PEITC (642-648).  We recently 
reported that PEITC induced apoptosis, decreased cell proliferation, and inhibited 
migration in pancreatic cancer cells all of these responses were ameliorated by 
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pretreatment with the antioxidant glutathione (648).  PEITC downregulated Sp 
(specificity protein) transcription factors in an ROS-dependent manner (648).  This 
effect was initiated by ROS-dependent downregulation of c-Myc in an epigenetic 
fashion, which led to a decrease in miRNAs 17, 20, and 27a (Figure 44) (648).  
These miRNAs are negative regulators of ZBTB proteins which are induced (by 
ROS) resulting in downregulating of pro-oncogenic Sp-regulated genes (648). 
 
 
RMS and ROS: histone deacetylases (HDACs) and HDAC inhibitors 
 RMS has also recently been shown to be sensitive to ROS inducing agents 
(635,626).  The anti-malaria drug artemisinin, induced apoptosis in RMS and had 
antitumor effects (647).  The drug curcumin has also been demonstrated to inhibit 
RMS tumorigenesis by inhibiting the mTOR pathway (649).  In Cancer cell, a 
Figure 44: Mechanism of ROS anticancer activity. Drugs that induce ROS inhibit cancer growth by targeting 
cMyc.  This downregulation of cMyc leads to downregulation of miR-27a, miR-20a, and miR-17.  This leads to 
an increase in ZBTB 10 and 4 expression.  ZBTB proteins negatively regulate Sp proteins and inhibit their 
transactivational activities.  Drugs such as isothiocyanates, NSAIDs, triterpenoids, curcumin, artemisinin, and 
HDAC inhibitors have been demonstrated to induce ROS. 
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critical paper was published that demonstrated the effects of a myriad of ROS 
inducing agents and their anticancer effects on a multiple types of tumors (650).  
They used genomic analysis to demonstrate that ERMS have high copy number 
variants associated with genes, namely those involved in the RAS/NF1 pathways, 
which is associated with increased risk (650).  They developed orthotopic 
xenografts and through high throughput screening of primary cultures concluded 
that oxidative stress was a significant pathways that had therapeutic  
 
 
relevance in treating ERMS (as well as other tumor types such as pancreatic and 
ovarian) (650). One of these agents was a histone deacetylase inhibitor (HDACi) 
Figure 45:HDAC inhibitors (HDACi).  All HDACi consist of a capping group, an aliphatic linker, and a functional 
group which interacts with the Zn2+ binding pocket and inhibits the HDAC. B) There are 4 classes of HDAC 
inhibitors: hydoraxmic acid derivatives (vorinostate and belinostat), aliphatic acids (magnesium valproate, 
sodium phenylbutyrate, depsipeptides (rhomidepsin), and benzimides (mocetinostate and etinostat).  They have 
varying specificity and potency against cancer and their efficacy is tissue specific.  HDAC inhibitors have shown 
great promise in hematological malignancies and vorinstat is FDA approved for cutaneous T-cell lymphoma. 
 
Reprinted with permission from: Mottamal M., Zheng S., Huang TL., Wang G., Molecules 2015 Mar 
2;20(3):3898-941. (650) 
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panobinostat (LBH589) (650).   HDACi are a class of compounds that inhibit the 
enzymes known as histone deacetylases (HDAC) (Figure 48) (650).  These 
enzymes deacetylate lysine residues on histone tails (650).  HDACi (illustrated in 
figure 45) have long been of interest in cancer research as chemotherapeutic 
agents.  While their anticarcinogenic effects have been very promising in 
hematological malignancies, their efficacy in solid tumors is modest and they have 
been considered only as adjuvants to existing more cytotoxic chemotherapeutic 
regimens.  Vorinostat has been FDA approved for treatment of cutaneous and 
peripheral T-cell lymphoma (CLTL) and vorinostat is in clinical trials for treating 
GBM as an adjuvant with temozolomide (651).   Rhomidepsin has also been 
approved for CTCL and is clinical trials for T-cell lymphomas.  Another pan-HDACi 
that has been used extensively in research and clinical setting id the drug 
belinostat.  In addition, it has been approved for treatment of peripheral T-cell 
lymphoma (PTCL) (652).  Panobinostat is a pan-HDACi that is sold under the 
trade name Raydak by Novartis and on February 2015, it received FDA approval 
for treating multiple myeloma in patients that had already received two other 
treatments that included bortezomib and thalidomide or one of its analogs 
(lenalidomide) (653).   It is currently in clinical trials for Hodgkin’s Lymphoma, 
CTCL, myelodysplastic syndromes, breast cancer, and chronic myelomonocytic 
leukemia (CMML) and prostate cancer (653-656).   Recently Panobinostat has 
been shown to selectively target TNBC breast cancer and reduce hypoxia induced 
cisplatin resistance in NSCLC by destabilizing the HIF1-α (654).   Panobinostat 
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also induces autophagic cell death in liver cancer (657).  Many of these effects of 
panobinostat and other HDACi may have an underlying oxidative stress 
component and in this thesis, the research of panobinostat as an ROS inducing 
agent that specifically targets RMS (both ERMS and ARMS) cancer cells and the 
results will be reported in chapter IV. 
 
Colorectal Cancer (CRC) 
CRC classification 
Colon or colorectal cancer (CRC) is the second and third most commonly 
diagnosed cancer in women and men respectively and more than one million 
people worldwide are diagnosed with tumors in the colon every year and recent 
molecular studies demonstrate that tumors in colon and the rectum are the same 
type (20,21).  Colon or colorectal Thus CRC is the generic term for several types 
of cancer that arise in the colon and rectum, including adenocarcinoma, carcinoid 
and stroma tumors, lymphoma and sarcoma (20,21,658).  Adenocarcinomas 
originate from the gland cells that make the mucus of the colon and rectum and 
are epithelial in origin (658).  Carcinoid and stromal tumors originate from 
specialized hormone-producing cells and barrier-forming cells respectively and 
they can be found in other regions of the gastrointestinal tract (659).   Lymphomas 
originate from cells in the lymph nodes associated with the intestinal tract and 
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sarcomas originate from connective tissues and cells of mesenchymal origin such 
as muscles, blood vessels (658,659).   
CRC: lifestyle and diet 
Factors that directly influence CRC include diet (high fat, alcohol, and low 
fiber, high consumption of red and processed meats), sedentary lifestyle, 
smoking, and obesity (658,659).   High fat and low fiber consumption lead to a 
state of constant inflammation within the colon that promotes cancer and the 
formation of polyps.  Obesity exacerbates this condition and so does lack of 
exercise.  Smoking release a myriad of carcinogenic compounds, the most 
notable being benzo (a) pyrene (32,658,659).  Red meat and processed meat 
have high levels of nitrites, which can form nitrosamines, which are known 
carcinogens.  Consumption of barbequed meat also leads to the of carcinogenic 
polyaromatic heterocyclic amines such as PhIP (2-amino-1-methyl-6-
phenylimidazo(4,5-b)pyridine (660).  Adenocarcinomas are the most commonly 
diagnosed colon cancers and account for 95% of all colon cancer cases (21,660).  
They arise from adenomatous polyps such as adenoma formed in the innermost 
lining of the colon that eventually grow past the wall and into the underlying tissue 
(660).  When cancer cells invade the blood and lymphatic vessels, they 
metastasize to other parts of the body, favoring tissues such as the liver by 
traveling the portal vein (51-54,660).   
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CRC staging and chemotherapeutic regimens 
 
 
Colon cancer can be categorized into four different stages with each stage 
representing an increased aggressiveness and likelihood of metastasis with the 
disease (Figure 46) (661).  After carcinogenic transformation, neoplastic cells form 
a high-grade dysplasia, which is either a hyperplastic or inflammatory polyp.  This 
http://fightcolorectalcancer.org/fightcrc-fightit/diagnosis-staging/ (661) 
 Figure 46: Stages of colorectal cancer.  Stage 1 tumors are polyps that have infiltrated the submucosa or the 
muscularis propria, designated T1 or T2, and no lymph node invasion or metastases are observed yet.  Stage 
2 tumors can be broken down into three different categories: Stage IIa, Stage IIb, and Stage IIc.  Stage IIa the 
tumor has grown into the outermost layers of the colon wall but has not grown through them.  Stage IIb the 
tumor has both grown into and through the colon wall.  With both Stage IIa and Stage IIb, the tumor has yet 
to make contact or attach to any nearby organs, which is in contract to stage IIc, where the tumor has made 
contact/attached to a nearby tissue or organ.  Most cases the tumor has not spread to the lymph nodes or 
metastasized at any of these stages.  In stage III the tumor has grown through the mucosa into the submucosa 
and into the muscularis propria, or through the visceral peritoneum.   Stage IV colon cancer indicates that it 
has metastasized to other tissues, such as the liver or the lungs. 
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polyp is termed carcinoma in situ (or an intramucosal carcinoma) which is a 
superficial non-invasive pre-cancer lesion.  This can be designated as stage 0.  
These polyps can be removed successfully without any future disease recurrence 
or potential of cancer later on in life with an endoscopic method called a 
polypectomy.  Stage 1 tumors are polyps that have infiltrated the submucosa or 
the muscularis propria, designated T1 or T2, and have no lymph node invasion or 
metastases (661).  Stage 2 tumors can be broken down into three different 
categories: Stage IIa, Stage IIb, and Stage IIc (661).  In Stage IIa the tumor has 
grown into the outermost layers of the colon wall but has not grown through them 
where in Stage IIb the tumor has both grown into and through the colon wall (661).  
With both Stage IIa and Stage IIb, the tumor has yet to make contact or attach to 
any nearby organs, which is in contrast to stage IIc, where the tumor has made 
contact/attached to a nearby tissue or organ.  Most cases Stage 2 tumors have 
not spread to the lymph nodes or metastasized at any of these stages.  In stage 
III the tumor has grown through the mucosa into the submucosa and into the 
muscularis propria, or through the visceral peritoneum, and it has spread to 1-3, 
or 4-6 lymph nodes (661).  These stages again can be ranked as Stage III A, 
Stage IIIB or Stage IIIC, depending on its level of penetration and how many lymph 
nodes have been infiltrated (661).   Stage IV colon cancer indicates that it has 
metastasized to other tissues, such as the liver or the lungs (661).  Surgery is the 
initial treatment for early stage CRC and a complete removal of the tumor without 
disease remission can be accomplished (661).  This type of therapy however, is 
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not fully efficacious for stage IV patients since the metastases have already 
colonized sites at distal organs and systemic cytotoxic chemotherapeutic 
regimens are required to fully remove the cancer (661).  Chemotherapeutic drugs 
often used to treat CRC, especially in advanced stages and these include the K-
ras inhibitor panitumumab, platinum based DNA crosslinking drug  oxiplatin, toxic 
nucleotide analog capecitabine, thymidylate synthase inhibitor 5-FU and folate 
analogs (leucovorin), EGFR inhibitor cetuximab, VEGF signaling inhibitors 
bevacizumab aflibercept and ramucirumab, and the DNA topoisomerase I inhibitor 
irinotecan (662-669). 
CRC: hereditary component 
 Hereditary colon cancers are usually initiated by loss of heterozygosity 
(LOH) at the genomic loci that encode or regulate a tumor suppressor protein 
product (670).  There are two major types of hereditary CRC: familial 
adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer 
(HNPCC) (670,671).   FAP and familial colorectal polyposis (Gardner syndrome) 
have mutations in the gene adenomatous polyposis coli (APC) which is a powerful 
tumor suppressor that suppresses Wnt signaling (672).  Wnt signaling stimulates 
nuclear localization of the transcription factor β-catenin, which is a powerful 
proliferative factor and driver of CRC (672).  HNPCC is caused by defects in DNA 
repair proteins involved in MMR (mismatch repair) such as MSH2, MLH1, 
MSH6/GTBP, and PMS2 (411-416,673). 
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CRC: Crohn’s disease and IBD 
People who have Crohn’s disease or any other kind of inflammatory bowel 
disease or also at greater risk for CRC (674).  Meta-analysis studies indicate that 
the risk for colon cancer increases with the duration and extent of inflammation in 
ulcerative colitis but not in Crone’s disease, which coincides with the higher 
incidence of cancer in patients who have ulcerative colitis (674-676).  More than 
20% IBD result in CRC within 30 years of the onset of disease and these cases 
are often referred to as colitis-associated cancer (CAC), a colon cancer subtype 
that has a mortality rate higher than 50% (674-676).  CAC and non-CAC cancers 
share similar mechanisms of parthenogenesis, which can be summarized as the 
adenoma-carcinoma sequence (674-676).   
The adenoma-carcinoma sequence 
 The concept of carcinogenesis being a multistep process was first applied 
in the development of CRC in 1990 (677).   The adenoma-carcinoma sequence 
model (vogelgram) was later proposed to describe the consecutive genetic 
changes, which progress over several years and eventually lead to colon 
carcinoma (Figure 47) (677).  Environmental factors such as mutagens and ROS 
induce DNA damage and initiate the formation of aberrant crypt foci (ACF) (677).  
Mutations in APC, Wnt signaling pathways are early events that trigger the 
outgrowth of ACF to hyperplastic lesions projecting above the colorectal mucosa 
known as polyps (677).  As stated earlier β-catenin, is a potent driver of cell 
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proliferation that mediates the effects of Wnt signaling on stem cell proliferation, 
differentiation and shedding of crypt cells into the lumen (671,672,677).   
 
 
Other components of the Wnt signaling pathway include APC, GSK3β, CK 
1, and Axin and mutations in either APC (loss of function) or β-catenin (gain of 
function) enhance the formation of ACF and polyps, with APC being a very large 
gene with multiple regions for spontaneous inactivating mutations to occur 
(671,672,677).  Not all hyperplastic polyps become cancerous, however, as only 
polyps from the glandular epithelium or adenomatous polyps development into 
adenomas.  The formation of adenomas is characterized by the upregulation of 
Reprinted with permission from: Walther A., Johnstone E, Swanton C., Midgley R., Tomlinson I., Kerr D., 
Nat Rev Cancer 2009 Jul;9(7):489-99. (677) 
Figure 47: The adenoma-carcinoma sequence.  Environmental carcinogens serve as initiators and then 
mutations in APC lead to promotion of these cells that grow into an early adenomas.  Mutations in Kras then 
excelerate the growth of these benign neoplasms.  Carcinomas of the colon are also like other tumors in which 
they are loss of function diseases, which include loss of tumor suppressors and loss of pro-apoptotic signaling 
by TGFβRII.  Activation of oncogenes and inactivation of tumor suppressors contribute to uncontrolled cell 
proliferation and genetic instability which results in an invasive and metastatic colon carcinoma. 
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oncogenes such as K-ras (80% of CRC patients), NFκB, Stat3, and B-Raf 
(677,678).  The transition from adenoma to carcinoma requires inflammatory 
conditions, which is associated with the upregulation of cyclooxygenase 2 (COX-
2) (459-466,677).  Carcinomas of the colon are also like other tumors in which 
they are loss of function diseases, which include loss of tumor suppressors and 
loss of pro-apoptotic signaling by TGFβRII (678,679).  Activation of oncogenes 
and inactivation of tumor suppressors contribute to uncontrolled cell proliferation 
and genetic instability which results in an invasive and metastatic colon carcinoma 
(676-678). 
 
Pancreatic Cancer 
Pancreatic cancer classification 
 It is estimated by the American cancer society that about 53,070 individuals 
will be diagnosed with pancreatic cancer and of these over 41,000 will die from 
the disease (20,21,680).   It is the fourth leading cause of cancer related death 
and 7% of cancer related death are attributed to pancreatic cancer (20,21,680). 
Pancreatic cancer is a debilitating disease with one of the lowest 5-year survival 
rates of any cancer at less than 6%.  It is predicted to be the second deadliest 
malignancy in the USA by 2020 (680).   While the survival rates for other cancers, 
especially gastrointestinal cancers, has increased substantially in the last 30 
years the progress with pancreatic cancer has been rather stagnant.  Traditionally 
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surgery is the best strategy for removal of the cancer with chemotherapeutic 
strategies having little efficacy and usually patents after a long battle will only have 
palliative treatment (680,681).  Even when surgery is successful, over 80% of 
patients have disease relapse and only 10-15% of pancreatic tumors are 
considered resectable at diagnosis (680,681).  The high mortality rate and lack of 
truly efficacious treatment is due to the paucity of early stage molecular markers 
available for pancreatic cancer.  Preclinical evidence suggests pancreatic cancer 
is a systemic disease, which suggests potential ameliorative effects through pre-
emptive systemic therapy (680,681).  Currently therapeutic regimens for 
metastatic pancreatic cancer are FOLFIRINOX (folinic acid, 5-FU, irinotecan, and 
oxiplatin) and nab-paclitaxel plus gemcitabine, which have modest efficacy at best 
(682).  Therefore, there is a high necessity for not only the discovery of novel 
biomarkers, but innovation of more efficacious therapy. 
Pancreatic cancer are all malignancies, which originate in the body of the 
pancreas, which is composed of the endocrine component called the islets of 
Langerhans (680,681,683).   These cells produce hormones such as glucagon, 
insulin, somatostatin, and enzymes for digestion such as trypsin and lipases, 
which are secreted into the duodenum (680,681,683).  Tumors originating from 
endocrine glands are rare and are designated neuroendocrine tumors with 85% 
of pancreatic cancer is pancreatic adenocarcinoma (680,681,683).  These can 
also be classified as exocrine tumors and can be subcategorized into different 
subtypes.  After adenocarcinoma, acinar cell carcinoma of the pancreas is the 
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next common (680,681,683).  They can over-produce certain enzymes, mainly 
lipases and present with subcutaneous fat necrosis, polyarthritis and eosinophilia 
(the so call Schmidt Triad) (684).  Cystadenocarcinomas account for 1% of all 
exocrine tumors and are malignant cystadenomas.  Pancreatic cancer associated 
with children is pancreatoblastoma (680,681,683,684).  Other exocrine tumors 
present as pancreatic mucinous cystic neoplasms and they appear as mucin filled 
cysts (683,684).  All these exocrine tumors are formed in the ductal epithelium 
and are referred to collectively as pancreatic ductal carcinoma.   
Pancreatic intraepithelial neoplasia (PanIN) staging 
 
 
Figure 48: Pancreatic Intraepithelial Neoplasia (PanIN) staging.  The pathological features of pancreatic ductal 
adenocarcinomas are categorized by the pancreatic intraepithelial neoplasia (PanIN) nomenclature system 
(PanIN-1 to 3) which depicts the consecutive changes in morphology and histology. These stages are also 
associated with changes in gene expression and upregulation of proteins.  For example, in PanIN1 you have 
constitutive Kras activation and gene amplification of HER2.  In later stage PanIN you have loss of p16 (PanIN-
2) followed by loss of p53, SMAD4, and BRCA2 (PanIN-3). 
 
 
Reprinted with permission from: Morris JP 4th, Wang SC, Hebrok M., Nat Rev Cancer 2010 
Oct;10(10):683-95. (685) 
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The epithelium of the pancreatic duct consists of cuboidal or low-columnar 
cells with amphiphilic cytoplasm and occasionally this epithelium is replaced with 
mature squamous cells, which form transitional metaplasias and they are not 
necessarily precancerous (685).  In many cases, this is accompanied by atypia, 
or other abnormalities, which initiate cancer (685).  The pathological features of 
pancreatic ductal adenocarcinomas are categorized by the pancreatic 
intraepithelial neoplasia (PanIN) nomenclature system (PanIN-1 to 3) which 
depicts the consecutive changes in morphology and histology (Figure 48) (685).  
These lesions exhibit varying levels of cellular atypia and are considered 
precursors of metastatic PDAC that develops over many years (685).  
The initial stage of these lesions is PanIN-1A, which refers to epithelium 
that has normal appearance and is almost histologically congruent to normal 
pancreatic epithelium (685).  PanIN-1B is histologically similar to PanIN-1A except 
for the presentation of micropapillary and basally pseudostratified structure (685).  
PanIN-2 has large nuclei, which are crowded, loss of cell polarity, 
hyperchromatism, and the majority of the cells are surprising quiescent (685).  
PanIN-3 lesions have morphology similar to goblet cells with mucinous cytoplasm 
orientated towards the basement membrane, large nucleoli and other nuclear 
irregularities (685).  These lesions also will sporadically release necrotic epithelial 
cells into the lumen.  These cells undergo rapid mitosis and can be classified as 
carcinoma in situ, which is Stage 0.   
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Pancreatic cancer staging 
 
Pancreatic cancer uses the same TNM classification as other cancer types 
(Figure 49) (686).  Stage 0 dysplasia is limited to the top layer of the pancreatic 
duct (Tis), and the carcinoma is contained within the pancreas.  Stage 1 refers to 
pancreatic tumors that are grown locally and are less than 2 cm across (T1) (686).  
Stage1 T2 indicates greater than 2 cm and in either case there is no spreading 
(N0, M0) (686).  Stage II indicates infiltration of the tumor outside the pancreatic 
parenchyma with some infiltrating lymph nodes but no metastases (T3) (686).  
Stage III is similar to stage II, to where the tumor has grown larger and is proximal 
to blood vessels and nerves (T4) (686).  Stage IV pancreatic cancer indicates 
metastasis (M1 or greater) and this is the most devastating stage of this disease 
with a very desolate prognosis (686).  Stage I and Stage II pancreatic tumors can 
be treated by using the Whipple procedure, which is a procedure involving a 
Figure 49: Pancreatic cancer staging. TNM classification system for pancreatic cancer. 
 
 
http://geekymedics.com/pancreatic-cancer/  (686) 
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pancreaticduodenectomy (686,687).  This involves removal of the head of the 
pancreas, lymph nodes, and parts of the stomach and upper half of the small 
intestine (duodenum), the gallbladder and common bile duct (687).  
Chemotherapy using gemcitabine is performed after the procedure along with 
radiation therapy to prevent disease relapse (688).  Techniques used to diagnose 
pancreatic cancer include endoscopic ultrasound (EUS), computed tomography 
(CT), magnetic resonance imaging (MRI), and endoscopic retrograde 
cholangiopancreatography (ERCP) along with cytological and histological 
methods (686-690).  Early stage pancreatic cancer is commonly asymptomatic 
and are hard to distinguish those from pancreatic cancer versus pancreatitis (686-
690).  Currently there are putative biomarkers that are being used for detection of 
early stage pancreatic cancer, which include carbohydrate antigen 19-9 (CA 19-
9) (690,691).  However, the American Society of clinical Oncology does not 
recommend such screening due to lack of specificity, false positives/negatives, 
and lack of consistency (692).  The conspicuous paucity of effective biomarkers 
for pancreatic cancer truly accentuates the urgent need for elucidating the 
molecular mechanism of pancreatic cancer formation and how it evolves from 
early to late stage disease.   
Pancreatic cancer: lifestyle and diet  
Signs and symptoms of pancreatic cancer include abdominal and back 
pain, unexplained weight loss, lack of appetite, and light colored stools (685,693).  
There is an age factor associated with pancreatic cancer as those below the age 
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of 40 rarely contrive the disease and more than half occur in individuals over the 
age of 70 (685,693).  Risk factors include diabetes, obesity, smoking, and 
sedentary lifestyle (693,694).  Smoking is an established risk factor for pancreatic 
cancer, and the International Pancreatic Cancer Consortium conducted a nested 
case control study looking at smoking intensity, duration, and cumulative smoking 
dose (694,695).  The results clearly showed that smokers had a greater risk than 
non-smokers did. It should also be noted that risk of pancreatic cancer was 
reduced to levels of that of a never smoker 20 years after quitting (694,695). 
Obesity and a diet consuming highly processed red meat is also directly 
associated with higher pancreatic cancer risk.  These meats contain high amounts 
of nitrite, which can form nitrosamines, which are known carcinogens (658-
660,696).  Epidemiological studies show a strong correlation between increased 
pancreatic cancer and consumption of meat cooked at high temperatures 
(690,691).  Not only can diet have deleterious effects on cancer but it can also 
have a strong preventive effect.  Indeed, diets rich in fruits and cruciferous 
vegetables have shown to not only reduce the risk of pancreatic cancer, but also 
colorectal and other forms of cancer (25-27,658-660,690,691).   Pancreatitis and 
diabetes are potential risk factors, with pancreatitis also being common in heavy 
drinkers and there is an increased risk four fold for pancreatic cancer in individuals 
with pancreatitis (692,693).  Approximately 25% of pancreatic cancer patients 
have diabetes mellitus and more than 40% present with hyperglycemia and other 
pre-diabetes presentations (692,693).  Diabetes Type-II is also implicated in 
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pancreatic cancer with 50% increased risk however, if there is a direct link it has 
not yet been unequivocally determined. 
Pancreatic cancer: hereditary and genetic component 
There is also a hereditary component associated with pancreatic cancer.  
Hereditary syndromes due to mutations in tumor suppressor genes are also risk 
factors but this accounts for approximately 5% of cases (694).  Familial atypical 
multiple mole melanoma syndrome (FAMMM), hereditary pancreatitis (PRSS 
mutations), Lynch syndrome (MLH1, MSH2 and other MMR enzymes) Peutz-
Jehgers syndrome (LKB1), Cowden syndrome (PTEN), germline mutations in 
BRCA2 and p16 mutations represent common examples of these (418-422,694-
698).    Mutations are linked to PanIN pathogenesis model.  KRAS mutations are 
observed in approximately 80% of pancreatic cancer; other mutations include 
ErbB2/HER2, CDKN2A/p16, TP53, and DPC4/SMAD4 (699-702).  Early PanIN 
lesions exhibit KRAS mutations that promote sustained proliferation along with 
overexpression of HER2, which is rarely expressed in normal pancreatic ductal 
epithelium but overexpressed in approximately 92% of pancreatic ductal dysplasia 
(699,700).  Activation mutations can also present without atypia but frequency and 
prevalence of KRAS mutations increases with atypia in PanIN lesions 
(685,868,699,700).  Surprisingly HER2 expression is absent in poorly 
differentiated invasive carcinomas which suggests that this gene is involved in 
early stage growth and survival but is repressed or lost in stages of EMT and 
invasion/metastasis (700,703).  HER2 also activates Ras through the 
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Raf/MEK/ERK pathway to synergistically augment cell proliferation and growth 
mechanisms in early stages of pancreatic cancer (699,703).   
Many tumor suppressors follow the two-hit hypothesis model and require 
biallelic mutations and this seems to be a driver in metastatic/advance pancreatic 
tumor development.  The tumor suppressor gene CDKN2A encodes two potent 
cyclin dependent kinase inhibitors, p16 and p14ARF (206-209).  The protein p16 
inhibits entry of cells into S phase from G1 phase by binding to and inhibiting 
Cdk4/Cdk6, preventing them from associating with cyclin D1 (206-209).  This 
prevents the hyperphosphorylation of Rb, which enables Rb to suppress cyclin E 
and A transcriptional activator E2F (188,206-209).  The p16-Rb axis is inactivated 
in 95% of invasive pancreatic carcinomas and CDKN2A/p16 expression is 
progressively lost in 30, 55, and 75% of PanIN-1, PanIN-2, and PanIN-3 lesions 
respectively (704,705).  Later stage carcinomas show deletions in tumor 
suppressor genes TP53, DPC4, and BRCA2 (374-376,594-596,704,705).  The 
absence of p53 is observed predominantly in PanIN-3 and 75% of invasive 
pancreatic carcinomas (704,705).  DPC4 stands for “deleted in pancreatic cancer 
locus 4” and is absent in 30 to 40% of PanIN-3 lesions and 55% of pancreatic 
carcinomas (704,705).  It encodes the protein Smad 4 which is important in TGF-
β signaling pathway (374-376).  Upon activation of TGFβRII/I, Smad 2 and 3 are 
phosphorylated and this enables binding of Smad 4, which translocates to the 
nucleus and transcribes growth-inhibiting genes (374-376).  BRCA2 (along with 
BRCA1) are tumor suppressor genes (described in the breast cancer section) and 
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is mutated in only PanIN-3 lesions and less than 10% of invasive pancreatic 
carcinomas (594-596,704).  Diagnostic screenings for pancreatic cancer may be 
focused on individuals with specific genetic backgrounds, however, there is no 
single “smoking gun” gene that can be used to detect early pancreatic cancer.   
 
Specificity Protein (Sp) Transcription Factors 
Specificity proteins in embryological and normal biology 
Specificity proteins (Sp proteins) such as Sp1 are members of a family of 
transcription factors which have similar structures to transcription factors known 
as Krüppel-like factors and the Sp/KLF family has 25 members (706-709).  KLF 
family members share strong homology with a segment polarity gene called 
Krüppel, which is an important maternally derived factor in the development of the 
fruit fly syncytium (Drosophila melanogaster) (706-709).  There are 9 Sp factors 
which contain three tandem Cys2-His2 (C2H2) type zinc fingers, which confer DNA 
binding capabilities (709,710).  Sp proteins preferentially bind to GC rich regions 
with the consensus sequence [5’-GGGGCGGGG-3’] (Figure 50) as opposed to 
the KLFs, which bind CACCC boxes and the sequence [5’-GGTGTGGGG-3’] 
(708-710).  Sp transcription factors are divided into two groups with Sp1-4 having 
very similar domain structure and organization whereas 5-9 have domain 
structure that more closely resemble KLFs and seem to be truncated forms of Sp 
1-4 lacking the N-terminal TADs (706-710).  Sp1-4 are characterized by an N-
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terminal transactivation domain that contains glutamine rich regions proximal to 
serine and threonine rich regions (Figure 51) (708,710,711).  These constitute 
transactivation domains A and B respectively, which bind with other transcription 
factors and enhance transactivation of target genes.  Sp transcription factors also 
contain a zinc finger DNA binding domain (D), with the exception of Sp3 which 
has an extra inhibitory domain and Sp2 only having one transactivation domain 
(708,710,711).  Sp2 also contains a histidine to leucine mutation in the first zinc 
finger which results in a switch to a GT binding preference for Sp2, whereas 
Sp1,3,4 zinc fingers are conserved (712,713).  It has been shown that Sp1,3,4 
share similar functional roles and have the highest physiological relevance when 
it comes to cancer (to be discussed) (706-710,714-718]).  Although the  
 
 
 
Figure 50: Sp proteins bind GC boxes. Sp proteins 1,3 and 4 bind to GC rich regions by using Cys2His2 type 
Zinc Fingers. 
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Sp transcription factor transactivation domains are similar in terms of their 
overall amino acid content, there actual primary structures differ and this is one 
reason why different Sp proteins can bind to different partners and have differing 
functions and physiological responses (711,712).  There is also the C-domain, 
which is a highly charged region that is C-terminal with respect to the 
transactivation domains and promotes binding of the zinc fingers to the DNA 
(708,709,711,712).  The first zinc finger has the highest affinity and sequence 
specificity and the zinc fingers seem to play a role in nuclear localization as 
deletion of any of the zinc fingers not only abolished DNA binding but abrogates 
nuclear localization (711-713).  In contrast to other Sp members, Sp1 contains a 
multimerization domain at the further C-terminal region that mediates super-
activation of promoters containing multiple adjacent Sp1 sites, as well as a Btd 
domain (buttonhead, the protein that is the putative fruit fly homolog to Sp1) 
(706,708,711).  Sp1 molecules interact and form oligomers that promote 
associate with multiple proximal promoter sites with distal enhancers that loop 
DNA, that expose Sp1 for further protein-protein interactions and post-
translational modifications (709-711).   
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The Sp family genes are located adjacent to a homeobox (HOX) gene 
cluster; which encode genes that dictate the anterior-posterior axis of the embryo 
(719).  The Sp transcription factors are important for embryological development 
and Sp1 knockout mice die after 11th day of gestation with mice observing multiple 
abnormalities beforehand (171,720).  Sp3 mice display impaired ossification, 
tooth development, and die shortly after birth succumbing to respiratory failure 
(721).  Sp4 knockout mice exhibit embryonic lethality; however, about 33% of the 
mice survive with severe growth retardation and male infertility (722).  This 
Figure 51: Sp protein transcription factors 1-4.  Sp proteins are Cys2His2 zinc finger DNA binding transcription 
factors.  They share a high level of homology and also have significant differnces.  They have two 
transactivational domains (TAD) A and B which correspond to glutamine rich and serine rich regions 
respectively.  Sp1 is unique in the fact it contains an N-terminal inhibitory domain, and a C-terminal 
multimerization domain. 
 
 
Reprinted with permission from: Beishline K., Azizkhan-Clifford J. FEBS J. 2015 
Jan;282(2):224-58. (710) 
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underscores the physiological important of the Sp proteins during development.  
Sp proteins directly bind with basal transcriptional machinery, including the TATA 
binding protein associated factors (TAFs) and other cofactors, which include many 
other basal transcription factors, including histone acetyl transferase, HDACs, 
histone methyl transferases etc (383-385,706,709,723-726).  Indeed, many 
mammalian genes are regulated by Sp proteins, which play a critical role in 
carcinogenesis by being important effectors of cell proliferation, growth, 
angiogenesis, and migration/invasion (712-716,727,728). 
Specificity protein 1 (Sp1) 
 Sp1 full-length protein is highly conserved among mammalian species and 
they are defined by their DNA-bonding domain (708,710,711).  Sp1 is known to 
have three isoforms (A, B, and C) which are alternate splice variants, with B using 
an alternative start codon and isoform B being an alternate splice variant of exon 
3 (lacking amino acids 55-102) (708,710,711).  The role that these isoforms play 
in development, as well as cancer, has not been well characterized however, and 
their roles could be functionally redundant or compensatory (710,711).  The 
Sp1/KLF factors play multiple roles in development and their expression and 
interplay is regulated during development.  The DNA binding zinc finger domain 
exhibits the highest degree of conservation and is conserved in fish birds, reptiles, 
and even fruit flies (there has yet to be one in saccharomyces cerevisiae or 
pombe).  The protein buttonhead in Drosophila melanogaster is the fruit fly 
homology of Sp1 and there is a small region of homology in the Sp1 protein that 
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is the eponymous buttonhead domain (706-710,728,729).  Sp1 transactivation 
domains exhibit no sequence specificity among species and sequence specificity 
is conferred by the Sp1 DNA binding domain, which also demonstrates the only 
structural element of the protein (706-710).  Domains A, B, C are largely 
unstructured and this is believed to confer the high degree of interaction with a 
large number of binding partners, and the ability of the Sp proteins to regulate a 
myriad of genes (706-710,726-729).  Along with basal transcription factors Sp1 is 
known to interact with p53, E2F, c-Myc ( genes involved in the cell cycle), NF-YA 
(a p53 regulated gene that induces apoptosis) SWI/SNF complex, HMGA1 and 2, 
DNMT1, HDAC1 and p300 (chromatin modifying complexes) (706-710,726-731) 
Post translational modifications of Sp1 
Many of the post-translation modifications of Sp1 have unknown 
consequence, however many have been documented and play a role in protein 
stability, DNA binding, transcriptional activity, and subcellular localization.  For 
example, phosphorylation by Erk1/2 or JNK1 on T355 leads to enhanced 
transcriptional activity of Sp1 resulting in induction of apolipoprotein A-1 which is 
mediated by enhanced EGFR expression (732), whereas atThr278/739 by JNK1 
leads to decreased stability and transcriptional activity (733).  T287 
phosphorylation has a similar effect and is important in the cell cycle by enhancing 
Sp1 stability (734).  Similar stability and DNA binding effects are observed by 
CDK2 during the cell cycle by its phosphorylation of S59 on Sp1 (735).  
Phosphorylation of Sp1 can also lead to its degradation as evidenced by the 
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phosphorylation mediated by GSKβ on S728 and S732 (736).   MAPK dependent 
phosphorylation can also upregulate Sp1-mediated transcription of VEGF and 
gastrin (317, 737).  Glycosylation seems to play an important role in nuclear 
localization of Sp1 and O-linked Glycosylation of S612, 641, 698, 702 and T640 
(as well as phosphorylation by DNA polymerase ζ on S612, 641 670 and T640, 
651, 668, result in nuclear accumulation of Sp1 and activation of calmodulin (738-
747).  Whereas dephosphorylation of Sp1 by PP2A (T681) leads to increased 
chromatin association and increased cell proliferation in primary human T-
lymphocytes (748).  Sp1 acetylation (K703) is associated with loss of binding to 
gene promoters involved in apoptosis and cell cycle arrest in colon cells and 
deacetylation of Sp1 (K703) recruits p300 HAT to the promoter of 12(S)-
lipoxygenase gene and upregulates its expression (749). The posttranslational 
modifications of Sp3 and four are not well understood; however, it is likely they 
are regulated as described for Sp1.   Indeed, the degree of post-translational 
modification, both in number and type, emphasize the vast and diverse roles Sp 
proteins plays in cancer cell function and physiology. 
Sp3 and Sp4 
Sp3 has the highest degree of homology to Sp1 and they can act in concert 
or Sp3 can exhibit repressive activity on some genes (706-710,750,751).  Sp3 has 
an extra inhibitory domain that is located just N terminal to its DNA binding domain 
and C-terminal with respect to the Transactivation domains and this domain 
mediates cell context-specific transcriptional repressor activity (706-710,749-
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751).  The D domain of Sp3 differs from that of Sp1 and this confers propensity to 
serve as an inhibitory factor of Sp1 transcriptional activity (750,751).  Sp3 also 
lacks the multimerization domain of Sp1 and cannot induce super activation of 
genes as observed for Sp1 (750,751).  Sp1 and Sp3 have equal binding affinities 
for GC rich boxes; therefore, their stoichiometric ratios, proximity to cognate 
promoters, subcellular location, and posttranslational modification status play a 
critical role in how they regulate genes.  Sp1 binding also does not display 
cooperative binding since there is an equal likelihood of either Sp1 or Sp3 is 
observed after a single molecule of Sp1 binds to a GC-rich promoter 
(706,708,712,750,751).  For genes that require multiple Sp1 molecules to bind on 
a promoter to enhance activation Sp3 can serve as a potent inhibitor of such 
genes (706,708,712,750,751).  A fundamental example of this phenomenon can 
be observed in the regulation of the human topoisomerase IIa promoter (752).  
The activation of topoisomerase IIa promoter begins by Sp1 molecules binding to 
proximal promoters and then to distal enhancers (752).  The loop is made and the 
Sp1 molecules, therefore enabling super activation of the topoisomerase IIa gene, 
generate a bridge (752).  Sp3 competitive binding for either the proximal or distal 
promoter site leads to repression of the topoisomerase IIA gene (752).   
Sp4 is similar to Sp1 and Sp3, however it has properties that make it 
distinct and its functions are not redundant (753-756).  Sp4 serves as a 
transcription factor that has a highly homologus DNA binding region to that of Sp1, 
however, unlike Sp1, it cannot participate in synergistic cooperative activation 
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through adjacent binding sites (706,708,710,712,750, 753-756).  Sp4 –mediated 
transactivation can also be suppressed by Sp3 and deletion of Sp4 results in 
phenotypically normal mice until they are born (724).  Many die after 4 weeks but 
the ones that survive exhibit growth retardation, delayed sexual maturation, 
inability to breed, and underdeveloped thymus, spleen and uterus in females 
(724).  One example of the unique transcriptional role of Sp4 is in the transcription 
of the beta-subunit in the cyclic guanosine monophosphate (cGMP)-
phosphodiesterase, which is critical in phototransduction in the rod 
photoreceptors and as a co-transactivator with cone-rod-homeobox (Crx) on the 
promoter of rod opsin (757).  Sp4 and Sp3 are indispensable for the murine 
gamma-aminobutyric acid type A receptors (GABAA-R), which is vital for the fast 
inhibitory synaptic transmission in neurons (758).  Sp4 also plays a role in cerebral 
maturation and controls dendritic patterning during cerebellar development by 
limiting branch formation and promoting activity-dependent pruning and regulates 
the transcription of AMPA receptor subunit GluA2 (Gria2) (759). Less is known 
about Sp4 but emerging evidence is demonstrating its nonredundant and plays a 
unique role in cancer (712-716,760,761).  In melanoma cells, Sp4, along with c-
Myc and HIF-1α, cooperate in the activation of arginosuccinate synthetase (AS), 
which confers resistance in these cells to arginine deiminase treatment (762).  We 
have also demonstrated that Sp4 is critical for inhibiting apoptosis in colon cancer 
cell lines such as SW480, breast cancer cell line SKBR3, and lung cancer cell line 
A549 (763-765).  Integrins such as β1-integrin and α5-integrin are regulated by 
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Sp4 in RKO colon cancer cell line and pancreatic cancer (L3.6pL, MiaPaCa2, and 
Panc1) cell lines and not by Sp1.  Studies in this laboratory have also uniquely 
demonstrated that Sp4 is a direct co-activator of the PAX3-FOXO fusion gene 
product in ARMS.  This highlights the emerging nonredundant role of Sp4 in 
cancer and that its potential value as a drug target. 
Sp proteins in cancer 
 
 
The role of Sp transcription factors in cancer has been reported in multiple 
cancer types including pancreatic, colon, bladder, GBM, prostate, lung, and breast 
cancers (712-716,765-772).  We have described and characterized these genes 
Figure 52: Sp proteins in cancer.  Sp proteins recognize GC rich regions within promoters of oncogenes.  This 
involves monomeric or oligomeric homo or heterodimeric Sp protein complexes which bind to the promoters 
of genes involved in angiogenesis (VEGF, VEGR1, VEGFR2, CXCR4, MMP9), cell proliferation (EGFR, c-Met, 
CD1, IGF1R) and survival (bcl-2, survivn).   
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as non-oncogene addiction (NOA) genes, which is distinctively different from the 
canonical distinction of a bonafide oncogene addiction in cancer (77).  Oncogene 
addiction refers to a gene (either amplified, overexpressed, or a mutant 
constitutively active form is endogenously or ectopically expressed such as 
through genetic translocation or via transposon activity) that a cancer cell depends 
on not only for its transformed phenotype but also its survival.  Examples of this 
include HER2/ErbB2 overexpression in breast cancer, K-ras in colon and 
pancreatic cancer, bcr-Abl fusion gene product in CML, and EGFR in NSCLC.  
These genes are vital to normal tissue function and are expressed at moderate 
levels.  However, Sp proteins have minimal expression in adult tissues and their 
expression decreases with age but Sp1, Sp3, and Sp4 are highly expressed in 
most tumors (710-716,766-772).  This is a distinguishing characteristic of a NOA 
and Sp proteins represent a novel and promising class of NOAs that are not only 
vital to tumor growth and survival but can be targeted by drugs.  Sp1 
overexpression is observed in colorectal, gastric, breast, thyroid, and brain tumors 
as compared to their normal tissues counterparts and its expression has been 
demonstrated to be a negative prognostic factor for these cancers (710-716).  The 
prognostic relevance of Sp3 and Sp4 have not been reported even though their 
expression levels follow the same pattern as those observed with Sp1 (710-
716,766-772).  Sp proteins have been demonstrated to be master regulators of 
genes essential for cancer cell morphology, physiology, proliferation, growth, and 
migration/invasion (766-772). Sp transcription factors bind to GC-rich promoters 
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and induce expression of a myriad of pro-oncogenic factors that include survivin, 
XIAP, EGFR, VEGF, VEGFR2, EGFR, IGF1r, c-MET, cyclin-D1, PDGFR, bcl2, c-
fos, c-jun, E2F1, TGF-α, and TGFβRII (Figure 52) (710-716, 763-772).  Thus 
drugs that downregulate expression of Sp transcription factors would also down-
regulate multiple Sp-regulated pro-oncogenic factors and therefore be highly-
effective anti-tumor agents.  
Sp proteins as drug targets 
 
Several strategies to decrease Sp1, Sp3, and Sp4 in cancer cells and 
tumors have been reported (706-710,712-716,766-772).  These include 
enzyme/chemical dependent modulations, drugs that competitively inhibit their 
Curcumin 
Turmeric 
Celastrol 
Tripterygium 
wilfordii 
Phenethyl Isothiocyanate 
(PEITC) 
Broccoli/Brussel Sprouts 
Figure 53: Sp proteins as drug targets for cancer.  Sp proteins are downregulated in both an ROS -dependent 
(celastrol, curcumin, PEITC, betulinic acid, HDACi) ROS-independent (tolfenamic acid), and proteasome 
dependent (metformin, betulinic acid).  They are composed of triterpenoids (betulinic acid, celastrol), 
isothiocynates (PEITC, BITC), NSAIDs (sulindac sulfide, tolfenamic acid).  The drastic differential in 
expression of Sp proteins in cancerous vs. normal tissue and the fact that they compound exhibit low toxicity 
in normal tissue demonstrate the chemotherapeutic potential of Sp targeting drugs. 
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DNA binding or abrogate GC-rich DNA binding regions (i.e. mithramycin), GC-rich 
oligonucleotides that squelch Sp proteins and prevent them from binding to 
promoters, NSAIDS (i.e. tolfenamic acid, sulindac sulfide), and drugs/chemicals 
that induce ROS and downregulate Sp proteins (i.e. AsO3, celastrol, curcumin) as 
outlined in Figure 53 (641-648, 766-772). Studies in this laboratory have shown 
that the cannabinoid, 2,3-dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-
de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2, (WIN)], 
represses Sp proteins in a protein phosphatase 2A (PP2A) dependent manner by 
disrupting the miR-27a-ZBTB10 interaction in glioblastoma multiforme (GBM) and 
colon cancer cells (773).  The pentacyclic triterpenoid betulinic acid also 
downregulates Sp proteins via binding cannabinoid receptors in a proteasome-
independent (mir-27a/ZBTB10) and dependent manner which target YY1 and 
HER2 (645,774).  The biguanide antidiabetic drug metformin inhibits Sp protein 
expression by activating MAP kinase phosphatases (MKP) MKP1 and MKP5 
which lead to proteasome-dependent degradation of Sp proteins (775).   
Sp proteins as targets of ROS inducing agents by targeting c-Myc 
ROS- inducing agents are highly effective at down regulating Sp proteins.  
These ROS inducing agents decrease Sp protein expression by a pathway 
elucidated, namely the c-Myc-miR17-92-ZBTB-Sp pathway characterized in our 
laboratory (641-648,768,769).  C-Myc is an oncogene and is overexpressed in 
approximately 20% of all cancers and is the cellular homolog (hence the c in c-
Myc) of v-Myc which is essential for avian retrovirus survival and viral induced 
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carcinogenesis (776-778). There are four other isoforms of Myc, which include N-
Myc, L-Myc, S-Myc, and B-Myc (776-778).  C-Myc has three conserved regions 
in its N-terminal called Myc boxes (MB) designated MB-MB-II, MB-III, and I (776-
778). These regions are found in Myc family members and are critical for protein-
protein interaction with many proteins, which regulate its expression, activity, and 
localization (776-778).  C-Myc enhances transcription by recruiting transcription 
factors such as P-TEFb (positive transcription elongation factor b) (779).  These 
MB regions also recruit kinases, which regulate its activity and degradation (779).  
Three phosphorylation sites within MB-1: T58, S62, and S71, are regulated by 
kinases GSK3α and β, MAP kinase ERK 1/2 and CDK kinase, and Rho associated 
kinase (ROCK) respectively (779,780).  The latter two phosphorylation sites 
enhance stability and activity of c-Myc whereas T58 phosphorylation promotes 
association of Skp2 E2 ubiquitin conjugating enzymes with its E3 ligase 
counterpart FBW7 to induce polyubiquitination and proteasome-dependent 
degradation (779,780).  The S62 site however is critical for docking for both 
GSK3β and the ubiquitin ligase complex as demonstrated by mutational analysis 
(776-780).  These MB domains also recruit chromatin-modifying complexes, 
which includes TIP48/49 and TIP60, which are a histone acetyltransferase (HAT) 
complex.  Other proteins called TTRAP and p400, an adaptor protein and histone 
acetyltransferase exchange factor for p300, recruit HATs such as GCN5 and p300 
respectively (776-780).  The C terminal domain (CTD) contains a bHLH (basic 
Helix-Loop-Helix) motif critical for DNA binding, and a leucine zipper, which 
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mediates interaction with transcriptional activator binding partners like Max, Miz1, 
and p300 (776-780).  There is also a NLS (nuclear localization signal) just N-
terminal with respect to the CTD (776-780).  Expression of c-Myc is mainly 
controlled by the Nuclease hypersensitivity element III-1 (NHEIII-1) which when 
bound by transcriptional activators enhances expression.  Negative regulation is 
conferred by 5’-UTR cis elements called negative regulatory elements (NRE) 1 
and 2 which bind to proteins such as CTF (776-780). 5’ regions of the c-Myc gene 
also contain poly-purine tracts, which can create guanine-rich duplexes, and 
quadraplexes that repress transcription (776-780). 
 
The c-Myc/miR17-92/ZBTB/Sp pathway 
Figure 54: The c-Myc/miR17-92/ZBTB/Sp pathway.  This pathway has been well characterized by our lab and 
involves an ROS inducing agent which promotes shifts within the chromatin modifying complexes and 
represses transcription of the cMyc gene.  cMyc binds to E-boxes within the promoters of miR-17, miR-20a, 
and mR-27a.  In cancer cells these miRs bind to the 3 UTR of ZBTB 4, 10, and 34 mRNA and suppress their 
translation.  As result of the ROS inducing agent there is an upregulation of ZBTB protein expression.  The 
proteins are Zn2+ finger BTB binding proteins which compete with Sp proteins for GC rich regions 
(presumably they concommitently suppress Sp expression because Sp proteins contain GC-rich regions 
within their promoters.  This leads to a decrease in cell groth, migration, and induction of apoptosis. 
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The pathway discovered in our laboratory involves ROS-dependent 
epigenetic silencing of c-Myc (Figure 54) (641-648,766,768,769).   Induction of 
ROS leads to chromatin modifying complexes (i.e. PRC1, PRC2, NCOR, SIRT1) 
from non-GC to GC-rich regions in a thus far an unexplained mechanism 
(781,782).  Although a substantial amount of c-Myc transcriptional regulation is 
controlled by an upstream cis-element known as NHEIII, there are also GC rich 
regions in the c-Myc promoter and this leads to ROS-dependent epigenetic 
silencing of c-Myc (648,766,768,769).  C-Myc regulates expression of miR 17-92 
cluster (as well as miR27a) by binding to E-Box recognition motifs (CANNNTG) 
(641-648,766,768,769).   
Thus downregulation of Myc results in a rapid decrease in the expression 
of miR-17, miR-20a, and miR-27a, which are negative regulators of zinc finger 
and BTB domain containing DNA binding proteins, namely the “Sp” transcriptional 
repressors ZBTB 4, ZBTB 10, and ZBTB 34 that compete with Sp  proteins for 
binding to GC rich sites (641-648,766,768,769).  The miRs bind to the 3’ UTR of 
the ZBTB mRNA sand repress their expression; therefore, the decrease in the 
miR expression, increases in expression of ZBTB 4, 10 and 34 expression, and 
the subsequent inhibition of Sp proteins and pro-oncogenic Sp-regulated genes 
(641-648,766,768,769).  In this thesis, I will demonstrate the role of Sp proteins in 
multiple cancer types and how these Sp proteins can be targeted through an ROS 
dependent mechanism that is similar to the pathway outlined in figure 53, using 
hydroxamic class HDAC inhibitors panobinostat (LBH589) and vorinostat (SAHA 
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or suberyolanilide hydroxamic acid.  Antipsychotic drugs such as penfluridol also 
induce ROS and suppress triple negative breast cancer (TNBC).  Penfluridol also 
decreased expression of integrins α6 and β4 and our studies now show that 
penfluridol downregulates multiple integrins via induction of ROS and the pathway 
illustrated in figure 54. 
 
NR4A Nuclear Receptor: NR4A1 
Nuclear receptors 
Nuclear receptors comprise of a large family of intracellular transcription 
factors that are involved in diverse developmental and physiological processes 
such as organogenesis, homeostasis, metabolism, steroidogenesis, reproduction, 
and neurological health (558,563,783).  There are 48 human nuclear receptors, 
which can be grouped into four general categories: Type I, Type II, Type III, and 
Type IV (Figure 55) (558,563,783).  Type I nuclear receptors consists of receptors 
associated with steroid-induced pathways such as the androgen receptor (AR) 
and the estrogen receptors (ERα and ERβ), progesterone receptor (PR) as well 
as the glucocorticoid receptor (GR) (558,563,783).  These receptors exist in an 
inactive state in the cytosol associated with heat shock (HSP) proteins, which 
prevent premature dimerization, and unfolding of the receptor (558,563,783). 
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Upon ligand binding to the receptor, the HSP proteins dissociate, and the 
receptor translocates to the nucleus to form homo-dimers, that bind sequences 
known as hormone responses elements, which consist of two inverted half sites, 
which are separated by a variable length of DNA (558,563,783).  This confers 
specificity for the hormone receptors, for example, an estrogen response element 
contains AGGTCA-nnn- TGACCT, with n meaning any nucleotide (783,784).  
Type II receptors are located in the nucleus and they heterodimerize with the 
receptor RXR (retinoid X receptor) (558,563,783,784).  Ligand binding induces 
recruitment of cofactors/coactivators resulting in activation of target gene 
expression; they stimulate expression of genes that contain direct tandem half 
Figure 55: The nuclear receptor superfamily.  Nuclear receptors are a very large and diverse family which play 
extensive roles in development, reproductive biology, normal physiology, metabolism, and cancer 
progression.  Group I receptors exist complexed in the cytoplasm with Hsp90 molecules and upon ligand 
activation translocate to the nucleus as homodimers and bind to inerted repeat response elements (ER, AR, 
PR, GR).  Group II receptors reside in the nucleus regardless of ligand binding and heterodimerize with the 
RXR (retinoid X receptor), binding to direct repeat response elements.  These include The vitamin D receptor 
(VDR) and pregnane X receptor (PXR).  Group III receptors upon ligand binding can exist in cytoplasm or 
nucleus but bind to direct repeats as monomers (sometimes dimers) (steroidgenic factor 1 (SF-1)).  Group IV 
exist as either monomers or dimers but bind to only half site HRE (hormone response elements) 
 
 
Reprinted with permission from: Glass CK, Ogawa S., Nat Rev Immunol 2006 Jan;6(1):44-55. (783) 
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sites that are spaced by a variable length of DNA (558,563,783,784).  Examples 
of these receptors are the RAR (retinoic acid receptor) and the PXR (pregnane X 
receptor) (558,563,783,784).  The PXR is a very important receptor, which along 
with binding pregnane related compounds binds to drugs such as rifampicin and 
ketoconazole (783,785).  PXR is an important drug metabolizing enzyme that 
stimulates expression of cytochromep450 3A4 (CYP3A4) which is a very 
important drug metabolizing enzymes that metabolize drugs such as rifampicin 
(785).  
Type III nuclear receptors, are similar to Type one in that they bind as 
homodimers, however they recognize and bind to direct as opposed to inverted 
repeats (558,563,783-785).  SF-1 (steroidogenic factor 1) is a Type III receptor 
that is involved in puberty and sexual development (also known as the NR5A1) 
(786).  It upregulates the expression of genes such as CYP11A1 (cleaves the side 
chain of cholesterol in the steroidogenesis pathway), steroid acute regulatory 
protein, Sox9, and genes critical in the hypothalamic-pituitary gonadal axis 
(786,787).  Type IV receptors most often bind as monomers, but can dimerize to 
form either in a homo- or hetero-dimers (563,783,784,786).  There are seven 
subfamilies based on sequence homology which include the thyroid hormone 
receptor-like (NR1), the retinoid X receptor -like (NR2), the estrogen receptor-like 
(NR3), nerve growth factor IB-like (NR4), steroidogenic factor-like (NR5), germ 
cell nuclear factor-like (NR6) and miscellaneous (NR0) receptors (786-788).  
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Orphan nuclear receptors: NR4A1 
 
The orphan nuclear receptors, for which no known endogenous ligands 
have been identified, include COUP-TF (NR2F), TLX (NR2E), SHP (NR0B), PNR 
(NR2E3), GCNF (NR6A), and nerve growth factor IB-like subfamily (NR4A) 
(Figure 56) (786-789).  The NR4A subfamily genes consist of three members that 
are subcategorized as group A (NR4A) and include NR4A1 [(nerve growth factor 
IB NGFIB), testicular receptor 3 (TR3), nurr77], NR4A2 [Nurr1 (nuclear receptor 
related 1)] and NR4A3 [Nor1 (neuron-derived orphan receptor 1)] (790-792).  The 
first member, NR4A1 was initially identified as a nerve growth factor-induced early 
immediate gene in rat pheochromocytoma PC12 cells (790,793).  NR4A receptors 
Figure 56: The nuclear receptor 4A (NR4A1) family.  They Have high homology within their DNA-binding 
domains and have high variability within their AF regions (A/B and E/F ).  NR4A receptors are orphan nuclear 
receptors which have a vast role in neurological function, metabolism, steroidgenesis, and physiology.  The 
NR4A1 receptor is overexpressed in the majority of solid tumors and has a major role as an oncogene.  It 
serves as a transactivator of a myriad of genes involved in carcinogenesis.  The other receptors NR4A2 and 
NR4A3 have lesser known roles in carcinogenesis and their exact contribution to cancer progression is being 
further investigated. 
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exhibit a wide range of functions in humans (790,793-796).  NR4A1 has been 
shown critical for metabolism in normal and neuronal cells and its aberrant 
expression has been implicated in Parkinson’s disease (794).  NR4A2 is important 
in neuron development and maintenance in the central nervous system and both 
NR4A1 and NR4A2 both orchestrate neuroendocrine regulation in the 
hypothalamic-pituitary adrenal axis (794,797-799). NR4A1 and NR4A3 are 
involved in glucose metabolism and modulate adipocyte differentiation, and 
NR4A3 is involved in skeletal muscle metabolism (790-792,795,800-802).  There 
is also increasing evidence that NR4A family members play an important role in 
cancer (790-792, 803-809).  Several studies show that NR4A receptors are 
involved in tumor and cancer cell growth, proliferation, apoptosis, DNA repair, and 
glucose and fatty acid metabolism (793-796, 800-802).  The role of NR4A1 in 
cancer, however, has been extensively investigated and this thesis will provide 
evidence that NR4A1 regulates expression of pro-oncogenic factors and 
pathways. 
NR4A1 in cancer 
In many solid tumors NR4A1 is overexpressed and plays a role in cancer 
growth and physiology and is a negative prognostic factor for disease-free and 
metastasis-free survival (803-809).  In leukemias and other hematological 
malignancies, the role of NR4A1 is equivocal and some studies have reported a 
tumor-suppressive like function in these malignancies (810,811).  It has also 
shown that the subcellular localization of NR4A1 is also critical for determining the 
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function of NR4A1 (812-820).  In the studies that demonstrate a tumor-
suppressive role for NR4A1, these cells largely depend on its cytosolic and not its 
nuclear location (812-827).  
 In solid tumors, NR4A1 is primarily in the nucleus where it is constitutively 
expressed and serves as a transcriptional activator of oncogenes (790-793, 812-
820).  However, upon stimulation by some apoptosis inducers such as phorbol 
esters and retinoid-derived compounds, NR4A1 expression is induced and 
translocated to the mitochondria where it associates with bcl-2 to form a pro-
apoptotic complex (812,813).  It accomplishes this by exposing its BH3 domain 
(which as stated earlier confers pro-apoptotic activity) and inducing MOMP 
(812,813).  This apoptotic pathway for NR4A1 has been reported in several types 
of cancer and a similar mechanism is observed in negative selection of T-cells 
(818).  In colorectal cancer, NR4A1 indirectly activates Bax, which results in 
MOMP and cytochrome c release into the cytosol and induction of apoptosis 
(819). NR4A1 also suppresses colorectal tumorigenesis by inhibiting Wnt 
signaling by induction of β-catenin degradation (817).  In gastric cancer cells, PKC 
signaling is activated and this promotes NR4A1 nuclear export (820). 
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NR4A1 as an oncogene that is drug targetable 
 Our laboratory has focused predominantly on the nuclear functions of 
NR4A1 as a transcriptional activator of oncogenes and its role in promoting pro-
oncogenic and pro-invasive functions (Figure 57) (803-809).  We have discovered 
a series of C-DIMs (1,1-bis(3’-indolyl)-1-(p-substituted phenyl) methane analogs) 
that bind NR4A1 and act as antagonists of this receptor.  DIM-C-pPhOH (C-DIM8) 
is an NR4A1 ligand that acts as an antagonist that inhibits lung cell and tumor 
growth and this was due in part to inhibition of mTOR and decreased expression 
Figure 57: NR4A1 as an oncogene that is drug targetable. 1) NR4A1 regulates mTOR by binding to p53.  P53 
activates sestrin2 which activates AMPKα.  2) NR4A1 also regulates the expression of ROS modulators 
TXNDC5 (thiodoxin domain containing 5) and IDH1 (isocitrate dehydrogenase 1).  3)NR4A1 also forms a 
transactivational complex with Sp proteins and p300 histone acetyltransferase, which regulate expression of 
p regulated genes (such as bcl2, survivin, and EGFR).  NR4A1 also participates in migration and invasion, 
which involves transcriptional upregulation of β1-integrin. 
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of survivin being observed (803-812).  The C-DIM/NR4A1 antagonist inactivated 
expression of survivin by disruption of an NR4A1/Sp1/p300 transactivational 
complex (803,804).  This thesis will demonstrate the anticancer activity of C-
DIM/NR4A1 antagonists in breast, kidney, colon, and pancreatic cancers by 
inactivating NR4A1-regulated oncogenes that are critical for tumor growth 
survival, and migration.  Results of my studies will show that NR4A1 antagonists 
induce ROS by targeting key genes involved in maintaining levels of cellular 
reductants and increased ROS also induced sestrin2 (SESN2) which activates 
AMPKα resulting in inhibition of mTOR.  
NR4A1 and nongenomic pathways: apoptosis and autophagy 
 NR4A1 also participates in nongenomic pathways that regulate apoptosis, 
survival, and migration pathways.  NR4A1 binds with anti-apoptotic protein bcl2, 
which in normal conditions antagonizes Bax/Bak-induced apoptosis and prevents 
MOMP through homodimerization and heterodimerization with Bcl-XL (813,814).  
Certain compounds were demonstrated such as retinoid 3-Cl-AHPC (4-[3-(1-
adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid) and phorbol ester TPA (12-
O-Tetradecanoylphorbol-13-acetate, an inducer of PKC signaling) to induce 
NR4A1 nuclear export through its NES (nuclear export sequence) by association 
with RXR (813-815).  Through NR4A1 LBD, it binds to the N-terminal loop of Bcl-
2, which displaces its BH4 (anti-apoptotic conferring domain) and exposes its 
proapoptotic BH3 domain that is concealed prior to this association event.  This 
also reduced the anti-apoptotic propensity of Bcl-XL (813,814).  NR4A1 can also 
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associate with other Bcl-2 family members such as Bcl-B and Bfl-1 (814). 3-Cl-
AHPC is not unique in its ability to induce nuclear export of NR4A1 or association 
with bcl-2.  Recently, it was reported that a coumarin derivative, apaensin, can 
activate p38 (MAPK14) kinase which promotes mitochondrial translocation of 
NR4A1 and its subsequent association with bcl-2 (816).  In RAW264.7 T-cells, 
LPS can activate p38, induce phosphorylation of NR4A1 at T27 and T143, and 
induce apoptosis in these cells.  NR4A1 also induces autophagy at the 
mitochondria by associating with Nix and ANT1 (adenine nucleotide translocator 
1), with the latter being involved in MOMP and changes in mitochondrial inner 
membrane potential (817).  Other alkaloid compounds such as dendrogenin A 
(DDA) induce NR4A1-mediated autophagy in cancer cells such as melanoma 
cancer cells (818).   Induction of autophagy by NR4A1 is not always associated 
with apoptosis since certain activated receptors such as IGF1R and neurokinin-1 
receptor (NK1R) induce autophagy related to cancer cell survival, where NR4A1 
is translocated to the cytosol with p53 and inhibits p53 in HEK293 cells (819). 
Nuclear export of NR4A1 induced by AHPN, an adamantine-derived retinoid 
similar to 3-Cl-AHPC, also induces nuclear export of NR4A1 and is dependent on 
c-jun N-terminal kinase (JNK) and AKT (820).  NR4A1 can also localize to the ER, 
associate with TRAPγ (through LBD of NR4A1), and induce ER-mediated 
apoptosis (translocon associated protein subunit gamma) (821).  This inhibits the 
ability of TRAPγ to bind calcium to the ER membrane and retain ER resident 
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proteins within the ER lumen, as well as the efflux of calcium that triggers 
apoptosis through SERCA (821).   
NR4A1 nongenomic pathway: TGF-β 
 NR4A1 can also translocate to the cytosol and activate tumorigenesis and 
invasive/migratory pathways (822).  It was reported that NR4A1 was necessary 
for TGF-β induced migration in TNBC cells (822).  NR4A1 associates with RING 
ringer E3 ubiquitin ligases arkadia (RNF111) and RNF12, to promote the 
ubiquitination and subsequent proteasome-degradation of inhibitory Smad 7 and 
negative regulator of TGF-β (822).  TGF-β is a tumor suppressor in early stage 
cancer but in advanced cancer TGF-β is a promoter of migration/invasion and 
EMT and in breast cancer NR4A1 is important for this response (822).  In chapters 
V and IX of this thesis we describe the role and mechanism of action of NR4A1 in 
mediating TGF-β-induced TNBC invasion and the effects of C-DIM/NR4A1 
antagonists as inhibitors of TGF-β-induced migration and EMT. 
NR4A1 and β-catenin 
β-catenin is a potent driver of TGFβ-induced EMT in cancer cell lines (52-
54,823).  The β-catenin protein contains 40 armadillo repeats (the Drosophila 
melanogaster homolog of β-catenin) (823,824).  The repeats arrange into a rigid 
structure known as the armadillo domain (ARM) (823,824). This domain is found 
in many proteins that are important for cytoskeletal infrastructure (γ-catenin), 
development (APC β-catenin), and Wnt signaling (APC) (823-825).  Along with 
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this central containing highly structured motif, β-catenin also contains two 
unstructured regions at both its N-terminus and C-terminus (823,824).  With the 
N-terminus, there is a region for binding to an E3 ubiquitin ligase known as TrCP-
1 (823,824).  This promotes binding to the TRCP-1 protein, only when the N-
terminal region is phosphorylated (namely by GSK3-β and CK-1). The C-terminal 
region of β-catenin contains a strong transactivator domain, with a structural helix 
that is just C-terminal to the ARM domain, which confers high transactivational 
propensity, termed HelixC (823,824,826).  This region of β-catenin confers 
association with TCF/LEF transcription factors (namely LEF1, TCF1, TCF2, 
TCF3, and TCF4), which is important for the ability of β-catenin to act as a 
transcription factor as β-catenin itself cannot bind directly to DNA (826-828).  TCF 
proteins bind to a conserved DNA binding sequence (A/T)(A/T)CAA(A/T)G in the 
minor groove within cognate promoters.  One nucleotide within the LEF-1 
consensus site (TTCAAAG) is indispensable for binding and abolition or mutation 
of this nucleotide abrogates LEF binding (827,828).  These transcription factors 
are part of family of proteins known as high mobility group (HMG) proteins (826-
828).  These proteins are defined by the possession of a high mobility group 
(HMG) box that confers DNA binding propensity (826-828).  
There is evidence that β-catenin and NR4A1 interact and regulate one 
another’s stability (829-833) and one example shows an indirect correlation 
between the two proteins involving adrenal aldosterone-producing adenomas 
(APAs) Secondary hypertension is caused by primary aldosteronism (PA) (829).  
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PA is caused by APAs and it was recently demonstrated that β-catenin through 
the Wnt pathway promotes Angiotensin II-induced aldosterone secretion indirectly 
by activating AT1R, CYP21 and CYP11B2 by increased expression of NR4A1 
(829).      
The evidence for mutual regulation of NR4A1 and β-catenin is equivocal in 
a colorectal cancer.  One study reports that CRC is exacerbated by colonic 
carcinogen deoxycholic acid (DCA) induced expression of NR4A1 and this 
mechanism involves β-catenin activating the transcription factor AP-1 (c-Fos/c-
Jun), which binds the NR4A1 promoter and induces NR4A1 expression (830).  
Another study shows that NR4A1 and β-catenin coregulate one another and 
participate in a mutual feed-forward loop (831). β-catenin stimulated NR4A1 at the 
transcriptional level through HIF-1α and NR4A1 regulates β-catenin positively 
through a PI3K/Akt-dependent nongenomic pathway (831).  However, other 
studies report that NR4A1 antagonizes expression and stability of β-catenin (832-
834).  For example, in Escherichia coli-induced peritonitis, NR4A1 downregulated 
transcription of β-catenin and the converse was observed in the lungs of NR4A1-
deficient mice (832).  Other evidence suggests that nongenomic NR4A1 
antagonizes β-catenin expression by proteasome-dependent degradation of β-
catenin in vivo and in vitro by treating cells with two digitalis-like compounds 
(DLCs), H-9 and ATE-i2-b4 (833).  This proteasome-dependent degradation 
involves NR4A1 nuclear export and there was evidence that this export was 
dependent of the c-Jun N-terminal Kinase (c-JNK) (833).  In hepatocellular 
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carcinoma (HCC), it was reported that NR4A1 participates in degradation of β-
catenin and that NRDG1 (N-Myc downstream regulated gene) binds to NR4A1 
and GSK-3β, to enable β-catenin to escape degradation (834).  In chapter IX, we 
provide evidence demonstrating a role for β-catenin in NR4A1 regulation 
andNR4A1/TGFβ induced migration.  We also show (chapter IX) that β-catenin 
binds directly to the NR4A1 promoter with TCF3, TCF4, and LEF-1.  NR4A1 also 
contributes to the stability of β-catenin, since nuclear export of NR4A1 is required 
for β-catenin nuclear localization.  Treatment with NR4A1 antagonists, or CRM1 
(chromosomal maintenance 1 or Exportin 1(XPO1))-dependent nuclear export 
inhibitor leptomycin B promote cytosolic sequestration of β-catenin, which leads 
to a time dependent proteasome-dependent degradation of β-catenin.  This 
dissertation will show that NR4A1 and β-catenin play a role in their mutual 
regulation, stability, and subcellular location.  Previous reports and results 
obtained from studies in this laboratory significantly demonstrate that NR4A1 is a 
master regulator of pro-survival, invasive, and anti-apoptotic pathways and plays 
a critical nongenomic role in regulating TGFβ-induced migration and EMT in 
TNBC cells. 
C-DIMs as novel NR4A1 ligands and antagonists 
Studies from this laboratory show that a series of 1,1-bis(3’-indolyl)-1-(p-
substituted phenyl) methane (C-DIM) analogs can bind NR4A1 and inhibit 
NR4A1-dependent oncogenic and invasive pathways (Figure 58) (803-809).  The 
latter includes basal migration/invasion by NR4A1 serving as a transcription factor 
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for β1-integrin as well as a nongenomic and inducible migratory pathway 
stimulated by transforming growth factor β (TGFβ).  C-DIMS are derivatives of the 
known natural anticarcinogenic compound 3,3’-bis (indolyl) methane (DIM), and 
our synthetic derivatives a p-substituent phenyl group covalently attached to the 
methylene bridge connecting the two indole substituents.  DIM is a metabolic 
product in the GI tract (low pH), from the natural compound indole-3-carbinole 
(I3C) (835, 836).   Through luciferase activation assays and BIAcore binding 
studies, we have demonstrated that some C-DIMs bind NR4A1 and among an 
initial series of 14 p-substituted C-DIMs the p-hydroxyphenyl C-DIM analog (DIM-
C-pPhOH) bound with high affinity (Kd= 0.11µM) to NR4A1 (803,804).  The 
anticancer activities of DIM-C-pPhOH and related compounds were similar to that 
observed after knockdown of NR4A1 by RNA interference (RNAi) and these 
ligands act as NR4A1 antagonists (or inverse agonists) (803-809).   
 
Figure 58: C-DIM structure. Structure of the C-DIM/NR4A1 antagonists, which is composed of two indole 
substituents connected by a methylene bridge.  The methylene bridge also contains a phenyl ring with 
contains a para (p) substituent located at position (X).  In this thesis, the following chapters describe the DIM-
C-pPhOH (C-DIM 8) C-DIM, where X=OH and the DIM-C-pPhCO2Me (C-DIM 14) C-DIM where X=CO2Me 
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1-Integrin and breast cancer 
Cell adhesion and attachment are essential for tissue integrity and cellular 
homeostasis, and the heterodimeric integrin cell surface receptors play a critical 
role in these processes (369-373,837-838).  There are 18 different  and 8 
different  subunits that form 24 -integrin receptor heterodimers, and the large 
12-member 1-integrin sub-group binds to extracellular matrix (ECM) molecules 
such as collagen, laminin, fibronectin, tenascin C and vitronectin.  Interactions of 
the integrin receptors with ECM components activate multiple intracellular 
pathways and induce crosstalk with other signaling systems including EGFR and 
other receptor tyrosine kinases (369-373, 837-843).  The functions of integrin 
heterodimers are highly tissue-specific and many human pathologies also involve 
integrin signaling.  β1-Integrin is associated with 12 different integrins, with five of 
these being in breast cancer (α1, α2, α3, α5, α6) (844-860).  These bind to 
collagen, laminin, fibronectin, vitronectin, and tenascin C.  β1-Integrin is important 
for embryonic development, implantation, angiogenesis, and mammary gland 
development (844-860).   In the normal mammary gland, the interaction between 
the epithelial cells and the basement membrane is critical for the ductal formation 
and its integrity, which is comprised of a bilayer of luminal epithelial cells and basal 
myoepithelial cells (849,850).  This is segregated by stroma from the basement 
membrane.  Integrin expression is predominant in the myoepithelial layer as this 
layer directly interacts with the ECM, playing a major role in mammary tissue 
attachment and integrity, mammary cell growth, development, and differentiation 
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(849,850).  Of these integrins, β1-Integrin has shown to be indispensable for 
mammary gland longevity as it is a critical component of sustaining mammary 
gland stem cells (857-869).  β1-Integrin also promotes mammary morphogenesis 
and segregation of mammary ductal compartments (849,85,861,862).  Within the 
mammary gland β1-Integrin, containing heterodimers participate in intracellular-
ECM interactions within myoepithelial and alveolar epithelial cells (milk secreting 
cells).  The heterodimers α2β1, α3β1, α6β1 are present in luminal epithelial cell 
junctions whereas α1β1, α5β1 α6β4 are present predominantly at myoepithelial-
basement membrane junctions, with α5β1 demonstrating the highest expression 
(849,850, 864).    
1-Integrin has been identified as one of the most important integrin 
receptors in tumorigenesis with prognostic significance and multiple pro-
oncogenic functions in several tumor types (853-860).  1-Integrin is highly 
expressed in most tumors and is associated with a negative prognostic 
significance such as overall and disease-free survival, recurrence, and metastasis 
for head and neck and squamous cell carcinoma, melanoma, lung, breast, 
prostate, laryngeal and pancreatic cancers (857-863).  There is now increasing 
evidence that 1-integrin is a pivotal gene involved in tumor growth, survival, 
adhesion, migration and invasion of cancer cells, and the dominance of one or 
more of these pathways is dependent on the cell and tumor type and differential 
expression of other integrin sub-family members.  Therapeutics that target 
integrins have sales in excess of $1.5 billion annually and are being used for 
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treatment of thrombotic diseases, fibrosis, autoimmune disease, arthritis, age-
related macular degeneration and other inflammatory and infectious conditions 
(864-872).   Despite the critical role of 1-integrin in several cancers, therapeutics 
such as volociximab (monoclonal antibody against 51), JSM6427 (small 
molecule), and ANT-161 (peptide) which inhibits 51 binding have made limited 
clinical impacts for cancer chemotherapy (873-876).  β1-integrin has also been 
correlated with estrogen receptor activation and plays a pivotal role in ER positive 
breast cancer (877).  β1-integrin can control expression of ER and likewise the 
ER can of α5β1 heterodimer expression (877).  This seems to be mediated by 
kinase LMTK3 (lemur tyrosine kinase 3) (877).   Integrin signaling pathways are 
highly complex in both tumor and non-tumor tissues, and both 1-integrin and 
focal adhesion kinase (FAK) which is activated by 1-integrin are essential factors 
in breast cancer cell migration, invasion and metastasis.   
A recent immunostaining study of 225 breast invasive ductal carcinomas 
(IDCs) showed that 1-integrin was overexpressed in 32.8% of patients with IDCs 
(878).  Moreover, there was a correlation between expression of 1-integrin, the 
oncogene erbB2 and vascular endothelial growth factor (VEGF), and 1-integrin 
was a prognostic factor for tumor metastasis and decreased survival based on the 
time between initial diagnosis and death (879,880).  Numerous studies 
demonstrate that FAK is also a negative prognostic factor for breast cancer 
patients.  The important functional role of 1-integrin has been demonstrated in 
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mouse models, in vitro mechanistic studies and by genetic disruption of 
downstream signaling partners such as FAK and integrin-linked kinase (ILK) and 
upstream effects induced by fibronectin, tissue factor and L1 cell adhesion 
molecule (L1CAM) (881,882).  For example, in mice expressing erbB2 under the 
control of the mouse mammary tumor virus and crossed with mammary tissue-
specific 1-integrin-deficient mice, there was a decrease in tumor volume, 
increased apoptosis and decreased lung metastasis compared to animals 
expressing wild-type 1-integrin (883).  There was also a decrease in angiogenic 
filtration and decreases in activated levels of Src, FAK, p130Cas, and paxillin 
phosphorylation.  There was also a decrease in EGFR phosphorylation, which 
demonstrates the role that 1-integrin plays in EGFR activation and activation of 
pro survival PI3K/AKT and Ras pathways (883).   
1-integrin is also involved in Rab mediated endocytic trafficking of EGFR 
and its reciprocal endocytic recycling of α5β1 heterodimers.  Their interactions are 
important for invasiveness by interacting with the urokinase-type plasminogen 
activator receptor (884,885).  1-integrin also has an impact on the expression of 
two other integrins involved in breast cancer invasion: α6 and β4 integrin, which 
are part of the laminin receptor (886,887).  These integrins have been associated 
with poor prognosis and survival and they promote invasiveness in part by forming 
a ternary complex with EGFR and promoting Rho activation and invasipodia 
formation (893-895).  This is also critical in ErbB2 overexpressing breast cancer 
and these pathways all seem to be heavily dependent on 1-integrin (889,890).  
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1-integrin has also been studied in mice that have PyVmT-induced 
carcinogenesis, which represents TNBC (891,892).  In these studies, they used a 
Cre/Lox system to conditionally knockout 1-integrin and demonstrated that 1-
integrin was essential for tumor formation in these mice (891,892).   Moreover, 
proliferation of these cells were substantially attenuated as well as Fak localization 
and activation (891,892).  Recent studies also demonstrate that L1CAM and 
alternatively spliced tissue factor (asTF) enhanced breast cancer cell growth and 
epithelial to mesenchymal transition (EMT) through activation of 1-integrin 
(881,882,893).  Despite the extensive literature on the pivotal role of 1-integrin 
in breast cancer growth and metastasis, there is a staggering paucity of drugs that 
target 1-integrin for breast cancer chemotherapy (873-876).  Another problem 
with drugs that target β1-integrin (including knockdown) is the β1-β3 switching 
phenomena in which the loss of β1-integrin is accompanied by induction of β3-
integrin, another pro-oncogenic integrin (894).   
1-Integrin and pancreatic cancer   
1-Integrin mRNA and protein are overexpressed in pancreatic tumors, 
and 1-integrin silencing by RNA interference (RNAi) in pancreatic cancer cells 
decreases cell adhesion, migration and invasion, and downregulation of genes 
such as MMP-2 and MMP-9 (895-899).  Knockdown of 1-integrin in Colo-357 
pancreatic cancer cells by RNAi also decreases expression of 2-, 3-, 5- and 
v-integrins; these same integrins form heterodimers with 1-integrin and bind 
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collagen (2), laminin (3), and fibronectin (5 and v) (895-899).  1-Intregrin 
silencing by RNA interference (RNAi) also decreases tumor growth and 
metastasis, and similar results have been observed in vivo using 1-integrin 
antibodies (900,901).  Rip1Tag2 transgenic mice express the Simian Virus 40 
large T-antigen under the control of the rat insulin promoter and spontaneously 
develop pancreatic -cell tumors, and ablation of 1-integrin in tumor cells 
decreases tumor cell growth and metastasis (902,903).  
 Pancreatic cancer cells express 1- and other -integrin partners and, not 
surprisingly, 1-integrin heterodimers are activated by multiple extracellular matrix 
proteins (e.g. collagens, fibronectin, laminin, vitronectin) and many other 
extracellular factors, including tissue factor (TF) and alternatively spliced TF 
(asTF) which are overexpressed in pancreatic tumors (904-906) and exhibit 
potent growth promoting, angiogenic, and metastatic activity (907-910).  The L1 
cell adhesion molecule (L1CAM) is a transmembrane glycoprotein (200-220 kDA) 
that is overexpressed in pancreatic ductal adenocarcinoma cells (911).  L1CAM-
mediated drug-resistance, survival, and epithelial to mesenchymal transition 
(EMT) in pancreatic cancer cells is due to interactions of 5 and 1-integrins and 
the immediate downstream targets include FAK, integrin-linked kinase (ILK) and 
PI3-K (912-916).  L1CAM-1-integrin activation is associated with induction of IL-
1 and activation of NFB (914-916), and this signaling pathway "supports a 
motile and invasive tumor cell phenotype" (915).  Other factors including 
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neuropilin-1, glial cell line-derived neurotrophic factor, thrombin, Snail, Slug and 
interleukin  either interact with or enhance 1-integrin and thereby modulate 
downstream signaling in pancreatic cancer cells (917-921).   
1-Integrin and colon cancer  
1-integrin is also overexpressed in colon cancer and is critical for 
attachment of colon cancer cells to blood vessels, intravasation, and metastasis 
(922-924).  Knockdown of 1-integrin using RNAi in colon cancer cells results in 
decreased cancer cell growth migration and induces apoptosis.  High expression 
of α5β1 in colon cancer cells promotes malignant progression in colon cancer 
(922-924).  A recent report showed that E-selectin mediated increase in cancer 
cell attachment to vascular endothelium is due to upregulation of 1-integrin (922).  
Upregulation of β1-integrin in colon cancers also increase endotoxin levels that 
enhance association to laminin in endothelial cells (923).  Increased expression 
of 1-integrin or α5 integrin in HT29 colon cancer cells suppresses nutrient 
starvation triggered apoptosis (924).   Studies by our group has demonstrated that 
NR4A1 is overexpressed in colorectal cancer and that it is an important driver in 
oncogenesis, invasion, reduction of oxidative stress, and inhibitor of apoptosis.  
Recently we have demonstrated that NR4A1 mediates cancer cell migration which 
is also β1-integrin-dependent and our studies (chapter VII) demonstrate for the 
first time that NR4A1 regulates β1-integrin gene expression and C-DIMs/NR4A1 
antagonists inhibit β1-integrin expression without inducing β3-integrin. 
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   CHAPTER II 
NUCLEAR RECEPTOR 4A1 (NR4A1) AS A DRUG TARGET FOR 
RENAL CELL ADENOCARCINOMA 
 
Introduction 
 Kidney cancer is a complex and heterogenous disease and clear 
cell renal cell adenocarcinoma (RCC) is the most common sub-type and 
represents approximately 75% of renal parenchymal tumors (924-926).  The 
incidence of RCC has been increasing and it is estimated that in 2013 over 65,000 
new cases will be diagnosed and 13,680 kidney cancer patients will die from this 
disease (927).  Early stage RCC patients with localized tumors have a good 
prognosis after surgical removable of the primary tumor; however, approximately 
30% of all patients first diagnosed with RCC already have metastatic disease 
(924).  Patients with RCC are unusually resistant to radio and cytotoxic drug 
therapies compared to responses observed for other solid tumors, and 
immunotherapies have provided some limited benefits for patients with RCC 
metastases (928-931).  The recent development of targeted therapies for treating 
RCC has significantly improved the outlook for patients and the focus has primarily 
been on clinical application of receptor tyrosine kinase inhibitors, neutralizing 
antibodies against vascular endothelial growth factor (VEGF) and mTOR pathway 
inhibitors (932-936). 
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Studies in this laboratory have identified 1,1-bis(3'-indolyl)-1-(p-substituted 
phenyl)methanes (C-DIMs) as novel antineoplastic agents that act as antagonists 
of the orphan nuclear receptor 4A1 (NR4A1, TR3, Nur77) which exhibits pro-
oncogenic activity in several solid tumors (803,805,806,937).  For example, the p-
hydroxyphenyl C-DIM analog (DIM-C-pPhOH) binds nuclear NR4A1, and the 
effects on downstream genes and pathways are similar to that observed after 
knockdown of NR4A1 by RNA interference (RNAi).  Results of these studies in 
pancreatic, lung and colon cancer cell lines show that NR4A1 regulates at least 
three pathways that are important for cancer cell proliferation and survival (Fig. 
1A).  NR4A1 regulates expression of pro-survival (survivin, bcl-2) and growth 
promoting (EGFR) genes through interaction with Sp1 bound to their 
corresponding proximal GC-rich promoters (804).  NR4A1 binds to and inactivates 
p53 and p53-regulated sestrin 2 which results in activation of mTOR in cells 
expressing NR4A1 and wild-type p53.  NR4A1 also regulates expression of genes 
such as thioredoxin domain containing 5 (TXNDC5) and isocytrate 
dehydrogenase 1 (IDH1) to maintain low oxidative stress in cancer cells (805).  
Thus, inactivation of NR4A1 by the receptor antagonist DIM-C-pPhOH decreases 
expression of genes associated with cell proliferation and survival, induces 
oxidative stress, and inhibits mTOR in cancer cell lines (806).  
In this study, we show that NR4A1 is also expressed in the ACHN 
and 786-O kidney cancer cell lines and treatment of these cells with DIM-C-
pPhOH and the related NR4A1 antagonist 1,1-bis(3'-indolyl)-1-(p-
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carboxymethylphenyl)methane (DIM-C-pPhCO2Me) inhibits cell growth, induces 
apoptosis and cellular stress, and inhibits mTOR signaling.  A comparison of the 
effects of the NR4A1 antagonists and knockdown of NR4A1 by RNAi (siNR4A1) 
gave comparable results and inactivation of the previously characterized pro-
oncogenic NR4A1-regulated pathways (Fig. 1A).  These results suggest that 
NR4A1 is a potential drug target for treating RCC patients that overexpress this 
receptor. 
 
Materials and Methods  
Cell lines and antibodies 
ACHN and 786-0 human kidney cancer cell lines were purchased from 
American Type Culture Collection (Manassas, VA).  Cells were maintained 37˚C 
in the presence of 5% CO2 in Dulbecco’s modified Eagle’s medium/Ham’s F-12 
medium with 10% fetal bovine serum with antibiotic or RPMI-1640 Medium with 
10% fetal bovine serum and antibiotic respectively. Β-actin antibody Dulbecco’s 
Modified Eagle’s Medium, and RPMI-1640 Medium were purchased from Sigma-
Aldrich (St. Louis, MO).   Sp1 antibody and Glutathione (GSH) reduced free acid 
were purchased from Millipore (Temecula, CA); sestrin 2 (SESN2), bcl2, CHOP, 
ATF4, isocitrate dehydrogenase 1 (IDH1), and epidermal growth factor receptor 
(EGFR) antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA).  
Nur77(D63C5) XP®, caspase 3, cleaved poly ADP ribose polymerase (c-PARP; 
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9541), phospho mTOR, mTOR, phospho AMPKα, AMPKα, phospho p70S6K, 
p70S6K, phospho S6RP, S6RP, phospho 4EBP1, 4EBP1, and survivin antibodies 
were purchased from Cell Signaling technologies (Danvers, MA). TXNDC5 
antibody was purchased from Genetex (Irvine, CA).  Phospho PERK antibody was 
obtained from Biolegend (San Diego, CA).  Apoptotic, Necrotic, and Healthy Cells 
Quantification Kit was purchased from Biotium (Hayward, CA). Cells were 
visualized under an EVOS fl, Fluorescence microscope, from Advanced 
Microscopy Group using a multiband filter set for FITC, rhodamine, and DAPI.  
The C-DIM compounds were prepared as previously described (942-944). 
Cell proliferation assay  
ACHN and 786-0 kidney cancer cells (1.0 x 105 per well) were plated in 12 
well plates and allowed to attach for 24 hours and cells were treated with DIM-C-
pPhOH or DIM-C-pPhCO2Me ( dimethyl sulfoxide, DMSO, as empty vehicle) for 
24 or 48 hours or by siNR4A1(iGL2 as control siRNA with lipofectamine vehicle) 
for 72 hours.  Cells were then trypsinized and counted after respective treatment 
time intervals using a Coulter Z1 cell counter and growth inhibition was 
determined.  Each experiment was carried out in triplicate, and results were 
expressed as the mean ± SE for each set of experiments. 
Annexin V staining 
ACHN and 786-0 kidney cancer cells(1.0 x 105 per well)  were seeded in 
2-well Nunc Lab-Tek chambered B#1.0 Borosilicate coverglass slides from 
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Thermo Scientific and were allowed to attach for 24 hours.  The medium was then 
changed to DMEM/Ham F-12 medium contained 2.5% charcoal-stripped fetal 
bovine serum, and either DMSO or DIM-C-pPhCO2Me (15 µM) was added for 24 
hr.  For siRNA treatment, cells were treated with iGL2 or 100 nm siNR4A1 (1 or 
2) siRNA for 72 hours.  Apoptosis was analyzed by apoptotic and necrotic assay 
kit (Biotium CA), which contained fluorescein isothiocyanate-annexin-V, ethidium 
homodimer III and Hoechst 3342.  Apoptosis, necrotic and healthy cell detection 
kit was used according to the manufacturer’s protocol and were visualized under 
an EVOS fl, fluorescence microscope, from Advanced Microscopy.  The 
proportion of apoptotic cells was determined by the amount of green fluorescence 
observed in the treatment groups relative and normalized to control group. 
Immunofluorescence 
ACHN and 786-0 cells (1.0 x 105 per well)  were seeded in 2-well Nunc 
Lab-Tek chambered B#1.0 Borosilicate coverglass slides from Thermo Scientific 
and were allowed to attach for 24 hours.  The medium was then changed to 
DMEM/Ham F-12 medium contained 2.5% charcoal-stripped fetal bovine serum, 
and either DMSO or DIM-C-pPhCO2Me (15 µM) was added for 24 hr.  Cells were 
then treated with fluorescent NR4A1 primary antibody (Nur77 (D63C5)) XP®) and 
immunofluorescence was observed according to Cell Signaling Technology’s 
immunofluorescence protocol.  DAPI staining was observed using Hoechst 
staining according to Biotium’s apoptotic and Necrotic assay kit following the 
manufacturers protocol.  Cells were visualized by microscope (Advanced 
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Microscopy).  NR4A1 localization was determined by green fluorescence.  DAPI 
was used to stain the nucleus.  Images were taken sequentially of NR4A1, DAPI, 
and then merged. 
Western blot analysis 
ACHN and 786-0 kidney cancer cell lines (3.0 x 105 per well) were seeded 
in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 
2.5% charcoal-stripped fetal bovine serum and were allowed to attach for 24 h. 
Cells were seeded and subsequently treated with varying concentration of DIM-
C-pPhOH or DIM-C-pPhCO2Me for 24 hours or with 100 nm of siNR4A1 for 72 
hours.  Cells were lysed with high salt lysis buffer (with protease inhibitor cocktail) 
and quantitated with Bradford reagent.  Lysates were then analyzed by SDS-
PAGE and transferred onto a polyvinylidene difluoride (PVDF) membrane by wet 
electroblotting.  Membranes were then incubated with primary and then followed 
by secondary antibody.  Western blot analysis was determined as described and 
Immobilon western chemiluminescence  substrates (Millipore, Billerica, MA) were 
used to develop images captured on a Kodak 4000 MM Pro image station 
(Molecular Bioimaging, Bend, OR). 
Small interfering RNA interference assay 
ACHN and 786-0 kidney cancer cells were seeded (1.2 x 105 per well) in 
six well plates in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium 
supplemented with 2.5% charcoal-stripped fetal bovine serum and left to attach 
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for 24 hours.  Knockdown of NR4A1 was carried out using LIpofectamine 2000 
reagent according to the manufactures protocol.  Small inhibitory RNAs and GL2 
(non-specific oligonucleotide) were prepared and purchased Sigma-Aldrich (St. 
Louis MO).  The siRNA complexes used in the study are as follows: siGL2-5’, 
CGU ACG CGG AAU ACU UCG A; siNR4A1 (1)-SASI_Hs02_00333289; 
siNR4A1 (2)-SASI_Hs01_00182072 
Generation and measurement of ROS 
Cellular ROS levels were ascertained using the cell permeable probe CM-
H2DCFDA (5-(and-6)-chloromethyl-2’7’ dichlorodihydrofluorescein diacetate 
acetyl ester) from Invitrogen (Grand Island, NY).  CM-H2DCFDA is non-
fluorescent until cleavage of the acetyl groups by intracellular esterases and 
oxidation that transpires within the cell.  Following treatment of the cells for 12 or 
24 hours with DIM-C-pPhOH, DIM-C-pPHCO2Me or siNR4A1 for 72 hours, cells 
plated on a 6-well culture plate were trypsinized, neutralized, then loaded with 
10µM of probe for 20 min, washed once with serum free medium, and then ROS 
was measured by flow cytometry using Accuri’s C6 Flow Cytometer (Accuri, Ann 
Arbor, MI).  
Orthotopic Xenograft model 
Male athymic nude mice (Foxn1nu, aged 6–7 weeks) were purchased from 
Harlan (Indianapolis, IN). The mice were housed and maintained in laminar flow 
cabinets under specific pathogen-free conditions.  A xenograft was established by 
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subcutaneous injection of cultured ACHN cells (107 cells/150 µl) with Matrigel into 
the flanks of individual mice.  Tumors were allowed to grow for 7 days until tumors 
were palpable. Mice were then randomized into two groups of five mice per group 
and dosed by oral gavage with either corn oil or DIM-C-pPHOH (30 mg/kg/day) 
for 50 days. The mice were weighed, and tumor size was measured twice a week 
with calipers to permit calculation of tumor volumes, VxLxW2/2, where L and W 
were length and width.  Tumor lysates were obtained and analyzed for protein 
expression by western blots. 
Statistical analysis 
Statistical significance of differences between the treatment groups was 
determined by student’s t test.  The results are expressed as means with error 
bars representing 95% confidence intervals for 3 experiments for each group 
unless otherwise indicated, and a P value less than 0.05 was considered 
statistically significant.  All Statistical tests were 2-sided. 
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Results 
NR4A1 antagonists inhibit RCC cell proliferation and induce apoptosis 
Figure 59.  NR4A1 plays a role in RCC proliferation.  (A) Pathways activated by NR4A1 and targeted by NR4A1 
antagonists.  (B) Cells were transfected with two different oligonucleotides targeting NR4A1 [NR4A1(1) and 
NR4A1(2)] and after 72 hr, the number of cells were determined as outlined in the Materials and Methods.  (C) Cells 
were treated with DIM-C-pPhOH and DIM-C-pPhCO2Me and cell numbers were determined after treatment for 24 
hr.  (D) Cells were transfected with siCtl (non-specific) or siNR4A1 and treated with DIM-C-pPhOH and DIM-C-
pPhCO2Me and cell numbers were determined.  siNR4A1 alone decreased cell proliferation as indicated in (B) and 
this value was set at 100% to determine the effects of C-DIMs in cells after loss of NR4A1.  (E) Athymic nude mice 
bearing ACHN cells as xenografts were treated with 30 mg/kg/d DIM-C-pPhOH and tumor volumes were 
determined.  Results are means  SE for at least 3 separate determinations and significantly (p < 0.05) decreased 
growth/volume is indicated (*).  Significant attenuation of C-DIM-induced growth after NR4A1 is also indicated (**). 
Figure 59. 
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Figure 59A summarizes the growth and survival pthways that can be 
targetted by NR4A1 antagonists in lung pancreatic and colon cancers.  ACHN and 
786-O RCC cell lines are p53-positive and mutant cell lines, respectively, and 
were used to investigate the function of NR4A1 and effects of C-DIM/NR4A1 
antagonists.  In cells transfected with two different oligonucleotides that target 
NR4A1 (siNR4A1), there was a significant 50-60% decrease in proliferation of 
both cell lines (Fig. 59B).  Moreover, treatment of ACHN and 786-O cells for 24 hr 
with 0-20 M DIM-C-pPhOH or DIM-C-pPhCO2Me resulted in a significant 
decrease in cell proliferation (Fig. 59C), and IC50 values for both compounds in 
ACHN cells were 13.6 and 11.7 μM, respectively, and in 786-O cells the values 
were 13.0 and 13.4 μM, respectively.  The role of NR4A1 in mediating the growth 
inhibitory effects of DIM-C-pPhOH and DIM-C-pPhCO2Me was further 
investigated by treating ACHN cells with C-DIMs after knockdown of NR4A1 by 
RNAi.  The results show that the magnitude of the growth inhibitory effects of both 
compounds was significantly attenuated in cells in which NR4A1 was decreased, 
thus confirming a role for NR4A1 in mediating this response (Fig. 59D).  Moreover, 
treatment of athymic nude mice bearing ACHN cells as xenografts with DIM-C-
pPhOH (30 mg/kg/d) for 50 days also resulted in a significant inhibition of tumor 
growth (Fig. 59E) and this complemented results of the in vitro studies.  Thus, 
both knockdown of NR4A1 by RNAi or treatment with C-DIM/NR4A1 antagonists 
inhibited RCC cell and tumor growth.  Transfection of ACHN and 786-O cells with 
two different siNR4A1 oligonucleotides also increased Annexin V staining (Figs. 
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60A and 60B) ,which is a marker of apoptosis, and induced cleavage of 
caspases7, 8 and PARP (Suppl. Figs. A-1A and A1-B).  We also observed that 
both DIM-C-pPhOH and DIM-C-pPHCO2Me induced Annexin V staining in ACHN 
and 786-O cells (Figs. 60C and 60D, respectively), and cleavage of caspase7, 8 
and PARP (Suppl. Fig. A-1C and A-1D) confirming that C-DIM/NR4A1 antagonists 
induce apoptosis in RCC cell lines.   
Figure 60.  NR4A1 knockdown and C-DIM/NR4A1 antagonists induce apoptosis in RCC cells.  ACHN (A) or 786-O 
(B) cells were transfected with siNR4A1(1) and siNR4A1(2) and Annexin V staining was determined as outlined in 
the Materials and Methods.  ACHN (C) and 786-O (D) cells were treated with 20 M DIM-C-pPhOH or DIM-C-
pPhCO2Me for 24 hr and Annexin V staining was determined.  Results are means  SE for 3 replicated 
determinations and significant (p<0.05) induction of Annexin V staining is indicated (*). 
 
Figure 60. 
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Previous studies show that many apoptosis inducers that act through 
NR4A1 induce nuclear export of the receptor, which subsequently forms a pro-
apoptotic complex with the mitochondrial bcl-2 protein (906,916,938). In contrast, 
our studies show that C-DIMs act through nuclear NR4A1 in cancer cells (803-
806). ACHN and 786-O cells were treated with DIM-C-pPhOH and DIM-C-
pPHCO2Me and after 24 hr, cells were stained with NR4A1 antibodies and DAP1 
and the results show that DAP1 and the NR4A1 immunostaining were co-localized 
in the nucleus, demonstrating that the C-DIM/NR4A1 antagonists act through the 
nuclear receptor (Fig. 61). 
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Figure 61.  C-DIM/NR4A1 antagonists target nuclear NR4A1.  ACHN (A) and 786-O (B) cells were treated with 20 
M DIM-C-pPhOH and DIM-C-pPhCO2Me.  Cells were immunostained with NR4A1 antibodies or DAPI and images 
merged as outlined in the Materials and Methods. 
 
Figure 61. 
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Sp-regulated survival genes 
Previous studies showed that NR4A1 in combination with p300 activated 
Sp-regulated genes such as survivin, bcl-2 and EGFR in cancer cells (803-806). 
Transfection of ACHN and 786-O cells with siNR4A1 decreased expression of 
survivin, bcl-2 and EGFR and this was accompanied by increased PARP cleavage 
(primarily in ACHN cells), a marker of apoptosis (Fig. 62A).  Similar results were 
observed in both RCC cell lines after treatment with DIM-C-pPhOH (Fig. 62B) or 
DIM-C-pPhCO2Me (Fig. 62C), confirming that the NR4A1 antagonists inhibited 
NR4A1-regulated expression of survivin, bcl-2 and EGFR in ACHN and 786-O 
cells as previously reported in pancreatic, lung and colon cancers (803-805).  In 
addition, we also observed decreased expression of survivin, bcl-2, EGFR and 
induced PARP cleavage in tumor lysates from nude mice bearing ACHN cells as 
a xenograft and treated with DIM-C-pPhOH (30 mg/kg/d) (Fig. 62D). 
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Figure 62.  NR4A1 coregulates Sp-regulated oncogenic genes.  (A) Cells were transfected with siNR4A1 and whole 
cell lysates were analyzed by western blots as outlined in the Materials and Methods.  Cells were treated with DIM-
C-pPhOH (B) or DIM-C-pPhCO2Me (C) and after 24 hr, whole cell lysates were analyzed by western blots.  (D) 
Western blot analysis of tumor lysates from athymic nude mice bearing ACHN xenografts and treated with vehicle 
(control) or DIM-C-pPhOH (30 mg/kg/d) was also determined.  Band intensities were quantitated relative to -actin 
(means  SE) and significantly decreased staining intensities are indicated (*; p<0.05).   
Figure 62. 
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siNR4A1 and C-DIM/NR4A1 antagonist induce stress in RCC cells 
It has been shown that NR4A1 maintains low levels of stress in cancer cells 
by regulating expression of TXNDC5 and IDH1 (Fig. 59A) that in turn maintain 
high levels of cellular reducing agents (805,806).  Transfection of ACHN and 786-
O cells with siNR4A1 decreased expression of TXNDC5 and IDH1 in both cell 
lines and this was accompanied by increased expression of CHOP, ATF4 and 
phospho-PERK which are markers of ER stress (Fig. 63A).  Treatment of ACHN 
and 786-O cells with DIM-C-pPhOH (Fig. 63B) or DIM-C-pPhCO2Me (Fig. 63C) 
also decreased expression of TXNDC5 and IDH1 and induced markers of ER 
stress (CHOP, ATF4 and p-PERK).  Moreover, siNR4A or treatment with the C-
DIM/NR4A1 antagonists also induced ROS as determined using the cell permeant 
probe CM-H2-DFDA (Fig. 63D).  In addition, DIM-C-pPhOH (30 mg/kg/d) also 
decreased expression of TXNDC5 and IDH-1 and induced CHOP expression in 
tumors from athymic nude mouse xenografts (Fig. 63E), demonstrating that C-
DIM/NR4A1 antagonists-dependent inhibition of RCC cell and tumor growth is 
due, in part, to induction of stress (Fig. 59A). 
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Figure 63.  siNR4A1 and C-DIM/NR4A1 antagonists induce stress in RCC cells.  Cells were transfected 
with siNR4A1 (A) or treated with DIM-C-pPhOH (B) and DIM-C-pPhCO2Me (C) and whole cell lysates were 
analyzed by western blots.  (D) After treatment of cells as described in (A) - (C), ROS was measured 
using the cell permeant CM-H2FDA probe as outlined in the Materials and Methods.  Significant induction 
(p<0.05) of ROS is indicated (*).  Tumor lysates from athymic nude mice bearing ACHN cells as 
xenografts and treated with vehicle control or DIM-C-pPhCO2Me were analyzed by western blots and 
individual bands were quantitated (relative to -actin).  Significant (p<0.05) induction of ROS is     
indicated (*).   
Figure 63. 
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 siNR4A1 and C-DIM/NR4A1 antagonists inhibit mTOR 
NR4A1 binds and inactivates p53 (939) and treatment with siNR4A1 or C-
DIM/NR4A1 antagonists results in p53-dependent induction of sestrin 2 which 
activates AMPK and inhibits mTOR (803,806).  Knockdown of NR4A1 by RNAi 
in ACHN cells that express wild-type p53 resulted in the induction of sestrin 2, 
activation of AMPK, and inhibition of phospho-mTOR; this was also 
accompanied by decreased activation/phosphorylation of mTOR-regulated 
p70S6K, 6SRP and 4EBP1 (Fig. 64A).  Treatment of ACHN cells with the NR4A1 
antagonists DIM-C-pPhOH (Fig. 6B) and DIM-C-pPhCO2Me (Fig. 64C) also 
induced sestrin 2, activated AMPK and inhibited activation of mTOR and 
downstream kinases and these results are consistent with previous studies in 
other cancer cells expressing wild-type p53 (803,806).  The 786-O cell line 
expresses a mutant p53; however, transfection of these cells with siNR4A1 also 
resulted in the induction of sestrin 2 and inactivation of mTOR and mTOR 
signaling (Fig. 65A).  Moreover, similar results were observed after treatment of 
786-O cells with the NR4A1 antagonists DIM-C-pPhOH (Fig. 65B) and DIM-C-
pPhCO2Me (Fig. 65C).  It has previously been reported that sestrin 2 is induced 
by other factors including oxidative stress (940), and Figure 7D shows that 
induction of sestrin 2 by siNR4A1, DIM-C-pPhOH and DIM-C-pPhCO2Me was 
attenuated after cotreatment with the antioxidant glutathione (GSH).  Thus, 
induction of ROS by NR4A1 antagonist-mediated downregulation of TXNDC5 and 
IDH1 also results in the induction of sestrin 2 in cells expressing mutant p53, 
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suggesting that NR4A1 antagonists inhibit mTOR by both p53-dependent and -
independent induction of sestrin2. These studies demonstrate that NR4A1 is a 
target for NR4A1 antagonists in RCC cells; this leads to inhibition of several 
NR4A1-regulated pro-oncogenic pathways (Fig. 1A) including mTOR and these 
results are comparable to those observed in pancreatic, lung and colon cancer 
cells and tumors (803-806). 
 
Figure 64.  siNR4A1 and NR4A1 antagonist inhibit mTOR in ACHN cells.  Cells were transfected with siNR4A1 (A) 
and treated with DIMI-C-pPhOH (B) and DIM-C-pPhCO2Me (C), and whole cell lysates were analyzed by western 
blots as outlined in the Materials and Methods. 
Figure 64. 
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Figure 65.  siNR4A1 and NR4A1 antagonist inhibit mTOR in 786-0 cells.  Cells were transfected with siNR4A1 (A) 
and treated with DIMI-C-pPhOH (B) and DIM-C-pPhCO2Me (C), and whole cell lysates were analyzed by western 
blots as outlined in the Materials and Methods.  (D) Induction of sestrin 2 by western blots was determined in 780-
O cells treated with DIM-C-pPhOH and DIM-C-pPhCO2Me or transfected with siNR4A1 in the presence or absence 
of 5 mM GSH. 
 
Figure 65. 
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Discussion 
NR4A receptors are immediate-early genes that are induced by diverse 
stressors in multiple tissues/cell lines and these receptors play increasingly 
important role in maintaining cellular homeostasis (891,892).  There is evidence 
that NR4A receptors play a role in the central nervous system, inflammation, 
cardiovascular function, T cell and macrophage function, and metabolic function; 
these receptors also play a role in carcinogenesis and other diseases.  The 
function of NR4A1 in cancer cells has been extensively investigated and in solid 
tumors, there is evidence that this receptor exhibits unique functions that are 
dependent on its subcellular location (788, 808,905).  NR4A1 is a nuclear 
receptor; however, treatment of some cancer cell lines with apoptosis-inducing 
agents results in the induction and nuclear export of NR4A1, which associates 
with mitochondrial bcl-2 to form a pro-apoptotic complex (905,906,916, 938).  
Thus, mitochondrial NR4A1 exhibits tumor suppressor-like activity, and both 
paclitaxel and peptide mimetics of NR4A1 that bind bcl-2, also activate apoptosis 
in cancer cells (906,907).  In contrast, results of RNAi studies suggest that nuclear 
NR4A1 is pro-oncogenic and plays a role in cancer cell proliferation and survival, 
and studies in this laboratory have identified at least three pathways and 
associated genes that contribute to the functions of NR4A1 in cancer cells (Fig. 
59A).  Thus, NR4A1 is unique among orphan nuclear receptors, and the observed 
pro-oncogenic or tumor suppressor-like activity is dependent on the subcellular 
location of the receptor.  Several different structural classes of ligands bind NR4A1 
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and these include cytosporone B and related analogs (910,911), C-DIMs (806), 
ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate (TMPA) (941), and 1-
(3,4,5-trihydroxyphenyl)nonan-1-one (942).  Cytosporone B and related 
compounds and 1-(3,4,5-trihydroxyphenyl)nonan-1-one induce nuclear export of 
NR4A1 and TMPA antagonizes nuclear NR4A1-LKB1 interactions but does not 
affect NR4A1-dependent transactivation.  In contrast, our previous studies in 
pancreatic, lung and colon cancer cells show that C-DIM/NR4A1 antagonists act 
on nuclear NR4A1 and do not induce nuclear export of the receptor [confirmed in 
RCC cells (Fig. 3)] and these compounds also decrease NR4A1-dependent 
transactivation (803,805,806,937). These C-DIMs also require NR4A1 for 
inhibitory action as observed for cell proliferation in Supplemenatry Figure A-2 
Kidney injury can induce NR4A1 expression in non-tumor tissue, and one 
study reported the NR4A1 was expressed in 786-O cells and NR4A1 mRNA was 
more highly expressed in tumors from patients with RCC compared to surrounding 
non-tumor tissue (943-945).  Currently, we are accumulating tumors from kidney 
cancer patients to investigate the tumor-type specific expression and prognostic 
significance of NR4A1.  We further investigated the pro-oncogenic functions of 
NR4A1 by RNAi and compared the results with that observed after treatment of 
ACHN or 786-O cells with two prototypical NR4A1 antagonists, DIM-C-pPhOH 
and DIM-C-pPhCO2Me.  Both NR4A1 knockdown and the NR4A1 antagonists 
inhibited ACHN and 786-O cell proliferation, and DIM-C-pPhOH also inhibited 
tumor growth in athymic nude mice bearing ACHN cells as xenografts (Fig. 59) 
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and siNR4A1 and NR4A1 antagonists also induced apoptosis in these cell lines 
(Fig. 60).  These effects are comparable to previous studies in pancreatic, lung 
and colon cancer cell lines (803-806), suggesting the potential therapeutic 
potential for C-DIMs in treating RCC in patients that overexpress NR4A1. 
Figure 59A illustrates three pro-oncogenic pathways and related genes that 
are regulated by NR4A1 in pancreatic, lung and colon cancer cell lines, and we 
have also observed these NR4A1-dependent response/pathways in other cancer 
cell lines (data not shown).  NR4A1 in combination with p300 coactivates survivin 
and other Sp1-regulated genes (804), and results in Figure 4 show that survivin, 
bcl-2 and the EGFR were regulated by NR4A1 in RCC cells.  All three of these 
Sp-regulated genes play a role in cancer cell growth and survival and some 
studies show that expression of survivin, EGFR and bcl-2 are negative prognostic 
factors for patients with RCC (946-951).  Thus, NR4A1 regulation of these genes 
in RCC contributes to the tumor phenotype, and inhibition of these genes by C-
DIM/NR4A1 antagonists in RCC cells and tumors (Fig. 62) is an important 
component of their antineoplastic activity. 
A second NR4A1-regulated pathway in cancer cells is associated with 
regulation of genes such as TXNDC5 and IDH1 that maintain high levels of redox 
equivalents and decrease intracellular stress (805).  Knockdown of NR4A1 (and 
NR4A1 antagonists) decreases TXNDC5 and IDH1 and induced ROS and other 
stress responses in ACHN and 786-O cells (Fig. 63), suggesting that NR4A1 also 
maintains levels of stress that facilitate RCC growth and survival.  The functions 
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of TXNDC5 and IDH1 have not been characterized in RCC and it is also possible 
that NR4A1 regulates other similar genes and this is currently being investigated.  
Since previous studies show that other ROS-inducing antineoplastic agents inhibit 
growth and survival of RCC (952,953), the activation of ROS by C-DIM/NR4A1 
antagonists contributed to the anticancer activity of these compounds.   
mTOR inhibitors are currently in clinical trials for treating RCC (932-936), 
and our previous studies showed that in colon and lung cancer cells expressing 
wild-type p53, NR4A1 inhibits p53 activity and p53-dependent inhibition of the 
mTOR pathway (804).  However, treatment with C-DIM/NR4A1 antagonists or 
transfection with siNR4A1 activates p53 which in turn increases expression of 
sestrin 2 resulting in activation of AMPK and inhibition of mTOR (803,805,806).  
These same effects were observed in ACHN cells that express wild-type p53, 
demonstrating that C-DIM/NR4A1 antagonists represent a novel class of mTOR 
inhibitors with clinical potential for treating RCC patients expressing NR4A1 and 
wild-type p53 (Fig. 64).  Surprisingly, we also observed similar results in 786-O 
cells that express a mutant p53 and this response was attenuated by cotreatment 
with glutathione.  Sestrin 2 can be induced by oxidative stress (938) and since 
NR4A1 knockdown and NR4A1 antagonists induce ROS (Fig. 63), this represents 
a second NR4A1-mediated p53-independent pathway that can be targeted by 
NR4A1 antagonists to inhibit mTOR. 
In summary, our results show that NR4A1 is pro-oncogenic in RCC and 
regulates at least three pathways (Fig. 59A) important for cell proliferation and 
256 
 
survival, and these can be targeted by C-DIM/NR4A1 antagonists.  Our current 
studies are focused on further investigating the functional responses and 
molecular pathways regulated by NR4A1 in RCC and identifying RCC patient sub-
types that overexpress NR4A1 and are potential candidates for clinical 
applications of C-DIM/NR4A1 antagonists. 
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CHAPTER III 
NUCLEAR RECEPTOR 4A1 (NR4A1) AS A DRUG TARGET FOR BREAST 
CANCER CHEMOTHERAPY* 
Introduction 
Nuclear receptor 4A1 (NR4A1, Nur77, TR3) is a member of the NR4A 
orphan receptor sub-family of nuclear receptors and the NR4A receptors (NR4A1, 
NR4A2 and NR4A3) play essential roles in metabolic processes, inflammation, 
vascular function, steroidogenesis and the central nervous system (891,892,956).  
NR4A1 is overexpressed in multiple tumors and cancer cell lines and results of 
receptor knockdown by RNA interference (RNAi) demonstrate that in solid tumors 
the receptor is pro-oncogenic and regulates cell growth and survival 
(803,805,895,899-902,937,956).  Several pro-apoptotic agents including phorbol 
esters and adamantantyl-derived retinoids induce expression and nuclear export 
of NR4A1, which subsequently binds mitochondrial bcl-2 to form a pro-apoptotic 
complex that decreases mitochondrial membrane potential (905,938).  This has 
led to development of peptide mimics that convert bcl-2 into an apoptotic complex 
and similar results have reported for the taxane-derived anticancer agent 
paclitaxel (906,907).  Cytosporone B (CsnB) and related analogs have been 
* Reprinted with permission from “Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Breast Cancer 
Chemotherapy.” Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S, 2015 Endocrine Related Cancer, 
22,831-40 , Copyright[2015] Bioscientifica 
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identified as ligands for NR4A1 (910,911), and two additional compounds [ethyl 
2-[2,3,4-trimethoxy-6-(1-oct-anoyl)phenyl]acetate (TMPA) and 1-(3,4,5-
trihydroxyphenyl)no-nan-1-one (THPN)] also bind NR4A1 (941,942).  TMPA 
inactivates nuclear NR4A1, whereas THPN and CsnB induce nuclear export of 
NR4A1. 
 Studies in this laboratory have been investigating a series of 1,1-bis(3-
indolyl)-1-(p-substituted phenyl)methane (C-DIM) analogs and their effects on 
NR4A1 and NR4A1-dependent transactivation (803,805-807,896,909,937).  
Since NR4A1 exhibits pro-oncogenic activity, we have focused on identification of 
C-DIMs that inactivate NR4A1 and the p-hydroxyphenyl analog (DIM-C-pPhOH) 
was characterized as a compound that inactivated nuclear NR4A1 in cancer cell 
lines and this was not accompanied by nuclear export of NR4A1 (803,805,937).  
Subsequent studies comparing the effects of DIM-C-pPhOH and knockdown of 
NR4A1 (siNR4A1) by RNA interference identified three major pro-oncogenic 
pathways and associated genes regulated by NR4A1 that were inhibited by DIM-
C-pPhOH;  1) NR4A1 regulates expression of genes such as survivin through 
interactions with Sp1 bound to their proximal GC-rich promoters (937); 2) NR4A1 
inactivates p53 to enhance mTOR signaling in lung and colon cancer cells 
expressing wild-type p53 (803,806); and 3) NR4A1 regulates expression of 
thioredoxin domain-containing 5 (TXNDC5) and isocitrate dehydrogenase 1 
(IDH1) to maintain low levels of oxidative stress (805) (Fig. 1A).   
259 
 
 Recent studies show that NR4A1 is overexpressed in ER-positive and ER-
negative breast cancer cells (954), and NR4A1 expression in breast tumors is 
correlated with decreased relapse-free survival (822).  Results of NR4A1 
overexpression in breast cancer cells suggest that NR4A1 may be anti-migratory 
(955); however, a recent report indicates pro-migratory activity for this receptor 
(822).  Research in this laboratory has demonstrated pro-oncogenic functions of 
NR4A1 in pancreatic, colon and lung cancer cells, and this study investigates the 
function of this receptor in breast cancer cells and the effects of C-DIM/NR4A1 
antagonists.  The results clearly demonstrate the pro-oncogenic functions of 
NR4A1 in breast cancer and demonstrate that C-DIM/NR4A1 antagonists 
represent a potential novel approach for treating patients that overexpress this 
orphan receptor. 
 
Materials and Methods 
Cell lines and antibodies  
MCF-7, MDA-MB-231, and SKBR3 human breast cancer cell lines were 
purchased from American Type Culture Collection (Manassas, VA).  Cells were 
maintained 37C in the presence of 5% CO2 in Dulbecco’s modified Eagle’s 
medium/Ham’s F-12 medium with 10% fetal bovine serum with antibiotic.  -Actin 
antibody and Dulbecco’s Modified Eagle’s Medium were purchased from Sigma-
Aldrich (St. Louis, MO).  Sp1 antibody was purchased from Millipore (Temecula, 
CA); caspases 7 and 8, sestrin 2 (SESN2), bcl2, CHOP, ATF4, isocitrate 
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dehydrogenase 1 (IDH1), and epidermal growth factor receptor (EGFR) 
antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA).  Caspase 
3, cleaved poly ADP ribose polymerase (c-PARP; 9541), phospho mTOR, mTOR, 
phospho AMPK, AMPK, phospho p70S6K, p70S6K, phospho S6RP, S6RP, 
phospho 4EBP1, 4EBP1, and survivin antibodies were purchased from Cell 
Signaling Technologies (Danvers, MA).  TXNDC5 antibody was purchased from 
Genetex (Irvine, CA).  XBP-1s and phospho PERK were obtained from Biolegend 
(San Diego, CA).  Apoptotic, Necrotic, and Healthy Cells Quantification Kit was 
purchased from Biotium (Hayward, CA).  Cells were visualized under an EVOS fl, 
Fluorescence microscope, from Advanced Microscopy Group using a multiband 
filter set for FITC, rhodamine, and DAPI.  The C-DIM compounds were prepared 
as previously described (803,805,937). 
Cell proliferation assay   
MCF-7, MDA-MB-231, and SKBR3 breast cancer cells (1.0 x 105 per well) 
were plated in 12 well plates and allowed to attach for 24 hr and cells were treated 
with DIM-C-pPhCO2Me in dimethyl sulfoxide (DMSO) for 24 or 48 hr or transfected 
with siNR4A1 or iGL2 (control siRNA) in lipofectamine  for 72 hr.  Cells were then 
trypsinized and counted using a Coulter Z1 cell counter and growth inhibition was 
determined.  Each experiment was carried out in triplicate, and results were 
expressed as the mean  SE for each set of experiments.  Cells were also treated 
with C-DIMs after NR4A1 knockdown.   
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Annexin V staining  
MCF-7, MDA-MB-231, and SKBR3 cells(1.0 x 105 per well) were seeded 
in 2-well Nunc Lab-Tek chambered B#1.0 Borosilicate coverglass slides from 
Thermo Scientific and were allowed to attach for 24 hr.  The medium was then 
changed to DMEM/Ham F-12 medium contained 2.5% charcoal-stripped fetal 
bovine serum, and either DMSO or DIM-C-pPhCO2Me (15 M) was added for 24 
hr.  For siRNA treatment, cells were transfected with iGL2 or 100 nm siNR4A1 (1 
or 2) for 72 hr  Apoptosis was analyzed by apoptotic and necrotic assay kit 
(Biotium CA), which contained fluorescein isothiocyanate-annexin-V, ethidium 
homodimer III and Hoechst 3342.  Apoptosis, necrotic and healthy cell detection 
kit was used according to the manufacturer’s protocol and cells were visualized 
under an EVOS fl, fluorescence microscope, from Advanced Microscopy.  The 
proportion of apoptotic cells was determined by the amount of green fluorescence 
observed in the treatment groups relative and normalized to control group. 
Western blot analysis 
Breast cancer cells (3.0 x 105 per well) were seeded in Dulbecco’s modified 
Eagle’s medium/Ham’s F-12 medium in six well plates.  Cells were allowed to 
attach for 24 hr and treated with varying concentrations of DIM-C-pPhCO2Me for 
24 hr or with 100 nm of siNR4A1 for 72 hr.  Cells were lysed with high salt lysis 
buffer (with protease inhibitor cocktail) and quantitated with Bradford reagent.  
Lysates were then analyzed by SDS-PAGE and transferred onto a polyvinylidene 
difluoride (PVDF) membrane by wet electroblotting.  Membranes were then 
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incubated with primary and then followed by secondary antibody.  Western blot 
analysis was determined as described and Immobilon western 
chemiluminescence substrates (Millipore, Billerica, MA) were used to develop 
images captured on a Kodak 4000 MM Pro image station (Molecular Bioimaging, 
Bend, OR). 
Small interfering RNA interference assay  
 Breast cancer cells were seeded (1.2 x 105 per well) in six well plates 
in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 
2.5% charcoal-stripped fetal bovine serum and left to attach for 24 hours.  
Knockdown of NR4A1 was carried out using LIpofectamine 2000 reagent 
according to the manufacture's protocol.  Small inhibitory RNAs and GL2 (non-
specific oligonucleotide) were prepared and purchased Sigma-Aldrich (St. Louis 
MO).  The siRNA complexes used in the study are as follows:  siGL2-5', CGU 
ACG CGG AAU ACU UCG A; siNR4A1 (1)-SASI_Hs02_00333289; siNR4A1 
(2)-SASI_Hs01_00182072 
Generation and measurement of ROS 
Cellular ROS levels were ascertained using the cell permeable probe CM-
H2DCFDA (5-(and-6)-chloromethyl-2'7'-dichlorodihydrofluorescein diacetate 
acetyl ester) from Invitrogen (Grand Island, NY).  Following treatment of the cells 
for 12 or 24 hr with DIM-C-pPHCO2Me or siNR4A1 for 72 hr, cells were plated on 
a 6-well culture plate were trypsinized, neutralized, then loaded with 10 M of 
probe for 20 min, washed once with serum free medium, and then ROS was 
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measured by flow cytometry using Accuri’s C6 Flow Cytometer (Accuri, Ann Arbor, 
MI).   
TNBC orthotopic xenograft model 
Female BALB/c nude mice (6-8 weeks old) were obtained (Charles River 
Laboratory, Wilmington, MA) and maintained under specific pathogen-free 
conditions, housed in isolated vented cages and allowed to acclimate for one 
week with standard chow diet.  The animals were housed at Florida A&M 
University in accordance with the standards of the Guide for the Care and Use of 
Laboratory Animals and the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC).  The protocol of the animal study was 
approved by the Institutional Animal Care and Use Committee (IACUC), Florida 
A&M University, Fl.  MDA-MB-231 cells (1X106 cells) were detached, 
resuspended in 100 l of phosphate-buffered saline with matrigel (BD Bioscience, 
Bedford, MA), and implanted subcutaneously in the mammary fat pad of mice.  
When tumors reached about 40-500 mm3 size, the animals were randomized into 
control and treatment groups (6 animals per group) and mice were treated with 
placebo or DIM-C-pPhCO2Me or DIM-C-pPhCN (50 mg/kg/d) in nano liquid carrier 
(administered in sodium carboxymethyl cellulose) by oral gavage every second 
day for 4 weeks.  Tumor volumes and weights, and body weight were determined; 
the tumor size was measured using Vernier calipers, and the tumor volume was 
estimated by the formula: tumor volume (mm3) = (L X W2) x ½, where L is the 
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length and W is the width of the tumor.  Tumor lysates were obtained and analyzed 
for protein expression by western blots. 
Statistical analysis  
Statistical significance of differences between the treatment groups was 
determined by Student’s t test. The results are expressed as means with error 
bars representing 95% confidence intervals for 3 experiments for each group 
unless otherwise indicated, and a P value less than 0.05 was considered 
statistically significant.  All Statistical tests were 2-sided. 
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Results 
 
 
 
 
 
Figure 66.  NR4A1-regulated pathways and effects of NR4A1 knockdown on breast cancer cell proliferation.  (A) 
NR4A1-regulated pathways/genes that can be targeted by C-DIM/NR4A1 antagonists.  (B) Cells were transfected 
with two siNR4A1 oligonucleotides (1 and 2) and cell numbers were determined after 72 hr.  (C) Cells were treated 
with different concentrations of DIM-C-pPhCO2Me for 24 hr and the number of cells were then determined.  (D) 
Cells were transfected with siCtl (non-specific oligonucleotide) or siNR4A1 and then treated with 20 M DIM-C-
pPhcO2Me for 24 hr and the number of cells were then counted.  Results (B – D) are means  SE for at least 3 
separate determinations for each treatment group.  Significant (p < 0.05) growth inhibition is indicated (*) and a 
significant decrease in the growth inhibitory effects of DIM-C-pPhCO2Me after NR4A1 knockdown is also indicated 
(**). 
Figure 66. 
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Inhibition of cell proliferation by siNR4A1 and DIM-C-pPhCO2Me 
 The orphan nuclear receptor NR4A1 is overexpressed in ER-positive and 
ER-negative breast cancer cells  and the role of this receptor in regulating breast 
cancer cell growth and survival was investigated by RNA interference (RNAi) in 
ER-positive (MCF-7), ER-negative (MDA-MB-231) and erbB2 (SKBR3) 
overexpressing breast cancer cell lines. Figure 66A summarizes the pathways 
regulated by NR4A1 and the structure of our C-DIM/NR4A1 anatgonists. Cells 
were transfected with two different oligonucleotides against NR4A1 (siNR4A1-
1/siNR4A1-2) and this resulted in 50% growth inhibition in MCF-7 and SKBR3 
cells and 35% inhibition of MDA-MB-231 cell proliferation (Fig. 66B).  The C-DIM 
compound with a p-carboxymethylpenyl group (DIM-C-pPhCO2Me) has been 
identified as an NR4A1 antagonist, which inhibits nuclear NR4A1 (Suppl. Fig. A-
3) and Figures 66C and this compound significantly inhibits growth of MCF-7, 
MDAMB-231 cells after treatment for 24 and 48 hr (Suppl. Fig. A-4A).  IC50 values 
were 19.74, 18.62 and 18.92 M after treatment of MCF-7, MDA-MB-231 and 
SKBR3 cells for 24 hr and 12.73,19.02 and 12.28 M after treatment for 48 hr.  In 
contrast, after knockdown of NR4A1 in these cells, treatment with DIM-C-
pPhCO2Me resulted in only minimal growth inhibition confirming a role for NR4A1 
in mediating the growth inhibitory effects of DIM-C-pPhCO2Me (Fig. 66D). 
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Figure 67.  siNR4A1 induces apoptosis in breast cancer cells.  (A) Cells were transfected with siNR4A1 and whole 
cell lysates were analyzed by western blots.  Cells were transfected with siNR4A1 (2 oligonucleotides) and effects 
on Annexin V staining in MCF-7 (B), MDA-MB-231 (C) and SKBR3 (D) cells were determined and quantitated.  
Results (B – D) are means  SE for at least 3 separate determinations and significant (p < 0.05) induction of Annexin 
V staining is indicated (*). 
Figure 67. 
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siNR4A1 and DIM-C-pPhCO2Me induce apoptosis in breast cancer cells 
 NR4A1 also regulates pro-survival genes and pathways in pancreatic and 
lung cancer cells, and results in Figure 67A show that transfection of breast cancer 
cells with siNR4A1 induced cleavage of caspase 8 and caspase 7 and also PARP 
cleavage.  Moreover, siNR4A1 also induced annexin V staining MCF-7 (Fig. 67B), 
MDA-MB-231 (Fig. 67C), and SKBR3 (Fig. 67D) cells confirming that NR4A1 
regulated anti-apoptotic pathways in these cell lines.  Treatment of the cells with 
DIM-C-pPhCO2Me for 24 hr also induced cleavage (activation) of caspases 7 and 
8 and PARP (Fig. 68A) and similar results were observed for the p-cyanophenyl 
compound (DIM-C-pPhCN) (Suppl. Fig. A-4B)which is an NR4A1 ligand and 
antagonist in colon cancer cells (806).  DIM-C-pPhCO2Me also enhanced annexin 
V staining in MCF-7 (Fig. 68B), MDA-MB-231 (Fig. 68C), and SKBR3 (Fig. 68D) 
cell lines.  Thus, both NR4A1 knockdown and NR4A1 antagonists decreased 
breast cancer cell growth and induced apoptosis. 
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Figure 68.  DIM-C-pPhCO2Me induces apoptosis in breast cancer cells.  (A) Cells were treated with DIM-C-
pPhCO2Me for 24 hr and whole cell lysates were analyzed by western blots.  MCF-7, MDA-MB-231,and SKBR3 cells 
were treated with DIM-C-pPhCO2Me for 24 hr and Annexin V staining was determined and quantitated (B).  DIM-C-
pPhCO2Me also induced PARP cleavage (C). siNR4A1 (D) and DIM-C-pPhCO2Me (E) decreased Sp regulated gene 
expression without decreasing Sp1 expression. Quantitative results are means  SE for 3 separate determinations 
and significant (p < 0.05) induction of Annexin V is indicated (*). 
 
Figure 68. 
270 
 
siNR4A1 and DIM-C-pPhCO2Me activate growth 
 inhibitory pro-apoptotic pathways/genes in breast cancer cells 
 mTOR activation in lung and colon cancer cells is dependent on NR4A1-
p53 interactions that inactivate p53, and siNR4A1 or NR4A1 antagonists activate 
p53 which induces expression of sestrin 2, resulting in phosphorylation of AMPK 
and inhibition of mTOR (803,806).  Knockdown of NR4A1 in p53-wild-type MCF-
7 cells resulted in the induction of sestrin 2 and phosphorylation of AMPK and 
this was accompanied by decreased activation (phosphorylation) of the mTOR 
downstream gene products p70S6K and S6RP (Fig. 69A).  MCF-7 cells were also 
treated with the NR4A1 antagonist DIM-C-pPhCO2Me (Fig. 69B) and DIM-C-
pPhCN (Suppl. Fig. A-4C) and results were similar to that observed after 
transfection with siNR4A1.  Previous studies also show that NR4A1 regulates 
expression of growth promoting and pro-survival (e.g. survivin, bcl-2 and EGFR) 
genes through interactions with Sp1 bound to their corresponding proximal GC-
rich cis-promoter elements (803,806,937).  Figure 69C shows that after 
knockdown of NR4A1 (siNR4A1) in MCF-7, MDA-MB-231 and SKBR3 cells, there 
was a significant decrease in expression of several Sp1-regulated genes including 
EGFR, survivin and bcl-2; however, Sp1 protein levels were unchanged.  Similar 
results were observed in the same cell lines after treatment with the NR4A1 
antagonists DIM-C-pPhCO2Me (Fig. 69D) and DIM-C-pPhCN (Suppl. Fig.A-4D).  
These observations are consistent with previous reports in pancreatic, colon and 
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lung cancer cells where NR4A1 regulates expression of survivin and other Sp1-
regulated genes (803,806,937). 
 
 
 
Figure 69.  NR4A1 knockdown induces ROS and ER stress.  (A) Cells were transfected with siNR4A1 or siCtl and 
ROS was determined.  (B) Cells were transfected with siNR4A1 and whole cell lysates were analyzed by western 
blots for IDH1 or TXNDC5 and ER stress gene products (C).  Results in (A) are means  SE for 3 separate 
determinations and significant (p < 0.05) induction of ROS is indicated (*). 
 
 
 
Figure 69. 
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It was recently reported that NR4A1 regulates expression of genes such 
as IDH1 and TXNDC5 that maintain high levels of reducing equivalents and 
minimize ROS-mediated cellular stress (805,806).  Knockdown of NR4A1 by RNAi 
induced ROS by 2- to 4-fold in MCF-7, MDA-MB-231 and SKBR3 cells and this 
was accompanied by decreased expression of both TXNDC5 and IDH1 in these 
cell lines (Fig. 70B).  Moreover, after transfection with siNR4A1, we also observed 
enhanced markers of ER stress including increased phosphorylation of PERK and 
increased expression of ATF-4, CHOP and XBP-1 in the breast cancer cell lines 
(Fig. 70C).  Treatment of MCF-7, MDA-MB-231 and SKBR3 cells with the NR4A1 
antagonist DIM-C-pPhCO2Me also increased ROS after 12 and 24 (Figs. 71A-
71C) hr and this was also  accompanied by decreased expression of TXNDC5 
and IDH1 and induction of markers of ER stress (p-PERK, ATF4, CHOP and XBP-
1) as previously observed in pancreatic cancer cells (805).  We also observed that 
the NR4A1 antagonist DIM-C-pPhCN decreased expression of IDH1 and 
TXNDC5 in breast cancer cells (Suppl. Fig. A-4E). 
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Figure 70.  DIM-C-pPhCO2Me induces ROS and ER stress.  MCF-7 (A), MDA-MB-231 (B) and SKBR3 (C) cells were 
treated with DIM-C-pPhCO2Me and ROS was determined after 12 or 24 hr.  (D) Cells were treated with DIM-C-
pPhCO2Me and whole cell lysates were analyzed by western blots for expression of TXNDC5, IDH1 and stress 
gene products (E). (F) Cells were treated with DMSO, DIM-C-pPhCO2Me alone or in combination with GSH, and 
whole cell lysates were analyzed for stress gene products by western blots.  Results (A) are expressed as means 
 SE for 3 separate determinations and significant (p < 0.05) induction of ROS is indicated (*). 
  
Figure 70. 
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Figure 71.  NR4A1 knockdown inhibits mTOR.  MCF-7 cells were transfected with siNR4A1 (A) or treated with DIM-
C-pPhCO2Me (B) and whole cell lysates were analyzed for mTOR pathway gene products.  Cells were transfected 
with siNR4A1 (C) or treated with DIM-C-pPhCO2Me (D) and whole cell lysates were analyzed by western blots for 
selected genes with GC-rich promoters. 
 
Figure 71. 
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 The effects of DIM-C-pPhCO2Me and DIM-C-pPhCN as inhibitors of 
mammary tumorigenesis were investigated in an orthotopic model using MDA-
MB-231 cells in athymic nude mice.  At a dose of 50 mg/kg/d, DIM-C-pPhCO2Me 
inhibited tumor growth and weight (Fig. 72A).  Western blot analysis of tumor 
lysate from control and DIM-C-pPhCO2Me-treated mice confirmed that DIM-C-
pPhCO2Me significantly induced PARP cleavage, decreased expression of Sp-
regulated survivin, EGFR and bcl2 gene products and also decreased levels of 
TXNDC5 and IDH1 (Figs. 72B and 72C).  This effect was also observed for DIM-
C-pPhCN (  These results are consistent with the in vitro effects of DIM-C-
pPhCO2Me (and siNR4A1) in breast cancer cells and demonstrates that C-
DIM/NR4A1 antagonists  inhibit common NR4A1-mediated pro-oncogenic 
pathways in breast, pancreatic, colon and lung cancer cell lines. 
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Figure 72.  Inhibition of tumor growth by NR4A1 antagonists.  (A) Orthotopic tumors in athymic nude mice bearing 
MDA-MB-231 cells were treated with 50 mg/kg/d DIM-C-pPhCO2Me or DIM-C-pPhCN o corn oil (control) for 28 days 
and tumor volumes were determined.  (B) Lysates from tumors from control and DIM-C-pPhCO2Me-treated mice 
were analyzed by western blots and bands were quantitated (C) and normalized relative to -actin. 
 
 
Figure 72. 
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Discussion 
 NR4A1 exhibits pro-oncogenic activity in cancer cell lines derived from 
solid tumors and is overexpressed in tumors from patients with lung, pancreatic 
and colon tumors (803,805-807,895,896,937).  Moreover, in lung cancer patients, 
high expression of NR4A1 is a negative prognostic indicator for decreased 
survival (803).  Similar results were recently reported for the expression and 
prognostic activity of NR4A1 in breast cancer patients, and it was also observed 
that NR4A1 was one of only a few nuclear receptors overexpressed in both ER-
positive and ER-negative breast tumors (822,954).  Since an early report indicated 
that NR4A1 is more highly expressed in early vs. late stage more aggressive 
breast tumors and exhibited some tumor suppressor-like activity (955), we 
investigated the function of NR4A1 in three different breast cancer cell lines by 
RNA interference and treatment with NR4A1 antagonists.  We have recently 
identified several C-DIMs including the para-hydroxy, carbomethoxy, cyano and 
bromophenyl analogs that directly bind the ligand binding domain of NR4A1 and 
exhibit NR4A1 antagonist activity in colon cancer cells (806).  The p-
carbomethyoxyphenyl analog (DIM-C-pPhCO2Me) was used as a prototypical C-
DIM/NR4A1 antagonist for investigating the anticancer activity drugs targeting 
NR4A1 in breast cancer cells and we have confirmed that DIM-C-pPhCN also 
exhibits similar activities. 
 Initial studies investigated the role of NR4A1 in the growth of three 
prototypical breast cancer cell lines (ER-positive MCF-7, erbB2 overexpression 
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SKBR3, and triple negative MDA-MB-231), and knockdown of NR4A1 using two 
different oligonucleotides significantly decreased proliferation of all three breast 
cancer cell lines and similar growth inhibitory effects were observed for DIM-C-
pPhCO2Me (Fig. 1A-1C).  Moreover, after knockdown of NR4A1 in MCF-7, MDA-
MB-231 and SKBR3 cells, treatment with DIM-C-pPhCO2Me had minimal effects 
(Fig. 66), suggesting that the growth inhibitory effects of DIM-C-pPhCO2Me were 
primarily NR4A1-dependent (Fig. 66D).  The effects of NR4A1 knockdown and 
treatment with DIM-C-pPhCO2Me on several markers of apoptosis, including 
cleavage of caspases 7 and 8 and PARP and induction of annexin V staining, 
were also determined in the breast cancer cell lines (Figs. 67 and 68).  These 
results demonstrate that NR4A1 regulates pathways that contribute to the growth 
and survival of breast cancer cells and this parallels the functions previously 
observed for this receptor in pancreatic, lung and colon cancer cells 
(803,805,806,937). 
 NR4A1 binds and inactivates p53 (939), and knockdown of NR4A1 or 
treatment of p53 wild-type lung cancer cells with an NR4A1 antagonist or 
transfection with siNR4A1 results in activation of p53 (803).  p53 induces sestrin 
2 which activates AMPK and this leads to inhibition of the mTOR pathway (803).  
The mTOR pathway inhibitors have been extensively developed for cancer 
chemotherapy (955,956), and C-DIM/NR4A1 antagonists are a new class of 
mTOR inhibitors which block NR4A1-regulated mTOR activation (803).  Results 
illustrated in Figures 4A and 4B show that both siNR4A1 and DIM-C-pPhCO2Me 
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inhibited mTOR pathway in MCF-7 breast cancer cells that express wild-type p53.  
In p53 wild-type lung cancer cells, siNR4A1 and NR4A1 antagonists also induce 
sestrin 2 which activates AMPK and inhibits mTOR, whereas this is not observed 
in lung cancer cells expressing mutant p53 (803).  Interestingly, DIM-C-
pPhCO2Me and siNR4A1 induced sestrin 2 and inhibited mTOR in p53 mutant 
SKBR3 and MDA-MB-231 cells (data not shown) and the mechanisms of this 
response are currently being investigated.  Like other nuclear receptors, NR4A1 
interacts with the Sp1 transcription factor bound to GC-rich sites to activate 
survivin and other anti-apoptotic/growth promoting genes, and siNR4A1 or 
treatment with a NR4A1 antagonist decreases expression of these genes (957-
962) (Fig. 72D).  Figures 69C and 69D show that siNR4A1 or treatment with DIM-
C-pPhCO2Me decreased expression of survivin, bcl2 and EGFR in MDA-MB-231, 
MCF-7 and SKBR3 cells; however, Sp protein levels were unchanged.  Molecular 
analysis of NR4A1-dependent regulation of survivin showed that in pancreatic 
cancer cells, NR4A1 and p300 cooperatively activated survivin expression by 
interacting with Sp1 bound to the proximal GC-rich region of the survivin promoter 
(937).  Regulation of growth-promoting and survival genes which contain GC-rich 
promoters by NR4A1 is consistent with the growth inhibitory and apoptotic effects 
of siNR4A1 and C-DIM/NR4A1 antagonists on breast cancer cells (Fig. 1) and 
tumors (Figs. 72A-72C) and is comparable to that observed in lung, colon and 
pancreatic cancer cell lines (803,805,806,937).   
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 A recent study showed that NR4A1 maintains low levels of oxidative and 
endoplasmic reticulum (ER) stress in pancreatic cancer cells by regulating 
expression of TXNDC5 and IDH1 which maintain cellular levels of reducing 
equivalents (805).  DIM-C-pPhCO2Me or siNR4A1 also decreased expression of 
TXNDC5 and IDH1 in breast tumors (in vivo) (Figs. 72B-72C) and MCF-7, MDA-
MB-231 and SKBR3 cells, and this was accompanied by increased levels of ROS 
and induction of markers of ER stress (Figs. 70 and 71).  These results are 
consistent with previous studies in pancreatic cancer cells, and there is also 
emerging evidence that both TXNDC5 and IDH1 are overexpressed in breast 
cancer cells and tumors (963,964) and their expression and functions in breast 
cancer cells are currently being investigated. 
 In summary, results of this study are consistent with a pro-oncogenic role 
for NR4A1 in breast cancer as an important regulator of cell growth and survival, 
and NR4A1-regulated pro-oncogenic pathways and genes are similar to those 
observed in pancreatic, lung and colon cancer cells and tumors 
(803,805,806,937).  This study also demonstrated the effectiveness of the NR4A1 
antagonist DIM-C-pPhCO2Me as an inhibitor of breast cancer growth and survival 
and current structure-activity studies are focused on identifying the most effective 
C-DIM/NR4A1 antagonists for future clinical applications. 
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CHAPTER IV 
HISTONE DEACETYLASE INHIBITORS INHIBIT RHABDOMYOSARCOMA 
BY REACTIVE OXYGEN SPECIES TARGETING OF SPECIFICITY PROTEIN 
TRANSCRIPTION FACTORS*
Introduction 
Rhabdomyosarcomas (RMS) is the most common soft tissue sarcoma that 
is primarily observed in children and adolescents and accounts for 5% of all 
pediatric cancers and 50% of soft tissue sarcomas in children (965-967).  
Embryonal RMS (ERMS) and alveolar RMS (ARMS) are the two major classes of 
RMS in children and adolescents and differ with respect to their histology, 
genetics, treatment, and prognosis (968,969).  ERMS accounts for over 60% of 
RMS patients and is associated with loss of heterozygosity at the 11p15 locus 
(970).  ERMS patients have a favorable initial prognosis; however, the overall 
survival of patients with metastatic ERMS is only 40% (971).  ARMS occurs in 
approximately 20% of RMS patients and is associated with translocations 
resulting in formation of pro-oncogenic gene products resulting from the fusion of 
PAX3 or PAX7 with the Forkhead gene FOXO1A (972,973).  ARMS patients have 
*Reprinted with permission from “Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive 
Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.” Hedrick E, Crose L, 
Linardic CM, Safe S, 2015 Molecular Cancer Therapeutics, 14,2143-53,Copyright[2015] American 
Association for Cancer Research 
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a poor diagnosis and patient survival is <20% for metastatic ARMS.  Treatments 
include radiotherapy, surgery, and chemotherapy with cytotoxic drugs and/or drug 
combinations of vincristine, dactinomycin, cyclophosphamide, irinotecan, 
fosfamide, etoposide, doxorubicin and others (974,975).  A serious problem also 
exists for RMS patients that survive current therapies since these individuals as 
adults have an increased risk for several diseases (626).  Thus, there is a critical 
need for development of new therapeutic regimens for treating childhood RMS.  
Specificity protein 1 (Sp1) transcription factor is overexpressed in human RMS 
tumors and other Sp family members including Sp3 and Sp4 are also 
overexpressed in RMS cell lines (976).  The importance of Sp transcription factors 
(TFs) in RMS is primarily due to pro-oncogenic Sp-regulated genes that are 
themselves drug targets for RMS and these include CXCR4, hepatocyte growth 
factor receptor (C-MET), insulin-like growth factor 1 receptor (IGF-1R), and 
platelet-derived growth-factor receptor  (PDGFR) (977-980).  Clinical studies 
using drugs that specifically target Sp TFs and Sp-regulated genes for treatment 
of RMS have not yet been reported; however, there is an open phase I/II trial 
(NCT01610570) evaluating the efficacy of mithramcyin in solid tumors including 
RMS.  Mithramycin acts in part by binding to GC-rich sequences and regulating 
chromatin accessibility, including the ability to displace Sp1 from oncogenic 
promoters.  Thus the therapeutic potential of Sp TF in RMS is gaining traction.   
 Genomic analysis of RMS from several patients indicated that “skeletal 
muscle (rhabdomyosarcoma) may have even higher levels of ROS than other 
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cancer cells and may be particularly sensitive to therapeutics that induce oxidative 
stress (650).  This sensitivity is thought to occur because with such a high baseline 
burden of ROS, there is little tolerance for further oxidative stress and this was 
confirmed by showing that ROS inducers were highly effective inhibitors of RMS 
tumor growth using patient-derived xenografts in mouse models (650).  Recent 
studies in our laboratory (648) demonstrate that ROS inducers also inhibit 
pancreatic cancer cell and tumor growth and this is due, in part, to a novel 
epigenetic pathway (781) in which ROS-mediated repression of c-Myc results in 
downregulation of Sp TFs and pro-oncogenic Sp-regulated genes.    In this study, 
we demonstrate that ROS-inducing histone deacetylase (HDAC) inhibitors block 
RMS cell and tumor growth by initially targeting c-Myc which results in 
downregulation of microRNAs (miRs) and induction of ZBTB transcriptional 
repressors which in turn downregulate Sp TFs. 
 
Materials and Methods 
Cell lines and antibodies 
RD and Rh30 rhabdomyosarcoma cell lines were purchased from 
American Type Culture Collection (Manassas, VA).  Cells were maintained 37˚C 
in the presence of 5% CO2 in Dulbecco’s modified Eagle’s medium/Ham’s F-12 
medium with 10% fetal bovine serum with antibiotic or RPMI-1640 Medium with 
10% fetal bovine serum and antibiotic respectively. Β-actin antibody Dulbecco’s 
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Modified Eagle’s Medium, and RPMI-1640 Medium, and 36% formaldehyde were 
purchased from Sigma-Aldrich (St. Louis, MO).   Hematoxylin was purchased from 
Vector Laboratories (Burlingame, CA).  Sp1 antibody and Glutathione (GSH) 
reduced free acid were purchased from Millipore (Temecula, CA); Sp3, Sp4 
antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA).  Acetyl-
Histone H3 (K9/K14) and c-Myc antibodies were purchased from Cell Signaling 
technologies (Danvers, MA). Apoptotic, Necrotic, and Healthy Cells Quantification 
Kit was purchased from Biotium (Hayward, CA). Cells were visualized under an 
EVOS fl, Fluorescence microscope, from Advanced Microscopy Group using a 
multiband filter set for FITC, rhodamine, and DAPI.  The panobinostat and 
vorinostat were purchased from LC laboratories (Woburn, MA). 
Cell proliferation assay  
RD and Rh30 rhabdomyosarcoma cells (1.0 x 105 per well) were plated in 
12 well plates and allowed to attach for 24 hours and cells were treated with 
panobinostat and vorinostat ( dimethyl sulfoxide, DMSO, as empty vehicle) (+/-
GSH 3 h prior to treatment) for 24 hours or by siSp1, siSp3, siSp4 (iGL2 as control 
siRNA with lipofectamine vehicle) for 72 hours.  Cells were then trypsinized and 
counted after respective treatment time intervals using a Coulter Z1 cell counter 
and growth inhibition was determined.  Each experiment was carried out in 
triplicate, and results were expressed as the mean ± SE for each set of 
experiments. 
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MTT assay 
Primary human myoblasts (HSMM, Lonza), Rh30, or RD cells were plated 
in 96-well plates at a density of 10,000 cells per well. The next day, cells were 
treated with vehicle (DMSO) or increasing doses of Panobinostat. Twenty-four 
hours post-treatment, cell viability was analyzed by MTT assay, as described 
previously (Crose et al, Clin Cancer Research 2012). 
 Annexin V staining 
RD and Rh30 rhabdomyosarcoma cell (1.0 x 105 per well)  were seeded in 
2-well Nunc Lab-Tek chambered B#1.0 Borosilicate coverglass slides from 
Thermo Scientific and were allowed to attach for 24 hours.  The medium was then 
changed to DMEM/Ham F-12 medium contained 2.5% charcoal-stripped fetal 
bovine serum, and either DMSO Panobinostat (50-100 nM) or Vorinostat (0.5-1.0 
µM) (+/-5mM GSH 3 h prior to treatment)  was added for 24 hr.  For siRNA 
treatment, cells were treated with iGL2 or 100 nm siSp1, siSp3, siSp4 siRNA for 
72 hours.  Apoptosis was analyzed by apoptotic and necrotic assay kit (Biotium 
CA), which contained fluorescein isothiocyanate-annexin-V, ethidium homodimer 
III and Hoechst 3342.  Apoptosis, necrotic and healthy cell detection kit was used 
according to the manufacturer’s protocol and were visualized under an EVOS fl, 
fluorescence microscope, from Advanced Microscopy. The proportion of 
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apoptotic cells was determined by the amount of green fluorescence observed in 
the treatment groups relative and normalized to control group. 
Boyden Chamber Assay 
RD and Rh30 rhabdomyosarcoma cells (3.0 x 105 per well) were seeded 
in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 
2.5% charcoal-stripped fetal bovine serum and were allowed to attach for 24 h. 
Cells were seeded and subsequently treated with varying concentration of 
panobinostat or vorinostat for 24 hours (+/- GSH 3 h prior to treatment) or with 
100 nm of siSp1, siSp3, siSp4 for 48 hours.  Cells were trypsinized, counted then 
placed in 12-well 8.0µm pore ThinCerts from Greiner bio-one (Monroe , NC) 
allowed to migrate for 24 hr, fixed with formaldehyde, and then stained with 
hematoxylin.  Cells that migrated through the pores were then counted. 
RT-PCR 
 miRNA was isolated using the mirVana miRNA isolation kit (Ambion, 
Austin, TX) according to the manufacturer's protocol. Quantification of miRNA 
(RNU6B and miR-17, -20a, and -27a) was done using the TaqMan miRNA assay 
kit (Life Technologies) according to the manufacturer's protocol with real-time 
PCR. U6 small nuclear RNA was used as a control to determine relative miRNA 
expression. 
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Chromatin Immunoprecipitation 
The chromatin immunoprecipitation (ChIP) assay was performed using the 
ChIP-IT Express magnetic chromatin immunoprecipitation kit (Active Motif, 
Carlsbad, CA) according to the manufacturer's protocol. RD and Rh30 cells were 
treated with 100 nM panobiostat for 3 or 6 hr. Cells were then fixed with 1% 
formaldehyde, and the cross-linking reaction was stopped by addition of 0.125 M 
glycine. After washing twice with phosphate-buffered saline, cells were scraped 
and pelleted. Collected cells were hypotonically lysed, and nuclei were collected. 
Nuclei were then sonicated to the desired chromatin length (∼200 to 1,500 bp). 
The sonicated chromatin was immunoprecipitated with normal IgG (Santa Cruz), 
H3K27me3 (Abcam), H3K4me3 (Abcam), H4K16Ac (Active Motif), or RNA 
polymerase II (pol II; GeneTex) antibodies and protein A-conjugated magnetic 
beads at 4°C for overnight. After the magnetic beads were extensively washed, 
protein-DNA cross-links were reversed and eluted. DNA was prepared by 
proteinase K digestion followed by PCR amplification. The primers for detection 
of the c-Myc promoter region were 5′-GCC CTT TCC CCA GCC TTA GC-3′ 
(sense) and 5′-AAC CGC ATC CTT GTC CTG TGA GTA-3′ (antisense), the 
primers for detection of the Sp1 promoter region were 5′-CTA ACT CCA ATC ATA 
ACG TTC C-3′ (sense) and 5′-GAG CTG GAG ATG ATT GGC TTG-3′ (antisense). 
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PCR products were resolved on a 2% agarose gel in the presence of RGB-4103 
GelRed Nucleic Acid Stain. 
Western blot analysis 
RD and Rh30 rhabdomyosarcoma cells (3.0 x 105 per well) were seeded 
in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 
2.5% charcoal-stripped fetal bovine serum and were allowed to attach for 24 h. 
Cells were seeded and subsequently treated with varying concentration of 
panobinostat or vorinostat for 3, 6, 9, 12, or 24 hours or with 100 nm of siSp1, 
siSp3, siSp4 for 72 hours.  Cells were lysed with high salt lysis buffer (with 
protease inhibitor cocktail) and quantitated with Bradford reagent.  Lysates were 
then analyzed by SDS-PAGE and transferred onto a polyvinylidene difluoride 
(PVDF) membrane by wet electroblotting.  Membranes were then incubated with 
primary and then followed by secondary antibody.  Western blot analysis was 
determined as described and Immobilon western chemiluminescence  substrates 
(Millipore, Billerica, MA) were used to develop images captured on a Kodak 4000 
MM Pro image station (Molecular Bioimaging, Bend, OR). 
Small interfering RNA interference assay 
RD and Rh30 rhabdomyosarcoma cells were seeded (1.2 x 105 per well) 
in six well plates in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium 
supplemented with 2.5% charcoal-stripped fetal bovine serum and left to attach 
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for 24 hours.  Knockdown of NR4A1 was carried out using LIpofectamine 2000 
reagent according to the manufactures protocol.  Small inhibitory RNAs and GL2 
(non-specific oligonucleotide) were prepared and purchased Sigma-Aldrich (St. 
Louis MO).  The siRNA complexes used in the study are as follows: siGL2-5’, 
CGU ACG CGG AAU ACU UCG A; siMyc, SASI_Hs01_00222676; 
siSp1,SASI_Hs02_00333289; siSp3, SASI_Hs01_00211941; siSp4, 
SASI_Hs01_00114420 
Generation and measurement of ROS 
Cellular ROS levels were ascertained using the cell permeable probe CM-
H2DCFDA (5-(and-6)-chloromethyl-2’7’ dichlorodihydrofluorescein diacetate 
acetyl ester) from Invitrogen (Grand Island, NY).  CM-H2DCFDA is non-
fluorescent until cleavage of the acetyl groups by intracellular esterases and 
oxidation that transpires within the cell.  Following treatment of the cells for 12 or 
24 hours with panobinostat or vorinostat (+/- 5mM GSH 3 h prior to treatment) for 
72 hours, cells plated on a 6-well culture plate were trypsinized, neutralized, then 
loaded with 10µM of probe for 20 min, washed once with serum free medium, and 
then ROS was measured by flow cytometry using Accuri’s C6 Flow Cytometer 
(Accuri, Ann Arbor, MI).  
Orthotopic implantation in vivo studies 
 Male SCID/beige mice were subcutaneously implanted with 5 *10^6 RD 
cells suspended in Matrigel (BD Biosciences). At 12 days post-implantation, when 
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tumors were palpable, mice were begun on a treatment regimen of 17.5 mg/kg 
Panobinostat or vehicle (DMSO), dosed intraperitoneally. Mice were treated daily 
for four days, no treatment for two days, and then every other day for 10 days. 
Animals were examined every other day for tumor burden (approximated by 
external caliper measurements, where [(width)2 × length] / 2), animal weight, and 
overall well-being. At study end, animals were humanely sacrificed and tumors 
were harvested for analysis. 
Statistical analysis 
Statistical significance of differences between the treatment groups was 
determined by student’s t test.  The results are expressed as means with error 
bars representing 95% confidence intervals for 3 experiments for each group 
unless otherwise indicated, and a P value less than 0.05 was considered 
statistically significant.  All Statistical tests were 2-sided. 
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Results 
 
Figure 73.  ROS-dependent inhibition of RMS cell growth by HDAC inhibitors.  (A) RD and Rh30 cells were treated 
with DMSO, 100 nM panobinostat, or 1 M vorinostat alone or in combination with 5 mM GSH, and ROS was 
determined fluorimetrically.  (B) RD and Rh 30 cells were treated with panobinostat or varinostat and after 24 hr, 
cell growth was determined by counting cells in a Coulter counter.  (C) Metabolic activity was also determined in 
RD, Rh30 and HSMM cells treated with panobinostat.  (D) RD and Rh30 cells were treated with DMSO, panobinostat 
and vorinostat alone or in combination with 5 mM GSH, and cells were counted using a Coulter counter.  Results 
are expressed means  SE for at least 3 replicated determinations and significant (p<0.05) induction of ROS or 
growth inhibition (*) or reversal by GSH (**) is indicated. 
 
 The effectiveness of HDAC inhibitors such as panobinostat on the inhibition 
of patient-derived RMS xenografts was attributed, in part, to their activity as ROS 
Figure 73. 
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inducers.  Figure 73A shows that both panobinostat and vorinostat induced ROS 
in RD and Rh30 cells and these responses were attenuated in cells cotreated with 
the HDAC inhibitors plus glutathione (GSH).  Treatment of RD and Rh30 cells with 
different concentrations of both HDAC inhibitors also decreased proliferation of 
both cell lines with IC50 values of 96.7, 61.13 nM for panobinostat and 1.59, 1.1 
µM for vorinostat in RD and Rh30 cell lines, respectively (Fig. 73B).  Figure 73C 
shows that for the more potent HDAC inhibitor (panobinostat) we observed 
inhibition of metabolic activity using the MTT assay in RD and Rh30 cells, whereas 
in primary human skeletal muscle myoblasts (HSMMs) significant inhibition was 
not observed at concentrations as high as 500 nM, demonstrating specificity of 
the drug for the transformed cell lines.  Finally, we also observed inhibition of RD 
and Rh30 cell growth by panobinostat and vorinostat was significantly attenuated 
after cotreatment with GSH (Fig. 73D) , indicating that induction of ROS by the 
HDAC inhibitors was important for their growth inhibitory effects.   
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Figure 74.  ROS-dependent induction of apoptosis, inhibition of invasion and downregulation of Sp proteins by 
panobinostat and vorinostat.  RD and Rh30 cells were treated with DMSO, panobinostat or vorinostat alone or in 
combination with 5 mM GSH, and induction of Annexin V staining (A) or inhibition of invasion (B) were determined 
by fluorescence and a Boyden chamber assay, respectively.  Results are expressed as means  SE for at least 3 
replicate determinations and significant (p<0.05) induction of Annexin V staining or inhibition of invasion (*) and 
inhibition by GSH (**) are indicated.  RD and Rh30 cells were treated with panobinostat (C) or vorinostat (D) alone 
or in combination with 5 mM GSH for 24 hr, and whole cell lysates were analyzed by western blots. 
Figure 74. 
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Panobinostat and vorinostat also induced Annexin V staining, a marker of 
apoptosis in RD and Rh30 cells (Fig. 74A) and cotreatment with GSH attenuated 
this response.  Panobinostat and vorinostat inhibited invasion in RD and Rh30 
cells in a Boyden chamber assay (Fig. 74B) and this response was also 
attenuated in cells cotreated with GSH.  Thus, ROS induction by both HDAC 
inhibitors resulted in the induction of apoptosis and inhibition of cell growth and 
invasion in RD and Rh30 cells.  It has previously been reported that hydrogen 
peroxide and ROS-inducing anticancer agents decrease expression of Sp1, Sp3, 
and Sp4 transcription factors in pancreatic, colon and bladder cancer cells, and 
Sp1, Sp3, and Sp4 are also highly expressed in RMS and tumors 
(642,645,646,648,981-983).  Panobinostat also decreased expression of Sp1, 
Sp3 (high and low molecular weight forms) and Sp4 in RD and Rh30 cells and 
cotreatment with GSH attenuated this response (Fig. 74C).  We also observed 
similar effects in RD and Rh30 cells treated with vorinostat alone or in combination 
with GSH (Figure 74D) and both HDAC inhibitors increased histone-3 acetylation 
in RD and Rh30 cells which was unaffected by cotreatment with GSH.  This 
suggests that the effects of panobinostat and vorinostat in this system are due to 
induction of ROS and are independent of their activity as inhibitors of histone 
deacetylation. 
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Figure 75.  Hydrogen peroxide and t-butylhydroperoxide inhibit RMS cell growth and decreases Sp1, Sp3 and Sp4 
in RMS cells.  Rh30 and RD cells were treated with hydrogen perioxide (A) and t-butylhydroperoxide (B), and 
effects on cell proliferation were determined using a Coulter counter.  Results are expressed as means  SE for 
at least 3 replicate determinations and significant (p<0.05) growth inhibition (*) is indicated.  Rh30 (C) and RD (D) 
cells were treated with hydrogen peroxide and t-butylhydroperoxide for 24 hr, and whole cell lysates were 
analyzed by western blots.   
Figure 75. 
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In pancreatic and bladder cancer cells, ROS such as hydrogen peroxide 
inhibits growth and decreased expression of Sp proteins (648,769).  Figures 75A 
and 75B show that 75-150 M hydrogen peroxide and 100-200 M t-
butylhydroperoxide, respectively, inhibited growth of RD and Rh30 cells.  
Moreover, the same concentrations of these compounds also decreased 
expression of Sp1, Sp3, and Sp4 proteins and cMyc (Fig. 75C and 75D) and these 
results were consistent with the effects we observed for panobinostat in RMS cells 
(Fig. 75C and 74D).  Supplemental Figure 1 shows that after knockdown of Sp1, 
Sp3 and Sp4 by RNA interference there is inhibition of Rh30 and RD cell growth 
(Suppl. Fig. A-5A), induction of Annexin V staining (Suppl. Fig. A-5B) and 
decreased invasion in a Boyden chamber assay (Suppl. Fig. A-5C), 
demonstrating the important role of Sp TFs in the growth, survival and invasion of 
RMS cells and this was consistent with previous studies in RMS cells (976). 
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Figure 76.  Panobinostat decreases Myc and Sp TFs through epigenetic pathways.  RD and Rh30 cells were treated 
with panobinostat for different times, and whole cell lysates were analyzed for c-Myc and Sp TFs (A) and Sp-
regulated genes (B) by western blot analysis.  RD (C) and Rh30 (D) cells were treated with DMSO or panobinostat 
for 3 or 6 hr and analyzed in a ChiP assay using antibodies against pol II, IgG (control), and selected histone 
marks. 
Figure 76. 
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Hydrogen peroxide not only inhibits cancer cell growth but also induces 
genome wide shifts of repressor complexes from non-GC-rich to GC-rich 
promoters in SW480 cells resulting in rapid downregulation of Myc (781).  Results 
illustrated in Figure 76A show that within 3 hr after treatment of RD and Rh30 cells 
with panobinostat, there was a significant decrease in expression of c-Myc and 
after 6 hr Myc protein levels were not detected for the 24 hr duration of the 
experiment.  Interestingly, we also observed a rapid decrease in expression of 
Sp1 within 3-6 hr, whereas decreased expression of Sp3 and Sp4 proteins was 
observed only at longer time points.  This suggests that like c-Myc, Sp1 
expression may also be reduced by rapid ROS-dependent chromatin shifts that 
have previously been observed in colon and pancreatic cancer cells after 
treatment with hydrogen peroxide and PEITC (an ROS inducer), respectively 
(648,781).  In contrast, the rate of degradation of Sp-regulated gene products 
including EGFR, bcl2, and survivin (Fig. 76B) was similar to that observed for Sp3 
and Sp4 proteins and different from either c-Myc or Sp1.  ROS-induced changes 
in histone marks in RD and Rh30 cells were investigated in a ChIP assay after 
treatment with panobinostat for 3 and 6 hr.  In RD cells (Fig. 76C), there was a 
decrease in Pol II and the H3K4me3 activation mark on the c-Myc and Sp1 
promoters and an increase in H4K16Ac.  In Rh30 cells (Fig. 76D), there was also 
a decrease in Pol II and H3K4me3 and an increase in H4K16Ac on the c-Myc and 
Sp1 promoters as observed in RD cells; however, we also observed an increase 
in the H3K27me3 deactivation mark on the c-Myc promoter.  These results are 
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consistent with previous studies on ROS-induced changes in histone marks  (781) 
and with the exception of the increase in H4K16Ac (activation mark), the 
epigenetic changes correlate with the observed rapid decreases in c-Myc and Sp1 
protein expression (Fig. 76A).   
 
Figure 77.  Panobinostat regulates c-Myc, and c-Myc and Sp TFs regulate miR-27a and miR-20/miR-17 in RMS 
cells.  RMS cells were treated with panobinostat alone or in combination with GSH for 24 hr, and whole cell lysates 
were analyzed by western blots (A) or analyzed for miR expression (B) by real time PCR.  RD and Rh30 cells were 
transfected sic-Myc (C) or siSp1, siSp3 and siSp4 (D), and miR expression was determined by real time PCR.  
Results (B-D) are expressed as means  SE for 3 replicate determinations and significantly (p<0.05) decreased 
mir expression is indicated (*). 
Figure 77. 
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Previous studies in pancreatic cancers cells show that ROS-dependent 
downregulation of Myc also results in decreased expression of miR-27a and miR-
20a/miR-17 and upregulation of the corresponding miR-regulated Sp repressors 
ZBTB34/ZBTB10 and ZBTB4, respectively (648).  Results in Figure 77A show that 
after treatment of RD and Rh30 cells with panobinostat there was a decrease in 
c-Myc expression and this was attenuated in cells cotreated with panobinostat 
plus glutathione.  Previous studies showed that miR-27a is expressed in RD and 
Rh30 cells (976), and treatment of these cell lines with 100 nM panobinostat 
decreased expression of miR-27a and this decrease was also attenuated in cells 
cotreated  panobinostat plus glutathione (Fig. 77B).  We also observed that miR-
20a and miR-17 were expressed in both RMS cell lines and downregulation of 
these miRs with panobinostat was also inhibited in cells cotreated with the HDAC 
inhibitor plus glutathione.  MiR-27a and miR20a/miR-17 are members of the miR-
23a-27a-24-2 and miR-17-92 clusters, respectively, and there is evidence that 
both miR clusters are regulated by c-Myc (648,984-986), and transfection of RD 
and Rh30 cells with siMyc decreased miR-27a and miR-20a/miR17 expression 
(Fig. 77C).  There is also some evidence that Sp1 regulates these same miR 
clusters, and knockdown of Sp1, Sp3 and Sp4 by RNAi decreased miR-27a and 
miR-20/miR-17 expression and the most dramatic effects were observed for miR-
27a in both RD and Rh30 cells (Fig. 77B). These results could also be due in part 
to downregulationn of cMyc which can be regulated by Sp TFs. 
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Figure 78.  Panobinostat and c-Myc knockdown induce ZBTB transcriptional repressors; sic-Myc decreases Sp 
TFs in RMS cells.  RD (A) and Rh30 (B) cells were treated with panobinostat for up to 24 hr, and whole cell lysates 
were analyzed by western vlots.  RD and Rh30 cells were transfected with sic-Myc, and whole cell lysates were 
analyzed for ZBTB (D) and Sp (D) proteins by western blots. 
 
Treatment of RD and Rh30 cells with panobinostat resulted in the induction 
of ZBTB10 and ZBTB34 (Figs. 78A and 78B) which are regulated by miR-27a, 
and ZBTB4 which is regulated by miR-20a/miR-17 (642,646,648,981-983).  In 
addition, transfection of RD and Rh30 cells with siMyc increased expression of 
ZBTB10, ZBTB34, and ZBTB4 (Fig. 78C) and also decreased levels of Sp1, Sp3, 
Figure 78. 
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and Sp4 (Fig. 78D). This was also observed in the ERMS cell line SMS-CTR 
(Suppl. Fig. A-6)  
Thus cMyc knockdown decreases expression of miRs, induces ZBTBs and 
decreases Sp TFs and thereby mimics the effects of ROS.  In vivo studies with 
SCID mice bearing RD cells also showed that daily administration of panobinostat 
(17.5 mg/kg) decreased tumor volume (Fig. 79A) and growth (Fig. 79B), and 
analysis of the tumors showed that panobinostat also decreased Sp1, Sp3, Sp4 
and c-Myc expression (Fig. 79C).  These results are consistent with in vitro studies 
and demonstrate that the effectiveness of panobinostat as an anticancer agent in 
RMS cells is primarily due to targeting of Sp1, Sp3 and Sp4 transcription factors 
through an ROS-dependent mechanism involving downregulation of c-Myc and 
Myc-regulated miRs (Fig. 79D). 
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Figure 79.  Panobinostat inhibits growth of RMS tumors.  Panobinostat (17.5 mg/kg) was administered to SCID 
mice and tumor volumes (A) and weights (B) were determined.  (C) Tumor lysates from control and 
panobinostat-treated mice were analyzed by western blots.  (D) Mechanism of action of ROS-inducing HDAC 
inhibitors in RMS. 
 
Figure 79. 
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Discussion 
 Transformation of normal cells into cancer cells is a complex cell- and 
tissue-specific process that involves activation of oncogenes and inactivation of 
tumor suppressor genes, resulting in cancer cells that exhibit the typical hallmarks 
of cancer (60,987).  In addition, there are many other genes that also significantly 
contribute to the cancer cell phenotype.  These genes are typically overexpressed 
in tumor vs. non-tumor tissues and have been termed as non-oncogene addiction 
(NOA) genes and are excellent targets for mechanism-based antineoplastic 
agents.  The transcription factor Sp1 plays a critical role in embryonic 
development but there is evidence that levels of Sp1 decrease with age in rodents 
and humans (988-990).  In contrast, Sp1 is highly expressed in tumors from RMS 
patients and in many other cancers and high expression of Sp1 is a negative 
prognostic factor for patient survival, tumor recurrence or tumor grade (976,991-
996).  
 Stable transduction of human skeletal muscle fibroblasts with PAX3-
FOX01, telomerase and N-Myc resulted in formation of transformed cell lines 
similar to ARMS cells  and both the genetically transformed and ARMS cells (997) 
expressed high levels of Sp1, Sp3 and Sp4 (976).  Interestingly, transformation of 
the muscle fibroblasts dramatically increased expression of Sp1 and Sp3 but not 
Sp4 proteins which were highly expressed in the non-transformed cells (976); 
carcinogen/oncogene-induced transformation of human fibroblasts also 
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dramatically increased Sp1 expression but levels of Sp3 and Sp4 were not 
determined (998). 
 The pro-oncogenic functions of Sp1 have been reported in many different 
cell lines (reviewed in 996); however, it is also important to determine the role of 
Sp1, Sp3 and Sp4 since all three proteins are overexpressed in RMS and other 
cancer cell lines.  Supplemental Figure 1 shows that after knockdown of Sp1, Sp3 
and Sp4 in Rh30 and RD cells, there was a significant decreased in cell 
proliferation, induction of apoptosis (Annexin V staining), and inhibition of invasion 
indicating that all three Sp proteins are NOA genes in RMS cells.  In previous 
studies, we demonstrated that tolfenamic acid-induced downregulation of Sp1, 
Sp3 and Sp4 inhibited growth, induced apoptosis and inhibited invasion in RMS 
cells, and this was accompanied by decreased expression of several pro-
oncogenic Sp-regulated genes (976).  
 It was recently reported that mice bearing ERMS patient-derived 
xenografts were highly sensitive to drugs that induce oxidative stress and these 
drugs significantly inhibited tumors (650).  We hypothesized that the efficacy of 
the ROS-inducing agents which included panobinostat was also due, in part, to 
repression of Sp1, Sp3 and Sp4.  This hypothesis was based on previous studies 
showing that several ROS-inducing anticancer drugs  including curcumin, 
phenethylisothiocyanate (PEITC), methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-
oate (CDDO-Me), GT-094 (a nitro-aspirin analog), celastrol and betulinic acid also 
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repressed Sp1, Sp3 and Sp4 expression (ROS-dependent) in pancreatic, bladder 
and colon cancer cells (642,645,646,648,981-983).   
 Therefore, we used the HDAC inhibitors panobinostat and vorinostat that 
are also ROS inducers (999) to investigate downregulation of Sp1, Sp3 and Sp4 
in RMS cells in culture and in an in vivo model.  Both panobinostat and vorinostat 
induced ROS, inhibited growth, induced apoptosis and inhibited invasion of RD 
and Rh30 cells, and all of these responses were attenuated after cotreatment with 
the antioxidant GSH (Figs. 73 and 74).  Moreover, panobinostat also inhibited 
tumor growth in SCID mice bearing RD cells as a xenograft (Fig. 6C).  In parallel 
studies, it was observed that panobinostat and vorinostat also decreased 
expression of Sp1, Sp3 and Sp4 in Rh30 and RD cells (Figs. 74C and 74D) and 
this response was attenuated after cotreatment with GSH.  Moreover, treatment 
with hydrogen peroxide and t-butylhydroperoxide also decreased expression of 
Sp1, Sp3 and Sp4 as previously observed in other cell lines (769,982,1000).  We 
also observed that panobinostat decreased c-Myc, Sp1, Sp3 and Sp4 proteins 
levels in tumors (Fig. 6C) and this paralleled the effects observed in cell culture 
(Fig. 74C).  Thus, both knockdown of Sp TFs by RNA (Suppl. Fig. 1) and treatment 
with ROS inducers results in decreased expression of Sp1, Sp3 and Sp4, 
decreased growth and invasion, and induction of apoptosis in vitro and tumor 
growth in vivo.  This suggests that the ROS-mediated repression of Sp TFs plays 
an important role in the antineoplastic effects of these HDAC inhibitors in RMS 
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cells and is consistent with the in vitro and in vivo efficacy of panobinostat in RMS 
patient-derived xenografts (650).   
 Previous studies show that ROS-dependent repression of Sp1, Sp3 and 
Sp4 was due to downregulation of miR-27a and/or miR-20a/miR-17-5 resulting in 
increased expression of the transcriptional repressors ZBTB10/ZBTB34 and 
ZBTB4, respectively (642,645,646,648,981-983).  The ZBTB proteins are 
members of the POK family of transcriptional repressors (1001) and competitively 
bind and displace Sp TFs from GC-rich sites on Sp promoters and Sp-regulated 
gene promoters.  Using panobinostat as a model ROS inducer, we show that this 
compound also decreases miR-27a and miR-20a/miR-17 in RD and Rh30 cells 
(ROS-dependent) (Fig. 77B) and this results in the induction of ZBTB10/ZBTB34 
and ZBTB4 (Fig. 78A).  These data also show that the high expression of Sp1, 
Sp3 and Sp4 in RMS cells is due, in part, to miR-dependent suppression of the 
ZBTB transcriptional repressors. 
 Treatment of colon cancer cells with hydrogen peroxide or pharmacological 
doses of ascorbate which induces hydrogen peroxide decreases expression of 
Sp1, Sp3 and Sp4 (1000).  Under these same conditions, hydrogen peroxide 
induces extensive epigenetic and genetic changes in colon cancer cells due to 
genome-wide migration of chromatin-modifying complexes from non-GC-rich to 
GC-rich gene promoters (781).  c-Myc was one of the genes rapidly 
downregulated by treatment with hydrogen peroxide, and similar results were 
observed for the ROS inducer PEITC in pancreatic cancer cells in which Sp1 was 
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also rapidly downregulated in some cell lines (648).  Sp1, Sp3, Sp4 and c-Myc all 
have GC-rich promoters, and treatment of RD and Rh30 cells with panobinostat 
rapidly decreased expression of c-Myc and Sp1 proteins, whereas with the 
exception of the rapid decrease in expression of Sp3 (high MW band in RD cells), 
downregulation of Sp3 and Sp4 was primarily observed at later time points (Fig. 
76A).  Results of ChIP assays confirmed that treatment with panobinostat 
decreased pol II and the H3K4me3 activation mark in the GC-rich c-Myc and Sp1 
promoters in RD and Rh30 cells, and the H3K27me3 inactivation mark was also 
increased on the c-Myc promoter only in Rh30 cells.  Surprisingly, the H4K16Ac 
activation mark was increased by panobinostat in RD and Rh30 cells but 
decreased by PEITC-induced ROS in pancreatic cancer cells (648), suggesting 
that the epigenetic effects of ROS inducers are cell context-dependent and this is 
currently being investigated. 
 The importance of the ROS-dependent decrease in c-Myc is that there are 
E-box and GC-rich elements in the miR-23a~27A~24-2 and mir-17-92 gene 
cluster promoters (984-986)  and knockdown of c-Myc or Sp TFs in RMS cells 
significantly decreased expression of miR-27a and miR-20a/miR-27 (Figs. 77C 
and 77D).  It was also observed for the first time that Sp1, Sp3 and Sp4 play a 
role in expression of miR-27a and this paralleled the highly effective 
downregulation of miR-27a in RMS cells treated with HDAC inhibitors (Fig. 77B). 
 In summary, results of this study  show that HDAC inhibitors that induce 
ROS are highly effective inhibitors of RMS cell in culture  and  tumor growth in 
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mice and the effects in vitro were independent of HDAC inhibition.  This 
complements results obtained with HDAC inhibitors using tumor-derived 
xenografts and genomic analysis, thus confirming the potential efficacy of ROS 
inducers for RMS chemotherapy (650).  This study demonstrates that 
panobinostat and vorinostat decrease expression of Sp1, Sp3, Sp4 and pro-
oncogenic Sp-regulated genes by ROS-dependent epigenetic downregulation of 
c-Myc and Sp1 which in turn decrease expression of miR-27a and miR-20a/miR-
17, resulting in the induction of the ZBTB transcriptional repressors (Fig. 79D).  
The study demonstrates why ROS inducers are highly effective for treating RMS 
since this pathway leads to a cascade of events leading to downregulation of Sp 
TFs and pro-oncogenic Sp-regulated genes.  ROS inducers and other drugs 
targeting Sp TFs represent promising new approaches for RMS chemotherapy; 
moreover, since miRs that repress ZBTB repressors have been detected in serum 
(1002,1003), this may also provide a biomarker for monitoring treatment efficacy. 
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CHAPTER V 
NR4A1 ANTAGONISTS INHIBIT β1-INTEGRIN-DEPENDENT BREAST 
CANCER CELL MIGRATION*
Introduction 
Cell adhesion and attachment are essential for tissue integrity and cellular 
homeostasis, and the heterodimeric integrin cell surface receptors play a critical 
role in these processes (838-840). There are 18 different α subunits and 8 different 
β subunits that form 24 αβ-integrin receptor heterodimers, and the large 12-
member β1-integrin subgroup bind multiple extracellular matrix (ECM) molecules 
to activate multiple intracellular pathways and also induce cross talk with other 
signaling systems (838-840).  The functions of integrin heterodimers are highly 
tissue specific, and many human pathologies also involve integrin signaling 
(reviewed in 841,842). β1-Integrin is highly expressed in most tumors and is 
associated with a negative prognostic significance such as overall and disease-
free survival, recurrence, and metastasis for head and neck and squamous cell 
carcinoma, melanoma, lung, breast, prostate, laryngeal, and pancreatic cancers 
(843-848,851-854,858,861). 
*Reprinted with permission from “NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell 
Migration.” By Hedrick E, Lee SO, Doddapaneni 3, Singh M, Safe S. 2016 Molecular and Cellular Biology, 
Volume 36: pp1383-94. COPYRIGHT [2016} American Society for Microbiology 
311 
A recent immunostaining study of 225 breast invasive ductal carcinomas 
(IDCs) showed that β1-integrin was overexpressed in 32.8% of patients with IDCs. 
Numerous studies show that focal adhesion kinase (FAK) which is downstream 
from β1-integrin is also a negative prognostic factor for breast cancer patients 
(1004-1006). The important functional role of β1-integrin has been demonstrated 
in mouse models expressing erbB2 under the control of the mouse mammary 
tumor virus and crossed with mammary tissue-specific β1-integrin-deficient mice. 
These mice exhibit a decrease in tumor volume, increased apoptosis, and 
decreased lung metastasis compared to animals expressing wild-type β1-integrin 
(862,1007,1008). Although small molecules, peptides, and antibodies that inhibit 
β1-integrin signaling have been developed, clinical agents that target β1-integrin 
for cancer chemotherapy are not currently available. 
The orphan nuclear receptor 4A1 (NR4A1) (also called TR3 or Nur77) is 
overexpressed in breast cancer and other tumors, and functional studies show 
that NR4A1 exhibits prooncogenic activity (reviewed in 788). Studies in this 
laboratory have characterized a series of 1,1-bis(3′-indolyl)-1-(p-substituted 
phenyl)methane (C-DIM) analogs that bind NR4A1 and act as receptor 
antagonists to inhibit growth and induce apoptosis in several cancer cell lines and 
in tumors from mouse xenografts (803-806,812,904). A recent study 
demonstrated functional interactions between NR4A1 and transforming growth 
factor β (TGF-β) and in estrogen receptor (ER)-negative MDA-MB-231 cells, 
knockdown of NR4A1 decreased migration and also inhibited TGF-β-induced 
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migration of this cell line (822). Results of gene array studies in pancreatic cancer 
cells identified β1-integrin as a potential NR4A1-regulated gene (805). In this 
study, we demonstrate that NR4A1 regulates β1-integrin expression and β1-
integrin-dependent migration of breast cancer cells, and this is accompanied by 
decreased expression of β3-integrin. In MDA-MB-231 cells, results of our studies 
show that both constitutive and TGF-β-induced migration are dependent on 
nuclear and extranuclear NR4A1-regulated pathways, respectively. C-
DIM/NR4A1 antagonists inhibit NR4A1-dependent expression of β1- and β3-
integrins and other prooncogenic NR4A1-regulated genes and pathways and 
represent a novel class of mechanism-based anticancer agents. 
Materials and Methods 
Cell lines and antibodies 
SKBR3, MDA-MB-231, and MCF-7 breast cancer cells were purchased 
from American Type Culture Collection (Manassas, VA). The cells were 
maintained at 37°C in the presence of 5% CO2 in Dulbecco's modified Eagle's 
medium (DMEM)–Ham's F-12 medium with 10% fetal bovine serum with 
antibiotic. NR4A1 antibody was purchased from Novus Biologicals (Littleton, CO). 
TGF-β was purchased from BD Biosystems (Bedford, MA). β-Actin antibody, 
Dulbecco's modified Eagle's medium, RPMI 1640 medium, and 36% 
formaldehyde were purchased from Sigma-Aldrich (St. Louis, MO). Hematoxylin 
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was purchased from Vector Laboratories (Burlingame, CA). β3-Integrin, 
phosphorylated focal adhesion kinase (p-FAK), FAK, axin 2, leptomycin B, and 
NR4A1 immunofluorescent antibody were purchased from Cell Signaling 
Technologies (Manassas, VA). β1-Integrin antibody was purchased from Santa 
Cruz Biotech (Santa Cruz, CA), p84 antibody was purchased from GeneTex 
(Irvine, CA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody 
was purchased from Biotium (Hayward, CA). 
Cell adhesion assay 
SKBR3, MDA-MB-231, and MCF-7 cancer cells (3.0 × 105 per well) were 
seeded in Dulbecco's modified Eagle's medium–Ham's F-12 medium 
supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed 
to attach for 24 h. The cells were seeded and subsequently treated with various 
concentrations of 1,1-bis(3′-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-
pPhOH) or p-carboxymethylphenyl (1,1-bis(3′-indolyl)-1-(p-
carboxymethylphenyl)methane [DIM-C-pPhCO2Me]) for 24 h or 1 h prior to 
treatment with TGF-β (5 ng/ml) (4-h cotreatment) or without TGF-β or with 100 nM 
siβ1-integrin (small interfering RNA against β1-integrin) or siNR4A1 for 48 h. The 
cells were trypsinized, counted, and then placed for 90 min on BD BioCoat human 
fibronectin cellware 24-well plates (BD Biosciences, Bedford, MA). The medium 
was then aspirated, and the wells were gently washed with phosphate-buffered 
saline (PBS) and stained with 0.5% crystal violet stain. The cells were then 
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counted for adhesion to fibronectin. Wells coated with bovine serum albumin 
(BSA) and poly-l-lysine were used as negative controls. 
Boyden chamber assay 
SKBR3, MDA-MB-231, and MCF-7 cancer cells (3.0 × 105 per well) were 
seeded in Dulbecco's modified Eagle's medium–Ham's F-12 medium 
supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed 
to attach for 24 h. The cells were seeded and subsequently treated with various 
concentrations of DIM-C-pPhOH or DIM-C-pPhCO2Me for 24 h or 1 h prior to 
treatment with TGF-β (5 ng/ml) (4 h cotreatment) or without TGF-β or with 100 nM 
siβ1-integrin, siNR4A1, siSp1 (Sp1 stands for specificity protein 1), or sip300 for 
48 h. The cells were trypsinized, counted, placed in 24-well 8.0-μm-pore 
ThinCerts from BD Biosciences (Bedford, MA), allowed to migrate for 24 h, fixed 
with formaldehyde, and then stained with hematoxylin. Cells that migrated through 
the pores were then counted. 
Real-time PCR 
RNA was isolated using Zymo Research Quick-RNA MiniPrep kit (Irvine, 
CA). Quantification of mRNA (β1-integrin, β3-integrin) was performed using Bio-
Rad iTaq universal SYBR green one-step kit (Richmond, CA) using the 
manufacturer's protocol with real-time PCR. TATA binding protein (TBP) mRNA 
was used as a control to determine relative mRNA expression. 
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MDA-MB-231 cancer cells (3.0 × 105 per well) were seeded in Dulbecco's 
modified Eagle's medium–Ham's F-12 medium supplemented with 2.5% charcoal-
stripped fetal bovine serum and allowed to attach for 24 h. The medium was then 
changed to DMEM–Ham's F-12 medium containing 2.5% charcoal-stripped fetal 
bovine serum, and either dimethyl sulfoxide (DMSO) or TGF-β (5 ng/ml) was 
added for 4 h (after pretreatment with leptomycin B [20 nM] for 24 h or 
pretreatment with 20 μM DIM-C-pPhOH or DIM-C-pPhCO2Me or no 
pretreatment). Protein A Dynabeads were prepared, and binding of antibody with 
protein and protein-protein interactions were isolated by Life Technologies 
immunoprecipitation kit using Dynabeads coated with protein A (Grand Island, 
NY) following the manufacturer's protocol. Protein-protein interactions of interest 
were determined by Western blot analysis. 
Chromatin immunoprecipitation 
The chromatin immunoprecipitation (ChIP) assay was performed using the 
ChIP-IT Express magnetic chromatin immunoprecipitation kit (Active Motif, 
Carlsbad, CA) according to the manufacturer's protocol. SKBR3 and MDA-MB-
231 cells were treated with DMSO, DIM-C-pPhOH, or DIM-C-pPhCO2Me (15 or 
20 μM) for 24 h. The cells were then fixed with 1% formaldehyde, and the cross-
linking reaction was stopped by the addition of 0.125 M glycine. After the cells 
were washed twice with phosphate-buffered saline, the cells were scraped and 
pelleted. Collected cells were hypotonically lysed, and nuclei were collected. 
Nuclei were then sonicated to the desired chromatin length (∼200 to 1,500 bp). 
Immunoprecipitation 
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The sonicated chromatin was immunoprecipitated with normal IgG, p300 (Santa 
Cruz), siSp1 (Abcam), NR4A1 (Novus Biologicals), or RNA polymerase II (Pol II) 
(Active Motif) antibodies and protein A-conjugated magnetic beads at 4°C 
overnight. After the magnetic beads were extensively washed, protein-DNA cross-
links were reversed and eluted. DNA was prepared by proteinase K digestion 
followed by PCR amplification. The primers for detection of the β1-integrin 
promoter region were 5′-TCACCACCCTTCGTGACAC-3′ (sense) and 5′-
GAGATCCTGCATCTCGGAAG-3′ (antisense), and the primers for detection of 
the β3-integrin promoter region were 5′-TCTCAGGCGCAGGGTCTAGAGAA-3′ 
(sense) and 5′-TCGCGGCGCCCACCGCCTGCTCTACGCT-3′ (antisense). PCR 
products were resolved on a 2% agarose gel in the presence of RGB-4103 
GelRed nucleic acid stain. 
Nuclear/cytosolic extraction 
MDA-MB-231 cancer cells (3.0 × 105 per well) were seeded in Dulbecco's 
modified Eagle's medium–Ham's F-12 medium supplemented with 2.5% charcoal-
stripped fetal bovine serum and were allowed to attach for 24 h. The medium was 
then changed to DMEM–Ham's F-12 medium containing 2.5% charcoal-stripped 
fetal bovine serum, and either DMSO or TGF-β (5 ng/ml) was added for 4 h (after 
pretreatment with 20 nM leptomycin B for 24 h or pretreatment with 20 μM DIM-
C-pPhOH or DIM-C-pPhCO2Me or no pretreatment). Nuclear and cytosolic 
fractions were then isolated using Thermo Scientific NE-PER nuclear and 
cytoplasmic extraction kit (Rockford, IL) according to the manufacturer's protocol. 
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Fractions were then analyzed by Western blotting. GAPDH and p84 were used as 
cytoplasmic and nuclear positive controls, respectively. 
Immunofluorescence 
MDA-MB-231 (1.0 × 105 per well) were seeded in two-well Nunc Lab-Tek 
chambered borosilicate cover glass slides (no. 1 borosilicate cover glass) from 
Thermo Scientific and were allowed to attach for 24 h. The medium was then 
changed to DMEM–Ham's F-12 medium containing 2.5% charcoal-stripped fetal 
bovine serum, and either DMSO or TGF-β (5 ng/ml) was added for 4 h (after 
pretreatment with leptomycin B [20 nM] for 24 h or pretreatment with 20 μM DIM-
C-pPhOH or DIM-C-pPhCO2Me or no pretreatment). The cells were then treated 
with fluorescent NR4A1 primary antibody [Nur77 (D63C5) XP], and 
immunofluorescence was observed according to Cell Signaling Technology's 
immunofluorescence protocol. 4′,6′-Diamidino-2-phenylindole (DAPI) staining 
was observed using Hoechst staining according to Biotium's apoptotic and 
necrotic assay kit by following the manufacturer's protocol. The cells were 
visualized by microscopy (Advanced Microscopy), and NR4A1 localization was 
determined by green fluorescence. DAPI was used to stain the nucleus, and 
images were taken sequentially of NR4A1, DAPI, and then merged (806,812,904). 
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Western blot analysis
SKBR3, MDA-MB-231, and MCF-7 cancer cells (3.0 × 105 per well) were seeded 
in Dulbecco's modified Eagle's medium–Ham's F-12 medium supplemented with 
2.5% charcoal-stripped fetal bovine serum and were allowed to attach for 24 h. 
The cells were transfected with 100 nM siβ1-integrin, siNR4A1, siSp1, or sip300 
for 72 h or treated with various C-DIM compounds. Cell lysates were analyzed by 
Western blotting as described previously (806,812,904). 
Small interfering RNA interference assay 
Small interfering RNA (siRNA) experiments were conducted as described 
previously. The siRNA complexes used in the study are as follows: siGL2-5′, CGU 
ACG CGG AAU ACU UCG A; siNR4A1, SASI_Hs02_00333289[1], 
SASI_Hs02_00333290[2]; siβ1-integrin, SASI_Hs02_00333437[1], 
SASI_Hs01_00159474; siSp1, SASI_Hs02_003; sip300, SASI_Hs01_00052818. 
Triple-negative breast cancer (TNBC) orthotopic xenograft studies 
Female BALB/c nude mice (6 to 8 weeks old) were obtained (Charles River 
Laboratory, Wilmington, MA) and maintained and treated as previously described 
(904). Tumor volumes and tumor weights were determined as previously 
described (904). Tumor lysates were obtained and analyzed by Western blotting. 
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Statistical significance of differences between the treatment groups was 
determined by Student's t test. The results are expressed as means with error 
bars representing 95% confidence intervals (95% CIs) for at least three 
experiments for each group unless otherwise indicated. A P value of <0.05 was 
considered statistically significant. All statistical tests were two sided. 
Results 
Figure 80. NR4A1 regulates β1-integrin expression in breast cancer cells and tumors. (A) Breastcancer cells were 
transfected with siNR4A1 and cell extracts were analyzed for protein  and mRNA expression by western blots or 
real time PCR, respectively, as outlined in the Materials and Methods.  Breast cancer cells were treated with DMSO, 
DIM-C-pPhOH or DIM-C-pPhCO2Me for 24 hr and extracts were analyzed for protein (B) or mRNA (C)  levels by 
western blots and real time PCR, respectively, as outlined in the Materials and Methods. (D) Cell lysates from 
tumors (MDA-MB-231 orthotopic) (30) derived from animals treated with corn oil (control) or DIM-C-pPhCO2Me (C-
DIM-14; 40 mg/kg/d) were analyzed by western blots and decreased protein expression was determined and 
normalized the β-actin protein loading control. Quantified data are presented as means ± SE (at least 3 replicates) 
and significant (P<0.05) decreases are indicated (*). 
Figure 80. 
Statistical analysis 
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Figure 81. NR4A1 regulates β1-integrin-dependent responses. Breast cancer cells were transfected with siNR4A1 
(A), treated with DMSO and DIM-C-pPhOH (B) or DIM-C-pPhCO2Me (C) for 24 hr, and whole cell lysates were 
analyzed by western blots as outlined in the Materials and Methods. (D) Tumor lysates from mice (MDA-MB-231 
orthotopic derived (30) treated with corn oil or DIM-C-pPhCO2Me (40 mg/kg/d) were analyzed by western blots and 
quantitated as outlined in Figure 1D. The effects of siNR4A1 and siβ1- integrin (E) or DIM-C-pPhOH and DIM-C-
pPhCO2Me (F) on fibronectin-induced adhesion of breast cancer cells was determined as outlined in the Materials 
and Methods. Results (D-F) are means ± SE (at least 3 replicates) and a significant (P<0.05) decrease indicated (*). 
Western blots in Figures 1 and 2 were derived from the same experiment showing effects on β1-integrin (Fig. 80) 
and β1-integrin-regulated responses (Fig. 81).
Figure 81. 
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NR4A1 regulates β1-integrin expression 
β1-Integrin is expressed in ER-positive MCF-7, ER-negative MDA-MB-231, 
and erbB2-overexpressing SKBR3 breast cancer cells, and knockdown of NR4A1 
(siNR4A1) by RNA interference (RNAi) decreased expression of β1-integrin 
protein and mRNA (Fig. 80A). Previous studies identified 1,1-bis(3′-indolyl)-1-(p-
hydroxyphenyl)methane (DIM-C-pPhOH; C-DIM8) and 1,1-bis(3′-indolyl)-1-(p-
carboxymethylphenyl)methane (DIM-C-pPhCO2Me; C-DIM14) as NR4A1 ligands 
that act as antagonists in breast and other cancer cell lines (804-806,812,904), 
and both compounds also decreased expression of β1-integrin protein (Fig. 80B) 
and mRNA (Fig. 80C) in MCF-7, MDA-MB-231, and SKBR3 cells. Moreover, 
Western blot analysis of tumor lysates from mice bearing MDA-MB-231 cells 
(orthotopic) (904) showed that DIM-C-pPhCO2Me significantly decreases β1-
integrin protein expression (Fig. 80D). β1-Integrin regulates phosphorylation of 
FAK (p-FAK), and transfection of MCF-7, MDA-MB-231, and SKBR3 cells with 
siNR4A1 (Fig. 81A) or treatment with DIM-CpPhOH (Fig. 81B) or DIM-C-
pPhCO2Me (Fig. 81C) decreased phosphorylation of FAK. In addition, results from 
the in vivo orthotopic study (904) showed that p-FAK is decreased in tumors from 
mice bearing MDA-MB-231 cells and treated with DIM-C-pPhCO2Me (Fig. 80D). 
Fibronectin-induced cell adhesion is also a prototypical β1-integrin-regulated 
response, and cell adhesion was significantly decreased in MCF-7, MDA-MB-231, 
and SKBR3 cells after transfection with siNR4A1 (Fig. 81E) or after treatment with 
DIM-C-pPhOH or DIM-C-pPhCO2Me (Fig. 81F). For a positive control, we showed 
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that knockdown of β1-integrin (siβ1-integrin) by RNA also decreased cell adhesion 
(Fig. 80E) (Suppl. Fig. A-7). 
Figure 82. Role of NR4A1/p300/Sp1 in regulation of β1- and β3-integrin. (A) Analysis of polII, NR4A1, Sp1 and 
p300 binding to the β1-integrin promoter was determined in a ChIP assay using primers as indicated. (B) Cells 
were treated with oligonucleotides that knockdown Sp1 (siSp1) and p300 (sip300), and whole cell lysates were 
analyzed by western blots as outlined in the Materials and Methods. (C) Cells were transfected with siNR4A1 or 
treated with DIM-C-pPhOH (C-DIM8) or DIM-C-pPhCO2Me (C-DIM14), and whole cell lysates were analyzed by 
western blots as outlined in the Materials and Methods. (D) Cells were transfected with siNR4A1 or treated with 
C-DIM8 or C-DIM14 and effects on β3-integrin (ITGB3) mRNA levels were determined. The treatments 
significantly (P<0.05) decrease mRNA levels. (E) Analysis of polII, NR4A1, Sp1 and p300 binding to the proximal 
GC-rich region of the β3-integrin promoter was determined in a ChIP assay as outlined in the Materials and 
Methods. (F) Cells were transfected with siSp1 and sip300 and analyzed by real time PCR for β3-integrin mRNA 
levels. Both oligonucleotides significantly (P<0.05) decreased β3-integrin mRNA levels.
Figure 82. 
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Mechanisms of NR4A1 regulation of β1-integrin and β3-integrin 
NR4A1 regulates gene expression through direct interactions with genomic 
nerve growth factor Bα (NGFBα) response elements (NBRE) and Nur response 
elements (NuRE) or by interactions with specificity protein 1 (Sp1) bound to GC-
rich promoter elements (1009,1010). NBRE and NuRE were not identified in the 
β1-integrin promoter, whereas two GC-rich sequences were located at −760 and 
−676 in the proximal region of the β1-integrin promoter (Fig. 82A). Previous 
studies show that NR4A1, Sp1, and the nuclear coregulatory gene p300 interact 
with the GC-rich region of the survivin promoter to regulate survivin gene 
expression (804). Using the more aggressive SKBR3 and MDA-MB-231 cells as 
models, cells were treated with dimethyl sulfoxide (DMSO), DIM-C-pPhOH, or 
DIM-C-pPhCO2Me and analyzed in a chromatin immunoprecipitation (ChIP) 
assay using primers targeted to the GC-rich region of the β1-integrin promoter. 
The results show that Pol II, NR4A1, Sp1, and p300 interact with the GC-
rich promoter regions, and after treatment with DIM-C-pPhOH or DIM-C-
pPhCO2Me for 24 h, the band for Pol II was decreased in both cell lines (Fig. 82A), 
and this was consistent with decreased β1-integrin expression. Ligand-induced 
inactivation of NR4A1 also decreased NR4A1 binding to the promoter; however, 
changes in the Sp1 and p300 bands were somewhat variable and dependent on 
cell context and ligand. For example, the loss of p300 was observed in SKBR3 
cells but not MDA-MB-231 cells, and it is possible that p300 was interacting with 
the trans-acting factors in the proximal region of the β1-integrin promoter. We 
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further investigated the roles of Sp1 and p300 in regulating β1-integrin expression 
in SKBR3 and MDA-MB-231 cells by RNAi, and knockdown of Sp1 (siSp1) and 
p300 (sip300) also decreased β1-integrin expression (Fig. 82B), suggesting that 
like survivin (804), NR4A1 regulates β1-integrin expression through a 
NR4A1/p300/Sp1 complex. p300 knockdown also decreases Sp1 expression, 
suggesting that p300 plays a role in regulating expression of this gene. These 
results do not exclude a role for other factors in NR4A1 regulation of β1-integrin, 
and this is currently being investigated.  levels. 
Previous reports show that inhibition of β1-integrin by RNAi or other β1-
integrin inhibitors increases expression of β3-integrin resulting in enhanced 
metastasis (382,1011,1012). The β3-integrin promoter is also GC rich (1013) and 
therefore, we investigated the possible regulation of β3-integrin by NR4A1. 
Western blot analysis showed that constitutive β3-integrin protein levels were 
barely detectable and remained low after treatment with C-DIM/NR4A1 
antagonists or siNR4A1 (Fig. 82C), whereas knockdown of β1-integrin by RNAi 
increased β3-integrin protein as previously reported (1012). There was more 
robust expression of β3-integrin mRNA in MDA-MB-231 and SKBR3 cells, and 
transfection of siNR4A1 or treatment with C-DIM/NR4A1 antagonists significantly 
decreased β3-integrin mRNA levels (Fig. 82D). 
ChIP assays showed that NR4A1, Sp1, and p300 bound the proximal GC-
rich region of the β3-integrin gene, and treatment with DIM-C-pPhOH or DIM-C-
pPhCO2Me decreased binding of Pol II, NR4A1, and Sp1 but differentially affected 
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p300 binding to the promoter. In addition, we also observed that knockdown of 
Sp1 (siSp1) or p300 (sip300) in MDA-MB-231 and SKBR3 cells decreased β3-
integrin mRNA levels (Fig. 82E). These results demonstrate that NR4A1 regulates 
both β1- and β3-integrin expression, and in contrast to β1-integrin-specific 
inhibitors, NR4A1 antagonists downregulate expression of both β1- and β3-
integrin. We also sucessfully demonstrate that the C-DIM/NR4A1 antagonists that 
act as nuclear inhibitors and keep NR4A1 nuclear in contrast to other known 
inhibitors of NR4A1 which induce mitochondrial translocation.  The C-DIM/NR4A1 
anatonists C-DIM8 and C-DIM14 (data not shown) both inhibit cell invasion in the 
absence or presence of leptomycin B (Fig. 83F).  Thus this corroborates, along 
with the rest of Figure 83, the concept of the C-DIM/NR4A1 antagonists inhibiting 
β1-integrin-dependent migration/invasion by virtue of inhibitng NR4A1 from 
serving as a transcriptional activator of β1-integrin. 
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Figure. 83. NR4A1-regulates β1-integrin-dependent breast cancer cell migration. Cells were transfected with 
siNR4A1 (A), siβ1-integrin (B), or treated with DIM-C-pPhOH and DIM-C-pPhCO2Me (C), and DIM-C-pPhOH ± LMB 
(D), and breast cancer cell migration was determined in a Boyden chamber assay as outlined in the Materials and 
Methods. (E) Cells were transfected with a non-specific oligonucleotide (siCtl), siNR4A1, siβ1-integrin and treated 
with DIM-C-pPhCO2Me, and cell migration was determined in a Boyden chamber assay as outlined in the Materials 
and Methods. Cells were transfected with siNR4A1 alone (F) or treated with DIM-C-pPhOH/DIM-CpPhCO2Me in 
combination with β1-integrin (ITGB1) expression plasmid, and effects on cell migration were determined in a 
Boyden chamber assay as outlined in the Materials and Methods. Results are expressed as means ± SE for at 
least 3 replicates for each treatment group and significantly (P<0.05) decreased migration (*) or rescue by β1-
integrin overexpression (**) are indicated.
Figure 83. 
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Migration of MDA-MB-231 and SKBR3 cells: roles of NR4A1 and β1-integrin 
Both MDA-MB-231 and SKBR3 cells undergo migration (constitutive) in a 
Boyden chamber assay in the absence of a stimulus. Transfection of these cells 
with siNR4A1 (Fig. 83A) or siβ1-integrin (Fig. 83B) decreased migration of both 
cell lines, and similar results were observed with two oligonucleotides targeting 
NR4A1 and β1-integrin. Treatment of SKBR3 and MDA-MB-231 cells with DIM-
C-pPhOH (CDIM8) or DIM-C-pPhCO2Me (CDIM14) also decreased migration 
(Fig. 83C), and the effects of DIM-C-pPhOH as an inhibitor of cell migration was 
not affected by cotreatment with leptomycin B (LMB), confirming that the inhibitory 
effects of this NR4A1 antagonist did not require nuclear export. We also 
investigated the role of NR4A1 in mediating DIM-C-pPhCO2Me-dependent 
inhibition of migration of MDA-MB-231 and SKBR3 cells by knocking down NR4A1 
and then treating with the NR4A1 antagonist DIM-C-pPhcO2Me (Fig. 83E). 
Treatment of the NR4A1-depleted cells with DIM-C-pPhCO2Me resulted in 
minimal inhibition of cell migration. Similar results were observed after treatment 
of β1-integrin-depleted cells with DIM-C-pPhCO2Me, and we also observed that 
DIM-C-pPhOH did not inhibit invasion in cells depleted of NR4A1 or β1-integrin 
(Suppl. Fig. A-8). This would suggest that induction of β3-integrin after knockdown 
of β1-integrin (Fig. 82B) does not play a very significant role in cell migration using 
the Boyden chamber assay. Thus, inhibition of breast cancer cell migration by C-
DIMs/NR4A1 antagonists is dependent on both NR4A1 and β1-integrin and 
consistent with regulation of β1-integrin by NR4A1. Overexpression of β1-integrin 
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in SKBR3 and MDA-MB-231 cells slightly increases cell migration, and in NR4A1-
depleted cells which exhibit decreased migration, overexpression of β1-integrin 
significantly reverses this response (Fig. 83F). In addition, NR4A1 ligand-
mediated inhibition of breast cancer cell migration was also rescued by β1-integrin 
overexpression (Fig. 83G), further confirming that β1-integrin-mediated migration 
is NR4A1 dependent.  Previous studies show that C-DIMs specifically target 
nuclear NR4A1 and antagonism of NR4A1-dependent genes/responses are not 
affected by leptomycin B (LMB)-mediated inhibition of nuclear export (804), and 
results in Figure 4F show that LMB also did not affect DIM-C-pPhOH-depepndent 
inhibition of breast cancer cell migration. Thus, the constitutive or basal migration 
of SKBR3 and MDA-MB-231 cells in the absence of endogenous stimuli is linked 
to nuclear NR4A1 regulation of β1-integrin.  
TGF-β-induced migration of MDA-MB-231 cells: role of extranuclear NR4A1 
A recent study reported that TGF-β-induced migration of MDA-MB-231 
cells was also NR4A1 dependent and involved a pathway associated with SMAD7 
degradation resulting in activation of TGF-βR receptor 1 (TGF-βR1) (822). 
Treatment of MDA-MB-231 cells with 5 ng/ml TGF-β significantly induced cell 
migration (Fig. 84A) as previously described (822), and knockdown of NR4A1 or 
treatment with DIM-C-pPhOH or DIM-C-pPhCO2Me blocked TGF-β-induced 
migration and significantly decreased overall migration, similar to that observed 
after knockdown of NR4A1 or treatment with the NR4A1 antagonists alone (Fig. 
83A to C). TGF-β-induced migration was inhibited after cotreatment with the TGF-
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βR1 inhibitor ALK5i and also the nuclear export inhibitor LMB, and ALK5i had no 
effect on endogenous cell migration (data not shown). Analysis of cytosolic and 
nuclear extracts show that TGF-β induced expression and nuclear export of 
NR4A1 which was blocked by LMB (Fig. 84B) indicating that TGF-β-induced 
migration requires cytosolic NR4A1, whereas constitutive migration which is not 
inhibited by ALK5i is due to nuclear NR4A1-dependent regulation of β1-integrin. 
We also examined SMAD7 expression and observed minimal endogenous 
expression in MDA-MB-231 and SKBR3 cells, and TGF-β increased SMAD7 only 
in SKBR3 cells (Fig. 84C). In contrast, cotreatment with TGF-β plus LMB, CDIM8, 
or CDIM14 dramatically increased SMAD7 protein expression of both cell lines, 
suggesting that nuclear localization of NR4A1 inhibits degradation of SMAD7, 
which is a cytosolic protein. These results are consistent with previous studies, 
suggesting that NR4A1 (cytosolic) plays a role in proteasome-dependent 
degradation of SMAD7. Immunostaining of NR4A1 in MDA-MB-231 cells confirms 
that NR4A1 is nuclear, and treatment with TGF-β induces nuclear export of this 
receptor, and this is blocked by LMB (Fig. 84C).    
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Figure 84. Role of NR4A1 on TGFβ-induced migration of MDA-MB-231 cells. (A) MDA-MB-231 cells were treated 
with TGFβ alone for 5 hr or in combination with siNR4A1, DIM-CpPhOH and DIM-C-pPhCO2Me (24 hr treatment), 
LMB and ALK5i, and LMB (alone). Cell migration was determined in a Boyden chamber assay. (B) MDA-MB-231 
cells were treated with DMSO, TGFβ and LMB (alone) and in combination for 5 hr. Nuclear and cytosolic extracts 
were analyzed by western blots using nuclear (p84) and cytosolic (GADPH) loading controls. (C) Cells were treated 
with DMSO, TGFβ, LMB alone and TGFβ in combination with LMB, DIM-C-pPhOH (CDIM8) or DIM-C-pPhCO2Me 
(CDIM14) for 4 hr, and whole cell lysates were analyzed for SMAD7 expression by western blot analysis. (D) Cells 
were treated with DMSO, 5 ng/ml TGFβ, LMB and LMB plus TGFβ for 5 hr and immunostained with both NR4A1 
antibodies and DAPI as outlined in the Materials and Methods. 
 
Figure 84. 
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Since C-DIM/NR4A1 antagonists act through binding nuclear NR4A1, we 
examined the effects of short-term (4-h) treatment of MDA-MB-231 with DIM-C-
pPhOH or DIM-C-pPhCO2Me on TGF-β-induced migration. Like LMB, both 
compounds blocked TGF-β-induced migration (Fig. 85A), and this was 
accompanied by inhibition of TGF-β-induced nuclear export of NR4A1 (Fig. 85B) 
and paralleled results observed for LMB (Fig. 5A and B). The inhibitory effects 
observed after treatment with the C-DIM/NR4A1 ligands for 4 h were not due to 
decreased β1-integrin expression (Fig. 85C), suggesting that bound NR4A1 was 
resistant to TGF-β-induced nuclear export, and the factors that regulate nuclear 
export are currently being investigated. A previous report showed that TGF-β-
induced NR4A1 interacts with axin 2 and other factors (e.g., E3 ligases Arkadia 
and RNF12) to form a polyubiquitination complex, and after treatment of MDA-
MB-231 cells with TGF-β, LMB, C-DIMs, and their combinations, Western blot 
analysis of the cytosolic fraction immunoprecipitated with axin 2 antibodies gave 
a strong band for NR4A1 only in cells treated with TGF-β alone (Fig. 85D). In 
contrast, treatment with DIM-C-pPhOH, DIM-C-pPhCO2Me, or LMB, which inhibit 
TGF-β-induced nuclear export of NR4A1, resulted in decreased intensities of 
cytosolic NR4A1 bands associated with the axin 2 antibody immunoprecipitates. 
The results demonstrate that NR4A1 plays an important role in breast cancer cell 
migration by regulation of β1-integrin (endogenous activity) and TGF-β-induced 
migration, which is dependent on NR4A1 nuclear export (Fig. 85E).  
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Figure 85. C-DIMs inhibt TGF-β-induced migration and NR4A1 nuclear export. (A) MDA-MB-231 cells were treated 
with TGFβ, DIM-C-pPhOH and DIM-CpPhCO2Me alone and TGFβ plus C-DIMs for 4 hr, and cell migration was 
determined in a Boyden Chamber assay and immunostaining (NR4A1) and DAPI staining was determined as 
outlined in Figure 5C. (B) Cells were treated as described in (Fig. 5B) and the cytosolic and nuclear extracts were 
further examined by western blot analyses. (C) MDA-MB-231 cells were treated with DIM-C-pPhCO2Me or DIM-C-
pPhOH for different times and whole cell lysates were analyzed by western blots for β1-integrin expression. (D) 
Cells were treated as outlined in Figure 6B and whole cell lysates were immunoprecipitated with axin 2 antibodies 
and analyzed bywestern blots. (E) Schematic outline of the role of NR4A1 in constitutive and TGFβ-induced 
migration in breast cancer cells. 
Figure 85. 
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Discussion 
The NR4A family of orphan nuclear receptors NR4A1, NR4A2, and NR4A3 
were initially identified as stress-induced immediate early genes with a 
characteristic domain structure observed for nuclear receptors. NR4A receptors 
have both unique and overlapping functions, and there is increasing evidence that 
they play an important role in cellular homeostasis and diseases associated with 
metabolism, cardiovascular and neurological functions, inflammation, and the 
immune system (791,892,1014). Endogenous ligands for NR4A1 have not been 
identified; however, synthetic ligands that are structurally related to cytosporone 
B have been developed (906,911,941) and have potential clinical applications. 
For example, ethyl[2,3,4-trimethoxy-6-(i-octanoyl)phenyl]acetate is an NR4A1 
ligand that acts as a receptor antagonist to decrease NR4A1-dependent hepatic 
gluconeogenesis and lower blood glucose levels in a rodent model for type 2 
diabetes (941). NR4A1 is also overexpressed in solid tumors including both ER-
positive and ER-negative breast tumors and is a negative prognostic factor for 
lung, colon, and breast cancer patients (822,895,1007).  
Initial studies targeting NR4A1 for cancer chemotherapy showed that cell 
death observed in some cancer cell lines treated with several apoptosis agents 
was due to nuclear export of NR4A1 and the subsequent interactions of NR4A1 
with bcl-2 to form a proapoptotic complex that disrupted mitochondria (905,938). 
The proapoptotic effects were also observed using peptides and paclitaxel that 
mimic NR4A1 interactions with bcl-2 (906,907). Studies in this laboratory have 
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identified C-DIMs as NR4A1 ligands that act as antagonists in cancer cell lines, 
and previous studies have demonstrated that C-DIM/NR4A1 antagonists inhibit 
growth and induce cell death through inactivation of nuclear NR4A1-dependent 
prooncogenic pathways in pancreatic, lung, colon, kidney, and breast cancer cell 
lines (382,788,791,803-806,812,822,892,904,1009-1014).  
A recent report showed that high expression of NR4A1 in breast tumors 
correlated with decreased relapse-free survival, and this was linked to the role of 
NR4A1 in TGF-β and TGF-β/cytokine-induced migration/invasion and metastasis 
(822). Results of ongoing genomic and functional studies in several cancer cell 
lines identified β-integrin as a possible NR4A1-regulated promigration/invasion 
gene, and this correlated with previous in vivo studies showing that β1-integrin 
was important for metastasis of mammary tumors overexpressing the erbB2 
oncogene (846,862,1007,1008).  Results in Fig.80, 81, and 83 demonstrate that 
knockdown of NR4A1 or treatment with the NR4A1 antagonists DIM-C-pPhOH 
and DIM-C-pPhCO2Me decreased expression of β1-integrin protein and mRNA 
and β1-integrin-dependent responses in MCF7, MDA-MB-231, and SKBR3 cells 
and also inhibited migration of the latter two cell lines.  
The mechanism of NR4A1 regulation of β-integrin in SKBR3 and MDA-MB-
231 cells did not involve direct binding to cis-acting genomic sequences but 
through an indirect mechanism in which NR4A1/p300 act as a coregulatory 
complex to activate Sp1-regulated genes. The ChIP assays show that NR4A1, 
Sp1, and p300 interacted at the GC-rich region of the β1-integrin gene promoter 
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(Fig. 82), and knockdown of any one of these factors or treatment with C-
DIM/NR4A1 antagonists resulted in decreased β1-integrin expression. These 
results are similar to those previously observed for NR4A1/p300/Sp1-mediated 
regulation of survivin in pancreatic cancer cells (804) and are consistent with other 
reports showing that other nuclear receptors also regulate expression of other Sp-
dependent genes through NR4A1/Sp1 complexes (957-961). Previous studies 
show that knockdown or inhibition of β1-integrin in breast cancer cells results in 
the expression of β3-integrin, and this “integrin-switching” enhances TGF-β-
induced metastasis, which presents a problem for applications of β1-integrin 
inhibitors in treatment of breast cancer. Like β1-integrin, the 5′-promoter region of 
the β3-integrin gene contains GC-rich sequences, and our results demonstrate 
that NR4A1 also regulates β3-integrin expression, and NR4A1 antagonists or 
NR4A1 knockdown decreases expression of both genes (Fig. 82). Thus, 
coregulation of β1- and β3-integrin by NR4A1 negates the “integrin-switching” 
phenomena and further demonstrates that the C-DIM/NR4A1 antagonists 
represent a novel therapeutic approach for inhibiting β1/β3-integrin-induced 
signaling and metastasis in breast cancer cells.  
MDA-MB-231 and SKBR3 cells readily migrate in the absence of TGF-β or 
cytokine stimulus, and results of RNAi studies show that inhibition of cell migration 
by C-DIM/NR4A1 antagonists was observed only in cells expressing NR4A1 or 
β1-integrin (Fig. 83). Moreover, since the inhibitory effects of C-DIMs were similar 
in the presence or absence of the nuclear export inhibitor LMB (Fig. 83F), our 
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results indicate that constitutive migration of these cells was due to nuclear 
NR4A1-dependent regulation of β1-integrin. This is also supported by the 
observation that the TGF-β receptor inhibitor ALK5i inhibits TGF-β-induced 
migration but does not affect the high rate of constitutive migration of MDA-MB-
231 cells (Fig. 84A). A recent study showed that NR4A1 was also required for 
TGF-β-induced migration of MDA-MB-231 and other cell lines, and this was due 
to interactions of NR4A1, axin 2, and E3 ligases which enhanced SMAD7 
degradation, resulting in activation of the TGF-βR1 pathway (822).  
We also observed that TGF-β induced NR4A1 expression and migration of 
MDA-MB-231 cells; however, the key essential element in this pathway was that 
TGF-β induced nuclear export of NR4A1 (Fig. 84B and D and 85C). Moreover, 
inhibition of nuclear export by the NR4A1 ligands (DIM-C-pPhOH or DIM-C-
pPhcO2Me) or LMB also blocked TGF-β-induced migration and enhanced SMAD7 
expression (Fig. 84C). Previous studies on SMAD7 degradation in MDA-MB-231 
cells used transfected FLAG-SMAD7, whereas in this study, we observed low to 
nondetectable SMAD7 expression in MDA-MBA-231 and SKBR3 cells. However, 
LMB, DIM-C-pPhOH, and DIM-C-pPhCO2Me which prevent NR4A1 export also 
increased SMAD7 expression in cells cotreated with these compounds plus TGF-
β (Fig. 84C), and this is consistent with a role for cytosolic NR4A1 in SMAD7 
degradation as previously reported. Thus, TGF-β-induced migration of MDA-MB-
231 cells is due to nuclear export of NR4A1, and the C-DIM/NR4A1 antagonist 
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blocks this pathway presumably by inhibiting factors/pathways required for 
nuclear export, and these factors/pathways are currently being investigated.  
In summary, results of this study show that nuclear NR4A1 regulates β1-
integrin expression in breast cancer cells, and C-DIM/NR4A1 antagonists inhibit 
expression of β1-integrin and β1-integrin-mediated responses, including cell 
migration, and the antagonists also inhibit NR4A1-regulated expression of β3-
integrin. In contrast, TGF-β-induced migration of MDA-MB-231 cells requires 
nuclear export of NR4A1 which is inhibited not only by LMB but also by C-
DIM/NR4A1 antagonists. Thus, constitutive migration and TGF-β-induced 
migration are dependent on nuclear and extranuclear NR4A1, respectively, and 
the C-DIM/NR4A1 antagonists inhibit both pathways by decreasing NR4A1-
dependent expression of β1-integrin and by inhibition of TGF-β-induced nuclear 
export of NR4A1 (Fig. 85E). This study expands on the prooncogenic functions of 
NR4A1 and indicates that C-DIM compounds and other NR4A1 antagonists 
represent an important new class of mechanism-based anticancer drugs for 
treating patients with tumors overexpressing this receptor.  
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CHAPTER VI 
SPECIFICITY PROTEIN (Sp) TRANSCRIPTION FACTORS Sp1, Sp3, AND 
Sp4 ARE NON-ONCOGENE ADDICTION GENES IN CANCER CELLS 
 
Introduction 
 Activation or amplification of oncogenes play an important role in tumor 
formation, growth and metastasis, and multiple chemotherapies have been 
designed to target one or more oncogenes (987,1015).  The addiction of cancer 
cells and tumors to oncogenes is due, in part, to their regulation of multiple growth-
promoting, pro-survival and migration/invasion pathways that are the hallmarks of 
cancer (60).  Mechanism-based antineoplastic agents, such as the tyrosine kinase 
inhibitor Gleevac/Imatinib that inhibits the oncogene BCR-ABL, have been 
successful; however, clinical applications of many other drugs targeting 
oncogenes including the tyrosine kinase inhibitors have had limited success due 
to multiple factors including the development of drug resistance (1016).   
 The proposed concept of non-oncogene addiction (NOA) by cancer cells 
includes "genes and pathways (are) essential to support the oncogenic phenotype 
of cancer cells but are not required to the same degree for the viability of normal 
cells" (987).  For example, ATM-deficient cells exhibit decreased apoptosis and 
exhibit NOA to DNA-dependent protein kinases and, drugs that inhibit these 
kinases are highly effective for treating ATM-deficient lymphomas (1016).   
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 Specificity protein (Sp) transcription factors (TFs) Sp1, Sp3 and Sp4 are 
members of the Sp/Krüppel-like family (KLF), and results from Sp knockout mouse 
models demonstrate the importance of Sp genes to embryonic growth and early 
development (reviewed in 1017).  However, expression of Sp1 in humans and 
rodents decreases with age (988-990).  Moreover, several studies report that high 
expression of Sp1 and, in some cases, Sp3 in tumor vs. non-tumor tissue are 
negative prognostic factors for patients with pancreatic, glioma, colon, gastric, 
head and neck, prostate, lung and breast cancers (991,994,995,1018-1023).  
Studies in cancer cell lines show that Sp1, Sp3 and Sp4 are highly expressed, 
and RNA interference (RNAi) studies indicate that Sp transcription factors 
regulate genes associated with cell proliferation, survival and migration/invasion 
(reviewed in 996).  Although Sp1, Sp3 and Sp4 have similar modular structures 
and bind GC-rich promoter sequences, these transcription factors also exhibit 
unique properties including the number of isoforms and DNA binding 
characteristics (711,1024,1025).  Moreover, since Sp1 regulates expression of 
both pro-oncogenic and tumor suppressor-like genes, it has been suggested that 
"a more complete understanding of the function of Sp1 in cancer is required to 
validate its potential as a therapeutic target" (711).  
 Although knockdown of Sp1 by RNA interference (RNAi) in cancer cell lines 
inhibits cell growth, survival and migration/invasion (648,976,982,1026,1027), a 
systematic comparative analysis of the functional and genomic effects of Sp1, Sp3 
and Sp4 in cancer cells has not been reported.  In this study, we show that 
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knockdown of Sp1, Sp3 and Sp4 by RNAi in SKBR3 and MDA-MB-231 breast, 
A549 lung, SW480 colon, 786-O kidney, and Panc1, L3.6pL and MiaPaCa2 
pancreatic cell lines results in inhibition of cell growth, decreased survival, and 
inhibition of migration/invasion.  Using Panc1 cells as a model, a causal Ingenuity 
Pathway Analysis (IPA) of changes in gene expression after knockdown of Sp1, 
Sp3 and Sp4 strongly correlated with observed changes in functional responses.  
Thus, the oncogenic-like activity of Sp transcription factors and Sp-regulated 
genes coupled with their overexpression in tumor vs. non-tumor tissue indicates 
that Sp1, Sp3 and Sp4 are NOA genes that are "attractive drug targets" (987).   
 
Materials and Methods 
Cell lines and antibodies 
Breast cancer (SKBR3, MDA-MB-231), kidney cancer (786-0), colorectal 
cancer (SW480), lung cancer (A549), and pancreatic cancer (PANC1,l3.6pL, 
Miapaca2) cell lines were purchased from American Type Culture Collection 
(Manassas, VA).  Cells were maintained 37˚C in the presence of 5% CO2 in 
Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium with 10% fetal bovine 
serum with antibiotic or RPMI-1640 Medium with 10% fetal bovine serum and 
antibiotic. Β-actin antibody Dulbecco’s Modified Eagle’s Medium, and RPMI-1640 
Medium, and 36% formaldehyde were purchased from Sigma-Aldrich (St. Louis, 
MO).   Hematoxylin was purchased from Vector Laboratories (Burlingame, CA).  
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Sp1 antibody from Millipore (Temecula, CA); Sp3, Sp4, EGFR, bcl2 antibodies 
from Santa Cruz Biotech (Santa Cruz, CA); survivin antibody from Cell Signaling 
technologies (Danvers, MA); VEGF antibody from GeneTex (Irvine, CA). 
Apoptotic, Necrotic, and Healthy Cells Quantification Kit was purchased from 
Biotium (Hayward, CA). Cells were visualized as described previously (711). 
Cell proliferation assay and Annexin V staining 
Cell proliferation assays were carried out as described previously 
(648,976,1027,1028)) and changes in cell number were determined by Coulter Z1 
cell counter.  Annexin V staining used the Vybrant apoptosis kit according to the 
manufacturer’s protocol (711). 
Boyden Chamber Assay 
SKBR3, MDA-MB-231, 786-0, SW480, A549, PANC1, l3.6PL, and 
Miapaca2 cancer cells (3.0 x 105 per well) were seeded in Dulbecco’s modified 
Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-stripped 
fetal bovine serum and were allowed to attach for 24 h. Cells were seeded and 
subsequently treated with varying concentration of panobinostat or vorinostat for 
24 hours (+/- GSH 3 h prior to treatment) or with 100 nm of siSp1, siSp3, siSp4 
for 48 hours.  Cells were trypsinized, counted then placed in 12-well 8.0µm pore 
ThinCerts from Greiner bio-one (Monroe , NC) allowed to migrate for 24 hr, fixed 
with formaldehyde, and then stained with hematoxylin.  Cells that migrated 
through the pores were then counted as described (711). 
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Western blot analysis 
SKBR3, MDA-MB-231, 786-0, SW480, A549, PANC1, l3.6PL, and 
Miapaca2 cancer cells (3.0 x 105 per well) were seeded in Dulbecco’s modified 
Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-stripped 
fetal bovine serum and were allowed to attach for 24 h. Cells were transfected 
with 100 nm of siSp1, siSp3, siSp4 for 72 hours.  Cells were analyzed by western 
blot as described previously (648,976,1027-1029)). 
Small interfering RNA interference assay 
SiRNA experiments were conducted as described previously()  The siRNA 
complexes used in the study are as follows: siGL2-5’: CGU ACG CGG AAU ACU 
UCG A; siSp1:SASI_Hs02_00333289[1], SASI_Hs01_00140198[2], 
SASI_Hs01_00070995[3]; siSp3: SASI_Hs01_00211941[1], 
SASI_Hs01_00211942[2], SASI_Hs01_00211943[3]; siSp4: 
SASI_Hs01_00114420[1], SASI_Hs01_00114421[2], SASI_Hs01_00114420[3] 
Xenograft Studies 
Female athymic nude mice 4-6 old were purchased as previously 
described (28).  L3.6pL cells in culture were transfected with 100 nM of siCtl (7 
mice), siSp1 (7 mice), or siSp1,3,4 (7 mice).  After 48hr 1.0 x106 cells were 
suspended in Matrigel (1:1 ratio) and injected into the right flank of athymic nude 
mice.  Tumor volumes, tumor weights, and tumor lysates were determined and 
analyzed as previously described (711). 
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Microarray and IPA analysis 
After knockdown by RNAi total RNA was extracted using a mirVanaTM 
miRNA Isolation Labeling Kit (Ambion, Austin, TX) and used for microarray 
analysis with a HumanHT-12 v4 expression beadchip (Illumina, San Diego, CA) 
according to the manufactures' protocol. Microarray data were normalized and 
results from replicate (3X) experiments were used to identify differentially 
expressed genes with a ≥ 1.5-fold change. Function and pathways analysis of Sp-
regulated genes was determined using Ingenuity Pathways Analysis (IPA) 
database (Invitrogen, Carlsbad, CA). 
Statistical analysis 
Statistical significance of differences between the treatment groups was 
determined as previously described (711). 
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Results 
 
Figure 86.  Functional effects of Sp1, Sp3 and Sp4 knockdown in cancer cells.  Effects of knockdown in A549, 
MiaPaCa2, SW480, 786-O, SKBR3, MDA-MB-231, Panc1 and L3.6pL cancer cell lines.  Cells were transfected with 
siSp1, siSp3 and siSp4 and effects on cell proliferation (A), Annexin V staining (B) and invasion in a Boyden 
chamber assay (C) were determined as described in the Materials and Methods.  Results are expressed as means 
 SE for at least 3 biological replicates for each determination, and significant (p<0.05) changes compared to cells 
transfected with a nonspecific oligonucleotide (siCtl) are indicated (*).  (D) Knockdown of Sp1, Sp3 and Sp4 
(combined) or Sp1 alone in L3.6pL cells were used in xenografts experiments and changes in tumor 
volumes/weights were determined essentially as described (22-25).  Significant changes (p < 0.05) after Sp 
knockdown are indicated (*). 
Figure 86. 
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Knockdown of Sp transcription factors in cancer cell lines:  functional 
effects. 
 The functional and genomic effects of Sp1, Sp3 and Sp4 and their possible 
roles as NOA genes were investigated by RNAi in several different cancer cell 
lines.  Multiple oligonucleotides for Sp1, Sp3 and Sp4 have previously been used 
for studying Sp-regulated gene expression and functional responses (Suppl. Fig. 
A-9) (648,976,1027-1029), and a single representative oligonucleotide was used 
for this study.  Figure 1 summarizes the effects of knockdown of Sp1, Sp3 and 
Sp4 in A549, MiaPaCa2, L3.6pL, Panc1, SW480, 786-O, SKBR3 and MDA-MBA-
231 cancer cell lines.  Decreased expression of Sp1, Sp3 and Sp4 resulted in 
significant inhibition of cancer cell proliferation (Fig. 86A), induction of Annexin V 
(a marker of apoptosis) (Fig. 86B), and inhibition of cancer cell invasion in a 
Boyden Chamber assay (Fig. 86C) and knockdown of all three genes (siSp1,3,4) 
enhanced the observed responses.  The magnitude of the effects showed some 
variability and was dependent on the individual Sp protein and cell context.  Most 
previous functional studies have focused on Sp1; however, results illustrated in 
Figure 1 clearly demonstrate that both Sp3 and Sp4 also contribute to the growth, 
survival and migration/invasion of the eight cancer cells lines.  In a parallel 
experiment, combined knockdown of Sp1, Sp3 and Sp4 or individual knockdown 
of Sp1 in L3.6pL cells used in an athymic nude mouse xenograft model showed 
that loss of Sp TFs resulted in a significant inhibition of tumor growth (Fig. 86D). 
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siSp Categories Diseases or 
Functions 
Annotation 
p-
Value 
Predicted 
Activation 
State 
Activation 
z-Score 
# of 
Molecules 
siSp1 Cell death and 
survival 
Cell death 1.11E-
43 
Increased 2.821 749 
 Cellular 
growth and 
proliferation 
Proliferation 
of cells 
2.66E-
39 
Decreased -3.240 788 
 Cellular 
movement 
Migration of 
tumor cell 
lines 
6.40E-
11 
Decreased -2.063 150 
       
siSp3 Cell death and 
survival 
Cell death 1.19E-
32 
Increased 2.526 975 
 Cellular 
growth and 
proliferation 
Proliferation 
of cells 
 
8.07E-
27 
Decreased -5.410 1024 
 Cellular 
movement 
Migration of 
tumor cell 
lines 
2.54E-
08 
Decreased -6.346 190 
       
siSp4 Cell death and 
survival 
Cell death 2.62E-
34 
Increased 3.809 995 
 Cellular 
growth and 
proliferation 
Proliferation 
of cells 
4.41E-
28 
Decreased -6.222 1044 
 Cellular 
movement 
Migration of 
tumor cell 
lines 
2.42E-
09 
Decreased -6.411 197 
Table 1: Causal IPA analysis of Sp knockdown.  Causal IPA analysis gene functions of 
Sp knockdown by RNAi in Panc1 cells. 
Table 1 
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Figure 87.  Knockdown of Sp TFs by RNAi.  (A) SKBR3 and MDA-MBA-231, (B) SW480 and 786-O, (C) L3.6PL and 
A549, and (D) Panc1 and MiaPaCa2 cells were transfected with siSp1, siSp3 and siSp4, and whole cell lysates 
were analyzed by Western blots as outlined in the Materials and Methods. 
 
Figure 87. 
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Knockdown of Sp1, Sp3 and Sp4 in cancer cell lines:  effects on Sp TFs 
and Sp-regulated gene products 
 The individual effects of Sp1, Sp3 and Sp4 knockdown could be indirect 
since the three genes contain GC-rich promoters and they could be self-regulatory 
(1027-1029) and this was further investigated.  Western blot analysis of 
expression of Sp TFs after transfection of the cancer cell lines with siControl (siCtl, 
non-specific oligonucleotide) or oligonucleotides targeting Sp1 (siSp1), Sp3 
(siSp3), Sp4 (siSp4), or their combination (siSp1,3,4) showed that Sp1, Sp3 and 
Sp4 proteins were highly expressed in the eight cancer cell lines (Fig. 87).  
Knockdown of Sp1, Sp3 and Sp4 was specific for the individual proteins in 
SW480, 786-O, A549, Panc1 and MiaPaCa2 cells.  In contrast, siSp3 decreased 
expression of Sp1 (SKBR3) and Sp4 (L3.6pL) proteins and siSp4 decreased Sp1 
(SKBR3) and Sp3 (SKBR3 and MDA-MB-231) proteins.  These results 
demonstrate that autoregulation of Sp1, Sp3 and Sp4 was minimal among the 
eight cancer cell lines and primarily involved Sp3 and Sp4 and their regulation of 
each other or of Sp1.  Sp TFs regulate expression of several pro-oncogenic 
factors including vascular endothelial growth factor (VEGF), epidermal growth 
factor receptor (EGFR), survivin and bcl2 (996).  In this study, we examined the 
effects of Sp knockdown on expression of these genes and induction of the 
apoptotic marker cleaved PARP in the cancer cell lines.  Transfection of siSp1, 
siSp3, siSp4 and siSp1,3,4 induced PARP cleavage in all eight cell lines (Fig. 88) 
and this complemented the induction of Annexin V staining (Fig. 86B) observed 
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after the same treatments.  EGFR, VEGF, bcl-2 and survivin were expressed in 
the eight cancer cell lines, and siSp1, siSp3 and siSp4 downregulated these gene 
products but some variability that was si-oligonucleotide-, gene- and cell context-
dependent was observed. 
 
 
Figure 88.  Knockdown of Sp TFs decreases expression of Sp-regulated gene products.  Cell lines (A – D) and 
L3.6pl xenogratfs (E) were transfected as described in Figure 2 and these same lysates were analyzed for 
expression of Sp-regulated gene products as outlined in the Materials and Methods.  Tumor lysates were 
normalized to β-actin (F). 
Figure 88. 
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Figure 89.  Analysis of changes in gene expression after knockdown of Sp1, Sp3 and Sp4 in Panc1 cells.  (A) 
Panc1 cells were transfected with siSp1, siSp3 or siSp4, and changes in gene expression were determined using 
Human HT-12 V4 expression bead chip arrays.  The overlap of total genes (B) and proliferation (C), survival (D) 
and invasion (E) genes coregulated by Sp1/Sp3, Sp1, Sp4 and Sp3/Sp4 in Panc1 cells after RNAi was determined 
by IPA. 
Figure 89. 
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Analysis of gene expression changes in Panc1 cells after knockdown of 
Sp1, Sp3 and Sp4 
 Results of RNAi studies show that Sp1, Sp3 and Sp4 exhibited pro-
oncogenic activity and regulated pro-oncogenic factors (Figs. 86 and 88).  This 
was further investigated in gene array studies using Panc1 cells as a model.  
Transfection of Panc1 cells with siSp1, siSp3 and siSp4 and analysis of gene 
expression using arrays resulted in inhibition or induction of 3,532, 4,826 and 
4,293 genes, respectively (Fig. 89A).  After knockdown of Sp1, Sp3 and Sp4, 
Venn diagrams show considerable overlap of genes commonly regulated by 
Sp1:Sp3 (1,113); Sp1:Sp4 (1,114) and Sp3:Sp4 (2,753) with the most pronounced 
gene overlap observed for Sp3 and Sp4 (Fig. 89B).  IPA was used to investigate 
common and differentially expressed genes after knockdown of Sp1, Sp3 and Sp4 
associated with cell proliferation, survival and migration/invasion and there were 
significant changes in total gene expression associated with cell proliferation (788, 
1,204 and 1,044 genes, respectively), survival (759, 975 and 995 genes, 
respectively) and migration/invasion (150, 190 and 197 genes, respectively) (Fig. 
89C-89E).  Venn diagrams also showed that there was also a considerable 
overlap of common genes coregulated by Sp1:Sp3, Sp1:Sp4 and Sp3:Sp4 
associated with cell proliferation (Fig. 89C), survival (Fig. 89D) and 
migration/invasion (Fig. 89E).  For example, after knockdown of Sp3 and Sp4 by 
RNAi, there was a 60-70% overlap of genes associated with Panc1 cell 
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proliferation, survival and migration/invasion and this correlated with their 
common regulation of total genes (Fig. 89B).   
Examination of the changes in gene expression after RNAi showed that 
there were Sp1-, Sp3- and Sp4-regulated genes that correlated or inversely 
correlated with the observed functional responses induced by knockdown of Sp 
TFs (Fig. 86).  This was confirmed by real time PCR analysis (Fig. 90) showing 
that one or more Sp TFs decreased expression of the tumor promoting genes 
ribonucleotide reductase M2 (RRM2) and Aurora kinase A (AURKA) and 
increases expression of the tumor suppressor-like genes such as thioredoxin-
interacting protein (TXNIP) and the polycomb CBX7 genes (1029-1032).  
However, knockdown of one or more Sp TFs also increased expression of genes 
such as heme oxygenase 1 (HMOX1) and interferon-stimulated gene 15 (ISG15) 
that promote carcinogenesis and decreased expression of caspase 3 (CASP3) 
and Sprouty2 (SPRY2) that inhibit pancreatic tumorigenesis (1034-1037).  These 
results are consistent with the array data showing that Sp TFs regulate genes that 
both correlate and inversely correlate with the results of functional studies (Suppl. 
Tables B1-B3).   
Causal analysis using IPA is a quantitative approach that integrates all of 
the changes in expression of genes and pathways in large data sets to predict 
biologic function (1038).  Table 1 summarizes the analysis of the total changes in 
gene expression after knockdown of Sp1, Sp3 and Sp4 in Panc1 cells.  The low 
p-values and activation score values (>2 or <-2) obtained from this analysis 
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strongly predicted that Sp1, Sp3 and Sp4 were associated with Panc1 cell 
proliferation, survival and migration/invasion and were consistent with the 
functional results illustrated in Figure 86.  These functional and genomic data 
coupled with the high expression of Sp transcription factors in tumor vs. non-tumor 
tissue suggests that Sp1, Sp3 and Sp4 are NOA genes and attractive drug targets.   
 
Figure 90.  Changes in expression of specific genes after Sp knockdown in Panc1 cells.  Panc1 cells were 
transfected with siSp1, siSp3 or siSp4, and real time PCR analysis was used to determine changes in expression 
of (A) RRM2 and AURK, (B) TXNIP and CBX7, (C) CASP3 and SPRY2, (D) HMOX1 and ISG15, and (E) Sp1, Sp3 and 
Sp4.  Results are expressed as means  SE for at least 3 replicates for each treatment group, and significantly 
(p<0.05) decreased changes in gene expression are indicated (*).   
Figure 90. 
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Discussion 
 The concept of NOA highlights the fact that the cancer genotype and 
hallmarks of cancer are maintained by both oncogenes and NOA genes which are 
also important targets for mechanism-based anticancer agonists (60,987,1015).  
Among Sp/KLF transcription factors, Sp1 has been most extensively investigated 
and fulfills many of the criteria for an NOA gene.  Sp1 levels decrease with age in 
rodents and humans (988-990) and several studies show that Sp1 levels are high 
in tumor vs. non-tumor tissue (991,994,995,1018-1023).  The differential 
expression of Sp1 has also been observed in human fibroblasts where 
carcinogen- or oncogene-induced transformation resulted in an 8- to 18-fold 
increase in Sp1 levels (998).  Moreover, in xenograft experiments, the loss of Sp1 
in fibrosarcoma cells decreased their ability to form tumors (998) and the role of 
Sp1 in tumor growth, survival and migration/invasion has been confirmed in other 
reports (648,976,982,996,1026).   
Our results in multiple cancer cell lines clearly demonstrate that not only 
Sp1 but also Sp3 and Sp4 play a role in cancer cell growth, survival and 
migration/invasion (Fig. 86) and regulate expression of gene products (Fig. 88) 
consistent with these observations.  Moreover, transfection of Panc1 cells with 
siSp1, siSp3 or siSp4 and IPA of changes in gene expression by arrays showed 
that all three transcription factors regulated genes that enhance cell proliferation, 
survival and migration/invasion (Suppl. Tables B1-B3).  Despite overlap in their 
regulation of common genes (Fig. 89), RNAi studies on functional effects of Sp 
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TFs (Fig. 86) showed that individual loss of Sp1, Sp3 or Sp4 was sufficient to 
decrease growth, survival and invasion and compensation by the other two Sp 
genes was not observed, suggesting unique gene regulatory functions for these 
transcription factors.   
 As recently pointed out (711), Sp1 regulates expression of genes that both 
enhance and inhibit carcinogenesis as indicated in Supplemental Tables S1-S3 
and Figure 5 and this is a possible cautionary consideration for clinical 
development of anticancer drugs that specifically target Sp proteins.  However, 
causal IPA approaches which weigh contributions of individual genes to various 
networks/pathways (Table 1) showed that examination of all genes associated 
with cancer cell proliferation, survival and migration/invasion after Sp knockdown 
strongly correlated with the observed functional responses (Fig. 86).   
 Previous studies have reported differences in the prognostic value of Sp1 
overexpression in breast and lung cancer patients and also differences in the pro- 
and anti-carcinogenic role of Sp1 in MDA-MB-231 breast and A549 lung cancer 
cell lines (1020,1039-1043).  Using an RNAi approach (Fig. 86), our results show 
that not only Sp1 but also Sp3 and Sp4 exhibit pro-oncogenic activities in MDA-
MB-231 and A549 cells.  Some of the differences between studies may be due to 
the methods used to modulate Sp expression since overexpression of Sp1 and 
Sp3 in some cancer cell lines induces apoptosis and inhibits growth (1044-1047).  
It is possible that overexpressing Sp1, Sp3 and Sp4 may not always be ideal for 
probing the "constitutive" functions of these transcription factors since high 
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intracellular levels of Sp1, Sp3 and Sp4 may activate expression of genes with 
GC-rich promoters that are not normally expressed, and this is currently being 
investigated.   
 In summary, this study indicates that Sp1, Sp3 and Sp4 are NOA genes 
that are highly expressed in tumor vs. non-tumor tissue and regulate expression 
of pro-oncogenic factors that contribute to cancer cell growth, survival and 
migration/invasion.  Several different classes of antineoplastic agents that target 
Sp transcription factors have been identified and these include natural products 
and their derivatives, metformin, non-steroidal anti-inflammatory drugs, and ROS-
inducing anticancer agents, including isothiocyanates, piperlongumine and 
arsenic trioxide (1020,1039-1043).  Moreover, drugs, such as ascorbate, 
tolfenamic acid and betulinic acid that downregulate Sp proteins, are highly 
effective in drug combinations for inhibiting tumor growth in laboratory animal 
studies (1048-1050).  Important advantages for development and clinical 
applications of anticancer agents that target Sp1, Sp3 and Sp4 include:  (a) these 
compounds decrease Sp-regulated genes such as EGFR, VEGF, cMET and other 
tyrosine kinases that are themselves individual drug targets; and (b) these agents 
also decrease expression of drug resistance genes (survivin, MDR1) (996) and 
are ideal for drug combination therapies.  The choice of a specific drug for 
targeting Sp TFs will be tumor-specific and dependent on pharmacokinetics and 
efficient delivery of the agent to the tumor site. 
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CHAPTER VII 
 
THE NUCLEAR ORPHAN RECEPTOR NR4A1 REGULATES 1-INTEGRIN 
EXPRESSION IN PANCREATIC AND COLON CANCER CELLS AND CAN BE 
TARGETED BY NR4A1 ANTAGONISTS 
 
Introduction 
 The nuclear receptor 4A (NR4A) subfamily of orphan receptors including 
NR4A1 (Nur77/TR3), NR4A2 (Nurr1) and NR4A3 (Nor1) are stress-inducible 
immediate early genes that play both unique and overlapping roles in metabolic, 
cardiovascular, neurological and immune functions, inflammation, and cancer 
(892,1014)).  Although endogenous ligands for NR4A receptors have not been 
identified, there is evidence that ligands for these receptors acting as agonists or 
antagonists are emerging as a novel class of therapeutics (788,808,905,1014).  
For example, Wu and coworkers have characterized cytosporone and related 
synthetic analogs as NR4A1 ligands (817,910,911,941,942) and have shown that 
one of their analogs inhibits endotoxin-induced sepsis in RAW 264.7 cells and in 
vivo (817).  The mechanism of this NR4A1-dependent antiinflammatory response 
is due to ligand-induced dissociation of p38-NR4A1 interactions and restoration 
of the p65-NR4A1 complex resulting in inhibition of NFB signaling (817).   
 In double knockout animals, the loss of both NR4A1 and NR4A3 results in 
the rapid development of acute myeloid leukemia (AML) in mice (1051) indicating 
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a tumor suppressor-like role for these receptors.  In contrast, NR4A1 is 
overexpressed in many solid tumors and their derived cell lines, and in breast, 
colon and lung tumors overexpression of NR4A1 is a negative prognostic factor 
(803,804,822,895,954,1052,1053).  Moreover, knockdown or overexpression of 
NR4A1 shows that this receptor is pro-oncogenic and regulates one or more of 
cell proliferation, survival and migration/invasion in lung, melanoma, lymphoma, 
kidney, pancreatic, colon, cervical, ovarian and gastric cancer cells 
(805,806,812,822,895,898,900,901,904,1053-1056).   
Studies in this laboratory have identified 1,1-bis(3'-indolyl)-1-(substituted 
phenyl)methane (C-DIM) analogs as NR4A1 ligands that act as nuclear receptor 
antagonists (803-806,812,904).  RNAseq or array analysis have shown that 
treatment with specific C-DIM/NR4A1 antagonists results in both induced and 
repressed gene expression which contribute to the NR4A1-regulated pro-
oncogenic pathways.  For example, in both liver and colon cancer cells, treatment 
with the NR4A1 antagonist 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-
C-pPhOH) induces reactive oxygen species (ROS) through downregulation of 
isocitrate dehydrogenase 1 (IDH1) and thioredoxin domain containing 5 
(TXNDC5) and downregulates survivin and other specificity protein (Sp)-regulated 
genes containing GC-rich promoters (803-806,812,904).  Ligand-dependent 
inactivation of NR4A1 activates p53 and induces ROS which induce sestrin 2 and 
activation of AMPK resulting in inhibition of mTOR (803,812,904).  All of these 
pro-oncogenic NR4A1-regulated genes/pathways and functions are blocked by 
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C-DIM/NR4A1 antagonists in breast, pancreatic, colon, kidney and lung cancer 
cell lines (803-806,812,904).   
 Recent studies have identified 1-integrin as an NR4A1-regulated gene in 
breast cancer cells and the NR4A1 antagonist DIM-C-pPhOH decreases 1-
integrin expression and also inhibits 1-integrin-dependent cell migration (805).  
Since 1-integrin is a negative prognostic factor and induces migration/invasion 
and metastasis in both pancreatic and colon cancer cells (1056-1067), this study 
investigated the role of NR4A1 in regulating 1-integrin expression and 
subsequent inhibition of 1-integrin-dependent migration/invasion by C-
DIM/NR4A1 antagonists.  The results confirm that C-DIM/NR4A1 antagonists 
target NR4A1 and inhibit invasion of pancreatic and colon cancer cells, 
demonstrating that these compounds represent a novel class of mechanism-
based drugs for pancreatic and colon cancer chemotherapy. 
 
Materials and Methods 
Cell lines and antibodies 
Pancreatic cancer (Panc1 and MiaPaCa2) and colon cancer (RKO, 
SW480) cell lines were purchased from American Type Culture Collection 
(Manassas, VA) and were authenticated on April 29, 2016 by Biosynthesis 
(Lewisville, TX).  L3.6pL cells were kindly provided by Dr. I.J. Fidler (University of 
Texas MD Anderson Cancer Center, Houston, TX).  Cells were maintained 37C 
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in the presence of 5% CO2 in Dulbecco’s modified Eagle’s medium/Ham’s F-12 
medium with 10% fetal bovine serum with antibiotic.  NR4A1 antibody was 
purchased from Novus Biologicals (Littleton, CO).  Sp1 antibody and glutathione 
(GSH) reduced free acid were purchased from Millipore (Temecula, CA); 1-
integrin, p300, Sp3 and Sp4 antibodies were purchased from Santa Cruz Biotech 
(Santa Cruz, CA).  -Actin antibody, Dulbecco’s Modified Eagle’s Medium, and 
36% formaldehyde were purchased from Sigma-Aldrich (St.  Louis, MO).   
Hematoxylin was purchased from Vector Laboratories (Burlingame, CA).  FAK, p-
FAK, 5-integrin antibodies and leptomycin were purchased from Cell Signaling 
Technologies (Manassas, VA)   
Cell adhesion assay 
Panc1, L3.6pL, MiaPaCa2, RKO and SW480 cancer cells (3.0 x 105 per 
well) were seeded in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium 
supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed 
to attach for 24 hr.  Cells were seeded and subsequently treated with varying 
concentrations of DIM-C-pPhOH or DIM-C-pPhCO2Me for 24 hr or with 100 nm of 
si1-integrin or siNR4A1 for 48 hr.  Cells were trypsinized, counted, then placed 
for 90 min on BD BioCoat Human Fibronectin Cellware 24-well plates (Bedford , 
MA); medium was then aspirated, wells gently washed with PBS, and stained with 
0.5% Crystal Violet Stain.  Cells were then counted for adhesion to fibronectin.  
Wells coated with BSA and poly-L-lysine were used as negative controls. 
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Boyden chamber assay   
Panc1, L3.6pL, MiaPaCa2, RKO and SW480 cancer cells (3.0 x 105 per 
well) were seeded in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium 
supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed 
to attach for 24 hr.  Cells were seeded and subsequently treated with varying 
concentrations of DIM-C-pPhOH or DIM-C-pPhCO2Me for 24 hr or with 100 nm of 
si1-integrin, siNR4A1, siSp1, or sip300 for 48 hr.  Cells then treated with varying 
concentrations of DIM-C-pPhOH or DIM-C-pPhCO2Me for 24 hr after transfection.  
Cells were trypsinized, counted then placed in 24-well 8.0 m pore ThinCerts from 
BD Biosciences (Bedford, MA) allowed to migrate for 24 hr, fixed with 
formaldehyde, and then stained with hematoxylin.  Cells that migrated through the 
pores were then counted as described (812,904,1056). 
RT PCR   
RNA was isolated using Zymo Research Quick-RNA MiniPrep kit (Irvine, 
CA).  Quantification of mRNA (1-integrin) was performed using Bio-Rad iTaq 
Universal SYBER Green 1-Step Kit (Richmond, CA) using the manufacturer’s 
protocol with real-time PCR.  TATA Binding Protein (TBP) mRNA was used as a 
control to determine relative mRNA expression. 
Chromatin immunoprecipitation 
The chromatin immunoprecipitation (ChIP) assay was performed using the 
ChIP-IT Express magnetic chromatin immunoprecipitation kit (Active Motif, 
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Carlsbad, CA) according to the manufacturer's protocol.  Panc1, L3.6pL, 
MiaPaCa2, RKO and SW480 cancer cells were treated with DMSO, DIM-C-
pPhOH (15, 20 M), or DIM-C-pPhCO2Me (15, 20 M) for 24 hr.  Cells were then 
fixed with 1% formaldehyde, and the cross-linking reaction was stopped by 
addition of 0.125 M glycine.  After washing twice with phosphate-buffered saline, 
cells were scraped and pelleted.  Collected cells were hypotonically lysed, and 
nuclei were collected.  Nuclei were then sonicated to the desired chromatin length 
(∼200 to 1,500 bp).  The sonicated chromatin was immunoprecipitated with 
normal IgG, p300 (Santa Cruz), Sp1 (Abcam), NR4A1 (Novus Biologicals), Sp3, 
Sp4 (Santa Cruz), or RNA polymerase II (pol II; Active Motif) antibodies and 
protein A-conjugated magnetic beads at 4C for overnight.  After the magnetic 
beads were extensively washed, protein-DNA cross-links were reversed and 
eluted.  DNA was prepared by proteinase K digestion followed by PCR 
amplification.  The primers for detection of the 1-integrin promoter region were 
5'- TCACCACCCTTCGTGACAC -3' (sense) and 5'-
GAGATCCTGCATCTCGGAAG-3' (antisense).  PCR products were resolved on 
a 2% agarose gel in the presence of RGB-4103 GelRed Nucleic Acid Stain. 
Western blot analysis 
Panc1, L3.6pL, MiaPaCa2, RKO and SW480 cancer cells (3.0 x 105 per 
well) were seeded in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium 
supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed 
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to attach for 24 hr.  Cells were transfected with 100 nm of si1-integrin, siNR4A1, 
siSp1, siSp3, siSp4 (or in combination), or sip300 for 72 hr or treated with C-
DIM/NR4A1 antagonists.  Cells were analyzed by western blot as described 
previously (812,904,1056). Bands were also quantitated relative to β-actin with 
the DMSO/siCtl set at 1.0.  Low intensity bands (>90% decreased compared to 
the control) were assigned a value of <0.01. 
Small interfering RNA interference assay 
  SiRNA experiments were conducted as described previously 
(812,904,1056).  The siRNA complexes used in the study were as follows:  siGL2-
5': CGU ACG CGG AAU ACU UCG A; siNR4A1: SASI_Hs02_00333289[1], 
SASI_Hs02_00333290[2];  si1-integrin: SASI_Hs02_00333437[1], 
SASI_Hs01_00159474; siSp1:SASI_Hs02_003; sip300: SASI_Hs01_00052818; 
siSp3, SASI_Hs01_00211941; siSp4, SASI_Hs01_00114420.   
Statistical analysis 
Statistical significance of differences between the treatment groups was 
determined as previously described (812,904,1056). 
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Results 
NR4A1 regulates 1-integrin gene expression 
Figure 91.  1-Integrin is an NR4A1-regulated gene.  Pancreatic (A) and colon (B) cancer cells were transfected 
with siNR4A1, and 1-integrin (ITGB1) mRNA levels were determined by real time PCR as outlined in the Materials 
and Methods.  Pancreatic (C) and colon (D) cancer cells were treated with 15 and 20 M DIM-C-pPhOH (C-DIM8) 
and DIM-C-pPhCO2Me (C-DIM14) for 24 hr, and mRNA levels were determined by real time PCR as outlined in the 
Materials and Methods.  Results are expressed means  SE for three determinations per treatment group and 
significantly (p<0.05) decreased expression is indicated (*). 
  
Knockdown of NR4A1 by RNAi in pancreatic (Panc1, L3.6pL and 
MiaPaCa2) (Fig. 91A) and colon (RKO and SW480) (Fig. 91B) cancer cells 
Figure 91. 
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significantly decreased 1-integrin (ITGB1) mRNA levels as determined by real 
time PCR.  Moreover, treatment of the same cell lines with 15 and 20 M of the 
two C-DIM/NR4A1 antagonists DIM-C-pPhOH (C-DIM8) and the p-carboxymethyl 
analog (DIM-C-pPhCO2Me, C-DIM14) also decreased expression of 1-integrin 
mRNA levels (Figs. 91C and 91D).  Western blot analysis of whole cell lysates 
from Panc1, L3.6pL and MiaPaCa2 cells transfected with siCtl (non-specific 
oligonucleotide) or siNR4A1 showed that loss of NR4A1 resulted in decreased 
expression of 1-integrin, phosphorylated FAK (pFAK) and 5-integrin in all three 
cell lines (Fig. 92A).  Moreover, after knockdown of 1-integrin (si1-integrin), we 
also observed decreased expression of 1-integrin, 5-integrin and pFAK 
(downstream from 1-integrin).   
Similar results were observed in RKO and SW480 cells; knockdown of 
NR4A1 decreased 1-integrin, 5-integrin and pFAK, and knockdown of 1-
integrin also decreased pFAK and 5-integrin (Fig. 92B).  Treatment of the 
pancreatic cancer cell lines with 15 or 20 M DIM-C-pPhCO2Me and DIM-C-
pPhOH also decreased expression of 1-integrin, pFAK and 5-integrin (Figs. 
92C and 92D) and the NR4A1 antagonists caused similar effects in RKO and 
SW480 cells (Figs. 92E and 92F) demonstrating that NR4A1 regulates 1-integrin 
in both pancreatic and colon cancer cells and that knockdown of NR4A1 
(siNR4A1) or treatment with NR4A1 antagonist decreases 1-integrin expression.  
We also observed that DIM-C-pPhOH decreased 1-integrin and 5-integrin 
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expression in tumor lysates from an orthotopic pancreatic cancer model using 
L3.6pL cells (Suppl. Fig. A-10) (804). A previous study reported that knockdown 
of β1-integrin also decreased α5-integrin (1057). 
2NR4A1 antagonists inhibit cancer cell adhesion and migration 
  
Figure 92.  NR4A1 regulates 1-integrin and 1-integrin-regulated genes.  Pancreatic (A) and colon (B) cancer 
cells were transfected with siNR4A1 or si1-integrin, and whole cell lysates were analyzed by western blots as 
outlined in the Materials and Methods.  Pancreatic cancer cells were treated with DIM-C-pPhCO2Me (C-DIM14) 
(C) and DIM-C-pPhOH (C-DIM8) (D), and colon cancer cells were treated with the same C-DIMs (E and F) for 24 
hr, and whole cell lysates were analyzed by western blots as outlined in the Materials and Methods.  Similar 
results were observed in more than one experiment for each panel. 
 
Figure 92. 
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1-Integrin regulates multiple pathways including cell migration and 
adhesion, and knockdown of NR4A1 by RNAi significantly decreased migration of 
Panc1, L3.6pL and MiaPaCa2 cells in a Boyden chamber assay (Fig. 93A) and 
similar results were observed in RKO and SW480 colon cancer cells transfected 
with siNR4A1 (Fig. 93B).  Migration of Panc1, L3.6pL and MiaPaCa2 cells was 
also significantly decreased after treatment with the NR4A1 antagonists DIM-C-
pPhOH and DIM-C-pPhCO2Me (Figs. 93C and 93D) and similar results were 
observed in RKO and SW480 cells treated with the same compounds (Figs. 93E 
and 93F).  Results demonstrate a dose dependent response in migration and this 
coincided with the data obtained from siNR4A1 treatment.  We also used 
pancreatic cancer cell lines BxPC3 and the colon cancer cell line HCT116 and 
similar results were obtained (data not shown) with siNR4A1 and using the NR4A1 
anatgonists DIM-C-pPhOH and DIM-C-pPhCO2Me. 
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Figure 93.  NR4A1 regulates pancreatic and colon cancer cell migration.  Pancreatic (A) and colon (B) cancer cells 
were transfected with siCtl (control) or siNR4A1, and migration was determined in a Boyden chamber assay.  
Pancreatic cancer cells were treated with DIM-C-pPhOH (C) and DIM-C-pPhCO2Me (D) and colon cancer cells were 
treated with DIM-C-pPhOH (E) and DIM-C-pPhCO2Me (F) for 24 hr and migration was determined in a Boyden 
chamber assay as outlined in the Materials and Methods.  Each experiment was carried out in triplicate, and results 
are expressed as mean  SE and significantly (p<0.05) decreases in migration are indicated (*). 
 
Figure 93. 
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We also investigated the antimigratory effects of DIM-C-pPhCO2Me in 
pancreatic cancer cells after knockdown of NR4A1 or 1-integrin.  DIM-C-
pPhCO2Me decreased migration; however, in cells depleted of NR4A1 or 1-
integrin minimum inhibition was observed in cells after treatment with DIM-C-
pPhCO2Me (Fig. 94A) and similar results were observed in colon cancer cells (Fig. 
94B) and also with DIM-C-pPhOH (Suppl. Fig. A-11).  These results not only 
confirm the importance of both NR4A1 and 1-integrin in cell migration but also 
demonstrate that in the absence of 1-integrin, DIM-C-pPhCO2Me-mediated 
antagonism of other NR4A1-mediated pro-oncogenic pathways has minimal 
effects on cell migration.  Moreover, in pancreatic and colon cancer cells 
transfected with siNR4A1, the resulting decreased migration was rescued by 1-
integrin (ITGB1) gene overexpression (Fig. 94C).  Previous studies show that 
NR4A1-dependent anticancer activities of C-DIMs in colon and pancreatic cancer 
cells were due to modulation of nuclear NR4A1-mediated changes in gene 
expression (803-806) and this contrasted to several apoptosis-inducing agents 
which cause nuclear export of NR4A1 [(reviewed in 905)].  This was also 
confirmed in this study showing that the inhibitory effects of DIM-C-pPhCO2Me on 
cell migration in pancreatic (Fig. 94D) and colon (Fig. 94E) cancer cells were 
comparable in the absence or presence of the nuclear export inhibitor leptomycin 
B (LMB) demonstrating that the effects of the antagonist on NR4A1 (and 1-
integrin) were nuclear effects and not associated with receptor export.   
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Figure 94.  1-Integrin-dependent migration is dependent on NR4A1.  Pancreatic (A) and colon (B) cancer cells 
were treated with DMSO or 20 M DIM-C-pPhCO2Me alone or after transfection with siCtl (control), siNR4A1 or 
si1-integrin, and migration was determined in a Boyden chamber assay as outlined in the Materials and Methods.  
(C) Pancreatic and colon cancer cells were transfected with siCtl (control), siCtl+1-integrin (ITGB1) expression 
plasmid, siNR4A1, and siNR4A1+1-integrin expression plasmid, and cell migration was determined in a Boyden 
chamber assay.  Pancreatic (D) and colon (E) cancer cells were treated with DMSO, 20 M DIM-C-pPhOH or DIM-
C-pPhCO2Me alone or in combination with leptomycin for 24 hr, and migration was determined in a Boyden 
chamber assay.  Results are expressed as mean  SE for three separate determinations for each treatment group 
and significant (p<0.05) inhibition of migration (*) and rescue by 1-integrin overexpression (**) (C) are indicated. 
Figure 94. 
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Extracellular matrix components such as fibronectin are ligands for 
integrins and induce - and -integrin heterodimer formation and activation of 
downstream pathways.  Fibronectin-induced adhesion was investigated using BD-
coated fibronectin in 24-well plates and transfection of pancreatic (Fig. 95A) and 
colon (Fig. 95B) cancer cells with siNR4A1 or si1-integrin significantly decreased 
adhesion demonstrating that like 1-integrin, NR4A1 plays a role in cell adhesion. 
This was further confirmed in pancreatic (Fig. 95C) and colon (Fig. 95D) cancer 
cells treated with DIM-C-pPhOH and DIM-C-pPhCO2Me which significantly 
inhibited fibronectin-mediated adhesion  Thus, NR4A1 regulation of 1-integrin 
maintains adhesion in cancer cells and this can also be significantly inhibited by 
NR4A1 antagonists or knockdown of NR4A1. 
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Figure 95.  NR4A1 inactivation decreases cancer cell adhesion.  Pancreatic (A) and colon (B) cancer cells were 
transfected with siCtl (control), siNR4A1 and si1-integrin, and cell adhesion was determined as outlined in the 
Materials and Methods.  Pancreatic (C) and colon (D) cancer cells were treated with DIM-C-pPhOH or DIM-C-
pPhCO2Me for 24 hr, and cell adhesion was determined as outlined in the Materials and Methods.  Results are 
expressed as means  SE for three replicate determinations for each treatment group and significant (p<0.05) 
inhibition of adhesion is indicated (*). 
 
Figure 95. 
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Mechanism of NR4A1 regulation of 1-integrin 
 Previous studies in breast cancer cells showed that 1-integrin is regulated 
by a NR4A1/p300/Sp1 complex bound to a proximal GC-rich region of the 1-
integrin promoter (Fig. 96A) (903) and this same complex also regulates survivin 
expression in pancreatic and colon cancer cells (804,806).  The functional role of 
these complexes was investigated by RNAi, and knockdown of p300 decreased 
1-integrin protein expression (Fig. 96B) in the five pancreatic and colon cancer 
cell lines and this paralleled the effects observed after knockdown of NR4A1 or 
treatment with NR4A1 antagonists (Fig. 92).  In a separate experiment, cells were 
transfected with siSp1, and decreased expression of 1-integrin was observed 
only in SW480 cells (Fig. 96C) and this corresponded with the role of Sp1 in 
regulating 1-integrin in breast cancer cells (903).  Interestingly, knockdown of 
Sp1 also decreased expression of p300 in SW480 cells and this may also 
contribute to the decreased expression of 1-integrin.  However, since Sp1 
knockdown did not affect 1-integrin expression in Panc1, L3.6pL, MiaPaCa2 and 
RKO cells (data not shown), we further investigated the role of Sp3 and Sp4 in 
regulation of 1-integrin using lysates from a previous study on suppression of Sp 
proteins (763).  Figure 6D shows that knockdown of Sp4 and all three Sp proteins 
combined (siSp1/3/4) decreased 1-integrin expression in all four cell lines and in 
L3.6pL cells, knockdown of Sp3 also decreased 1-integrin expression.  Thus, the 
role of Sp1, Sp3 and Sp4 in NR4A1-dependent regulation of 1-integrin is cell 
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context dependent.  The effects of Sp1, Sp3 and Sp4 (singly and combined) 
knockdown in RKO cells were not previously determined and it was evident that 
Sp3 and Sp4 but not Sp1 coregulated each other (Fig. 96E) from their respective 
GC-rich promoters (1028,1071).  Figure 96F summarizes results of ChIP assays 
on interactions with the GC-rich sequence of the 1-integrin promoter in all five 
pancreatic and colon cancer cell lines.  In untreated cells, pol II, NR4A1, Sp1, 
Sp3, Sp4 and p300 were bound to the GC-rich region with one exception; Sp3 
binding was barely detectable in SW480 cells.   
Treatment with the two NR4A1 antagonists (C-DIM8 and C-DIM14) 
induced similar effects on promoter interactions but differed in the magnitude of 
the response for some factors.  Treatment with NR4A1 antagonists decreased pol 
II and NR4A1 interaction to the 1-integrin promoter in all five cell lines and Sp1 
was decreased only in SW480 cells.  Sp3 interactions were variable (increased, 
decreased and unchanged) and Sp4 was decreased in all cells with the exception 
of SW480 cells.  The NR4A1 antagonists decreased p300 interactions with the 
1-integrin promoter in SW480 and RKO colon cancer cells but not in the 
pancreatic cancer cell lines.  These results demonstrate that the effects of NR4A1 
antagonists on the NR4A1/p300/Sp interactions with the 1-integrin promoter are 
complex and cell context dependent with DNA-bound Sp4 being a major factor 
based on the knockdown and ChIP assays (Fig. 96D).  This is the first example of 
an important role for NR4A1/Sp4-mediated transactivation, and examples of other 
genes regulated by this complex are currently being investigated.    
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Figure 96.  Mechanism of NR4A1 regulation of 1-integrin gene expression.  (A) 1-Integrin promoter and proximal 
GC-rich sequence.  (B) Pancreatic and colon cancer cells were transfected with siCtl (control) and sip300, and 
whole cell lysates were analyzed by western blots as outlined in the Materials and Methods.  (C) SW480 cells were 
transfected with siCtl (control), siSp1 and sip300, and whole cell lysates were analyzed by western blots.  (D) RKO, 
Panc1, L3.6pL and MiaPaCa2 lysates from cells transfected with siCtl (control), siSp1, siSp3, siSp4 or siSp1,3,4 
were obtained from a previous study (42) and analyzed by western blots.  (E) Using a similar protocol, Sp proteins 
were also knockdowned in RKO cells and analyzed for different Sp proteins by western blots.  [Note:  RKO cells 
were not included in a previous study on the effects of Sp knockdown in multiple cancer cell lines (42).]  (F) 
Pancreatic and colon cancer cells were analyzed in ChIP assays to determine interactions with the GC-rich region 
of the 1-integrin promoter as outlined in the Materials and Methods.  C-DIM8 = DIM-C-pPhOH; C-DIM14 = DIM-C-
pPhCO2Me. 
Figure 96. 
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Discussion 
 Integrins are heterodimeric cell surface receptors that consist of an - and 
-subunit and these receptors play critical roles in maintaining cellular 
homeostasis and also in several human pathologies.  There are 18 different  and 
8 different  integrin subunits and among the 24 /-integrin heterodimers, 1-
integrin forms the largest subgroup of 12 receptor complexes (840-842,844,1072).  
1-Integrin heterodimers interact with other signaling pathways and activate 
multiple genes and kinases such as focal adhesion kinase resulting in the 
induction of cell adhesion, migration and invasion.  The role of integrins in multiple 
diseases has spurred studies on development of drugs that target integrins and 
these include antibodies, peptides that inhibit heterodimer formation, and other 
small molecules (841,842,844).  However, the success of these agents in cancer 
chemotherapy has been limited and integrin inhibitors have not been approved for 
clinical applications in cancer chemotherapy. 
 C-DIMs have been identified as a novel class of NR4A1 ligands that 
modulate nuclear NR4A1-mediated gene expression and associated pathways 
(803,804,806,812, 904,1052,903).  DIM-C-pPhOH and DIM-C-pPhCO2Me inhibit 
mTOR, decrease cell proliferation and survival, and induce ROS in multiple cancer 
cell lines where these compounds act as NR4A1 antagonists (803,805).  Our 
recent study showed that these NR4A1 ligands also inhibit breast cancer cell 
migration through inhibition of 1-integrin expression which is an NR4A1-
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regulated gene in breast cancer cells (903).  There is also evidence that 1-
integrin is a negative prognostic factor for colon and pancreatic patients and plays 
an important role in cancer cell migration/invasion and metastasis (1056-1067).  It 
was evident from the results of RNAi studies that decreased expression of NR4A1 
resulted in decreased expression of 1-integrin RNA and protein, 5-integrin and 
a 1-integrin-activated FAK gene phosphorylation (Figs. 91A, 91B, 92A and 92E).  
Moreover, siNR4A1 also decreased 1-integrin-regulated migration and adhesion 
(Figs. 93 and 95) and the effects of NR4A1 or 1-integrin knockdown were 
comparable indicating that NR4A1 regulates 1-integrin in pancreatic and colon 
cancer cells as previously observed for breast cancer cell lines (903).  We also 
observed that knockdown of NR4A1 by RNAi or treatment with DIM-C-pPhOH and 
DIM-C-pPhCO2Me gave comparable results demonstrating that these C-DIMs act 
as NR4A1 antagonists to decrease 1-integrin expression and thereby represent 
a novel class of agents targeting 1-integrin in pancreatic and colon cancer. 
 Although NR4A1 regulates expression of genes through binding as a 
monomer or dimer to cognate response elements in breast cancer cells, NR4A1 
regulates expression of 1-integrin by cooperative interactions of NR4A1 and 
p300 with promoter DNA (GC-rich)-bound Sp1 (903).  NR4A1/p300 also induced 
survivin expression through interactions with Sp1 bound to the GC-rich survivin 
promoter (804).  Results of RNAi and ChIP assays showed that in SW480 colon 
cancer cells, 1-integrin was regulated by an NR4A1/p300/Sp1 complex bound to 
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the proximal GC-rich site of the 1-integrin promoter (Fig. 96A).  ChIP assays 
showed that Sp1, Sp3 and Sp4 bound the proximal GC-rich site in the 1-integrin 
promoter; however, it is clear from Sp knockdown studies that the functional Sp 
protein was cell context dependent (Fig. 96C and 96D).  Thus, Sp4 and to a lesser 
extent Sp3 in combination with NR4A1 and p300 also regulate 1-integrin 
expression is some colon and pancreatic cancer cell lines and this contrasts to 
previous studies in breast cancer cells where β1-integrin is an NR4A1/p300/Sp-1 
regulated gene (903).  The reason for the cell selective and functional role of Sp1, 
Sp3 and Sp4 in regulating 1-integrin expression via an NR4A1/p300/Sp complex 
is unclear and is currently being investigated. 
 In summary, results of this study demonstrate the role of NR4A1 in 
regulation of pancreatic and colon cancer cell migration through transcriptional 
activation of 1-integrin which is an NR4A1/p300/Sp-regulated gene.  This 
observation is consistent with previous studies demonstrating that NR4A1 
regulates multiple pro-oncogenic genes/pathways in solid tumors.  We also show 
that C-DIM/NR4A1 antagonists represent a novel class of drugs that target 1-
integrin in pancreatic and colon cancer, and current studies are focused on 
developing these compounds for future clinical applications. 
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CHAPTER VIII 
PENFLURIDOL REPRESSES INTEGRIN EXPRESSION IN BREAST CANCER 
THROUGH INDUCTION OF REACTIVE OXYGEN SPECIES AND 
DOWNREGULATION OF SP TRANSCRIPTION FACTORS 
 
Introduction 
 Repositioning clinically-approved drugs for cancer chemotherapy has 
several advantages including a more rapid drug approval process coupled with 
potential development of mechanism-based compounds that can be clinically 
used to target important pro-oncogenic pathways.  This approach has been 
particularly successful with non-steroidal antiinflammatory drugs (NSAIDs) and 
antidiabetics such as metformin (1073,1074).  Phenothiazine-derived 
antipsychotic drugs such as thioridazine and chlorpromazine exhibit 
anticarcinogenic activity in several different cancer cell lines (1075-1081).  More 
recent studies have demonstrated that penfluridol, another typical antipsychotic 
drug of the diphenylbutylpiperidine class, also inhibits breast and pancreatic 
cancer cell growth (1081,1082).  For example, in pancreatic cancer a series of 
phenothiazene analogs induced apoptosis and inhibited growth and colon 
formation, and more detailed studies with penfluridol indicated that induction of 
protein phosphatase 2A (PP2A) was a key effect of this compound (1081).  
Penfluridol exhibited antimetastatic activity in triple negative breast cancer cells 
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and inhibited tumor growth and brain metastasis in three different in vivo models 
and the key elements were inhibition of 6- and 4-integrin expression (1082).  
However, the mechanisms of the penfluridol-induced responses were not well 
defined, and this limits potential clinical applications of the compound. 
 Recent studies in this laboratory showed that 1- and 3-integrin 
expression in breast cancer cells is regulated by specificity protein 1 (Sp1) 
transcription factor (TF) in combination with the orphan nuclear receptor 4A1 
(NR4A1, Nur77, TR3) which acts as a nuclear cofactor (903).  Many of the effects 
observed in breast and other cancer cell lines treated with penfluridol and other 
phenothiazine derivatives are similar to that observed after knockdown of Sp 
transcription factors Sp1, Sp3 or Sp4 or after treatment with agents that target Sp 
TFs (645,646,648,763,996,903,1082-1084).  For example, knockdown of Sp1, 
Sp3 or Sp4 individually or combined decreased proliferation and 
migration/invasion of breast (MDA-MB-231 and SKBR3) and other cancer cell 
lines (763) and similar results were observed for drugs that repress Sp TF 
expression (645,646,648,996,1083,1084).  Moreover, the effects of penfluridol 
and other phenothazines on inhibition of several genes including cyclin D1, bcl-2, 
vascular endothelial growth factor (VEGF) receptors, myc and activation/cleavage 
caspase-3/PARP (1075-1082) have also been observed after Sp knockdown 
(645,646,648,763,996,903,1082-1084).  It was recently reported that the 
antimetastatic activity of penfluridol in triple negative breast cancer cells was 
related to downregulation of 6- and 4-integrin expression (1082); however, 
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since both integrin gene promoters are GC-rich, it is possible that Sp1 and other 
Sp TFs may regulate expression of 6- and 4-integrins as well as 5-integrin 
(1085-1087). 
 Therefore, we hypothesize that the mechanism of action of penfluridol as 
an antimetastatic agent for triple negative breast cancer is due to downregulation 
of Sp TFs.  This hypothesis was confirmed in this study which shows that 
penfluridol induces reactive oxygen species (ROS) in breast cancer cells and 
ROS-dependent downregulation of Sp1, Sp3 and Sp4 and Sp-dependent genes 
including 6-, 5-, 1- and 4-integrins which are also coregulated by NR4A1. 
 
Materials and Methods 
Cell lines and antibodies   
Breast cancer (SKBR3, MDA-MB-231) cell lines were purchased from 
in the presence of 5% CO2 in Dulbecco’s modified Eagle’s medium/Ham’s F-12 
medium with 10% fetal bovine serum with antibiotic.  Dulbecco’s Modified Eagle’s 
Medium was purchased from GenDepot (Barker, TX).  Penfluridol and 36% 
formaldehyde were purchased from Sigma-Aldrich (St. Louis, MO).  Glutathione 
(GSH) reduced free acid was purchased from Millipore (Temecula, CA).  
Hematoxylin was purchased from Vector Laboratories (Burlingame, CA).  
Apoptotic, Necrotic, and Healthy Cells Quantification Kit was purchased from 
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Biotium (Hayward, CA).  Antibodies were purchased as outlined in Supplementary 
Table 1.  
Cell proliferation assay and Annexin V staining 
Cell proliferation assays were carried out as described previously (11-13), 
and changes in cell number were determined by Coulter Z1 cell counter.  Annexin 
V staining used the Vybrant apoptosis kit according to the manufacturer’s 
protocol.   
Boyden chamber assay   
SKBR3 and MDA-MB-231 cancer cells (3.0 x 105 per well) were seeded in 
Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 
2.5% charcoal-stripped fetal bovine serum and were allowed to attach for 24 hr.  
Cells were seeded and subsequently treated with varying concentrations of 
penfluridol for 24 hr (+/- GSH, 3 hr prior to treatment).  Cells were trypsinized, 
counted, placed in 12-well 8.0 µm pore ThinCerts from Greiner Bio-one (Monroe 
, NC), allowed to migrate for 24 hr, fixed with formaldehyde, and then stained with 
hematoxylin.  Cells that migrated through the pores were then counted as 
described.   
RT-PCR 
miRNA was isolated using the mirVana miRNA isolation kit (Ambion, 
Austin, TX) according to the manufacturer's protocol.  Quantification of miRNA 
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(RNU6B and miR-17, miR-20a, and miR-27a) was done using the TaqMan miRNA 
assay kit (Life Technologies) according to the manufacturer's protocol with real-
time PCR.  U6 small nuclear RNA was used as a control to determine relative 
miRNA expression.   
Western blot analysis  
SKBR3 and MDA-MB-231 cancer cells (3.0 x 105 per well) were seeded in 
Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 
2.5% charcoal-stripped fetal bovine serum and were allowed to attach for 24 hr.  
Cells were treated with varying doses of penfluridol for 24 hr.  Cells were analyzed 
by western blot as described previously.   
Small interfering RNA interference assay  
siRNAs used are outlined in Supplementary Table 4.  SiRNA experiments 
were conducted as described previously.   
Chromatin immunoprecipitation  
The chromatin immunoprecipitation (ChIP) assay was performed using the 
ChIP-IT Express magnetic chromatin immunoprecipitation kit (Active Motif, 
Carlsbad, CA) according to the manufacturer's protocol.  SKBR3 and MDA-MB-
231 cells were treated with DMSO, DIM-C-pPhOH (15 or 20 μM), DIM-C-
) for 24 hr, or penfluridol (5 μM) for 3 or 6 hr.  Cells were 
then fixed with 1% formaldehyde, and the cross-linking reaction was stopped by 
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addition of 0.125 M glycine.  After washing twice with phosphate-buffered saline, 
cells were scraped and pelleted.  Collected cells were hypotonically lysed, and 
nuclei were collected.  Nuclei were then sonicated to the desired chromatin length 
(∼200 to 1,500 bp).  The sonicated chromatin was immunoprecipitated with 
normal IgG, p300, Sp1, Sp3, Sp4, NR4A1, or RNA polymerase II antibodies and 
protein A-conjugated magnetic beads at 4°C for overnight.  After the magnetic 
beads were extensively washed, protein-DNA cross-links were reversed and 
eluted.  DNA was prepared by proteinase K digestion followed by PCR 
amplification.  Primers used for detecting PCR products are listed in 
Supplementary Table 1.  PCR products were resolved on a 2% agarose gel in the 
presence of RGB-4103 GelRed Nucleic Acid Stain.   
Xenograft studies  
Female athymic nude mice 4-6 old were purchased, and MDA-MB-231 
cancer cells (2.0 x106 cells) were suspended in Matrigel (1:1 ratio) and injected 
into the mammary fat pad of athymic nude mice.  When tumors became palpable 
(150-200 mm3), mice were randomly assigned to control (corn oil vehicle) and 
penfluridol (10 mg/kg/day), and then treated every day for 19 days.  Tumor 
volumes, tumor weights, and tumor lysates were determined and analyzed as 
previously described (645,646,648).   
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Generation and measurement of ROS 
Cellular ROS levels were ascertained using the cell permeable probe CM-
H2DCFDA (5-(and-6)-chloromethyl-2'7'-dichlorodihydrofluorescein diacetate 
acetyl ester) from Invitrogen (Grand Island, NY).  CM-H2DCFDA is non-
fluorescent until cleavage of the acetyl groups by intracellular esterases and 
oxidation that transpires within the cell.  Cells were pretreated for 3 hr with 
antioxidant glutathione (GSH, 5 mM) or N-acetyl cysteine (NAC, 5 mM), then 
subsequently treated with respective doses of penfluridol for 3, 6 or 24 hr.  The 
antioxidant at the time of treatment of penfluridol was not washed away and 
penfluridol treatment was with antioxidant cotreatment.  Following treatment, cells 
plated on a 6-well culture plate were trypsinized, neutralized, then loaded with 10 
µM of probe for 20 min, washed once with serum free medium, and then ROS 
was measured by flow cytometry using Accuri’s C6 Flow Cytometer (Accuri, Ann 
Arbor, MI).  
Plasmids 
pCDH-puro-cMyc was a gift from Jialiang Wang (Addgene plasmid 
#46970) and pCDH-CMV-MCS-EF1-Puro was obtained from System Biosciences 
(Palo Alto, CA).  MDA-MB-231 and SKBR3 breast cancer cells were seeded (1.2 
x 105 per well) in 6-well plates in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 2.5% charcoal-stripped fetal bovine serum and left to attach 
for 24 hr.  Plasmid transfection was performed using Lipofectamine 2000 reagent 
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according to the manufacturer’s protocol.  Cells were transfected with c-Myc-
overexpressing (pCDH-puro-cMyc) or empty control vector (pCDH-CMV-MCS-
EF1-Puro) for 6 hr in fresh 2.5% charcoal-stripped fetal bovine serum DMEM.  
After 6 hr, medium was then replaced with fresh 2.5% charcoal-stripped fetal 
bovine serum DMEM and treated with either DMSO or 5 µM penfluridol.  Cells 
were then harvested for western blot analysis. 
Statistical analysis 
Statistical significance of differences between the treatment groups was 
determined as previously described (645,646,648).   
 
Results 
Drugs that downregulate Sp TFs act through ROS-dependent 
and -independent pathways (996), and results in Figure 97A show that different 
concentrations of penfluridol induced ROS in MDA-MB-231 and SKBR3 cells after 
treatment for 3 and 6 hr.  Moreover, after cotreatment with 5 mM GSH, the 
penfluridol-mediated induction of ROS as detected using the fluorescent probe 
CM-H2DCFD4 was significantly attenuated.  The role of penfluridol-induced ROS 
on cell proliferation (Fig. 97B), Annexin V staining (apoptosis) (Fig. 97C), and 
migration in a Boyden chamber assay (Fig. 97D) was also determined in MDA-
MBA-231 and SKBR3 cells treated with penfluridol alone and in combination with 
GSH.  Penfluridol inhibited cell growth and induced Annexin V staining, and these 
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results were consistent with previous studies.  However, we now show that all of 
these responses were ROS-dependent and significantly attenuated after 
cotreatment with GSH as well as N-acetyl cysteine (NAC) (Suppl. Fig. A-12). 
 
 
Figure 97.  Penfluridol induces ROS and ROS-dependent responses in breast cancer cells.  (A) MDA-MB-231 and 
SKBR3 cells were treated with DMSO, 2.5 or 5.0 M penfluridol alone, or in combination with 5 mM GSH for 3 hr, 
and ROS activity was determined as outlined in the Materials and Methods.  The cells were treated as outlined 
above for 24 hr and effects on cell proliferation (B), Annexin V staining (C), and migration (D) in a Boyden chamber 
assay were determined as outlined in the Materials and Methods.  Results are expressed as means  SE for 3 
replicates for each data points and significant (p<0.05) modulation by penfluridol (*) and reversal by GSH (**) are 
indicated. 
Figure 97. 
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Previous studies with multiple ROS-inducing anticancer agents show that 
ROS decreases Sp TFs (645,646,648,1083,1084), and results in Figures 98A and 
98B show that penfluridol decreased expression of Sp1, Sp3 and Sp4 in MDA-
MB-231 and SKBR3 cells and cotreatment with GSH attenuated these effects. 
Similar results were observed with knockdown of c-Myc by siRNA using more than 
one oligonucleotide (Supplemental Figure A-12) A recent report showed that 
penfluridol decreased focal adhesion kinase (FAK) phosphorylation and activated 
(cleaved) caspase 3 in breast cancer cells (1082) and this was also observed in 
MDA-MB-231 (Fig. 98C) and SKBR3 (Fig. 98D) cells, and these responses were 
attenuated by cotreatment with GSH. Overexpression of Myc (Suppl. Fig. A-13) 
or knockdown of ZBTB10 (Suppl. Fig. A-14) also ameliorates Sp protein 
expression.  We also observed that penfluridol induced ROS-dependent PARP 
cleavage (apoptosis) in both cell lines, confirming that induction of apoptosis and 
the growth and migration inhibitory effects of penfluridol in breast cancer cells 
were ROS-dependent.  We also demonstrate that H2O2 scavenger catalase 
ameliorates Sp protein expression (Fig. 98E) and the specificity of penfluridol for 
Sp proteins by inhiting luciferase expression controlled by a promoter, which 
contains GC rich Sp consensus binding sites (Fig.98F) 
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Penfluridol activates the ROS ⊣ Myc ⊣ miR-27a/miR-20/17a → ZBTB 
pathway. 
ROS induces a cascade of events which lead to ZBTB10/ZBTB4/ZBTB34-
mediated repression of Sp TFs  (Fig. 99A) (648,1083), and results in Figure 3B 
show that penfluridol decreased cMyc expression in MDA-MB-231 and SKBR3 
cells and this response was totally reversed after cotreatment with GSH.  
 
Figure 98.  Penfluridol induces ROS-dependent modulation of Sp1, Sp3, Sp4 and other responses in breast cancer 
cells.  MDA-MB-231 and SKBR3 cells were treated with different concentrations of penfluridol alone or in 
combination with GSH for 24 hr, and whole cell lysates were analyzed for Sp1, Sp3 and Sp4 (A and B, respectively) 
and other responses (C and D, respectively) as outlined in the Materials and Methods.  Pretreatment with catalase 
also ameliorated penfluridol-mediated Sp downregulation (E).  Penfluridol repressed luciferase induction from 
GC-rich Sp1-consensus promoters (F). 
Figure 98. 
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 It was reported that ROS-dependent cMyc downregulation is due to rapid shifts 
of chromatin-modifying complexes from non-GC-rich to GC-rich (e.g. cMyc) gene 
promoters (648,781,1083), and Figure 99C shows that cMyc was rapidly 
decreased in MDA-MB-231 and SKBR3 cells after treatment with penfluridol.   
Sp1, Sp3 and Sp4 were also rapidly decreased in one or more cell lines 
and this has previously been observed for other ROS inducers (648,1083) and is 
consistent with their GC-rich promoters (1027-1029).  ChIP analysis showed that 
pol II association with the GC-rich cMyc promoter was decreased after treatment 
of MDA-MB-231 and SKBR3 cells with penfluridol for 3 and 6 hr, and this was 
accompanied by an increase in the inhibitory H3K27me3 and a decrease in the 
activating H3K4me4 and H4K16Ac histone marks (Fig. 99D).  The ROS-
dependent decrease in cMyc was accompanied by a decrease in the cMyc-
regulated miR-27a and miR-20a/miR-17 after treatment penfluridol and this 
decrease was also inhibited after cotreatment with GSH (Fig. 99E).  Penfluridol-
mediated repression of miR-27a and miR-20/miR-17 (part of the miR-17-92 
cluster) resulted in induction of the miR-regulated Sp repressors ZBTB10 and 
ZBTB4, respectively, and this induction response was also attenuated in cells 
cotreated with GSH.  These results demonstrate that the mechanism of 
penfluridol-induced ROS is initiated by ROS-mediated epigenetic repression of 
cMyc (Fig. 99A) and this has previously been observed for 
phenethylisothiocyanate (PEITC) and HDAC inhibitors in pancreatic cancer and 
rhabdomyosarcoma (RMS) cells, respectively (648,1083).  
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Figure 99.  Mechanism of penfluridol-induced Sp downregulation.  (A) Molecular mechanism of drug-induced ROS 
and ROS effects on miR-ZBTB interactions and Sp downregulation (14).  MDA-MB-231 and SKBR3 cells were 
treated with penfluridol alone or in combination with GSH for 24 hr (B) or penfluridol alone for different times (C), 
and whole cell lysates were analyzed by western blots as outlined in the Materials and Methods.  (D) Cells were 
treated with 5 M penfluridol, and effects on interaction with the proximal GC-rich cMyc promoter were by ChIP 
assays as outlined in the Materials and Methods.  (E) Cells were treated as outlined in (B) and expression of 
microRNAs (miRs) was determined by real time PCR.  Penfluridol significantly (p<0.05) decreased all miRs and 
GSH significantly reversed these responses.  (F) Cells were treated as outlined in (B) and expression of ZBTB10 
and ZBTB4 were determined by western blot analysis as outlined in the Materials and Methods. 
Figure 99. 
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Penfluridol induces ROS-dependent repression of integrins 
 Penfluridol decreases 6- and 4-integrin in breast cancer cells (1082), 
and our results also show this same response in MDA-MB-231 and SKBR3 cells 
and cotreatment with GSH attenuated this effect (Fig. 100A).  We also observed 
that 5- and 1-integrin expression was also decreased by penfluridol and 
rescued after cotreatment with GSH (Figs. 100A and 100B) and this was 
consistent with our recent studies showing that 1-integrin is an Sp-regulated 
gene and 5-integrin appears to be coregulated with 1-integrin (903).  
Confirmation that 6, 5-, 4- and 1-integrin are Sp-regulated genes was 
determined by RNA interference where knockdown of one or more of Sp1 (siSp1), 
Sp3 (siSp3), Sp4 (siSp4) or all three Sps (siSp1,3,4) decreased expression of the 
integrins in MDA-MB-231 (Fig. 100C) and SKBR3 (Fig. 100D) cells.  Most of the 
four integrins were coregulated by two or all three of the Sp TFs; however, 6-
integrin and 1-integrin were regulated only by Sp4 (MDA-MB-231) and Sp1 
(SKBR3), respectively.  In addition, we also show that cMyc indirectly regulated 
integrin expression through Sp1.  Knockdown of cMyc by RNA decreased Sp1, 
Sp3 and Sp4 expression in MDA-MB-231 and SKBR3 cells (Fig. 100E), and the 
same treatment also decreased expression of 6-, 5-, 1- and 4-integrin in the 
same cell lines (Fig. 100F).  Thus, penfluridol activation of ROS results in cMyc 
downregulation, leading to decreased expression of Sp1, Sp3, Sp4 and Sp-
regulated genes 6-, 5-, 1- and 4-integrin.  
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Figure 100.  Penfluridol targets integrin expression via an ROS-cMyc (downregulation) pathway.  MDA-MB-231 (A) 
and SKBR3 (B) cells were treated with penfluridol alone or in combination with GSH, and whole cell lysates were 
analyzed by western blots.  Cells were transfected with oligonucleotides specifically targeted to Sp transcription 
factors [MDA-MB-231(C) and SKBR3 (D)] or cMyc (E and F), and whole cell lysates were analyzed by western blots.  
Whole cell lysates obtained after Sp knockdown in MDA-MB-231 and SKBR3 cells were generated in a previous 
study which also reports effects of these oligonucleotides on Sp1, Sp3 and Sp4 expression (C and D) (12).   
 
Figure 100. 
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Since the 6-, 5-, 1- and 4-integrins are Sp-regulated genes, we also 
investigated the effects of penfluridol on association of pol II and Sp1, Sp3, Sp4 
with the GC-rich regions of the integrin gene promoters (Fig. 101A) using a ChIP 
assay.  In addition, since we previously observed that NR4A1 and p300 act as 
cofactors for Sp-dependent activation of 1-integrin (903), the effects of 
penfluridol on their association with the integrin promoters was also determined.  
Figures 101B-101E show that pol II, Sp1, Sp3, Sp4, p300 and NR4A1 were all 
associated with the 6-, 4-, 5- and 1-integrin gene promoters as determined 
in a ChIP assay.  With the exception of p300, treatment of MDA-MB-231 and 
SKBR3 cells with penfluridol decreased association of Sp1, Sp3, Sp4 and NR4A1 
with the four integrin promoters, whereas the loss of p300 was promoter- and cell 
context-dependent.   
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Figure 101.  Penfluridol decreases interactions of Sp proteins and other nuclear factors with integrin gene 
promoters.  (A) Outline of GC-rich regions for 6-integrin (ITGA6), 4-integrin (ITGB4), 5-integrin (ITGA5) and 1-
integrin (ITGB1) gene promoters and primers targeting these regions.  Breast cancer cells were treated with DMSO 
and 5 M penfluridol, and interactions of Sp1, Sp3, Sp4 and other nuclear cofactors with the IGFA6 (B), ITGB4 (C), 
ITGA5 (D) and ITGB1 (E) gene promoters were determined in a ChIP assay as outlined in the Materials and 
Methods.   
 
Figure 101. 
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NR4A1/Sp regulation of integrins 
 Previous studies showed that NR4A1/Sp regulate expression of 1- and 
5-integrin in breast cancer cells, and knockdown of Sp or NR4A1 or treatment 
with an NR4A1 antagonist inhibits their expression (903).  We also demonstrate 
that penfluridol does not antagonize NR4A1 as demonstrated by luciferase assay 
(Suppl. Fig. A-15).  Panc1 cells transfected with a GAL4-NR4A1 chimera and a 
reporter gene containing a GAL4 response element can be used for screening 
NR4A1 antagonists (804,912), and penfluridol did not inhibit or activate this 
system (Suppl. Fig. S1).  Knockdown of NR4A1 (siNR4A1) or treatment with the 
NR4A1 antagonists 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-
pPhOH) or 1,1-bis(3'-indolyl)-1-1(p-carbomethoxyphenyl)methane (DIM-C-
pPhCO2Me) decreased expression of 6- and 4-integrin in MDA-MB-231 and 
SKBR3 cells (Fig. 102A and 102B) and similar results were previously observed 
for 1- and 5-integrin (903).  Treatment of MDA-MB-231 and SKBR3 cells with 
DIM-C-pPhOH (C-DIM8) or DIM-C-pPhCO2Me (C-DIM14) showed that these 
compounds induced loss of pol II from the 6- (Fig. 102C), 4- (Fig. 102D) and 
5- (Fig. 102E) integrin promoters in a ChIP assay and this was previously 
observed for the 1-integrin promoter (903).   
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Figure 102.  Integrin genes targeted by penfluridol are coregulated by Sp transcription factors and NR4A1.  Breast 
cancer cells were transfected with siNR4A1 (A) or treated with the NR4A1 antagonists DIM-C-pPhOH (C-DIM8) and 
DIM-C-pPhCO2Me (C-DIM14) (B), and whole cell lysates were analyzed by western blots.  Breast cancer cells were 
treated with DMSO and the two NR4A1 antagonists, and interactions of Sp1, Sp3, Sp4 and other nuclear cofactors 
with the ITGA6 (C), ITRG4 (D) and ITGA5 (E) gene promoters were determined in a ChIP assay.  The same 
interactions with the ITGB1 promoter were previously reported (11).  (F) Model of NR4A1/Sp interactions with GC-
rich integrin gene promoters and the differential targeting by penfluridol and NR4A1 antagonists. 
Figure 102. 
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Unlike penfluridol which decreased expression of Sp1, Sp3 and Sp4, 
resulting in loss of these TFs from the integrin promoters (Fig. 101), NR4A1 
antagonists or NR4A1 knockdown do not affect Sp expression (903) and their 
retention or loss from the integrin promoters is highly variable and gene promoter- 
and cell context-dependent.  This variability was observed for p300 (Figs. 102C-
102E) and also in our previous report (903).  Nevertheless, the results show that 
both penfluridol and NR4A1 antagonists downregulate expression of α5, α6-, β1- 
and β-4 integrin by selectively targeting the Sp and NR4A1 transcription factors, 
respectively, which are required for expression of the integrin genes (Fig. 102F).  
Treatment of athymic nude mice bearing MDA-MB-231 cells in an orthotopic 
model with penfluridol (10 mg/kg/day) decreased tumor volume over the treatment 
period (Fig. 103A) and inhibited tumor growth (Fig. 103B), and toxicity (organ 
damage or weight loss) was not observed.  Western blot analysis of lysates from 
control (solvent) and penfluridol-treated mice showed that penfluridol decreased 
expression of Sp1, Sp3 and Sp4, prototypical Sp-regulated genes (survivin and 
EGFR) including 6-, 5-, 1- and 4-integrin and induced apoptosis (Fig. 103C).  
These effects were also quantitated (Fig. 103D) and penfluridol significantly 
decreased or increased (PARP cleavage) compared to control protein set at 100% 
and normalized to -actin.  Thus, the in vivo results complement the in vitro studies 
demonstrating that the anticancer activities of penfluridol are ROS-dependent and 
this includes NR4A1/Sp-mediated downregulation of integrins. 
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Figure 103.  Penfluridol inhibits tumor growth in vivo.  Penfluridol (10 mg/kg/d) inhibit tumor volume (A) and weight 
(B) in athymic nude mice bearing MDA-MB-231 cells in an orthotopic model.  Western blot analysis of tumor 
lysates (C) and quantitation of various proteins (D and E) where control proteins normalized to -actin were set at 
100% and penfluridol-mediated changes (normalized to -action) compared to controls were determined as 
outlined in the Materials and Methods. 
Figure 103. 
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Discussion 
 Integrins are cell surface receptors that function as / heterodimers which 
are formed from the 18 alpha and 8 beta subunits, and the functions of the known 
24 /-integrin heterodimers are highly tissue-/cell type-specific.  In cancer cells, 
integrins are important for migration and invasion, and overexpression of some 
integrins in cancer patients is a negative prognostic factor (841,842).  Integrins 
play a key role in breast cancer stem cells and mammary tumors, and there is 
extensive evidence for the role of 1-, 4-, 5- and 6-integrins and their / 
heterodimers in breast cancer cell migration, invasion and metastasis (1088-
1094).  Although integrin inhibitors have been developed, their applications for 
cancer chemotherapy have been limited (841) and this is due, in part, to 1-3-
integrin switching in which drugs targeting 1-integrin induce 3-integrin 
(382,1095).  We recently showed that the orphan nuclear receptor NR4A1 
regulates expression of 1-integrin and treatment of breast cancer cells with bis-
indole-derived (C-DIMs) NR4A1 antagonists such as DIM-C-pPhOH and DIM-C-
pPhCO2Me decrease both 1- and 3-integrin expression and eliminate the 
switching pathway (903).  Both integrins are regulated by an NR4A1-Sp complex 
which binds to GC-rich regions of their gene promoters (Fig. 102F), suggesting 
that 1- and 3-integrin can be targeted by NR4A1 antagonists or drugs that target 
Sp transcription factors. 
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 The report that penfluridol decreases expression of 6- and 4-integrin 
(1082), coupled with previous reports showing that Sp proteins interact with the 
GC-rich regions of the 6- and 4-integrin gene promoters (1085,1086), suggests 
that the mechanism of action of penfluridol may be due to repression of Sp 
proteins.  We investigated 5-integrin expression which also has a GC-rich gene 
promoter (1087).  Using SKBR3 and MDA-MB-231 cells as a model, it was clear 
that penfluridol induced ROS and the resulting inhibition of cell growth and 
migration and induction of apoptosis were all inhibited after cotreatment with GSH 
(Fig. 97).  Subsequent experiments show that induction of ROS was the key factor 
in mediating downregulating Sp1, Sp3 and Sp4 through ROS-dependent 
epigenetic repression of cMyc, decreased expression of cMyc-regulated miR-27a 
and miR-20a/miR-17, and induction of the Sp repressors ZBTB10 and ZBTB4.  
This ROS-dependent pathway has previously been observed for other ROS 
inducers such as PEITC and HDAC inhibitors (648,1083).  The ROS-miR-ZBTB-
Sp pathway (Fig. 99A) has also been observed in cancer cells treated with a nitro-
aspirin derivative, celastrol, betulinic acid and curcumin; other ROS inducers 
including arsenic trioxide, ascorbate, hydrogen peroxide and t-butyl 
hydroperoxide also downregulate Sp1, Sp3 and Sp4 in cancer cell lines 
(645,648,769,981,983,1000,1084).  We also observed that penfluridol targeted 
Sp TFs and pro-oncogenic Sp-regulated genes in vivo and this was consistent 
with potent inhibition of tumor growth in an orthotopic model (Fig. 103). 
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 This paper also demonstrates that penfluridol-mediated downregulation of 
5-, 6-, 1 and 4-integrins is also ROS-dependent and Sp TFs regulate 
expression of these genes in breast cancer cell lines.  Moreover, like 1- and 3-
integrin (903), the 5-, 6- and 4-integrins are coregulated by NR4A1 and 
expression of this family of integrins is due to interactions of the NR4A1-Sp 
complex with their corresponding GC-rich gene promoter elements (Fig. 102G).  
Penfluridol does not exhibit NR4A1 antagonist activity but targets the integrins 
through repression of Sp TFs, whereas the C-DIM/NR4A1 antagonists inactivate 
the coactivator-like activity of NR4A1 (Fig. 102F).  Nuclear receptor-mediated 
activation of genes through interaction with DNA bound Sp TFs has been 
observed for several other receptors (1096) and like the integrins in this study can 
be targeted through inactivation of the receptor or downregulation of Sp TFs.  The 
identification of the mechanism of action of penfluridol coupled with the reported 
effectiveness of this compound as an inhibitor of breast cancer metastasis will 
facilitate the design of future clinical applications of this ROS inducer for breast 
cancer therapy. 
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CHAPTER IX 
MECHANISM OF NR4A1 REGULATION OF TGF--INDUCED MIGRATION 
AND EPITHELIAL TO MESENCHYMAL TRANSITION IN TRIPLE NEGATIVE 
BREAST CANCER CELLS 
 
Introduction 
Transforming growth factor  (TGF) signaling plays an important and 
complex role in cancer and exhibits both tumor-promoting and tumor-suppressor 
functions that are dependent on the cancer cell context (1097-1099).  For 
example, loss of TGF in immortalized but non-tumorigenic MCF-10A cell subtype 
resulted in enhanced growth due to a less differentiated phenotype and this was 
accompanied by a decreased population of early progenitor cells (1100).  In 
contrast, TGF stimulates later stage cancer cells to migrate and invade and this 
is linked to induction of epithelial to mesenchymal transition (EMT) and a more 
aggressive cancer cell phenotype (1097, 1101,1102).  TGF signaling is initiated 
by ligand-dependent TGF receptor activation which results in formation of an 
activated SMAD2/SMAD3-SMAD4 nuclear transcription factor complex (1103).  In 
contrast, SMAD7 functions as an inhibitory SMAD by recruiting factors leading to 
proteasome-dependent degradation of TGF receptor 1 (TGFBR1) (1104,1105). 
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Arkadia, RNF12 and Axin2 also play key roles in activation of TGF 
signaling by inducing polyubiquitination and degradation of inhibitory SMAD7 
(1105,1106), and a recent study demonstrated that the orphan nuclear receptor 
NR4A1 (Nur77, TR3) also has a critical role in SMAD7 degradation (822).  It was 
reported that NR4A1 induces Axin2 expression, and NR4A1 directly interacts with 
Axin2 and SMAD7 and is an obligatory factor for activation of SMAD7 degradation.  
This model was derived from studies on inflammatory cytokine-induced MDA-MB-
231 breast cancer cell invasion and showed that cytokine-induced NR4A1 was 
necessary for SMAD7 degradation and TGF-induced migration/invasion.   
Studies in this laboratory have investigated NR4A1-dependent pro-
oncogenic pathways in breast and other cancer cell lines and have developed 1,1-
bis(3-indolyl)-1-(p-substituted phenyl) methane (C-DIM) NR4A1 ligands that act 
as NR4A1 antagonists in cancer cell lines and tumors (788,803-
806,812,904,903).  In MDA-MB-231 breast cancer cells, we demonstrated that 
basal migration/invasion is dependent on NR4A1-regulated expression of 1-
integrin which can be inhibited by C-DIM/NR4A1 antagonist (903).  TGF 
markedly enhances MDA-MB-231 cell migration/invasion and, as previously 
reported (822), we observed that this response is NR4A1-dependent and could 
also be inhibited by C-DIM/NR4A1 antagonists.  Our studies demonstrated that 
the key inhibitory effect of the NR4A1 antagonist is to block nuclear export of 
NR4A1 and thereby prevent interactions with the cytosolic Axin2/RNF12/Arkadia-
SMAD7 complex.  
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In this study, we have further investigated the critical and essential role of 
NR4A1 in regulating TGF-induced migration/invasion and show that TGF-
induced nuclear export of NR4A1 is dependent on activation of the p38MAPK 
pathway.  We also show that TGF induces expression of both NR4A1 and -
catenin, and these responses are also p38-dependent.  However, induction of 
NR4A1 is dependent on -catenin and its interactions with LEF1/TCF3 and TCF4 
bound to the NR4A1 promoter.  These studies define a unique role for NR4A1 in 
TGF-induced migration and EMT in estrogen receptor (ER)-negative breast 
cancer cells and also demonstrate that NR4A1 antagonists block this response, 
indicating potential clinical applications for treatment of both early and late stages 
of this disease. 
 
Materials and Methods 
Cell lines, reagents, and antibodies 
Breast cancer (MDA-MB-231, H5887T, and SUM159) were purchased 
from American Type Culture Collection (Manassas, VA).  Cells were maintained 
37˚C in the presence of 5% CO2 in Dulbecco’s modified Eagle’s medium/Ham’s 
F-12 medium with 10% fetal bovine serum with antibiotic.  NR4A1, arkadia, 
immunofluoresent-grade arcadia (H00054778-M05) and RNF12 antibodies was 
purchased from Novus Biologicals (Littleton, CO). TGF-β was purchased from BD 
Biosystems (Bedford, MA). β-actin antibody, Dulbecco’s Modified Eagle’s 
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Medium, M2 Flag antibody, MG132 and 36% formaldehyde were purchased from 
Sigma-Aldrich (St. Louis, MO).   Hematoxylin was purchased from Vector 
Laboratories (Burlingame, CA).  β-catenin, GAPDH, p38, p-p38, p-NR4A1,  Axin2, 
Anti-rabbit IgG Fab2 Alexa Fluor® 488 or Anti-mouse IgG Fab2 Alexa Fluor®, 
phalloidin (Alexa Fluro® 555 Phalloidin),   leptomycin B, SP600125, SB202190, 
LY294002, PD98059 NR4A1 immunofluorescent antibody were purchased from 
Cell Signaling Technologies (Manassas, VA)  Smad 6/7 and ubiquitin antibody 
from Santa Cruz Biotech (Santa Cruz, CA); p84 antibody from GeneTex (Irvine, 
CA). 
Plasmids 
FLAG-NR4A1, FLAG-NR4A1-(A-B), and FLAG-NR4A1-(C-F) were 
synthesized in the lab using site directed mutagenesis. DDK-Myc-p38CA-(D176A; 
F327S), DDK-Myc-p38KD-(K53A), DDK-Myc-p38DN-(T180A;Y182F), DDK-Myc-
arkadia, , DDK-Myc-arkadia-(Δ405-989), DDK-Myc-arkadia-(Δ1-404), DDK-Myc-
arkadia- (241-404), and DDK-Myc-arkadia (C937A) were purchased from Origene 
Technologies (Rockville, MD).  Plasmids were transfected as described previously 
(891,892,910,941,942), media was removed and then cells were treated with 
respective compound. 
Boyden chamber assay 
MDA-MB-231, SUM159, and H5587T cancer cells (3.0 x 105 per well) were 
seeded in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium 
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supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed 
to attach for 24 h. Cells were seeded and subsequently treated with varying 
concentration of DIM-C-pPhOH or DIM-C-pPhCO2Me for 24 hours or 1 hr prior 
(+/- TGFβ [5ng/ml] 4 h cotreatment) or with 100 nm of siAxin2, siArkadia, 
siRNF12, siβ-catenin, siTAK1, siMKK3, siMKK6, sip38α, siTCF1, siTCF3, siTCF4, 
or siLEF1 for 48 hours.  Cells were trypsinized, counted then placed in 24-well 
8.0µm pore ThinCerts from BD Biosciences (Bedford, MA) allowed to migrate for 
24 hr, fixed with formaldehyde, and then stained with hematoxylin.  Cells that 
migrated through the pores were then counted as described 
(891,892,910,941,942). 
RT PCR 
RNA was isolated using Zymo Research Quick-RNA MiniPrep kit (Irvine, 
CA).  Quantification of mRNA (slug, snail, and NR4A1) was performed using 
Bio-Rad iTaq Universal SYBER Green 1-Step Kit (Richmond, CA) using the 
manufacturer’s protocol with real-time PCR.  TATA Binding Protein (TBP) mRNA 
was used as a control to determine relative mRNA expression.  The following 
primers were used: Slug: Forward primer: 5′ AGCAGTTGCACTGTGATGCC 3′, 
Reverse primer: 5′ ACACAGCAGCCAGATTCCTC 3′; Snail: Forward primer: 5′ 
TGCCCTCAAGATGCACATCC 3′, Reverse primer: 5′ 
TGACATCTGAGTGGGTCTGC 3′; NR4A1: Forward primer 5’ 
TCCCATATTGGGCTTGGATA 3’, Reverse primer: 5’ 
ATCTTGGGATTCTCCCTTCG 3’. 
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Immunoprecipitation 
MDA-MB-231 cancer cells (3.0 x 105 per well) were seeded in Dulbecco’s 
modified Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-
stripped fetal bovine serum and were allowed to attach for 24 h. The medium was 
then changed to DMEM/Ham F-12 medium contained 2.5% charcoal-stripped 
fetal bovine serum, and either DMSO or TGFβ(5 ng/ml) was added for 4 hr (after 
+/- pretreatment with leptomycin B (20 nM) for 24 hr or +/- pretreatment with +/- 
DIM-C-pPhOH (20 µM), DIM-C-pPhCO2Me (15 µM), SB202190 (30µM)  for 1 hr.,  
or transfection of DDK-Myc-p38CA, DDK-Myc-p38KD, DDK-Myc-p38DN, D-
NR4A1, FLAG-NR4A1-(A-B), FLAG-NR4A1-(C-F), DDK-Myc-arkadia, DDK-Myc-
arkadia (Δ405-989), DDK-Myc-arkadia (Δ1-404), DDK-Myc-arkadia (241-404), 
and DDK-Myc-arkadia (C937A) plasmids 6 hr. post transfection.   Protein A 
Dynabeads were prepared and binding of antibody with protein and protein-
protein interactions were isolated by Life technologies Immunoprecipitation Kit 
using Dynabeads coated with Protein A (Grand Island, NY) following 
manufacturer’s protocol.  Protein-protein interactions of interest were determined 
using western blot. 
Chromatin Immunoprecipitation 
The chromatin immunoprecipitation (ChIP) assay was performed using the 
ChIP-IT Express magnetic chromatin immunoprecipitation kit (Active Motif, 
Carlsbad, CA) according to the manufacturer's protocol.  MDA-MB-231 cells were 
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treated with DMSO or TGFβ (5 ng/ml) was added for 4 hr. (after +/- pretreatment 
with leptomycin B (20 nM) for 24 hr. or +/- pretreatment with +/- DIM-C-pPhOH 
(20 µM), DIM-C-pPhCO2Me (15 µM), SB202190 (30µM) for 1 hr., or DDK-Myc-
p38CA, DDK-Myc-p38KD, DDK-Myc-p38DN 6 hr. post transfection. Cells were 
then fixed with 1% formaldehyde, and the cross-linking reaction was stopped by 
addition of 0.125 M glycine. After washing twice with phosphate-buffered saline, 
cells were scraped and pelleted. Collected cells were hypotonically lysed, and 
nuclei were collected. Nuclei were then sonicated to the desired chromatin length 
(∼200 to 1,500 bp). The sonicated chromatin was immunoprecipitated with normal 
IgG, p300 (Santa Cruz), siSp1 (Abcam), NR4A1 (Novus Biologicals), or RNA 
polymerase II (pol II; Active Motif) antibodies and protein A-conjugated magnetic 
beads at 4°C for overnight. After the magnetic beads were extensively washed, 
protein-DNA cross-links were reversed and eluted. DNA was prepared by 
proteinase K digestion followed by PCR amplification. The primers for detection 
of the NR4A1 promoter region were 5′- CGAGGAGCCTATTTATAG -3′ (sense) 
and 5′- TCGACGTTTGGCCATACAAGG -3′ (antisense) PCR products were 
resolved on a 2% agarose gel in the presence of RGB-4103 GelRed Nucleic Acid 
Stain. 
Nuclear/cytosolic extraction 
MDA-MB-231 cancer cells (3.0 x 105 per well) were seeded in Dulbecco’s 
modified Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-
stripped fetal bovine serum and were allowed to attach for 24 h. The medium was 
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then changed to DMEM/Ham F-12 medium contained 2.5% charcoal-stripped 
fetal bovine serum, and either DMSO or TGFβ(5 ng/ml) was added for 4 hr. (after 
+/- pretreatment with leptomycin B (20 nM) for 24 hr. or +/- DIM-C-pPhOH (20 
µM), DIM-C-pPhCO2Me (15 µM), SP600125 (30µM), SB202190 (30µM), 
LY294002 (30µM) or PD98095 (30µM)  for 1 hr.,  or transfection of p38CA, p38KD, 
or p38DN plasmids 6 hr. post transfection.  Nuclear and cytosolic fractions were 
then isolated using Thermo Scientific NE-PER Nuclear and Cytoplasmic 
Extraction Kit (Rockford, IL) according to manufacturer’s protocol.  Fractions were 
then analyzed by western blot.  GAPDH and p84 were used as cytoplasmic and 
nuclear positive controls respectively. 
Immunofluorescence 
MDA-MB-231 (1.0 x 105 per well)  were seeded in 2-well Nunc Lab-Tek 
chambered B#1.0 Borosilicate coverglass slides from Thermo Scientific and were 
allowed to attach for 24 hours.  The medium was then changed to DMEM/Ham F-
12 medium contained 2.5% charcoal-stripped fetal bovine serum, and either 
DMSO or TGFβ(5 ng/ml) was added for 4 hr (after +/- pretreatment with 
leptomycin B (20 nM) for 24 hr or +/- pretreatment with +/- DIM-C-pPhOH (20 µM), 
DIM-C-pPhCO2Me (15 µM), SB202190 (30µM)  for 1 hr.,  or transfection of DDK-
Myc-p38CA, DDK-Myc-p38KD, DDK-Myc-p38DN, D-NR4A1, FLAG-NR4A1-(A-
B), FLAG-NR4A1-(C-F), DDK-Myc-arkadia, DDK-Myc-arkadia (Δ405-989), DDK-
Myc-arkadia (Δ1-404), DDK-Myc-arkadia (241-404), and DDK-Myc-arkadia 
(C937A) plasmids 6 hr. post transfection.   Cells were then treated with fluorescent 
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NR4A1 primary antibody (Nur77 (D63C5)) XP®), β-catenin primary antibody, or 
arkadia (H00054778-M05) primary antibody for 24 hrs.  Cells were then washed 
with PBS and then treated with Anti-rabbit IgG Fab2 Alexa Fluor® 488 or Anti-
mouse IgG Fab2 Alexa Fluor® secondary antibody for 3 hrs. Cells were then 
treated with DAPI (Biotium, Hayward, CA) and phalloidin (Alexa Fluro® 555 
Phalloidin) for 15 min in the dark following manufacturers protocol.  After washing 
with ice cold PBS cells were visualized by microscope (Advanced Microscopy).  
NR4A1, β-catenin, or  arcadia localization was determined by green fluorescence 
(GFP filter).  DAPI was used to stain the nucleus and phalloidin stained F-actin 
(rhodamine filter).  Images were taken sequentially of NR4A1 β-catenin, or 
arkadia, phalloidin, and DAPI, then merged. 
Western blot analysis 
MDA-MB-231, SUM159, and H5587T cancer cells (3.0 x 105 per well) were 
seeded in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium 
supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed 
to attach for 24 h. Cells were transfected with 100 nm of siAxin2, siArkadia, 
siRNF12, siβ-catenin, siTAK1, siMKK3, siMKK6, sip38α, siTCF1, siTCF3, siTCF4, 
or siLEF1 for 72 hours or treated with various conditions as described above. 
Cells were analyzed by western blot as described previously (24-28).Cells were 
analyzed by western blot as described previously (891,892,910,941,942). 
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SiRNA experiments were conducted as described previously ().  The 
siRNA complexes used in the study are as follows: siGL2-5’: CGU ACG CGG AAU 
ACU UCG A; siNR4A1: SASI_Hs02_00333289; siAxin2: SASI_Hs01_00110148; 
siArkadia: SASI_Hs01_00064840; siRNF12:SASI_Hs01_00238255; siTAK1: 
SASI_Hs02_00335227; siMKK3: SASI_Hs01_00228024; siMKK6: 
SASI_Hs01_00162806; sip38α: SASI_Hs01_00018467; siβ-catenin: 
SASI_Hs02_00318698; siTCF1: SASI_Hs01_00018982; siTCF3: 
SASI_Hs01_00214771; siTCF4: SASI_Hs02_00317381; siLEF1: 
SASI_Hs02_00349169 
Statistical analysis 
Statistical significance of differences between the treatment groups was 
determined as .previously described (891,892,910,941,942). 
Small interfering RNA interference assay 
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Results 
TGF-dependent inhibition of migration is dependent on activation of p38-
mediated nuclear export of NRA41 
It was initially reported that TGF-induced EMT and migration/invasion 
were dependent on NR4A1 which formed an E3 ligase-Axin2/RNF12/Arkadia 
complex that degraded SMAD7 and thereby activated TGFβR1 (822).  
Subsequent studies in this laboratory indicated that a key step in this pathway 
involved TGF-induced nuclear export of NR4A1 (903), and the mechanisms of 
TGF-NR4A1 crosstalk were further investigated in ER-negative breast cancer 
cells.  Results in Figure 1A show that among a series of kinase inhibitors, 
LY294002 and PD98059 inhibited basal migration of MDA-MB-231 cells, but only 
the p38MAPK inhibitor SB202190 significantly inhibited TGF-induced migration 
of MDA-MB-231 cells.  We also observed that the p38 inhibitor SB202190 also 
inhibited TGF-induced migration in H5587T and SUM159 triple negative breast 
cancer cells (Fig. 104A), whereas LY294002 and PD98059 decreased basal but 
not TGF-induced migration as observed in MDA-MB-231 cells.  TGF induces 
expression and nuclear export of NR4A1 (903), and we now show that this 
response was significantly inhibited in MDA-MB-231 cells cotreated with the p38 
inhibitor SB202190 (Fig. 104B).  In contrast, SP600125, LY294002 and PD98059 
did not inhibit TGF-dependent nuclear export of NR4A1; however, the latter two 
inhibitors decreased induction of NR4A1 by TGF (Fig. 104B).  
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These results suggest that TGF induces activation of p38, and this was 
confirmed in MDA-MB-231 cells where treatment with TGF enhanced 
phosphorylation of p38a T180/Y182 and also increased phospho-NR4A1 (S351) 
expression (Fig. 104B). TGF also induced NR4A1 expression and nuclear export 
Figure 104. Effects of kinase inhibitors on TGF-β/NR4A1 dependent cell migration. The p38 inhibitor SB02190 
inhibited TGFβ-induced migration (A) and NR4A1 nuclear export (B) whereas the c-JNK inhibitor SP600125, PI3K 
inhibitor LY294002, and the MEK inhibitor PD98059 did not.  TGFβ also induced migration in H5587T and SUM 159 
breast cancer cell lines and NR4A1 nuclear export and p38 inhibition also blocked these effects. C) TGFβ induced 
phosphorylation of NR4A1 (S355) which was inhibited by SB202190 and this was observed in all the three cell lines. 
Figure 104 
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in H5587T and SUM159 cells (Figs. 104C and 104D) and this was inhibited by 
SB202190.  SP600125, LY294002 and PD98059 did not inhibit TGF-mediated 
nuclear export of NR4A1 but enhanced expression of the receptor.  TGF also 
induced phosphorylation of NR4A1 (S351) and p38 (T180/Y182) in H5587T and 
SUM159 cells, and SB202190 inhibited this response (Figs. 104C and 104D), 
confirming the TGF-induced NR4A1 nuclear export was p38-dependent in the 
three ER-negative breast cancer cell lines. 
The role of p38 in mediating TGF-induced nuclear export of NR4A1 was 
further investigated using constructs expressing constitutively active [p38(CA)], 
kinase domain inactive [p38(KD)], and dominant negative p38 [p38(DN)] 
constructs in MDA-MB-231 cells.  p38(KD) and p38(DN) slightly increased 
expression of nuclear NR4A1 but did not induce nuclear export of the receptor, 
whereas both p38(CA) and TGF induced expression and nuclear export of 
NR4A1 protein (Fig. 105A).  Figure 105B illustrate that p38(CA) alone and in 
combination with TGF induced expression and nuclear export of NR4A1, 
whereas p38(KD) and p38(DN) alone and in combination with TGF did not 
induce expression or nuclear export of the receptor, demonstrating that TGF did 
not rescue/enhance nuclear export of NR4A1 in cells expressing p38(KD) or 
p38(DN).  Previous studies showed that the nuclear export inhibitor LMB and 
NR4A1 antagonists CDIM8 [1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane 
(DIM-C-pPhOH)] and CDIM14 [1,1-bis(3'-indolyl)-1-(p-
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carboxymethylphenyl)methane (DIM-C-pPhCO2Me)] blocked TGF-induced 
nuclear export of NR4A1 (903).  In this study, these same treatments plus 
LMB/TGF also inhibited p38(CA)-dependent nuclear export of NR4A1 (Fig. 
105C).  Overexpression of p38(CA) but not p38(KD) or p38(DN) induced MDA-
MB-231 cell migration after 5 and 12 hr (Fig. 105D) and the combination of p38 
and TGF did not induce cell migration greater than that observed for each 
treatment alone (Fig. 105F).  Both p38(KD) and p38(DN) alone did not induce 
MDA-MB-231 cell migration and in combination with TGF, this inhibitory effect 
was not rescued, indicating that both kinases inhibited TGF-induced migration.  
Results in Figure 105E and 105F demonstrate that the combination of TGF + 
p38(CA) did not enhance MDA-MB-231 cell invasion, and we also show that in 
combination with treatments (LMB, CDIM8, CDIM14 and SB202190) that inhibit 
nuclear export of NR4A1 (Figs. 104B and 104C), there was also inhibition of 
p38/TGF-induced invasion (Fig. 105F).  We also used immunostaining and 
microscopy to investigate treatment-related cytosolic and nuclear localization of 
NR4A1.  Results demonstrate that p38CA and TGFβ treatment induced nuclear 
export (Figure 3A) and this export was significantly abrogated by pretreatment 
with SB202190, leptomycin B, C-DIM 8, and C-DIM 14 (Figure 106A).  Both 
p38(KD) and p38(DN) alone did not induce NR4A1 nuclear export and 
supplementation with TGF did not rescue this effect (Fig. 106B), corroborating 
results obtained from Figures 105A and 105B. 
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Figure 105. p38α induces TNBC cell migration and NR4A1 nuclear export. Transfection of 
p38α (CA) induced NR4A1 nuclear export (A) and migration (D,E) whereas transfection of 
p38α (KD) and p38α (DN) failed to induce nuclear export (A,B) or induce migration (D,E) and 
this effect was not rescued by TGFβ (B,E).  Transfection of p38α (CA) and cotreatment with 
LMB, LMB+TGFβ, or NR4A1 antagonists inhibited this nuclear export (C) and migration (F) 
Figure 105. 
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NR4A1 interactions with Axin2, NRF12, Arkadia and SMAD7 
It was previously reported that NR4A1 played a role in Axin2-
RNF12/Arkadia-induced SMAD7 degradation (822), and in this study we 
investigated the interactions of NR4A1 with proteins required for that activity.  
Figure 106: NR4A1 localization by TGF-β,p38α, and C-DIMs. Transfection of p38α (CA) 
induces NR4A1 nuclear export (A) which is blocked by cotreatment with LMB, C-DIM/NR4A1 
antagonists and SB202190. Transfection of p38α (KD) or p38α (DN) failed to induce nuclear 
export of NR4A1 (B) and TGFβ did not rescue this phenotype. 
Figure 106. 
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MDA-MB-231 cells were treated with 5 ng/ml TGF for 4 hr, and cell protein 
lysates were immunoprecipitated with NR4A1 antibodies.  Western blots of the 
immunoprecipitated protein showed that NR4A1 was associated with Axin2, 
Arkadia, RNF12 and SMAD7 (Fig. 107A).  NR4A1 interactions with this cytosolic 
protein complex were abrogated after treatment with the NR4A1 ligands CDIM8, 
CDIM14, LMB alone and in combination with TGF (Fig. 107A).  These latter 
treatments maintained NR4A1 in the nucleus (903), suggesting that NR4A1 
interacts with these proteins in the cytosol.  We also examined interactions of the 
C- and N-terminal regions of N4RA1 with Axin2/RNF12/Arkadia/SMAD7 complex 
by transfecting cells with FLAG-NR4A1(C-F) or FLAG-NR4A1(A-B) and 
immunoprecipitated protein lysates with FLAG antibodies (Fig. 107B and 107C).  
The C-terminal domain [FLAG-NR4A1(C-F)] interacted with Axin 2 and Arkadia 
and to a lesser extent RNF12 (Fig. 4B), whereas TGF and p38CA induced 
interactions of the N-terminal domain of NR4A1 [FLAG-NR4A1(A-B)] with Axin2 
and SMAD7 (Figs. 107C and 107D) and these interactions were abrogated by 
leptomycin B, C-DIM 8, C-DIM 14, and SB202190 ( Fig. 107D).   
Moreover, association of NR4A1 with the complex was not observed after 
treatment with p38KD or p38DN alone or supplemented with TGFβ (Figs 107D 
and 107F).  We also observed in MDA-MB-231 cells transfected with FLAG-
NR4A1(full length) that FLAG antibodies co-immunoprecipitated Axin2, Arkadia, 
RNF12 and SMAD7 (Fig. 107E) only in cells transfected with p38(CA) but not 
p38(KD) or p38(DN).  Transfection of MDA-MB-231 cells with FLAG-NR4A1(A-B) 
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(Fig. 107C)  or FLAG-NR4A1(C-F) (Fig. 107E) and overexpression of p38(CA) ( 
TGF) followed by immunoprecipitation with FLAG antibodies demonstrates that 
the C-terminal domain of NR4A1 interacts with Axin2, Arkadia, RNF12 and 
SMAD7 (Fig. 107D) and the N-terminal domain interacts with only SMAD7 and 
Axin2 (Fig 107G).  In contrast, p38(KD) or p38(DN)  TGF did not induce 
interactions of NR4A1 with these proteins (Figs. 107D, 107E, 107F), suggesting 
that both p38 mutants inhibited the TGF-induced response. Similar results were 
obtained with cells transfected with DDK-Myc-arkadia under same treatment 
conditions (Suppl. Fig.  A-16). These results demonstrate that NR4A1 export is 
important for interactions with the ubiquitination complex and the C-terminal 
domain of NR4A1 is necessary for interactions with all members of this complex.  
The C-DIM/NR4A1 antagonists and the p38 inhibitor block NR4A1 nuclear export 
and interactions with the ubiquitination complex proteins.   
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Figure 107: Interactions of NR4A1 with ubiquitination complex. Treatment with TGFβ (A) or 
p38α (CA) (E) induces association of NR4A1 with Axin2, Arkadia, RNF12, and SMAD7 (A) 
and this was inhibited by C-DIM/NR4A1 antagonists, LMB and SB202190. SMAD7 and Axin2 
binds to NR4A1-(A-B) (C,D) whereas RNF12, Arkadia, and Axin2 bind to NR4A1-(C-F) 
(B,F,G). Transfection with p38α (KD) or p38α (DN) did not induce association (E) and TGFβ 
could not rescue this phenotype (F). 
Figure 107. 
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Results illustrated in Figure 108A show that knockdown of Axin2, Arkadia 
and RNF12, but not SMAD3 or SMAD2, by RNAi inhibit TFG-induced migration 
of MDA-MB-231 cells.  This demonstrates that like NR4A1, proteins constituting 
this ubiquitin ligase complex also play an important functional role in mediating 
TGF-induced cell migration and this may be due, in part, to their interactions with 
NR4A1 to form an active ubiquitin ligase complex.  However, it is also possible 
that decreased migration may be due to changes in TGF-induced nuclear export 
of NR4A1 or other proteins.  Therefore, MDA-MB-231 cells were treated with 
TGF and transfected with oligonucleotides that knockdown Axin2 (siAxin2), 
Arkadia (siArkadia) and RNF12 (siRNF12).  TGF induced nuclear export of 
NR4A1 and this was only partially inhibited by siAxin2 and significantly blocked 
by siArkadia and siRNF12 (Fig. 108B) and similar results were observed in cells 
expressing p38(CA) (Fig. 108C).  Thus, knockdown of members of the ubiquitin 
ligase complex completely (siArkadia and siRNF12) or partially (siAxin2) blocked 
TGF-induced nuclear export of NR4A1 and this is consistent with their inhibition 
of TGF-induced cell migration (Fig. 108A).   
Moreover, using the same knockdown protocol coupled with treatment with 
TGF, we also examined interactions of NR4A1 and SMAD7 with Arkadia, Axin2 
and RNF12 in immunoprecipation experiments (Figs. 108D and 108E).  
Knockdown of Axin2, Arkadia and RNF12 dramatically decreased interactions of 
NR4A1 with all complex proteins but not SMAD7 (Fig. 108D).  The fact that Smad7 
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and NR4A1 interact was surprising as they are in differential compartments upon 
knockdown of components of destruction complex.  This is being further 
investigated and perhaps can be explained by a percentage of NR4A1 remaining 
in equilibrium within nuclear and cytosolic compartments.  Smad7 may also exhibit 
such an equilibrium.  In contrast, SMAD7 interactions with Arkadia were 
decreased by siAxin2 and siRNF12 and interaction with RNF12 was decreased 
by siArkadia, whereas NR4A1 interactions with SMAD7 were unchanged by loss 
of Ardadia, Axin2 or RNF12 (Fig. 108E).  Figure 5F illustrates the knockdown 
efficiency of siArkadia, siAxin2 and siRNF12 and show that members of this 
ubiquitin ligase complex do not affect TGF-induced NR4A1 expression which is 
increased after transfection with siArkadia and siRNF12.   
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Although the activated ubiquitin ligase complex containing NR4A1 is 
cytosolic, the constitutive and TGF/p38-induced intracellular location of Arkadia, 
Figure 108. 
Figure 108: Ubiquitination complex components are required for NR4A1 nuclear export.  
Knockdown of Axin2, Arkadia, RNF12 (but not SMAD3 or SMAD2) inhibits TGFβ-induced migration 
(A).  Knockdown of Axin2, Arkadia, or RNF12 inhibted TGFβ (B) or p38α(CA) (B) induced nuclear 
export of NR4A1 and association of the E3 ligase complex (D,E).  TGFβ induces nuclear export of 
Axin2 and Arkadia (G) and this is blocked by LMB, C-DIM/NR4A1 anatgonists, SB202190 or 
knockdown of kiases upstream of p38α(H).  Knockdown efficiency of siAxin2,siArkadia, siRNF12 (F) 
siTAK1, siMKK3, siMKK6, and sip38α (I) is also demonstrated. 
425 
 
Axin2 and RNF12 have not previously been determined and were therefore 
investigated.  TGF alone induced Axin2 which was detected in both the nuclear 
and cytosolic fraction and cotreatment with inhibitors of NR4A1 nuclear export 
(LMB, CDIM8, CDIM14 and SB202190) did not affect expression or location of 
Axin2 (Fig. 108G).  In contrast, Arkadia expression was primarily nuclear and 
TGF-induced nuclear export of Arkadia was inhibited after cotreatment with LMB, 
CDIM8 and CDIM14.  This pattern of TGF-induced nuclear export and inhibition 
for Arkadia was similar to that observed for NR4A1 and since these proteins 
interact (Fig. 107A), they may be acting as co-chaperones.  We also examined 
the effects of p38 and upstream kinases on the subcellular distribution of the 
ubiquitin ligase complex proteins by knockdown of p38 (sip38) and upstream 
kinases TAK1 (siTAK1), MKK3 (siMKK3) and MKK6 (siMKK6) (Fig. 108H).  Axin2 
was both nuclear and cytosolic for most treatments; however, sip38 and siTAK1 
decreased levels of cytosolic Axin2.  TGF induced nuclear export of Arkadia as 
observed in Figure 5G; however, this induced response was inhibited by 
knockdown of p38 and upstream kinases (TAK1, MKK3 and MKK6). Figure 5I 
illustrates the knockdown efficiency of siTAK1, siMKK3, siMKK6, and sip38α  
RNF12 and SMAD7 were primarily cytosolic and were unaffected by the 
treatments.  These results confirm that TGF-induced p38 and upstream kinases 
were also important for Arkadia (and NR4A1) nuclear export which is necessary 
for formation of the active cytosolic ubiquitin ligase complex and TGF-induced 
invasion of MDA-MB-231 cells.  
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SMAD7 as a target of TGF-induced NR4A1 nuclear export 
TGF-induced degradation of SMAD7 is a key event for migration of breast 
cancer cells (822) and therefore, we investigated the role of NR4A1 and NR4A1 
nuclear export in mediating SMAD7 degradation.  SMAD7 is expressed in MDA-
MB-231 cells (Fig. 109A) and treatment with TGF decreased SMAD7.  However, 
treatment with TGF plus agents that inhibit nuclear export of NR4A1 (LMB, 
CDIM8 and CDIM14) or p38 activity (SB202190) blocked proteasome-dependent 
downregulation of SMAD7, and the proteasome inhibitor MG132 also blocked the 
TGF-induced response.  Moreover, TGF and p38(CA) alone or in combination 
also decreased SMAD7 protein and this was blocked by MG132, whereas 
p38(KD) and p38(DN) alone or in combination with TGF did not affect SMAD7 
expression (Fig. 109B).  Thus, treatment with TGF did not overcome or rescue 
the cells from the effects of p38(KD) or p38(DN).  These results show that TGF- 
and p38-induced nuclear export of NR4A1 are necessary for activating the E3 
ubiquitin ligase complex (Arkadia, NR4A1, RNF12 and Axin2) and for 
proteasome-dependent degradation of SMAD7.  This was also confirmed by 
examination of SMAD7 ubiquitination.  Inhibitors that blocked nuclear export of 
NR4A1 (Fig. 109C) and inactivation of p38 (Figs. 109D and 109E) all inhibited 
TGF-induced ubiquitination of SMAD7 which appears as a streaking band in the 
gel which is typical of blots containing multiple polyubiquitinated proteins.  In 
addition, we also show that TGF-induced ubiquitination is partially blocked by 
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Axin2 knockdown and completely inhibited by knockdown of Arkadia and RNF12 
(Fig. 109F), demonstrating the importance of members of the ubiquitin ligase 
complex in mediating ubiquitination and subsequent degradation of SMAD7.  
 
Figure 109. 
Figure 109: SMAD7 as a target of TGF-β-induced NR4A1 nuclear export. Treatment with TGFβ (A) or p38α(CA) 
(B) induced SMAD7 degradation and this phenotype was rescued by pretreatment with C-DIM/NR4A1 
antagonists, LMB,SB202190, or proteasome inhibitor MG132.  Transfection of p38α (KD) or p38α (DN) failed 
to induce SMAD7 degradation (B).  TGFβ and p38α (CA) also promoted poly-ubiquitination of SMAD7 which 
was abrogated by C-DIM/NR4A1 antagonists, LMB, and SB202190. Knockdown of Axin2, Arkadia, and RNF12 
also inhibited this effect (F) and transfection of p38α(KD) and p38α(DN) did not induce poly-ubiquitination of 
SMAD7 and this was not rescued by cotreatment with TGFβ 
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NR4A1 plays a role in TGF-induced -catenin and EMT 
Previous studies show that p38 induces expression of β-catenin and results 
illustrated in Figure 110A show that treatment with TGFβ for 5 hr induces β-
catenin protein expression in MDA-MB-231 cells and this response was 
decreased by cotreatment with the p38 inhibitor SB202190.  TGFβ also induced 
expression of several EMT marker proteins including Slug, Snail, ZEB-1, N-
cadherin, and vimentin; cotreatment with SB202190 inhibited these responses 
and this was accompanied by increased expression of the epithelial marker ZO-
1.  Surprisingly cotreatment of TGFβ with LMB or the C-DIM/NR4A1 antagonists 
also inhibited the β-catenin-regulated protein markers of EMT (Slug, Snail, ZEB-
1, N-cadherin, but not vimentin) however, the induced levels of β-catenin were not 
decreased.  As a positive control we also observed that TGFβ-induced Slug and 
Snail mRNA levels (Fig. 110B).  Transfection of MDA-MB-231 cells with p38α 
(CA), p38α (KD), or p38α (DN) alone or in combination with TGFβ demonstrate 
that p38α (CA) but not p38α (KD) or p38α (DN) also induce β-catenin and 
downstream EMT marker proteins (Fig. 110C).  TGFβ does not enhance the 
effects of p38α (CA) and the failure of p38α (KD) or p38α (DN) to induce β-catenin 
and downstream gene products was not affected by cotreatment with TGFβ.  
 The role of p38α (CA) in activating β-catenin and downstream EMT gene 
products was also confirmed in MDA-MB-231 cells treated with TGFβ coupled 
with knockdown of β-catenin, p38 and p38 upstream kinases TAK1, MKK3 and 
MKK6.  The TGFβ-induced responses were inhibited by decreasing β-catenin, 
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p38, and upstream genes further confirming the role for p38 in TGFβ-induced 
EMT.  LMB and the C-DIM/NR4A1 antagonists also inhibited induction of the EMT 
genes by treatment of MDA-MB-231 cells with TGFβ for 5 hr; however, these 
inhibitors did not affect β-catenin expression (Fig.110A).  Results in Figure 7C 
show that TGFβ induces nuclear β-catenin and SB202190 inhibits thia response; 
however, cotreatment with LMB results in both nuclear and cytosolic β-catenin 
whereas β-catenin is primarily cytosolic after cotreatment with TGFβ plus the C-
DIM/NR4A1 antagonists. Transfection of p38α also induced expression of β-
catenin and EMT markers, where C-DIM/NR4A1 antagonists, LMB, and 
SB202190  inhbited β-catenin nuclear localization (Fig. 110D) and inhibited the 
induction of EMT markers (Fig. 110E).   
The induction of β-catenin was abrogated by SB202190 (Fig. 110D and 
110E), indicating the necessity of p38 in induction of β-catenin and this was also 
observed when p38   upstream kinases were knocked down (Fig. 110F).  The 
partial nuclear export of β-catenin observed in cells cotreated with TGFβ plus LMB 
(an exportin-1 inhibitor) may be due, in part, to an equilibrium between nuclear 
and cytosolic β-catenin and this is currently being investigated.  In cells 
transfected with p38α (CA), p38α (KD), and p38α (DN) alone or in combination 
with TGFβ (Fig. 110G) the induced β-catenin (by p38α(CA) +/- TGFβ) was nuclear 
and consistent with activation of EMT (Fig. 7H) however in the other treatment 
groups β-catenin expression in the nucleus or cytosol was minimal to non-
detectable. A possible reason for the difference in β-catenin expression observed 
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in Figures 100E and 100F may be partially due to the duration of the treatment (5 
and 12 hr respectively) and this will be further investigated. 
  
Figure 110. 
Figure 110: NR4A1 and p38α are required for TGF-β-induced EMT.  TGF-β induced Slug and Snail 
mRNA expression (B) and EMT marker protein expression which was abrogated by C-DIM/NR4A1 
anatgonists, LMB, and SB202190 (A).  C-DIMs did not reduce β-catenin protein expression but 
induced its cytosolic sequestration (C).  p38α(CA) also induced β-catenin expression (D) and EMT 
protein expression (E) (which was inhibited by LMB, C-DIM/NR4A1 anatgonists, and SB202190) 
whereas p38α(KD) and p38α(DN) did not induce expression (G) or EMT protein expression (H) and 
this was not rescued by TGFβ.  Knockdown of kinases upstream of p38α also abrogated induction 
of EMT protein expression (F). 
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We also used immunostaining and microscopy to investigate treatment-
related cytosolic and nuclear localization of β-catenin.  Results demonstrate that 
p38CA and TGFβ treatment induced nuclear localization (Figure 111A) and β-
catenin was sequestered in the cytosol when pretreated with SB202190, 
leptomycin B, C-DIM 8, and C-DIM 14 (Figure 111A).  Both p38(KD) and p38(DN) 
alone resulted in β-catenin cytosolic sequestration and supplementation with 
TGF did not rescue this effect (Fig. 111B), corroborating results obtained from 
Figures 110B, 110C and 110F. 
 
  
Figure 111. 
A. 
B. 
Figure 111. Localization of β-catenin by TGF-β and C-DIMs. Transfection of p38α (CA) induces 
β-catenin nuclear localization (A) and cotreatment with LMB and C-DIM/NR4A1 antagonists 
promoted cytosolic sequestration of β-catenin whereas SB202190 abrogated β-catenin 
expression. Transfection of p38α (KD) or p38α (DN) repressed expression of β-catenin (B) and 
TGFβ did not rescue this phenotype. 
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NR4A1 plays a role in regulation of TGF-induced -catenin expression 
Results in Figure 7C show that TGF-induced -catenin was primarily 
nuclear but after cotreatment with NR4A1 antagonists for 5 hr, -catenin became 
cytosolic and levels were decreased, suggesting that NR4A1 may play a role in 
regulating -catenin expression.  This was confirmed in RNAi studies where 
knockdown of NR4A1 resulted in low to non-detectable levels of TGF-induced -
catenin in whole cell lysates (Fig. 112A).  In contrast, TGF or transfection with 
p38(CA) induced expression of -catenin which persisted for 24 hr and remained 
in the nucleus (Figs. 112B and 112C).  In a parallel study after treatment with the 
NR4A1 antagonist CDIM8, TGF- and p38(CA)-induced nuclear -catenin was 
exported to the cytosol (Figs. 112D and 112E) as observed in Figure 7C (5 hr 
treatment with CDIM8); however, after treatment with CDIM8 for 24 hr, the levels 
of -catenin were non-detectable.  Since cytosolic -catenin is subject to 
proteasome-dependent degradation, we repeated the studies outlined in Figures 
112D and 112E but in the absence or presence of the proteasome inhibitor 
MG132.   
The results show that MG132 blocked the loss of TGF-induced -catenin 
in MDA-MB-231 cells (Figs. 112F and 112G).  The mechanism of NR4A1 
regulation of -catenin is currently being investigated; however, our results 
demonstrate that NR4A1 antagonists that inhibit TGF-induced nuclear export of 
NR4A1 induce nuclear export of -catenin, demonstrating that NR4A1 antagonists 
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target TGF-induced migration and -catenin-mediated EMT in breast cancer 
cells through regulating nuclear export of NR4A1. 
 
 
Figure 112. C-DIMs induce proteasome dependent degradation of β-catenin by inducing nuclear export.  
Knockdown of NR4A1 inhibits TGFβ-induced EMT (A).  TGFβ (B) and p38α(CA) (C) both induce nuclear β-
catenin over 24 hr timepoint.  C-DIM 8 induces cytosolic sequestration of β-catenin at 4 hr in presence of both 
TGFβ (D) and p38α(CA) (E) which persists for up to 24 hr, leading to degradation of β-catenin.  β-catenin 
expression is restored in the presence of proteasome inhibitor MG132 for both TGFβ (F) p38α(CA) (G). 
Figure 112. 
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Role of p38 and -catenin in regulation of NR4A1 expression and subcellular 
localization 
TGF and p38 induce both -catenin and NR4A1, and NR4A1 regulates -
catenin-mediated expression of EMT genes by maintaining -catenin in the 
nucleus (Fig. 110C).  Figure 113A illustrates that NR4A1 is nuclear in MDA-MB-
231 cells and knockdown of -catenin, p38 and upstream kinases (TAK1, MKK3 
and MKK6) decreased nuclear expression of NR4A1, cytosolic NR4A1 levels 
were minimal and -catenin was non-detectable.  TGF induced NR4A1 and its 
export to the cytosol and this was accompanied by induction of nuclear -catenin 
(Fig. 113B), and knockdown of -catenin, p38 decreased expression of both 
NR4A1 and -catenin and decreased expression of p38α and upstream kinases 
also blocked nuclear export of NR4A1 as observed in Figures 113A and 113B.   
Results summarized in Figure 113C show that TGFβ-induced NR4A1 expression 
is blocked by knockdown of β-catenin, p38 and upstream kinases and using the 
same treatment protocol TGFβ-induced migration in MDA-MB-231 was also 
inhibited. 
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-Catenin is a nuclear transcription factor that regulates gene expression 
through interactions with DNA-bound TCF/LEF sites and the NR4A1 promoter 
contains two of these cis-elements at -346 to-328 and -191 to -170 (Fig. 113E).  
Figure 113. 
Figure 113. β-catenin and TCF factors induce NR4A1. Knockdown of kinases of upstream of 
p38α inhibits NR4A1 nuclear export and β-catenin expression (A,B), induction of NR4A1 mRNA 
(C), and cell migration (D) (where upstream kinases of c-JNK MKK4 and MKK7 did not).  
Schematic of the NR4A1 promoter with two identified consensus TCF/LEF response elements 
(TRE) (E), and β-catenin,TCF3, TCF4, and LEF1 associate at these regions However TCF1 was 
not detected.  Knockdown of β-catenin, TCF3, TCF4, and LEF1 (but not TCF1) abrogated TGFβ-
induced NR4A1 mRNA (F) and protein expression (G). 
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The potential role of -catenin/TCF/LEF in regulating -NR4A1 expression was 
investigated by RNAi and knockdown of -catenin, TCF3 (siTCF3), TCF4 
(siTCF4) and LEF1 (siLEF1) but not TCF1 (siTCF1) decreased TGF-induced 
NR4A1 mRNA (Fig. 113F) and protein (Fig. 113G) levels.  Further confirmation 
that -catenin regulates NR4A1 gene expression was investigated in a ChIP 
assay on the NR4A1 promoter which showed that treatment with TGF, 
TGF+LMB, p38(CA), and p38(CA)+TGF induced pol II and enhanced TCF3, 
TCF4 and LEF1 binding to the region of the NR4A1 promoter containing the 
TCF/LEF motifs.  In contrast, these promoter interactions were not observed in 
cells treated/transfected with p38(KD) and p38(DN) alone or in combination with 
TGF or with TGF plus the NR4A1 antagonists CDIM8 and CDIM14 (Fig. 113H).  
These data confirm that -catenin regulates TGF-induced NR4A1 expression 
(Figs. 113F and 113D), by acting as a nuclear cofactor along with TCF3, TCF4, 
and LEF1. Figure 114 is a schematic representing the TGFβ/p38α/NR4A1 
inducible cell migration and EMT pathway emerging from our studies. TGFβ-
inducible migration is dependent on NR4A1 nuclear export and interactions with 
the Arkadia, Axin2, RNF12 E3 ubiquitin ligase complex that targets SMAD7.  This 
process is NR4A1 and also p38-dependent and can be inhibited by SB202190 
and C-DIM/NR4A1 antagonists.  TGFβ-induced p38 is also critical for induction of 
β-catenin and EMT genes and for β-catenin-NR4A1 mutual coregulation where β-
catenin acts as a trans-acting transcription factor and NR4A1 and its antagonists 
regulate β-catenin nuclear export and degradation.   
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Figure 114. The TGFβ/p38α/NR4A1 pathway. Schematic representing the TGFβp38α/NR4A1 inducible 
cell migration and EMT pathway.   
Figure 114.   
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Discussion 
NR4A1 is a member of the NR4A orphan receptor sub-family and although 
NR4A1 plays a role in multiple physiological and pathophysiological processes, 
the endogenous ligand for this receptor has not been identified (891,892).  Several 
studies have now characterized ligands that bind NR4A1 (806,910,941,942,1107) 
and research in this laboratory has investigated the NR4A1 binding of several C-
DIM analogs to the receptor (806).  NR4A1 is pro-oncogenic in most solid tumors, 
and both CDIM8 and CDIM14 act as receptor antagonists and inhibit nuclear 
NR4A1-dependent gene expression, resulting in decreased tumor growth, 
survival and migration/invasion of breast and other cancer cells (788,803-
806,812,904,903).  Zhou and coworkers demonstrated that NR4A1 plays a key 
role in cytokine and TGF-induced invasion and EMT in breast cancer by 
interacting with the Axin2, RNF12 and Arkadia E3 ubiquitin ligase complex which 
degrades SMAD7 (822).  Studies in this laboratory demonstrated that NR4A1-
regulation of 1-integrin gene expression is primarily responsible for migration of 
MDA-MB-231 cells.  TGF-induced MDA-MB-231 cell migration is also NR4A1-
dependent as previously reported (822); however, this is dependent on nuclear 
export of NR4A1 which is inhibited by the NR4A1 ligand CDIM8 and CDIM14 
(903).  Thus, the C-DIM/NR4A1 antagonists effectively block TGF-induced 
migration of breast cancer cells, and this study is focused on delineating the 
mechanisms of TGF-NR4A1 interactions. 
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TGF induces multiple kinases including p38 (1097-1099, 1108-1115) and 
based on initial kinase inhibitor studies in 3 triple negative breast cancer cells 
(H5587T, MDA-MB-231 and SUM159), we identified p38 as the principle kinase 
required for nuclear export of NR4A1.  Moreover, p38(CA) but not p38(KD) or 
p38(DN) overexpression induced nuclear export of NR4A1 and subsequent MDA-
MB-231 cell migration but both TGF- and p38-induced migration were inhibited 
by C-DIM/NR4A1 antagonists and LMB (Figs.105 A-F).  Interestingly, we also 
observed in these initial experiments that TGF and p38(CA) alone or in 
combination induced the same magnitude of cell migration and other responses, 
and the lack of activity observed for p38(DN) and p38(KD) was not rescued by 
cotreatment with TGF for any response examined in our studies.  
Immunoprecipitation studies with NR4A1 antibodies confirmed that full 
length NR4A1 interacted with Axin2, Arkadia, RNF12 and SMAD7, and the C-
terminal (Axin2, Arkadia and RNF12) and N-terminal (Axin2 and SMAD7) domains 
of NR4A1 differentially interacted with members of this complex (Fig. 107).  
Although the functional E3 ubiquitin ligase complex containing NR4A1 is 
responsible for degradation of SMAD7 (a cytosolic protein) (822), we observed 
that like NR4A1, Arkadia was also a nuclear protein that underwent TGF/p38-
dependent nuclear export (Fig. 108G).  Moreover, the NR4A1 antagonists CDIM8 
and CDIM14 that inhibited TGF-/p38-mediated nuclear export of NR4A1 also 
inhibited nuclear export of Arkadia.  NR4A1 forms protein-protein complexes with 
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other nuclear factors such as p53 and LKB1 and treatment with receptor ligand 
induces dissociation from the receptor (941,1116), whereas NR4A1-Arkadia 
nuclear interactions remained intact in the presence or absence of ligand (Fig. 
108G).  The ultimate target of the E3 ubiquitin ligase complex is SMAD7 (822), 
and we also observed the TGF-/p38-induced proteasome-dependent SMAD7 
ubiquitination and degradation.  Moreover, inhibitors of NR4A1 (and Arkadia) 
nuclear export or knockdown of one or more members of this complex also 
decreased SMAD7 ubiquitination, and these observations are consistent with 
studies showing the importance of this complex in SMAD7 degradation (822). 
Previous studies show that TGF induces cancer cell migration and EMT, 
and activation of the latter pathway may also involve increased expression of -
catenin (1117-1119).  In addition, it has also been reported that -catenin not only 
interacts with NR4A1 but there is evidence for mutual functional responses and 
inter-protein regulatory pathways (1120-1125).  Knockdown or overexpression of 
NR4A1 in colon cancer cells decreases or increases -catenin expression, 
respectively, and knockdown or overexpression of -catenin decreases or 
increases NR4A1 expression (1120-1122).  Hypoxia also enhances -
catenin/NR4A1-mediated invasion of colon cancer cells; however, the mechanism 
of this response and the intracellular location of NR4A1 are unclear, and the role 
of NR4A1 is independent of DNA binding and transactivation (1122).  The role of 
NR4A1 in TGF-induced expression of -catenin and downstream EMT genes in 
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MDA-MB-231 cell is unique.  Both TGF and p38(CA) induced expression of -
catenin and downstream genes in MDA-MB-231 cells and this response was 
inhibited not only by p38(DN), p38(KD) and knockdown of kinases upstream from 
p38, but also by NR4A1 antagonists CDIM8 and CDIM14 (Figs. 110 and 111).  
Treatment with TGF resulted in induced -catenin expression in the nucleus and 
nuclear export of NR4A1, and the effects of NR4A1 antagonists (5 hr treatment) 
reversed the subcellular location of both proteins, suggesting nuclear (antagonist) 
ligand-bound NR4A1 either directly or indirectly enhanced nuclear export of -
catenin.  Moreover, CDIM8- and CDIM14-induced nuclear export of -catenin 
resulted in proteasome-dependent degradation of this protein within 24 hr after 
initial treatment (Fig. 112).  Knockdown of NR4A1 by RNA also decreased -
catenin expression (Fig. 112A), suggesting that the loss or inactivation of NR4A1-
regulated genes/pathways contributed to nuclear export of -catenin and its 
subsequent degradation, and this is currently being investigated. 
-Catenin overexpression or induction in colon cancer cells induces 
NR4A1 expression and this is linked to activation of AP1 and subsequent 
interactions with AP1 cis-elements in the proximal region (-200 to -2) of the NR4A1 
gene promoter (1121).  In contrast, TGF-induced -catenin-mediated induction 
of NR4A1 was due to nuclear -catenin interactions with TCF3/TCF4 (but not 
TCF1) and LEF cis-element (-346 to -328 and -190 to -170) in the proximal region 
of the NR4A1 gene promoter (Figs. 113 and 114).  These interactions were TGF-
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dependent and illustrate a unique crosstalk between NR4A1 and -catenin which 
are critical elements in late stage TGF-induced breast cancer cell 
migration/invasion.  Our results demonstrate that these TGF-induced responses 
are also dependent on induction of p38 and genomic regulation of NR4A1 by -
catenin/TCF/LEF complexes.  In contrast, TGF/p38-dependent induction of -
catenin results in nuclear accumulation of -catenin and activation of downstream 
EMT genes.  The precise role for NR4A1 in mediating TGF/p38-dependent 
induction of -catenin is unknown; however, NR4A1 antagonists that retain 
NR4A1 in the nucleus also induce -catenin nuclear export and degradation 
demonstrating a novel NR4A1 ligand-dependent approach for inhibiting EMT in 
breast cancer cells. 
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CHAPTER X 
SUMMARY AND CONCLUSIONS 
 
NR4A1 is overexpressed in transformed tissue as compared to its normal 
counterpart in the majority of solid tumors.  We have developed structurally-
diverse C-DIMs that bind to NR4A1 and antagonize its ability to serve as a 
transcription factor for expression of a myriad of oncogenes that are vital for 
tumorigenesis, evasion of apoptosis, suppression of ROS, migration, and 
invasion.  Specifically, this laboratory has investigated C-DIMs and their molecular 
mechanisms as anticancer agents in breast, kidney, colon, pancreatic, RMS, and 
other cancer cell lines Two NR4A1 ligands, 1,1-bis (3’-indolyl)-1-(p-
hydroxyphenyl)methane (DIM-C-pPhOH) (C-DIM 8) and the p-carbomethoxy 
derivate (DIM-C-pPhCO2Me) (C-DIM 14) inhibited cancer cell proliferation and 
induced apoptosis.  C-DIMs inhibited cancer cell growth by upregulating sestrin 2 
(SESN2) which activated AMPKα resulting in downregulation of mechanistic 
target of rapamycin (mTOR) signaling. These results were observed in both p53 
wt. and p53 mutant cell lines, and demonstrated that SESN2 can be induced in a 
p53 dependent and a p53 independent (ROS-induced) manner.  This in it of itself 
represents a new approach to targeting p53 mutated cancers as this effect was 
observed in all p53 mutant cell lines used in this dissertation.  C-DIMs also 
induced apoptosis by activating caspases 3, 7, 8, inducing poly ADP-ribose 
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polymerase (PARP) cleavage, which was corroborated using Annexin V staining.  
We also investigated two ROS mediators of apoptosis that were identified by 
RNA-seq analysis in cells after NR4A1 siRNA-mediated knockdown or treatment 
with NR4A1 antagonist.  Knockdown of NR4A1 and C-DIM/NR4A1 antagonists 
downregulated expression of thioredoxin domain containing 5 (TXNDC5) and 
isocitrate dehydrogenase 1 (IDH1) and ROS was induced as determined by flow 
cytometry.  The endoplasmic reticulum (ER) stress pathway was also activated 
as indicated by increased expression of ER stress markers: CHOP, XBP-1s, 
ATF4, p-PERK, ATF6, GRP78, and IRE1.  Similar results were obtained for all 
these pathways using RNA interference (RNAi) and oligonucleotides that target 
NR4A1 (siNR4A1).  These results indicate that C-DIMs are effective NR4A1 
antagonists and inhibit NR4A1-dependent oncogenic pathways.  Therefore, C-
DIMs exhibit promising chemotherapeutic potential NR4A1-overexpressing solid 
tumors observed. 
β1-Integrin as determined by RNA-seq analysis as a downstream target of 
both siNR4A1 and NR4A1 antagonists. In breast, pancreatic, and colon cancer, 
1-Integrin is highly expressed and it is associated with a negative prognosis 
including disease recurrence, metastasis and decreased overall and disease-free 
survival. Results of studies in vitro and in vivo preclinical models show that 1-
integrin plays an important role in mammary tumor initiation, progression and 
metastasis. NR4A1 has been demonstrated to coregulate oncogenic proteins 
along with p300 and Sp1.  We observed that NR4A1 regulates expression of both 
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β1- and β3-integrins through this transactivational complex and unlike other β1-
integrin inhibitors, which induce prometastatic β3-integrin; NR4A1 antagonists 
inhibit expression of both β1- and β3-integrin demonstrating a novel mechanism-
based approach for targeting integrins and integrin-dependent breast cancer 
metastasis.  This transactivational complex was also shown to be necessary for 
expression of other integrins such as β4-, α5-, and α-6 integrin in Chapter VIII, 
which can be targeted by ROS inducers like penfluridol.  However, this 
dissertation also demonstrated that not only does Sp1 cooperate in this 
transactivation complex, but Sp3 and Sp4 on certain oncogenic promoters.  
Indeed, in RKO, L3.6pL, MiaPaCa2 and Panc1 cells it was Sp3 and Sp4, not Sp1 
that was demonstrated to be required for transactivation of β1-integrin.  Therefore, 
this illustrates that Sp proteins have unique roles in tumorigenesis and cancer cell 
migration, which is cell context specific. 
Overexpression of NR4A1 in ER positivie and ER negative breast cancer.  
A specific subtype, triple negative breast cancer (TNBC) is refractory to most 
chemotherapeutic regimens and NR4A1 is a prognostic factor for decreased 
survival and increased metastasis.  Recently, metastasis has been linked to 
NR4A1-dependent regulation of TGFβ signaling, which is a powerful driver of 
epithelial to mesenchymal transition (EMT), migration/invasion, and progression 
of metastatic cancer.  NR4A1 is involved in TGFβ induced invasion in breast 
cancer by forming a complex with Axin2, RNF12, and ARKADIA, which catalyze 
ubiquitination of SMAD7, leading to its proteasome-dependent degradation, and 
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activation of TGF-β induced cell migration by stabilization of the TGFβR1 receptor. 
We provide insight into the mechanism of TGFβ mediated cell migration and that 
this requires nongenomic NR4A1 function. We demonstrate that migration of 
aggressive SKBR3 and MDA-MB-231 breast cancer cells is constitutive, TGFβ-
independent, and dependent on regulation of β1-integrin gene expression by 
NR4A1 which can be inhibited by the NR4A1 antagonists (DIM-C-pPhOH) and 
(DIM-C-pPhCO2Me) analog. The NR4A1 antagonists also inhibited TGFβ-induced 
migration of MDA-MB-231 cells by blocking nuclear export of NR4A1, which is an 
essential step in TGFβ-induced cell migration. 
 We also demonstrate that p38α is necessary and sufficient for TGFβ-
mediated migration, NR4A1 nuclear export, and NR4A1 induction by induction of 
β-catenin in triple negative breast cancer (TNBC) as overexpression of p38CA 
recapitulated TGFβ-mediated NR4A1 nuclear export and cancer cell migration 
and was attenuated with NR4A1 antagonists (C-DIMs), leptomycin B, and the p38 
inhibitor SB202190. The variants p38KD (kinase-dead) and p38DN (dominant 
negative) did not recapitulate the effects of p38CA and subsequent TGFβ 
treatment failed to rescue this phenotype. We also demonstrate that NR4A1 is 
essential for TGFβ-induced EMT as expression of EMT markers was abrogated 
in the presence of NR4A1 antagonists and SB202190. Moreover, NR4A1 
antagonists promoted cytosolic sequestration of the transcription factor β-catenin 
and its proteasome-dependent degradation in a time dependent manner. 
TCF/LEF response elements (TRE) were identified within the NR4A1 promoter 
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and chromatin immunoprecipitation analysis demonstrated that β-catenin (with 
TCF-3, TCF-4, and LEF-1) binds these TREs.  We also demonstrate that β-
catenin is required for TGFβ-dependent NR4A1 induction and is p38α-dependent. 
These results highlight a novel mechanism of TGFβ/NR4A1-dependent inducible 
migration and demonstrate therapeutic potential of NR41 in TNBC.  Our results 
show mutual coregulation of NR4A1 and β-catenin play a role in TGFβ-induced 
TNBC cell migration and EMT and NR4A1 antagonists inhibit this response and 
demonstrate a novel approach for TNBC chemotherapy for patients 
overexpressing NR4A1. 
Specificity protein (Sp) transcription factor (TF) Sp1 is overexpressed in 
multiple tumors and is a negative prognostic factor for patient survival.  Sp1, Sp3 
and Sp4 are highly expressed in cancer cells and in this study, we demonstrate 
that these TFs individually play a role in cancer cell growth, survival and 
migration/invasion in SKBR3, MDA-MB-231 breast, 786-0 kidney, L3.6pL, 
PANC1, Miapaca2 pancreatic, A549 lung and SW480 colon cancer cell lines.  
Surprisingly, after individual knockdown of Sp1, Sp3, or Sp4, which resulted in 
inhibition of cell growth and migration and induction of apoptosis, compensation 
by the other expressed Sp proteins, was not observed.  This underscores the 
necessity of all three Sp proteins in driving tumorigenesis in multiple tumor types.  
Moreover, tumor growth in athymic nude mice bearing L3.6pL pancreatic cancer 
cells as xenografts was significantly attenuated in cells were depleted of Sp1, Sp3, 
and Sp4 in combination or Sp1 alone. There was also a significant difference 
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between the combinatorially knocked down tumors and the ones that had Sp1 
alone, further demonstrating that Sp3 and Sp4 are vital for tumor growth.  
Ingenuity Pathway Analysis (IPA) of changes in gene expression in Panc1 
pancreatic cancer cells after individual knockdown of Sp1, Sp3 and Sp4 
demonstrates that these TFs regulate gene sets/pathways that both correlate and 
inversely correlate with the functional responses observed after knockdown.  
Causal IPA analysis also predicted that Sp1-, Sp3- and Sp4-regulated genes were 
associated with the pro-oncogenic activity and that the moajority of these were 
not mutaually exclusive.  These functional and genomic results coupled with 
overexpression of Sp transcription factors in tumor vs. non-tumor tissues and 
decreased Sp1 expression with age indicate that Sp1, Sp3 and Sp4 are non-
oncogene addiction (NOA) genes and are attractive drug targets for individual and 
combined cancer chemotherapies. 
These SP proteins were also demonstrated to be vital for RMS cell and 
tumor growth. Both the ERMS and ARMS cell lines were inhibited by panobinostat 
treatment with downregulated Sp proteins in a non-canonical fashion.  This 
involved the c-myc/miR 17-92/ZBTB/Sp pathway, which is iniated by ROS, which 
induce epigenetic changes in the c-myc promoter.  Therefore, development of 
innovative chemotherapeutic strategies is imperative and a recent genomic 
analysis suggested the potential efficacy of reactive oxygen species (ROS)-
inducing agents.  Here we demonstrate the efficacy of potent histone deacetylase 
(HDAC) inhibitors, panobinostat and vorinostat, as agents that inhibit tumor 
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growth in vivo, induce apoptosis, and inhibit invasion of RMS cell lines RD and 
Rh30.  These effects are due to ROS-dependent epigenetic repression of c-Myc, 
which leads to downregulation of miRs 17, 20a, 27a, upregulation of ZBTB 4, 10, 
34 and subsequent downregulation of Sp transcription factors.  We also 
demonstrate that this is an ROS-dependent mechanism and treatment with the 
antioxidant glutathione reversed the effects of the HDAC inhibitor substantially, 
while histone acetylation was unchanged.  These results elucidate a novel 
mechanism of antineoplastic activity for panobinostat and vorinostat that lies 
outside of their canonical HDAC inhibitory activity and present a potential new 
antitumorigenic approach to treat RMS, whether to be used individually or as an 
adjuvant to an existing chemotherapeutic regimen.   
Overall this dissertation has provided substantial evidence that NR4A1 and 
Sp transcription factors are potent oncogenes, with the former having both 
genomic and nongenomic oncogenic functions which can be targeted by our C-
DIM/NR4A1 antagonists and Sp proteins can be targeted by ROS inducers and 
phytochemicals.  We not only demonstrate the potency both in vitro and in vivo, 
but elucidate a mechanism that is physiologically relevant to many aggressive, 
drug-refractory cancers.  Both NR4A1 and Sp proteins are drug targetable and 
represent a promising class of chemotherapeutic targets for solid tumors and 
metastasis. 
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APPENDIX A 
 
 
ACHN 
Supplemental Fig A-1. Different oligonucleotides targeting NR4A1 induce apoptosis. Different 
oligonucleotides targeting NR4A1 induce caspase 8,7 and PARP cleavage in ACHN (A) and 786-0 (B) 
cancer cells and this is also observed with DIM-C-pPhOH and DIM-C-pPhCOOMe in ACHN (C) and 
786-0 (D) cells. 
786-0 
Supplemtal Figure A-1 
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Supplemental Fig A-2. C-DIMs inhibit cell proliferation through inactivation of NR4A1.  DIM-C-
pPhOH and DIM-C-pPhCO2Me required NR4A1 to inhibit cell proliferation in ACHN and 786-0 
cells. 
Supplemental Figure A-2.  
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SKBR3 
NR4A1 
DAPI 
MERGED 
DMSO DIM-C-pPhOH 
 
Supplemental Fig A3-: DIM-C-pPhOH inhibits nuclear NR4A1. NR4A1 remains nuclear after treatment 
with NR4A1 antagonist  DIM-C-pPHOH (20 µM) 
MDA-MB-231 
DMSO DIM-C-pPhOH 
Supplemental Figure A-3. 
MCF-7 
DMSO DIM-C-pPhOH 
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Supplemental Figure A-4 
Supplemental Figure A-4.  DIM-C-pPhCO2Me inhibits cell proliferation up to 48 hrs and DIM-C-pPhCN has similar 
effects on breast cancer cells. The C-DIMs DIM-C-pPhOH and DIM-C-pPhCO2Me decrease cell proliferation in 
MCF-7, MDA-MB-231, and SKBR3 cell lines at 24 and 48 hrs (A).  DIM-C-pPhCN induces PARP and caspase 3 
cleavage (B), inhibits mTOR signaling (C), downregulates Sp regulated protein expression (D), and 
downregulates TXNDC% and IDH1 (E).  
593 
 
Supplemental Figure A-5.  Sp knockdown inhibits growth, induces apoptosis, and dcreases RMS cell invasion.  
RD and Rh30 cells were transfected with siCtl, siSp1, siSp3 and siSp4, and effects on cell proliferation (A), 
apoptosis (B) and invasion (C) were determined by counting cells (Coulter counter), fluorescent detection of 
Annexin V and Boyden chamber assays, respectively.  Results are expressed as means  SE for 3 replicate 
determinations and significant (p<0.05) effects compared to siCtl (set at 100%) are indicated (*). 
  
Supplemental Figure A-5 
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Supplemental Figure A-6 
Supplemental Figure A-6. HDACi downregulate c-Myc and Sp proteins in SMS-CTR ERMS cells. Panobinostat 
and vorinostat both induce PARP and caspase 3 cleavage in RD (A) and Rh30 (B) cells which is ameliorated by 
cotreatment with GSH (A,B). Panobinostat and vorinostat also downregulate c-Myc and Sp proteins  in ERMS 
cell line SMS-CTR (C). 
595 
 
 
Supplemental Figure A-7 
A 
B 
Figure A-7. NR4A1 knockdown and C-DIMs inhibit cell adhesion. Cells 
were transfected with siNR4A1 or treated with NR4A1 antagonists and 
fibronectin-induced cell adhesion was determined. (A). Cells were 
transfected with siNR4A1 or siITGB1 (β1-integrin), treated with DIM-C-
pPhOH (20 µM), and cell adhesion was determined( B). 
596 
 
  
Figure A-8. DIM-C-pPhOH requires NR4A1 and β1-integrint cell migration. Cells were transfected with siNR4A1 or 
siITGB1 (β1-integrin), treated with DIM-C-pPhOH (20 µM), and cell migration was determined. Results are 
expressed as means +/- SE (3 replicates) and significantly (P<0.05) decreased migration is indicated (*). 
  
Supplemental Figure A-8 
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Figure A-9. Effects of different Sp oligonucleotides.  Multiple Sp oligonucleotides targeted against Sp1,Sp3, and 
Sp4 were transfected into L3.6PL cells and whole cell lysates were analyzed by Western blots.  Sp1(1), Sp3(1), and 
Sp4(1) were used in subsequent knockdown experiments.  
 
 
 
 
 
 
  
Supplemental Figure A-9 
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Supplemental Figure A-10.  DIM-C-pPhOH inhibits β1-integrin and α5-integrin in pancreatic xenografts. Tumor 
lysates from an L3.6pL orthotopic xenograft experiment in vivo show that DIM-C-pPhOH (30 mg/kg/d) decreased 
expression of 1-integrin and 5-integrin compared to corn oil control.   (Tumor lysates from 2 animals are shown.) 
  
Supplemental Figure A-10 
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Supplemental Figure A-11.  C-DIM inhibition of pancreatic and colon cancer cell migration is dependent on NR4A1 
and β1-integrin.  Pancreatic (A) and colon (B) cancer cells were treated with DMSO or 20 M DIM-C-pPhOH alone 
or after transfection with siCtl (control), siNR4A1 or si1-integrin, and migration was determined in a Boyden 
chamber assay as outlined in the Materials and Methods.  Results are expressed as means  SE for 3 
determinations per treatment group and significant (p<0.05) inhibition of migration is indicated (*). 
 
Supplemental Figure A-11 
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Supplemental Figure A-12.  Role of ROS and cMyc in penfluridol-induced responses.  (A) Induction of ROS.  Cells 
were treated with penfluridol alone or in combination with GSH, and ROS was determined after 24 hr.  (B) Role 
of ROS in penfluridol-induces responses.  Cells were treated with penfluridol alone or in combination with NAC 
for 24 hr, and whole cell lysates were analyzed by western blots.  (C) cMyc knockdown.  Cells were transfected 
with siCtl (control) or siMyc(#2), and whole cell lysates were analyzed by western blots. 
Supplemental Figure A-12 
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Supplemental Figure A-13.  Myc expression rescues cells from penfluridol.  Cells were treated with penfluridol or 
cMyc expression plasmid (pCDH-cMyc) or empty vector alone or in combination (A, B), and whole cell lysates 
were analyzed by western blots. 
Supplemental Figure A-13 
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Supplemental Figure A-14.  ZBTB10 knockdown rescues cells from penfluridol.  Cells were treated 
with penfluridol or transfected with siZBTB10 or control oligonucleotide alone or in combination (A, 
B), and whole cell lysates were analyzed by western blots. 
Supplemental Figure A-14 
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Supplementary Figure A-15.  Penfluridol as an NR4A1 antagonist.  Cells were treated with the 
NR4A1 antagonist DIM-C-pPhOH (4-OH) or penfluridol and transfected with a GAL4-NR4A1 
chimera and reporter-luciferase construct (containing GAL4 response elements).  Luciferase 
activity was determined (27).  Only DIM-C-pPhOH decreased luciferase activity, characteristic of 
an NR4A antagonist (26, 27). 
Supplementary Figure A-15 
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 Supplementary Figure A-16. Arkadia associations with ubiquitination complex and role in β-
catenin localization.  Pulldown of Arkadia demonstrates association with NR4A1 in the presence 
of TGFβ and p38α(CA) (A).  TGFβ and p38α(CA) induce NR4A1 (B) and this induction is blocked 
by inhibiting kinases upstream of p38α (C).  Knockdown of ubiquitination complex members 
promotes cytosolic sequestration of β-catenin (D). 
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APPENDIX B 
Supplemental Table B1.  Sp1-regulated associated with growth inhibition, cell death and inhibition of 
migration/invasion after Sp1 knockdown: expected and inversely regulated genes. This table as well as 
Supplemental B2 and B3 refer to Chapter VI. 
A. 
Expected Inversely related 
decreased cell proliferation 
 
 
 
increased cell proliferation 
 
 
up-genes (118) fold 
change 
down genes 
(241) 
fold 
change 
up-genes 
(150) 
fold 
change 
down 
genes 
(120) 
fold 
change 
IFITM1 12.322 RRM2 -7.791 LMNA 9.997 CASP3 -3.784 
HMOX1 7.399 VIM -5.703 ISG15 5.775 NFIB -3.751 
CEBPD 5.371 DKK1 -4.643 C1QBP 4.647 SIRT2 -3.049 
SOD2 5.022 EGR1 -4.506 CXCL2 4.516 SPRY1 -2.903 
OAS3 4.22 FOS -4.319 CBX7 4.368 TCF12 -2.839 
IFNL1 4.039 PKM -4.043 CX3CL1 4.048 ARRDC3 -2.72 
RNH1 4.007 CCNB1 -3.893 ISG20 3.98 NFIX -2.667 
MSX1 3.958 CD44 -3.853 CCL5 3.871 RND3 -2.651 
GEMIN2 3.761 BMI1 -3.772 BATF2 3.571 ABCC5 -2.643 
IFIT3 3.75 DUSP6 -3.68 ETS1 3.545 TJP1 -2.634 
IL32 3.678 CDK19 -3.586 RCE1 3.201 KLK3 -2.632 
ABCC3 3.603 CITED2 -3.579 SET 3.167 EIF4G2 -2.619 
TIMP2 3.59 PDE5A -3.301 TNF 3.013 TRIB1 -2.587 
NPTX1 3.572 CENPF -3.165 NOTCH4 2.904 PSRC1 -2.542 
CXCL10 3.57 KIF20A -3.119 NOLC1 2.76 AKAP12 -2.536 
SERPINA3 3.451 PXN -3.096 SRPK2 2.753 NRP1 -2.48 
CD83 3.429 CCND3 -2.962 UBD 2.732 SLC9A3R
1 
-2.433 
TNFAIP3 3.066 KIF11 -2.927 NDEL1 2.707 LIN9 -2.367 
CDCA4 2.909 ASPM -2.887 SERPINH1 2.695 KIF23 -2.156 
PTX3 2.81 TOP2A -2.876 EBI3 2.681 FRMD6 -2.094 
GPR56 2.782 DDAH1 -2.847 CCL2 2.649 SPRY2 -2.073 
DACT3 2.685 EOMES -2.712 ANTXR1 2.64 KIF2C -2.066 
GBP1 2.664 SS18 -2.698 RAC2 2.57 PLOD2 -2.063 
LEPROT 2.637 MAP3K7 -2.693 LRPAP1 2.531 CDKN3 -2.053 
COMMD5 2.596 EGFR -2.562 STAT5A 2.468 ASPH -2.036 
CBL 2.56 RAP1B -2.559 TPD52 2.428 SRGAP2 -1.99 
STC1 2.49 SLC2A1 -2.53 UPP1 2.424 SESN1 -1.986 
EIF1 2.471 BIRC5 -2.525 S100A4 2.414 TGFBR2 -1.966 
TAP1 2.422 CCNA2 -2.515 DIXDC1 2.407 WASPIP -1.943 
IFNL2 2.42 PRKCA -2.515 PTPMT1 2.395 CBFB -1.929 
PARP10 2.395 HIF1A -2.482 CYP1B1 2.32 HS.13003
6 
-1.927 
PHLPP2 2.366 BUB1 -2.457 CBS 2.316 RBL2 -1.897 
MUL1 2.343 HMMR -2.446 EMP1 2.271 PHC1 -1.894 
IRF1 2.31 USP47 -2.431 SDC4 2.252 MIB1 -1.861 
HRASLS 2.294 DLGAP5 -2.398 PTP4A3 2.247 CHES1 -1.85 
BECN1 2.285 IRS1 -2.37 SHC1 2.232 HIPK2 -1.85 
RALBP1 2.277 AURKA -2.368 MVP 2.184 EGR2 -1.842 
PLSCR1 2.267 PAPSS2 -2.334 BCL2L1 2.147 APBB2 -1.837 
RARRES3 2.248 KIF20B -2.318 NAP1L1 2.135 TFAM -1.823 
TNFRSF9 2.211 DICER1 -2.301 CTSD 2.132 GJA1 -1.821 
UCP2 2.179 NEK2 -2.297 SUMO2 2.117 CCNG2 -1.787 
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GAL 2.172 CYR61 -2.284 MGAT3 2.108 RB1 -1.786 
TNFRSF14 2.162 MAPK6 -2.25 YWHAG 2.096 TP53BP2 -1.776 
SIGIRR 2.162 AGO2 -2.238 CCRK 2.095 TFPI -1.762 
SOCS1 2.153 CDCA8 -2.234 CD320 2.078 ITGA6 -1.757 
EI24 2.151 PPIA -2.23 EWSR1 2.031 ERRFI1 -1.747 
DAXX 2.144 TESK1 -2.215 FSTL3 2.028 WNK2 -1.738 
PMP22 2.12 STAT5B -2.211 SRF 2.018 CAT -1.729 
RASSF5 2.108 P4HA1 -2.201 TBP 2.002 TRIM24 -1.709 
CAMK2N1 2.052 SPTBN1 -2.188 ARHGEF2 1.991 ATG5 -1.701 
MAFG 2.038 CDK1 -2.184 CORO1B 1.99 PKP2 -1.697 
GNE 2.014 TPX2 -2.147 FEZ1 1.98 FOXF2 -1.693 
DNAJA3 2.011 ERCC1 -2.115 NCOR2 1.973 RASA1 -1.692 
SMPD1 2.009 PBK -2.106 RALGDS 1.953 FBXO11 -1.686 
IFI16 2.008 RPRD1B -2.098 CCL20 1.95 SPRED1 -1.685 
SMARCA2 1.994 TTK -2.084 GBP2 1.947 HNRNPA1 -1.675 
TNFRSF1B 1.973 YBX1 -2.083 IGF2BP3 1.946 USP10 -1.672 
LRRC32 1.969 RGS2 -2.075 MAP1B 1.943 NDFIP1 -1.67 
IFITM3 1.962 PLXNB2 -2.066 BCL3 1.938 KLHL13 -1.667 
TRAF1 1.959 LRP5 -2.036 PSMA4 1.934 B3GNT2 -1.666 
MED25 1.934 TACC3 -2.036 MYD88 1.924 HS.37160
9 
-1.659 
IFNL3 1.923 RAB22A -2.018 SLC7A5 1.913 RAD17 -1.653 
NDRG4 1.898 EGLN1 -2.008 CDK4 1.911 MAP2K1I
P1 
-1.649 
NUMA1 1.893 ECT2 -1.989 STMN3 1.908 ENPP1 -1.642 
RPS6KA2 1.889 PIK3R1 -1.986 ARF1 1.903 G3BP1 -1.64 
FBXO2 1.847 EPAS1 -1.985 ATP5G1 1.903 TOP1 -1.637 
DIABLO 1.843 FAT4 -1.983 ST5 1.898 STARD13 -1.621 
TRIM22 1.835 PPP1R13L -1.979 ID3 1.898 RAD21 -1.618 
NACC2 1.818 KIF18A -1.976 STX3 1.895 CTBP2 -1.618 
IGFBP6 1.813 NFIA -1.971 PRNP 1.857 FOXA2 -1.607 
EFNB3 1.812 CDC20 -1.966 DCLRE1A 1.85 CMA1 -1.602 
DKK3 1.805 TRIB2 -1.943 JAG1 1.837 NAB1 -1.601 
PCBP4 1.79 TTLL4 -1.935 HMGB1 1.811 TES -1.594 
QPCT 1.77 NUDT1 -1.917 NACA 1.806 RANBP9 -1.591 
GADD45A 1.755 CTGF -1.906 NOD2 1.794 PLXNA3 -1.583 
NKX3-1 1.753 NRARP -1.9 ICAM1 1.793 RTN4 -1.583 
EPHA2 1.749 TRPC1 -1.889 ABCG1 1.77 CASP7 -1.582 
PMAIP1 1.745 LBR -1.886 TAGLN2 1.769 MIR1-2 -1.58 
GDF15 1.736 RPS6KB1 -1.872 LCN2 1.764 SMPD2 -1.573 
LIMK1 1.7 CSNK1G3 -1.862 NCOA4 1.763 H2AFY -1.57 
CCL3L3 1.698 PTK2 -1.858 ALG13 1.754 PMEPA1 -1.567 
STAT2 1.692 PIP4K2A -1.856 LAP3 1.742 KLF10 -1.566 
NDUFS3 1.675 CCDC88A -1.855 LIF 1.736 CHEK2 -1.562 
SREBF1 1.672 UIMC1 -1.854 ICOSLG 1.731 SEMA3A -1.561 
ATF3 1.666 LAMC1 -1.854 CSPG5 1.73 DAB2 -1.559 
B2M 1.665 TAB2 -1.852 GCLC 1.728 SUV39H1 -1.558 
RAP1GAP 1.64 MBP -1.848 BAMBI 1.726 CTCF -1.557 
ACTN4 1.638 HGF -1.847 PRMT5 1.722 SIAH1 -1.554 
PHF14 1.626 ATMIN -1.845 CDK6 1.714 COL4A1 -1.553 
LPIN1 1.619 FRS2 -1.838 NFKB2 1.707 MERTK -1.553 
BST2 1.612 ERO1LB -1.824 SKP2 1.706 SEC23A -1.553 
IRX3 1.61 TGIF1 -1.822 PSMB10 1.705 MIR203 -1.552 
INCA1 1.609 FBXW11 -1.808 GPC1 1.695 ADORA3 -1.55 
TSC1 1.606 RACGAP1 -1.806 ATM 1.695 MIR138-1 -1.549 
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TP53I11 1.593 ZIC2 -1.803 PPL 1.688 EMX2 -1.541 
ARHGDIB 1.58 CDCA2 -1.803 IL15 1.681 APRIN -1.54 
RHOB 1.579 GBF1 -1.793 XBP1 1.681 TNFRSF8 -1.538 
JUND 1.579 ANXA2 -1.791 MNAT1 1.679 CXADR -1.537 
ZMPSTE24 1.569 ITGA2 -1.789 NP 1.677 CNKSR1 -1.535 
SIRPA 1.566 GNAI2 -1.788 PRKAR2A 1.672 PATZ1 -1.533 
NFKBIB 1.563 FOXQ1 -1.783 CDC25B 1.67 P4HA2 -1.533 
LITAF 1.55 PTGER4 -1.781 CXCL1 1.667 FAM188A -1.529 
STAT1 1.549 NFYA -1.777 CISD1 1.666 CASK -1.526 
BAG6 1.548 NBN -1.766 PLAT 1.664 TSPYL2 -1.525 
EEF1E1 1.546 STAG1 -1.763 SLC25A4 1.658 MTBP -1.524 
CEACAM1 1.545 ZMYM2 -1.762 SNX12 1.651 SPRY4 -1.519 
UXT 1.544 BLM -1.76 MED28 1.646 CAST -1.518 
NUP62 1.54 HAS2 -1.758 SPTAN1 1.644 RUNX1 -1.518 
TSC22D3 1.539 KPNA2 -1.757 MST1 1.638 BMP5 -1.517 
HSPA1A/HSPA1
B 
1.527 PTP4A2 -1.746 GPR177 1.636 ADRA1A -1.516 
NUPR1 1.527 PTPN3 -1.744 SRC 1.634 CD55 -1.514 
E2F7 1.524 DVL3 -1.744 ESRRA 1.621 KRT7 -1.512 
SAT1 1.522 RNF126 -1.733 DPYSL2 1.618 DUX4 -1.512 
BIN1 1.521 SUV420H1 -1.713 ZFP36L1 1.617 IL1RN -1.51 
PHB 1.515 NCAPG -1.71 WDR12 1.613 CAPRIN1 -1.509 
LRIG1 1.515 PRPS2 -1.705 NFKB1 1.611 ARID4A -1.504 
NAIF1 1.511 H2AFX -1.703 IL15RA 1.606 CNN2 -1.502 
AGTRAP 1.508 PYCARD -1.702 DYRK1B 1.605 BACH2 -1.501 
    MAD2L1 -1.7 NOP58 1.605 CNTN1 -1.5 
    MKI67 -1.7 PDCL3 1.6 PTPN2 -1.5 
    NRG1 -1.697 TFE3 1.593     
    INO80 -1.694 CNPY2 1.59     
    ELMO2 -1.693 USP18 1.59     
    TYMS -1.692 NFKBIA 1.588     
    ABL1 -1.689 TXLNA 1.588     
    FOXM1 -1.688 RAB33A 1.583     
    POLR3E -1.687 DUSP12 1.577     
    NFAT5 -1.686 TSPAN3 1.577     
    RAN -1.683 MYH14 1.562     
    NCOA2 -1.683 POLR2L 1.56     
    NDRG1 -1.68 PDCD10 1.558     
    KCNMA1 -1.677 PPP1R15A 1.557     
    YBX3 -1.676 ALS2 1.556     
    FGFR4 -1.675 TNFSF10 1.555     
    NFS1 -1.674 CD58 1.546     
    HGS -1.672 TNFSF9 1.545     
    AGO4 -1.67 COPS2 1.534     
    BCAR3 -1.666 TNFAIP8 1.529     
    PLAG1 -1.666 SLC3A2 1.529     
    NASP -1.661 TOP1MT 1.525     
    GAD1 -1.659 VEGFB 1.519     
    MALT1 -1.656 VGF 1.517     
    DOCK1 -1.656 TRNP1 1.517     
    PAK2 -1.654 RNASEH2B 1.516     
    DVL2 -1.653 BCL2A1 1.515     
    AKR1C1/AKR1C
2 
-1.652 CLN3 1.514     
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    ATAD2 -1.651 CDC42 1.512     
    PRKAA1 -1.651 AKIRIN2 1.508     
    KMT2C -1.651 RCAN1 1.506     
    ACVR2A -1.648 CDK5R1 1.502     
    JAK2 -1.642         
    PDK1 -1.638         
    ROR1 -1.638         
    TXNDC5 -1.637         
    YAP1 -1.632         
    F2RL1 -1.631         
    NR2C2 -1.63         
    LSM1 -1.63         
    GPN3 -1.629         
    USP7 -1.627         
    CDC45 -1.619         
    SLC29A1 -1.618         
    PAK4 -1.617         
    ARFGAP3 -1.603         
    BUB3 -1.602         
    MAPK10 -1.602         
    DIDO1 -1.601         
    LDHA -1.6         
    PTPN13 -1.6         
    F2R -1.599         
    PTTG1 -1.595         
    ACTB -1.593         
    AURKB -1.593         
    KIF2A -1.591         
    MSRA -1.59         
    CAMK4 -1.589         
    WWTR1 -1.588         
    MCM4 -1.587         
    LDLRAP1 -1.586         
    PLK1 -1.583         
    BAIAP2L1 -1.583         
    DHFR -1.581         
    AKT2 -1.579         
    NEDD4L -1.578         
    TEAD4 -1.577         
    B4GALT6 -1.575         
    KRAS -1.573         
    AR -1.57         
    TBX1 -1.567         
    PDGFC -1.566         
    SERPINB9 -1.566         
    PCGF2 -1.561         
    IL13RA1 -1.561         
    ITGB1 -1.558         
    LIN28B -1.551         
    NTS -1.549         
    CHN1 -1.545         
    POLH -1.543         
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    KDM5B -1.541         
    E2F8 -1.54         
    IL2RG -1.539         
    AGO3 -1.538         
    TP63 -1.537         
    CREB1 -1.536         
    ID4 -1.534         
    LCK -1.534         
    CIZ1 -1.534         
    SMN1/SMN2 -1.533         
    CTTN -1.532         
    SH3KBP1 -1.531         
    EPS8 -1.53         
    MCM10 -1.53         
    MCL1 -1.529         
    AKT3 -1.527         
    AKIRIN1 -1.525         
    CAMKK1 -1.524         
    AFAP1 -1.522         
    TCF4 -1.521         
    DDX17 -1.52         
    RTKN2 -1.519         
    HOXB3 -1.518         
    SGK1 -1.516         
    MEF2C -1.515         
    CDC16 -1.514         
    FGF10 -1.514         
    ABCC9 -1.513         
    CDT1 -1.513         
    CALB1 -1.51         
    RIPK1 -1.509         
    PKP3 -1.509         
    PIK3R3 -1.508         
    ACSL4 -1.508         
    UBE2C -1.508         
    NUP98 -1.508         
    mir-154 -1.507         
    VASP -1.507         
    RAF1 -1.504         
    VEGFC -1.503         
    ST6GAL1 -1.502         
    F11R -1.501         
    CHEK1 -1.5         
 
B. 
Expected Inversely related 
Increased cell death Decreased cell death 
Up-genes 
(140) 
Fold 
change 
Down 
genes 
(223) 
Fold 
change 
Up-genes 
(149) 
 
90 
Fold 
change 
Down 
genes 
(141) 
Fold 
change 
ISG15 5.775 RRM2 -7.791 HMOX1 7.399 NME4 -5.372 
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OAS1 5.763 STK40 -4.272 IFI6 5.463 DKK1 -4.643 
CEBPD 5.371 PKM2 -4.043 SOD2 5.022 EGR1 -4.506 
MX1 4.743 SLC4A7 -3.856 CXCL2 4.516 FOS -4.319 
OAS3 4.220 CD44 -3.853 LGALS3B
P 
4.241 CCNB1 -3.893 
CX3CL1 4.048 BMI1 -3.772 IL29 4.039 CASP3 -3.784 
NPTX1 3.572 NFIB -3.751 MSX1 3.958 DUSP6 -3.680 
CXCL10 3.570 CITED2 -3.579 STX8 3.903 PDE5A -3.301 
ETS1 3.545 DEK -3.429 CCL5 3.871 SIRT2 -3.049 
HS1BP3 3.536 PCNA -3.224 SIP1 3.761 DNASE1L1 -3.038 
IFIH1 3.332 CENPF -3.165 IFIT3 3.750 TOP2A -2.876 
SMARCC1 3.297 PXN -3.096 IL32 3.678 TCF12 -2.839 
SET 3.167 CCND3 -2.962 ABCC3 3.603 TFDP2 -2.646 
TNF 3.013 KIF11 -2.927 TIMP2 3.590 APOBEC3B -2.518 
NOTCH4 2.904 EOMES -2.712 SERPINA3 3.451 HMMR -2.446 
NFKBIZ 2.775 MAP3K7 -2.693 SELE 3.414 SPAG5 -2.398 
SRPK2 2.753 NFIX -2.667 TUB 3.155 ANTXR2 -2.383 
UBD 2.732 RND3 -2.651 TNFAIP3 3.066 SLC25A24 -2.320 
BOK 2.709 ABCC5 -2.643 HSPBP1 2.927 ZFYVE16 -2.307 
CASP4 2.672 KLK3 -2.632 DAG1 2.771 ZAK -2.283 
ANTXR1 2.640 EIF4G2 -2.619 NOLC1 2.760 CCDC109A -2.260 
ADORA2A 2.600 TRIB1 -2.587 NDEL1 2.707 ATP2A2 -2.192 
RAC2 2.570 EGFR -2.562 HAND1 2.707 SPTBN1 -2.188 
STC1 2.490 RAP1B -2.559 SERPINH1 2.695 CDC2 -2.184 
ZC3H12A 2.471 PON2 -2.548 CCL2 2.649 UACA -2.156 
ITGB3BP 2.384 AKAP12 -2.536 CBL 2.560 FRMD6 -2.094 
CYP1B1 2.320 SLC2A1 -2.530 LRPAP1 2.531 GULP1 -2.088 
IRF1 2.310 BIRC5 -2.525 PCTP 2.523 TTK -2.084 
HRASLS 2.294 PRKCA -2.515 STAT5A 2.468 CKAP2 -2.054 
BECN1 2.285 HIF1A -2.482 TRIAP1 2.438 CDKN3 -2.053 
SP110 2.277 NRP1 -2.480 TPD52 2.428 LRP5 -2.036 
EMP1 2.271 USP47 -2.431 IL28A 2.420 ELF4 -2.022 
PLSCR1 2.267 NEK6 -2.426 S100A4 2.414 RAB22A -2.018 
PI3 2.266 NDC80 -2.415 PSMB8 2.407 FAF1 -1.993 
MYH9 2.255 KIF14 -2.384 PTPMT1 2.395 ECT2 -1.989 
SDC4 2.252 IRS1 -2.370 ACO2 2.371 SNAP25 -1.980 
SHC1 2.232 AURKA -2.368 LMO4 2.318 CDC20 -1.966 
TNFRSF9 2.211 SOX21 -2.322 CBS 2.316 WASPIP -1.943 
MVP 2.184 DICER1 -2.301 GBA 2.230 TRIB2 -1.943 
DAXX 2.144 NEK2 -2.297 GAL 2.172 TRAF7 -1.941 
IFIT2 2.121 CYR61 -2.284 SIGIRR 2.162 HS.130036 -1.927 
PMP22 2.120 EIF2C2 -2.238 SOCS1 2.153 ST3GAL3 -1.914 
RNF13 2.118 PPIA -2.230 EI24 2.151 TRPS1 -1.913 
FSTL3 2.028 STAT5B -2.211 BCL2L1 2.147 FBXO32 -1.910 
DNAJA3 2.011 CENPE -2.197 WFS1 2.137 SCP2 -1.900 
SMPD1 2.009 CCT3 -2.181 MGAT3 2.108 FAM72A -1.875 
IFI16 2.008 TUBB3 -2.150 YWHAG 2.096 BUB1B -1.867 
PRELID1 2.005 TPX2 -2.147 EBAG9 2.091 MIB1 -1.861 
SMARCA2 1.994 DHRS2 -2.132 ECGF1 2.090 CCDC88A -1.855 
LAMP1 1.975 NT5E -2.120 OSCAR 2.088 HIPK2 -1.850 
TNFRSF1
B 
1.973 SRI -2.120 BEX2 2.082 MBP -1.848 
NCOR2 1.973 ERCC1 -2.115 PINK1 2.062 XPR1 -1.842 
MAP3K8 1.958 PBK -2.106 WDR4 2.045 RFK -1.832 
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MAP1B 1.943 SORBS2 -2.105 MAFG 2.038 TIA1 -1.822 
XAF1 1.940 CCT5 -2.088 EWSR1 2.031 CDC25C -1.810 
MYD88 1.924 YBX1 -2.083 MAD2L2 2.028 CABLES2 -1.799 
CDK4 1.911 SPRY2 -2.073 RGS10 2.022 MAP3K9 -1.785 
ID3 1.898 STIL -2.041 SRF 2.018 PTGER4 -1.781 
PARP14 1.897 TACC3 -2.036 TBP 2.002 TP53BP2 -1.776 
NUMA1 1.893 EGLN1 -2.008 ARHGEF2 1.991 STAG1 -1.763 
RPS6KA2 1.889 HIPK3 -1.993 TAOK3 1.978 TFPI -1.762 
OGDH 1.888 PIK3R1 -1.986 TRAF1 1.959 BLM -1.760 
IRAK2 1.882 EPAS1 -1.985 BCL3 1.938 ITGA6 -1.757 
PRNP 1.857 FAT4 -1.983 CAMK2G 1.920 TSC22D2 -1.750 
DIABLO 1.843 MED29 -1.983 PLEC1 1.916 MELK -1.729 
PTRH2 1.836 PPP1R13L -1.979 NUAK1 1.890 MCM7 -1.723 
CANX 1.829 TGFBR2 -1.966 SCYL1 1.861 CD69 -1.707 
SFT2D2 1.821 CENPA -1.965 STXBP1 1.850 H2AFX -1.703 
NACC2 1.818 CKAP5 -1.947 FBXO2 1.847 PYCARD -1.702 
IGFBP6 1.813 CBFB -1.929 MAPKAP1 1.844 ATG5 -1.701 
HMGB1 1.811 NUDT1 -1.917 GCLM 1.837 MAD2L1 -1.700 
DKK3 1.805 GPHN -1.909 JAG1 1.837 HS.551128 -1.697 
ICAM1 1.793 CTGF -1.906 BCL2L2 1.837 FOXF2 -1.693 
OLR1 1.786 RBL2 -1.897 BFAR 1.800 RASA1 -1.692 
IRF7 1.774 TRPC1 -1.889 MEF2D 1.797 ABL1 -1.689 
TGFBI 1.772 FBXO5 -1.873 SH3GLB1 1.795 FGFR4 -1.675 
LCN2 1.764 RPS6KB1 -1.872 PEA15 1.779 PPP2R5A -1.660 
B4GALT5 1.760 PTK2 -1.858 SLC40A1 1.779 HS.371609 -1.659 
GADD45A 1.755 UIMC1 -1.854 ABCG1 1.770 MALT1 -1.656 
NKX3-1 1.753 MAP3K7IP2 -1.852 TAGLN2 1.769 DOCK1 -1.656 
CMIP 1.751 HGF -1.847 NCOA4 1.763 PAK2 -1.654 
EPHA2 1.749 ATMIN -1.845 HLA-F 1.761 SDC1 -1.638 
EIF2S1 1.747 PIAS2 -1.844 NAGLU 1.760 PDK1 -1.638 
PMAIP1 1.745 EGR2 -1.842 GDF15 1.736 TOP1 -1.637 
LIF 1.736 HS.334831 -1.838 ICOSLG 1.731 ATN1 -1.632 
CSTB 1.725 TFAM -1.823 GCLC 1.728 PERP -1.632 
CDK6 1.714 CDCP1 -1.816 PRMT5 1.722 F2RL1 -1.631 
SHISA5 1.709 RACGAP1 -1.806 CLCN7 1.709 USP7 -1.627 
DRAM1 1.708 CDCA2 -1.803 NFKB2 1.707 RAD21 -1.618 
CCL3L3 1.698 GJB2 -1.796 SKP2 1.706 SLC29A1 -1.618 
GPC1 1.695 ANXA2 -1.791 PSMB10 1.705 REPS2 -1.616 
ATM 1.695 ITGA2 -1.789 CYB5A 1.699 TLR1 -1.609 
STAT2 1.692 RB1 -1.786 HBXIP 1.690 STAP2 -1.607 
IL15 1.681 NFYA -1.777 XBP1 1.681 MAPK10 -1.602 
SREBF1 1.672 NSF -1.777 MNAT1 1.679 LDHA -1.600 
ZNF622 1.668 TBL1XR1 -1.771 NP 1.677 PTPN13 -1.600 
ATF3 1.666 NBN -1.766 RPS24 1.672 F2R -1.599 
B2M 1.665 ZMYM2 -1.762 ARID3B 1.668 PTTG1 -1.595 
PLAT 1.664 HAS2 -1.758 CXCL1 1.667 RANBP9 -1.591 
RFXANK 1.658 KPNA2 -1.757 BCL2L13 1.664 CAMK4 -1.589 
SLC25A4 1.658 PTP4A2 -1.746 CHMP4B 1.660 RTN4 -1.583 
BRMS1 1.657 HADHA -1.746 RAB32 1.658 CASP7 -1.582 
HRASLS3 1.645 SPG7 -1.740 MED28 1.646 CCBL1 -1.581 
ADI1 1.638 PSIP1 -1.734 RAP1GAP 1.640 MIR1-2 -1.580 
PPP1R15
B 
1.631 FBXL5 -1.733 MST1 1.638 SLAMF6 -1.579 
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EFHC1 1.627 DMD -1.731 DDAH2 1.635 KRAS -1.573 
MLKL 1.625 CAT -1.729 SRC 1.634 SMPD2 -1.573 
MLLT11 1.620 TOP2B -1.719 STRADB 1.623 AR -1.570 
PRR7 1.617 SERP1 -1.715 INTS1 1.619 PMEPA1 -1.567 
AKAP1 1.614 TRIM24 -1.709 NFKB1 1.611 CHEK2 -1.562 
SDHC 1.613 GLUD1 -1.705 IL15RA 1.606 SEMA3A -1.561 
DUSP2 1.612 MKI67 -1.700 TSC1 1.606 DAB2 -1.559 
TP53I11 1.593 TYMS -1.692 FLOT2 1.605 ITGB1 -1.558 
CNPY2 1.590 NUPL1 -1.691 APH1B 1.604 SIAH1 -1.554 
CTSL1 1.587 FOXM1 -1.688 DNAJA1 1.599 MIR203 -1.552 
MTCP1 1.583 NFAT5 -1.686 USP18 1.590 ADORA3 -1.550 
ARHGDIB 1.580 NCOA2 -1.683 DDIT4 1.589 MIR138-1 -1.549 
RHOB 1.579 NDRG1 -1.680 NFKBIA 1.588 CAPN10 -1.545 
DEDD2 1.569 KCNMA1 -1.677 JUND 1.579 POLH -1.543 
SIRPA 1.566 CSDA -1.676 SNCB 1.568 IL2RG -1.539 
NFKBIB 1.563 CCT6A -1.676 UBQLN1 1.560 TNFRSF8 -1.538 
RBM43 1.558 PLK4 -1.674 PDCD10 1.558 DEPDC1 -1.537 
PPP1R15
A 
1.557 USP10 -1.672 ALS2 1.556 ZMYND11 -1.536 
TNFSF10 1.555 EIF2C4 -1.670 WDR68 1.555 CNKSR1 -1.535 
STAT1 1.549 TNFRSF10
D 
-1.659 IFNGR2 1.554 RRM1 -1.534 
BAT3 1.548 PP8 -1.656 ATP5S 1.553 SH2D4A -1.534 
EEF1E1 1.546 SPC25 -1.655 CEACAM1 1.545 PRKDC -1.533 
TNFSF9 1.545 FIGNL1 -1.652 UXT 1.544 SH3KBP1 -1.531 
HCST 1.542 ATAD2 -1.651 NFE2L1 1.544 SCRIB -1.530 
CHMP5 1.542 PRKAA1 -1.651 VOPP1 1.542 AFAP1 -1.522 
MCOLN2 1.542 WEE1 -1.646 MBOAT7 1.541 RUNX1 -1.518 
NUPR1 1.527 TPM3 -1.646 NUP62 1.540 PCDHGA3 -1.514 
HTATIP2 1.525 CCNI -1.643 TSC22D3 1.539 CDT1 -1.513 
SAT1 1.522 JAK2 -1.642 BCL2L12 1.536 RIPK1 -1.509 
BIN1 1.521 CES1 -1.640 TNFAIP8 1.529 ULBP3 -1.508 
VGF 1.517 HS.128753 -1.638 SLC3A2 1.529 ING3 -1.506 
CDC42 1.512 TXNDC5 -1.637 HSPA1B 1.527 SELL -1.506 
TMEM158 1.506 BCKDK -1.637 HSPE1 1.527 TRIM13 -1.506 
SNN 1.500 ZNF184 -1.634 E2F7 1.524 PHF17 -1.503 
    YAP1 -1.632 GRINA 1.524 BACH2 -1.501 
    HLTF -1.632 VEGFB 1.519 PTPN2 -1.500 
    CASC5 -1.631 PI4KB 1.517     
    NR2C2 -1.630 BCL2A1 1.515     
    CDC45L -1.619 PHB 1.515     
    DPYD -1.618 CLN3 1.514     
    CIT -1.618 TNIP2 1.507     
    ELMO1 -1.618 RCAN1 1.506     
    RAD18 -1.618 DAD1 1.503     
    CTBP2 -1.618 CDK5R1 1.502     
    PAK4 -1.617         
    FOXA2 -1.607         
    DIDO1 -1.601         
    LGMN -1.586         
    PLK1 -1.583         
    AKT2 -1.579         
    NCAPG2 -1.577         
    PDGFC -1.566         
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    SERPINB9 -1.566         
    CDC14A -1.562         
    EDNRB -1.558         
    CTCF -1.557         
    CASZ1 -1.555         
    ASAH2 -1.554         
    COL4A1 -1.553         
    MERTK -1.553         
    NTS -1.549         
    FOXB1 -1.545         
    BLVRA -1.543         
    SP3 -1.542         
    EMX2 -1.541         
    GABRR1 -1.540         
    E2F8 -1.540         
    EXOC2 -1.538         
    EIF2C3 -1.538         
    TP73L -1.537         
    CXADR -1.537         
    CREB1 -1.536         
    SMN1 -1.533         
    CTTN -1.532         
    MCM10 -1.530         
    MIR135A2 -1.529         
    MCL1 -1.529         
    AKT3 -1.527         
    ABCC4 -1.524         
    MTBP -1.524         
    CAMKK1 -1.524         
    CP -1.524         
    PDE4B -1.522         
    TCF4 -1.521         
    LRP2 -1.519         
    NHEJ1 -1.519         
    CAST -1.518         
    BMP5 -1.517         
    ABCE1 -1.517         
    SGK1 -1.516         
    ADRA1A -1.516         
    MEF2C -1.515         
    CLEC5A -1.515         
    FGF10 -1.514         
    SIAH2 -1.514         
    CD55 -1.514         
    RABGGTB -1.511         
    VPS13A -1.511         
    IL1RN -1.510         
    CALB1 -1.510         
    NOVA1 -1.509         
    CAPRIN1 -1.509         
    PKP3 -1.509         
    ACSL4 -1.508         
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    UBE2C -1.508         
    DNAJB1 -1.507         
    MIR655 -1.507         
    VASP -1.507         
    PARD3 -1.505         
    HS.24119 -1.505         
    RAF1 -1.504         
    PDZK1 -1.503         
    VEGFC -1.503         
    ST6GAL1 -1.502         
    NEK1 -1.502         
    MOBKL2C -1.501         
    CHEK1 -1.500         
 
C. 
Expected Inversely related  
decreased migration 
 
 
 
 
 
 
increased migration 
 
 
 
 
 
 
up-genes 
(19) 
increased 
migration 
 
 
 
 
 
 
down genes 
(65) 
fold 
change 
up-genes 
(36) 
fold 
change 
down genes 
(19) 
fold 
change 
HMOX1 7.399 VIM -5.703 SOD2 5.022 ARRDC3 -2.72 
TIMP2 3.59 EGR1 -4.506 C1QBP 4.647 NRP1 -2.48 
EBI3 2.681 CD44 -3.853 CX3CL1 4.048 IRS1 -2.37 
MYH9 2.255 BMI1 -3.772 CCL5 3.871 SPRY2 -2.073 
CMTM8 2.139 PXN -3.096 CXCL10 3.57 FAF1 -1.993 
IFIT2 2.121 TCF12 -2.839 ETS1 3.545 GJA1 -1.821 
DNAJA3 2.011 MAP3K7 -2.693 DPAGT1 3.026 CAT -1.729 
IL15 1.681 EGFR -2.562 TNF 3.013 GNAI1 -1.705 
ATF3 1.666 RAP1B -2.559 CCL2 2.649 RASA1 -1.692 
BRMS1 1.657 SLC2A1 -2.53 S100A4 2.414 NDRG1 -1.68 
RAP1GAP 1.64 PRKCA -2.515 PTP4A3 2.247 TPM3 -1.646 
DPYSL2 1.618 HIF1A -2.482 SHC1 2.232 MIR1-2 -1.58 
TSC1 1.606 HMMR -2.446 MAP3K8 1.958 CHST10 -1.578 
ARHGDIB 1.58 SLC9A3R1 -2.433 CCL20 1.95 SEMA3A -1.561 
SIRPA 1.566 AURKA -2.368 STMN3 1.908 TP73L -1.537 
TNFSF10 1.555 CYR61 -2.284 ARF1 1.903 FAM188A -1.529 
STAT1 1.549 ECT2 -1.989 IGFBP6 1.813 MTBP -1.524 
HTATIP2 1.525 CTGF -1.906 EFNB3 1.812 LAMC2 -1.509 
GRINA 1.524 PPFIA1 -1.889 EPHA2 1.749 VASP -1.507 
    PTK2 -1.858 GDF15 1.736     
    CCDC88A -1.855 PRMT5 1.722     
    HGF -1.847 LIMK1 1.7     
    CDCP1 -1.816 CDC25B 1.67     
    ANXA2 -1.791 HRASLS3 1.645     
    ITGA2 -1.789 ACTN4 1.638     
    FOXQ1 -1.783 MST1 1.638     
    PTGER4 -1.781 SRC 1.634     
    HAS2 -1.758 ESRRA 1.621     
    KPNA2 -1.757 IL15RA 1.606     
    ITGA6 -1.757 DYRK1B 1.605     
    PTP4A2 -1.746 RHOB 1.579     
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    SSH1 -1.708 TNFAIP8 1.529     
    NRG1 -1.697 VEGFB 1.519     
    FOXM1 -1.688 VGF 1.517     
    BCAR3 -1.666 PHB 1.515     
    DOCK1 -1.656 CDC42 1.512     
    PAK2 -1.654         
    DVL2 -1.653         
    JAK2 -1.642         
    PDK1 -1.638         
    ROR1 -1.638         
    F2RL1 -1.631         
    ELMO1 -1.618         
    CTBP2 -1.618         
    LMO7 -1.618         
    DIDO1 -1.601         
    F2R -1.599         
    PTTG1 -1.595         
    RANBP9 -1.591         
    WWTR1 -1.588         
    KRAS -1.573         
    AR -1.57         
    DAB2 -1.559         
    RAP2A -1.559         
    ITGB1 -1.558         
    MERTK -1.553         
    LIN28B -1.551         
    LCK -1.534         
    CTTN -1.532         
    AKT3 -1.527         
    AFAP1 -1.522         
    FGF10 -1.514         
    ACSL4 -1.508         
    VEGFC -1.503         
    ST6GAL1 -1.502         
 
 
Supplemental Table B2.  Sp3-regulated associated with growth inhibition, cell death and inhibition of 
migration/invasion after Sp3 knockdown:  expected and inversely regulated genes.  
A. 
Expected  Inversely related  
decreased cell proliferation 
 
 
 
increased cell proliferation 
 
 
  
up-genes (58) fold 
change 
down genes 
(429) 
fold 
change 
up-genes (112) fold 
change 
down 
genes (244) 
fold change 
TXNIP 5.257 EGR1 -15.086 LMNA 12.109 TRIB1 -4.97 
SREBF1 4.275 RAC1 -8.138 CBX7 4.092 CAST -4.411 
CDCA4 3.527 RRM2 -7.011 SET 3.643 RNF144 -4.078 
RNH1 3.391 IL8 -6.204 C1QBP 3.473 STAT1 -4.047 
HMGB3 3.034 BIRC3 -6.182 DEPDC6 3.277 TNFRSF21 -4.036 
UCP2 2.945 FOS -5.573 TFF3 3.153 STEAP3 -3.66 
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SIP1 2.815 LAMC1 -5.183 HMGB2 2.987 PHLDA1 -3.657 
PCBP4 2.509 CTGF -4.591 HMGB1 2.955 ARRDC3 -3.535 
FBXO2 2.378 PLAU -4.394 LRPAP1 2.864 EGR2 -3.392 
SIGIRR 2.242 DUSP6 -4.233 SUMO2 2.73 YWHAZ -3.362 
MED25 2.232 PRPS2 -4.109 RCE1 2.715 WASPIP -3.325 
DACT3 2.223 DDX58 -4.085 PTPMT1 2.69 SPRY2 -3.196 
NUMA1 2.124 DKK1 -4.018 HOXC6 2.663 RAD17 -3.17 
DNAJA3 2.113 SDCBP -3.874 H3F3B 2.633 FRMD6 -3.158 
MXD4 2.018 VCL -3.829 NCOR2 2.551 TGFBR2 -3.154 
EIF1 2.017 CYP2J2 -3.777 PLAC8 2.516 KLK3 -3.093 
MSX1 1.973 ITGB1 -3.766 EMP1 2.435 CD83 -3.068 
ACTN4 1.946 NFKBIA -3.735 DIXDC1 2.364 TOM1L1 -2.981 
HSPA1B 1.939 E2F5 -3.714 YWHAG 2.3 AKAP12 -2.889 
CDKN2C 1.935 OPA1 -3.536 S100A4 2.256 SPRY1 -2.87 
GPR56 1.925 CXCL1 -3.471 PFDN5 2.173 ASPH -2.842 
NR2F2 1.864 F2RL1 -3.358 H2AFX 2.155 TFPI -2.787 
LGALS7 1.803 NQO1 -3.309 CORO1B 2.131 BMPR2 -2.784 
TSC22D3 1.778 DOCK1 -3.257 SERPINH1 2.094 DUSP5 -2.772 
MUL1 1.731 RAF1 -3.186 SRF 2.08 EIF4G2 -2.741 
COMMD5 1.722 NRG1 -3.129 PIM3 2.073 RB1 -2.707 
CDKN2D 1.717 SEMA4D -3.083 EWSR1 2.041 SPRY4 -2.691 
HRASLS 1.714 VASP -3.034 CBS 2.022 PPP2R2C -2.691 
AGR2 1.713 CTNNB1 -3.028 ACLY 2.006 CASP2 -2.648 
RPL26 1.712 PPP1R13L -3.01 TBP 2.003 SMAD3 -2.627 
SH2B3 1.705 KIF2A -2.967 NDEL1 1.973 PNPT1 -2.597 
DAXX 1.703 CD151 -2.924 ISG15 1.97 NFE2L2 -2.573 
MTA1 1.691 BIRC2 -2.921 NOP58 1.961 ABCC5 -2.562 
CBL 1.683 CCL20 -2.862 TPD52 1.951 EIF2AK2 -2.549 
STRA13 1.68 NASP -2.853 RPS15A 1.938 SERINC3 -2.518 
RALBP1 1.655 SERPINE1 -2.835 NACA 1.927 CAV1 -2.515 
PEBP1 1.63 EOMES -2.815 POLR2L 1.917 CAPRIN2 -2.477 
CDKN1C 1.62 PLK2 -2.805 NOLC1 1.909 RASA1 -2.476 
EI24 1.604 LCN2 -2.759 ATP5G1 1.893 IFNGR1 -2.47 
ATPIF1 1.6 TXNDC5 -2.702 ARF1 1.885 PIAS3 -2.463 
CD24 1.6 AFAP1 -2.7 LSMD1 1.868 RNASEL -2.461 
ERF 1.59 ERCC1 -2.684 MCM8 1.851 TRIB3 -2.368 
NFKBIB 1.581 ADAR -2.639 DVL2 1.826 BHLHB2 -2.357 
ARID1A 1.575 NBN -2.614 CTSD 1.819 CBFB -2.357 
EMD 1.558 MAPK9 -2.609 LGALS1 1.802 HAS3 -2.356 
MNX1 1.554 YAP1 -2.596 NAP1L1 1.802 BTG2 -2.355 
PKD1 1.553 PRKAA1 -2.582 SPTAN1 1.793 TFPI2 -2.296 
DBI 1.551 STAM2 -2.568 ETS1 1.787 ROCK1 -2.293 
LAMA5 1.54 MCL1 -2.526 CREB1 1.782 DFNA5 -2.283 
NDUFS3 1.539 DNM1L -2.506 PIP5K2B 1.78 PMP22 -2.272 
GPI 1.538 IER3 -2.506 CSF2RA 1.777 KDM3B -2.263 
UXT 1.536 SSR1 -2.498 VKORC1 1.777 APBB2 -2.252 
DNAJB6 1.534 CD81 -2.482 RPS9 1.755 PPP2R1B -2.252 
GADD45A 1.519 CDC16 -2.468 CDC42 1.731 NOTCH2 -2.247 
C1QL4 1.509 PIGN -2.447 DPYSL2 1.725 TICAM2 -2.242 
617 
 
GNE 1.508 SGK3 -2.441 E2F4 1.721 CTH -2.236 
MAFG 1.502 JAK1 -2.43 DYRK1B 1.716 G3BP1 -2.234 
IFITM1 1.501 NOC3L -2.425 RANBP1 1.715 CRLF3 -2.228 
    DICER1 -2.424 PSMA4 1.711 NDFIP1 -2.216 
    CCNB1 -2.424 AHNAK 1.71 CASP7 -2.216 
    CCDC6 -2.416 CRCP 1.707 TAX1BP3 -2.213 
    TNF -2.402 LEP 1.704 ITGA6 -2.21 
    B4GALT6 -2.395 HS.57079 1.694 ROCK2 -2.194 
    ADCY3 -2.394 S100A6 1.681 MERTK -2.188 
    CD44 -2.382 HS.535028 1.67 UBE2D3 -2.184 
    REL -2.38 BASP1 1.663 CAT -2.164 
    ITGB4 -2.377 MKL1 1.657 WDR48 -2.144 
    NR2C2 -2.373 ILF3 1.652 SEC23A -2.123 
    MAP3K11 -2.354 ODC1 1.652 ERRFI1 -2.107 
    PDE4D -2.344 S100A13 1.649 LIFR -2.1 
    EIF2C2 -2.342 HSPA5 1.648 PKP2 -2.097 
    HS.128753 -2.337 CYBA 1.645 RBL2 -2.096 
    CCDC115 -2.337 GPR177 1.644 RNF14 -2.086 
    RAB22A -2.332 CCNF 1.642 QPCT -2.085 
    RAN -2.33 CTSB 1.64 TJP1 -2.079 
    SDC4 -2.323 IL11 1.634 RCHY1 -2.075 
    ELMO2 -2.316 DIDO1 1.63 RNF10 -2.061 
    USP18 -2.311 VEGFB 1.627 ANXA7 -2.048 
    CTTN -2.309 PPARBP 1.613 JUNB -2.031 
    ATP7A -2.299 ICMT 1.609 KIFAP3 -2.015 
    CHUK -2.299 ISG20 1.6 KRIT1 -2.004 
    RNMT -2.288 CDC25B 1.597 WTAP -1.972 
    TRPC1 -2.287 PPL 1.587 B3GNT2 -1.968 
    MAP3K7 -2.285 BCL2L1 1.587 TBK1 -1.966 
    ICAM1 -2.285 CDK6 1.581 CUL2 -1.949 
    LATS2 -2.276 SHC1 1.58 APPL1 -1.947 
    BIRC5 -2.274 MGAT3 1.579 PTPN12 -1.934 
    GFM1 -2.27 MXD3 1.575 S100A11 -1.932 
    CX3CL1 -2.264 NME3 1.574 DAB2 -1.919 
    PPP3CB -2.249 ELAVL1 1.574 SFN -1.916 
    TGIF1 -2.236 SELK 1.573 PARG -1.915 
    MLL3 -2.234 STX3 1.571 ZFP36 -1.914 
    IL13RA1 -2.222 MCM4 1.549 TNFAIP3 -1.913 
    NUP98 -2.219 DCLRE1A 1.547 TUSC2 -1.907 
    MAP2K1 -2.213 SEC61G 1.54 OSBPL2 -1.907 
    FOSL1 -2.21 FASN 1.536 PPM1A -1.897 
    LIN28B -2.204 AES 1.529 PLOD2 -1.894 
    CENPF -2.199 PTGDS 1.527 KLF10 -1.893 
    SOX8 -2.198 SNX12 1.527 MAP3K7IP
3 
-1.889 
    HEYL -2.175 SUMO1 1.523 CASP3 -1.884 
    CSNK1G3 -2.175 GLRX 1.521 SPRED1 -1.882 
    NFKB1 -2.167 NSA2 1.521 DYRK1A -1.877 
    CDK2 -2.158 HES6 1.52 SGPL1 -1.877 
    STAT4 -2.128 MVP 1.518 ATG7 -1.869 
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    EBI3 -2.121 PEG10 1.518 ELF1 -1.868 
    SLC12A2 -2.114 CISD1 1.518 OAS3 -1.862 
    PDPK1 -2.104 COX17 1.514 FBXO11 -1.856 
    SMO -2.098 SLC44A4 1.514 MIB1 -1.849 
    ACVR1 -2.095 SLC25A33 1.51 INPPL1 -1.849 
    LBR -2.09 EDF1 1.508 ASNS -1.844 
    DDX5 -2.089 ULK1 1.501 PTX3 -1.843 
    SGK1 -2.077 ABCG1 1.5 PCYOX1 -1.843 
    AMACR -2.07     PPARA -1.841 
    TPR -2.064     ABLIM1 -1.833 
    UPP1 -2.06     IRF1 -1.833 
    RIPK1 -2.06     PPARG -1.831 
    PIK3R2 -2.06     DCBLD2 -1.829 
    PIK3CA -2.054     TES -1.826 
    SLC20A1 -2.054     CHEK2 -1.824 
    FAT4 -2.053     TRIM24 -1.803 
    CUL4A -2.051     SMAD4 -1.8 
    ZNF16 -2.05     BAT3 -1.795 
    IDE -2.049     CTNNBIP1 -1.794 
    PTPN3 -2.044     VHL -1.794 
    NCCRP1 -2.027     E2F7 -1.786 
    CUL1 -2.025     ULK2 -1.784 
    CDC14B -2.022     CCNG2 -1.781 
    CXCL2 -2.021     NPTX1 -1.78 
    PTHLH -2.018     ABTB1 -1.777 
    DSG2 -2.015     TNFRSF1B -1.771 
    HS.570988 -2.008     CYLD -1.771 
    IDH2 -2.008     LIPA -1.77 
    YES1 -2.004     VPS39 -1.766 
    VGF -2.002     P4HA2 -1.758 
    TIMP1 -2.002     ARID4B -1.754 
    SPTBN1 -2.002     IQGAP1 -1.751 
    PHIP -1.999     NME6 -1.746 
    MKNK1 -1.998     USP16 -1.741 
    S1PR3 -1.994     TRIM21 -1.739 
    DDX21 -1.992     JARID2 -1.736 
    USP47 -1.99     GEM -1.736 
    GAB2 -1.989     VAMP7 -1.733 
    DUSP10 -1.986     PARP10 -1.723 
    UBE2A -1.985     FAM188A -1.722 
    HSPA4 -1.984     IL28A -1.722 
    NAE1 -1.982     DUSP1 -1.72 
    HNRPK -1.981     PAK1IP1 -1.72 
    ARFGAP3 -1.98     CD40 -1.717 
    MINA -1.976     TANK -1.717 
    ADAM17 -1.975     AKTIP -1.717 
    CIAO1 -1.972     ARID4A -1.715 
    SEMA4C -1.971     CYP2S1 -1.712 
    PAPSS2 -1.967     TNFRSF1A -1.708 
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    CLN3 -1.966     DNER -1.708 
    E2F3 -1.964     HS.371609 -1.7 
    NFYA -1.962     PPP2R5C -1.695 
    ARFGEF1 -1.959     SRM -1.694 
    CYR61 -1.957     EPHX2 -1.69 
    SERTAD1 -1.953     RAPGEF2 -1.688 
    TRIM39 -1.95     HIAT1 -1.688 
    KIAA1429 -1.944     EFNA1 -1.684 
    TNFAIP8 -1.942     OBFC2A -1.68 
    PTPRA -1.941     CDKN1A -1.678 
    SUV420H1 -1.94     AXIN1 -1.676 
    RPS6KA3 -1.939     SESN1 -1.675 
    CD164 -1.937     SERPINA3 -1.675 
    NCK1 -1.935     CBLB -1.673 
    LAP3 -1.934     DDX3X -1.669 
    PRKAR1A -1.933     PROS1 -1.668 
    TIRAP -1.933     PPP2CA -1.667 
    PIK3C2A -1.931     TLR6 -1.666 
    ZMYM2 -1.931     TP53BP2 -1.659 
    GCH1 -1.93     CASK -1.659 
    UGCG -1.928     ENPP1 -1.657 
    OPTN -1.926     ITPR1 -1.653 
    CSNK2A1 -1.924     RHOB -1.651 
    ITGAV -1.924     VLDLR -1.648 
    ACTB -1.921     PHF14 -1.647 
    P4HA1 -1.911     KEAP1 -1.644 
    CITED2 -1.909     STX2 -1.641 
    PRMT6 -1.908     RANBP9 -1.641 
    KPNA2 -1.905     PXMP3 -1.639 
    IMPACT -1.904     MORC3 -1.622 
    EXOC5 -1.899     GABPB2 -1.62 
    AMD1 -1.898     MINPP1 -1.62 
    GAD1 -1.897     DYNC1H1 -1.617 
    NPC1 -1.897     TOP1 -1.615 
    SPAST -1.896     KLF6 -1.611 
    ZNF259 -1.893     ADIPOR1 -1.603 
    PRKCA -1.889     TAP1 -1.602 
    DDX17 -1.887     CAPRIN1 -1.6 
    CCPG1 -1.887     B3GNT5 -1.599 
    RAB5A -1.883     LAT2 -1.592 
    FOXQ1 -1.88     SAV1 -1.59 
    MAPK1 -1.879     AATF -1.585 
    FNDC3B -1.879     TMEM127 -1.584 
    MYD88 -1.878     RNF4 -1.58 
    KIAA0261 -1.876     UBIAD1 -1.579 
    TFDP1 -1.875     FOXF2 -1.578 
    ITGA2 -1.873     RND3 -1.577 
    ARHGAP1 -1.873     CTNNA1 -1.576 
    ACTL6A -1.873     PARK2 -1.575 
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    JUN -1.871     SMYD2 -1.574 
    XRCC5 -1.856     MXD1 -1.572 
    STK38L -1.848     CSNK1A1 -1.571 
    ADAM9 -1.842     ABI1 -1.569 
    FAS -1.837     RHOH -1.569 
    TLN1 -1.837     CTCF -1.566 
    SS18 -1.833     CSE1L -1.566 
    EML4 -1.831     KIF23 -1.565 
    KRAS -1.824     IGFBP4 -1.559 
    PDGFC -1.82     IL28B -1.558 
    PPP1CA -1.818     FKTN -1.551 
    SHMT1 -1.816     CDK8 -1.549 
    DLGAP5 -1.813     BACH2 -1.546 
    AKIRIN1 -1.812     TAF6 -1.546 
    DDAH1 -1.81     STRN -1.541 
    NAMPT -1.808     ABCC1 -1.541 
    KIF20B -1.807     PTPN2 -1.54 
    RBM3 -1.798     TOPBP1 -1.534 
    GLDC -1.797     RNF111 -1.534 
    VEGFC -1.796     H2AFY -1.534 
    MIR21 -1.795     IFT57 -1.531 
    RECQL -1.794     RB1CC1 -1.523 
    API5 -1.794     PBRM1 -1.523 
    STK39 -1.793     TCF12 -1.522 
    HS.334831 -1.789     HNRNPL -1.522 
    CBX2 -1.785     HES1 -1.522 
    BCAT1 -1.782     IVNS1ABP -1.519 
    LEPR -1.779     EMILIN2 -1.518 
    LARP1 -1.778     CDC2L1 -1.516 
    RGPD8 -1.776     IFIT3 -1.515 
    RFC1 -1.775     RBM5 -1.514 
    BMPR1A -1.775     ATF2 -1.513 
    ADAM10 -1.774     FBLN1 -1.513 
    CDC2L6 -1.774     KRT19 -1.511 
    ZBED1 -1.774     SOX17 -1.511 
    CD46 -1.773     MAPT -1.51 
    ASCC3 -1.769     CTBP2 -1.508 
    ALCAM -1.768     DNM2 -1.506 
    WRN -1.767     SOCS6 -1.506 
    ABI2 -1.765     DCUN1D3 -1.504 
    CDC2 -1.761     ATG5 -1.503 
    AHR -1.759     MCRS1 -1.502 
    POT1 -1.759         
    VANGL1 -1.758         
    ATMIN -1.758         
    EXTL3 -1.758         
    BPNT1 -1.756         
    MAP2K5 -1.755         
    APP -1.751         
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    RCAN1 -1.75         
    PHCA -1.75         
    STAT5B -1.749         
    WWTR1 -1.746         
    GCLC -1.744         
    LTB -1.743         
    FBXW11 -1.737         
    NFKB2 -1.737         
    SMARCB1 -1.734         
    PLD1 -1.734         
    CLIP1 -1.732         
    MAP4K4 -1.729         
    FER -1.721         
    USP22 -1.721         
    PDE5A -1.718         
    ULBP1 -1.717         
    GOLPH3 -1.717         
    CERK -1.717         
    PSME3 -1.716         
    FKBP1B -1.715         
    CCNDBP1 -1.714         
    TRIO -1.712         
    PTGER4 -1.712         
    USO1 -1.712         
    HMGA1 -1.711         
    FER1L3 -1.71         
    F2R -1.706         
    LSM1 -1.704         
    NCOA2 -1.703         
    HMGCR -1.701         
    KATNA1 -1.701         
    BCL2A1 -1.7         
    PLCE1 -1.7         
    RAB28 -1.699         
    AURKA -1.697         
    FGFR4 -1.693         
    KIF18A -1.688         
    MCMDC1 -1.686         
    TOP1MT -1.686         
    ERBB2 -1.683         
    PTPN13 -1.681         
    BIRC6 -1.68         
    SLC24A6 -1.677         
    PLCG2 -1.676         
    RIMS3 -1.675         
    ERO1LB -1.673         
    KIAA0776 -1.673         
    EXT1 -1.671         
    HAS2 -1.67         
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    ZEB1 -1.67         
    TP53BP1 -1.667         
    ZNF451 -1.667         
    RNF20 -1.664         
    ANGPTL4 -1.663         
    RALA -1.663         
    RFC3 -1.663         
    EGFR -1.661         
    EPS8 -1.659         
    MSH3 -1.657         
    TAF9L -1.657         
    CALCRL -1.656         
    GPR3 -1.652         
    GCNT2 -1.646         
    PAK2 -1.645         
    FIS1 -1.645         
    MALT1 -1.643         
    WWC1 -1.642         
    FKBP1A -1.64         
    GNAQ -1.638         
    NEDD4L -1.637         
    PPIA -1.636         
    PIK3CB -1.636         
    KIF11 -1.636         
    BARD1 -1.635         
    OSBPL1A -1.63         
    NFATC3 -1.629         
    RBCK1 -1.626         
    CD59 -1.625         
    RIPK2 -1.624         
    MTDH -1.623         
    RAD50 -1.619         
    ANXA2 -1.619         
    DLL1 -1.615         
    ACVR2A -1.614         
    C1GALT1C1 -1.614         
    PLS3 -1.608         
    CDC2L5 -1.607         
    CNOT2 -1.607         
    FNTB -1.606         
    E2F6 -1.606         
    XRCC4 -1.606         
    FGFR1OP -1.603         
    FYN -1.601         
    MLL5 -1.601         
    ETV4 -1.6         
    CCT2 -1.597         
    TTLL4 -1.596         
    ECT2 -1.593         
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    UBR5 -1.592         
    EPAS1 -1.59         
    PRCC -1.59         
    PRKD3 -1.59         
    STT3B -1.59         
    NOD2 -1.586         
    IFNAR2 -1.586         
    CAPN2 -1.585         
    CAMK2D -1.585         
    EIF2C3 -1.584         
    STK24 -1.583         
    CCNA2 -1.583         
    TRADD -1.582         
    RAB1A -1.58         
    MAP3K7IP2 -1.579         
    PIK3R1 -1.578         
    GPR172B -1.578         
    STAG1 -1.578         
    RPRD1B -1.578         
    PIK3C2B -1.576         
    MAPK13 -1.572         
    DNAJA2 -1.572         
    SLC2A1 -1.571         
    SOCS2 -1.568         
    RHOQ -1.568         
    JAK2 -1.568         
    NUDCD3 -1.564         
    THOC1 -1.564         
    MAP3K4 -1.563         
    TESK1 -1.562         
    STAT6 -1.561         
    TYMS -1.56         
    MSRA -1.558         
    EIF2B2 -1.557         
    C1GALT1 -1.557         
    SFRS5 -1.556         
    MUC1 -1.556         
    RECK -1.555         
    GJC1 -1.552         
    ARHGEF6 -1.551         
    ARNTL -1.55         
    RBBP9 -1.55         
    STEAP2 -1.547         
    HGF -1.545         
    KDM5B -1.543         
    AKR1C3 -1.543         
    WASF2 -1.54         
    TBX1 -1.54         
    SMC3 -1.54         
624 
 
    BLM -1.538         
    MMP25 -1.537         
    TICAM1 -1.536         
    CISD2 -1.533         
    CD2AP -1.532         
    TDG -1.531         
    TADA3 -1.529         
    RNF144B -1.528         
    NFS1 -1.525         
    SLC30A6 -1.524         
    AKAP13 -1.523         
    HIP1 -1.52         
    BUB3 -1.519         
    NRIP1 -1.519         
    ARRB2 -1.519         
    YEATS4 -1.519         
    CASP6 -1.519         
    RCL1 -1.519         
    FRAP1 -1.518         
    AKT2 -1.516         
    ACSL4 -1.515         
    CXCR4 -1.515         
    PFKFB3 -1.514         
    PALLD -1.512         
    AGGF1 -1.507         
    EZH2 -1.503         
    MAP2K4 -1.503         
    ST5 -1.502         
    GLB1 -1.502         
    ASPM -1.501         
    STK38 -1.501         
 
B. 
Expected Inversely related 
increased cell death 
 
 
 
decreased cell death 
 
 
 
up-genes 
(66) 
fold 
change 
down genes 
(393) 
fold 
change 
up-genes (94) fold 
change 
down genes 
(288) 
fold 
change 
TXNIP 5.257 RRM2 -7.011 NUAK1 3.768 EGR1 -15.086 
SREBF1 4.275 IL8 -6.204 DEPDC6 3.277 RAC1 -8.138 
SET 3.643 BIRC3 -6.182 TFF3 3.153 CD69 -7.186 
HMGB2 2.987 TRIB1 -4.97 LRPAP1 2.864 FOS -5.573 
HMGB1 2.955 CTGF -4.591 SIP1 2.815 MX1 -5.51 
SMARCC1 2.9 CAST -4.411 STX8 2.777 GULP1 -4.962 
ITGB3BP 2.747 PLAU -4.394 PTPMT1 2.69 B4GALT5 -4.263 
NCOR2 2.551 CDCP1 -4 HOXC6 2.663 DUSP6 -4.233 
EMP1 2.435 PPP2R2A -3.901 PLAC8 2.516 DDX58 -4.085 
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FAM162A 2.329 WEE1 -3.845 DAG1 2.452 STAT1 -4.047 
MYH9 2.289 VCL -3.829 DDIT4 2.389 TNFRSF21 -4.036 
H2AFX 2.155 CYP2J2 -3.777 FBXO2 2.378 OLR1 -4.027 
NUMA1 2.124 NFKBIA -3.735 YWHAG 2.3 DKK1 -4.018 
DNAJA3 2.113 OPA1 -3.536 S100A4 2.256 NFKBIZ -3.78 
DPM3 2.007 SP3 -3.521 ACO2 2.249 ITGB1 -3.766 
ACLY 2.006 CXCL1 -3.471 SIGIRR 2.242 STEAP3 -3.66 
BOK 2.003 SRXN1 -3.422 TAOK3 2.196 PHLDA1 -3.657 
ISG15 1.97 EGR2 -3.392 HSPBP1 2.146 IFIH1 -3.606 
CDKN2C 1.935 SIAH2 -3.389 RGS10 2.127 PRMT2 -3.414 
EGLN2 1.882 YWHAZ -3.362 WDR4 2.114 F2RL1 -3.358 
IL17RD 1.873 SLC4A7 -3.353 SERPINH1 2.094 WASPIP -3.325 
LAMP1 1.843 STK40 -3.272 SRF 2.08 NQO1 -3.309 
IL10 1.834 SPRY2 -3.196 MEF2D 2.078 DOCK1 -3.257 
HS1BP3 1.825 RAF1 -3.186 PIM3 2.073 FRMD6 -3.158 
TGFBI 1.808 TGFBR2 -3.154 CAMK2G 2.064 NRG1 -3.129 
LGALS7 1.803 VPS4B -3.147 EWSR1 2.041 PERP -2.924 
LGALS1 1.802 NEK6 -3.142 INTS1 2.028 TFPI -2.787 
ETS1 1.787 LGMN -3.136 CBS 2.022 ANTXR2 -2.773 
RASSF6 1.787 KLK3 -3.093 TBP 2.003 CTSL1 -2.763 
HIST1H1C 1.781 RRM2B -3.053 MSX1 1.973 LCN2 -2.759 
PRELID1 1.781 VASP -3.034 NDEL1 1.973 IL1R1 -2.75 
CSF2RA 1.777 CTNNB1 -3.028 TPD52 1.951 AFAP1 -2.7 
PTRH2 1.754 PPP1R13L -3.01 HSPA1B 1.939 CASP2 -2.648 
FAU 1.737 GLUD1 -2.966 PINK1 1.915 GPR37 -2.639 
CDC42 1.731 CD151 -2.924 NOLC1 1.909 SMAD3 -2.627 
PRPS1 1.727 BIRC2 -2.921 LSMD1 1.868 MAPK9 -2.609 
HRASLS 1.714 AKAP12 -2.889 DYNLL1 1.854 PNPT1 -2.597 
AGR2 1.713 SERPINE1 -2.835 TUB 1.812 STAM2 -2.568 
DAXX 1.703 EOMES -2.815 DMC1 1.803 EIF2AK2 -2.549 
S100A6 1.681 PLK2 -2.805 CREB1 1.782 SERINC3 -2.518 
ENDOG 1.666 EIF4G2 -2.741 UBQLN1 1.778 ATP2A2 -2.512 
CYBA 1.645 VAMP3 -2.717 TSC22D3 1.778 DNM1L -2.506 
CTSB 1.64 RB1 -2.707 NKX6-2 1.774 IER3 -2.506 
ADRM1 1.633 TXNDC5 -2.702 TRIAP1 1.743 CAPRIN2 -2.477 
TMEM107 1.631 ERCC1 -2.684 E2F4 1.721 RASA1 -2.476 
PEBP1 1.63 ADAR -2.639 CDKN2D 1.717 IFNGR1 -2.47 
CDKN1C 1.62 NBN -2.614 NUF2 1.717 PIAS3 -2.463 
PPARBP 1.613 YAP1 -2.596 LEP 1.704 RNASEL -2.461 
CD24 1.6 PRKAA1 -2.582 CALM3 1.695 JAK1 -2.43 
PRR7 1.586 NFE2L2 -2.573 CBL 1.683 CCNB1 -2.424 
NFKBIB 1.581 AADACL1 -2.568 PI4KB 1.667 CCDC6 -2.416 
CDK6 1.581 ABCC5 -2.562 CBX4 1.662 TNF -2.402 
SHC1 1.58 MCL1 -2.526 MKL1 1.657 SCP2 -2.396 
NME3 1.574 CAV1 -2.515 ILF3 1.652 TRIB3 -2.368 
UBE2L3 1.549 ERC1 -2.476 ODC1 1.652 ZFYVE16 -2.362 
BRMS1 1.548 TPM3 -2.476 STXBP1 1.648 HAS3 -2.356 
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MRPL41 1.545 PIGA -2.451 HSPA5 1.648 MAP3K11 -2.354 
LAMA5 1.54 SGK3 -2.441 TNNI3 1.639 PARP14 -2.35 
AES 1.529 ANXA4 -2.427 IL11 1.634 LGALS8 -2.334 
PTGDS 1.527 DICER1 -2.424 DIDO1 1.63 RAB22A -2.332 
PRAF2 1.527 ABCE1 -2.389 LMO4 1.627 OAS1 -2.332 
SUMO1 1.523 MBTPS1 -2.388 VEGFB 1.627 SDC4 -2.323 
MAP3K12 1.522 CD44 -2.382 ICMT 1.609 SLC25A24 -2.323 
GADD45A 1.519 REL -2.38 PLEC1 1.606 TFPI2 -2.296 
MVP 1.518 ITGB4 -2.377 EI24 1.604 ICAM1 -2.285 
MT1F 1.503 NR2C2 -2.373 OSCAR 1.602 LATS2 -2.276 
    HIPK3 -2.362 ERF 1.59 ZFAND5 -2.273 
    BHLHB2 -2.357 BCL2L1 1.587 PMP22 -2.272 
    CBFB -2.357 MGAT3 1.579 CX3CL1 -2.264 
    BTG2 -2.355 YWHAE 1.576 USP12 -2.251 
    ADH5 -2.353 MXD3 1.575 NOTCH2 -2.247 
    SELE -2.349 ARID1A 1.575 TICAM2 -2.242 
    CES1 -2.348 ELAVL1 1.574 CTH -2.236 
    PDE4D -2.344 GADD45GIP1 1.563 ICAM3 -2.236 
    EIF2C2 -2.342 EMD 1.558 TJP2 -2.228 
    HS.128753 -2.337 TAF10 1.553 CASP7 -2.216 
    CYB5A -2.321 PKD1 1.553 XPR1 -2.216 
    USP18 -2.311 BCL2L12 1.552 FOSL1 -2.21 
    CTTN -2.309 SEC61G 1.54 ITGA6 -2.21 
    ATP7A -2.299 CALR 1.539 ROCK2 -2.194 
    CHUK -2.299 GPI 1.538 MAP2K3 -2.193 
    TRPC1 -2.287 WFS1 1.537 BID -2.178 
    MAP3K7 -2.285 UXT 1.536 PRKDC -2.171 
    SMARCA5 -2.285 FASN 1.536 ELF4 -2.159 
    SRI -2.279 DNAJB6 1.534 CDK2 -2.158 
    BIRC5 -2.274 HBXIP 1.531 CCDC109A -2.149 
    IPPK -2.263 EBAG9 1.53 SP110 -2.147 
    PPP2R1B -2.252 MAPKAP1 1.529 WDR48 -2.144 
    PPP3CB -2.249 HSPE1 1.521 STAT4 -2.128 
    HSD17B4 -2.229 PEG10 1.518 ATG4A -2.095 
    MTM1 -2.229 APRT 1.514 DDX5 -2.089 
    MAP2K1 -2.213 GPX4 1.504 CKAP2 -2.069 
    CENPF -2.199 MAFG 1.502 RIPK1 -2.06 
    SOX8 -2.198 ABCG1 1.5 PIK3R2 -2.06 
    RELB -2.197     IDE -2.049 
    HADHA -2.197     NSMAF -2.038 
    IFI6 -2.195     TMEM158 -2.027 
    MERTK -2.188     SESN2 -2.019 
    ZNF184 -2.177     DSG2 -2.015 
    HEYL -2.175     SENP2 -2.008 
    SERP1 -2.168     YES1 -2.004 
    NFKB1 -2.167     VGF -2.002 
    CAT -2.164     SPTBN1 -2.002 
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    HS.532698 -2.162     HMOX2 -1.996 
    MSRB3 -2.161     ZAK -1.993 
    PDE4B -2.127     NAE1 -1.982 
    SLC12A2 -2.114     SLC25A38 -1.979 
    PDPK1 -2.104     WTAP -1.972 
    RABGGTA -2.103     E2F3 -1.964 
    SMO -2.098     SNAP25 -1.957 
    RBL2 -2.096     TIA1 -1.955 
    PAFAH2 -2.093     APPL1 -1.947 
    DSP -2.088     PTPRA -1.941 
    SGK1 -2.077     OMA1 -1.939 
    CCNI -2.077     NCK1 -1.935 
    AMACR -2.07     PRKAR1A -1.933 
    FIGNL1 -2.066     TIRAP -1.933 
    TPR -2.064     GCH1 -1.93 
    PIK3CA -2.054     PPP2R5A -1.925 
    SLC20A1 -2.054     CSNK2A1 -1.924 
    FAT4 -2.053     TBCCD1 -1.922 
    ZNF16 -2.05     DAB2 -1.919 
    ANXA7 -2.048     PARG -1.915 
    HS.24119 -2.037     ZFP36 -1.914 
    UBR2 -2.032     PDCD6IP -1.899 
    JUNB -2.031     PPM1A -1.897 
    CUL1 -2.025     CASP3 -1.884 
    PON2 -2.023     ZMYND11 -1.88 
    CXCL2 -2.021     MYD88 -1.878 
    PTHLH -2.018     SGPL1 -1.877 
    KIFAP3 -2.015     TFDP1 -1.875 
    GLO1 -2.01     ACTL6A -1.873 
    HS.570988 -2.008     MAP3K8 -1.871 
    IDH2 -2.008     JUN -1.871 
    TIMP1 -2.002     ATG7 -1.869 
    PHIP -1.999     OAS3 -1.862 
    MKNK1 -1.998     RFK -1.856 
    S1PR3 -1.994     WWC3 -1.855 
    NSF -1.992     MIB1 -1.849 
    USP47 -1.99     PSEN2 -1.848 
    GAB2 -1.989     QKI -1.845 
    DUSP10 -1.986     TLR1 -1.84 
    HSPA4 -1.984     TFDP2 -1.84 
    HNRPK -1.981     FAS -1.837 
    ADAM17 -1.975     IRF1 -1.833 
    TBK1 -1.966     THAP1 -1.833 
    TOP2B -1.966     ANKRD1 -1.831 
    CLN3 -1.966     PPARG -1.831 
    TAX1BP1 -1.963     KRAS -1.824 
    NFYA -1.962     CHEK2 -1.824 
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    CYR61 -1.957     PPP1CA -1.818 
    SCARB2 -1.95     ATP1A1 -1.807 
    TRIM39 -1.95     SMAD4 -1.8 
    CUL2 -1.949     FAF1 -1.798 
    TNFAIP8 -1.942     BAT3 -1.795 
    RPS6KA3 -1.939     VHL -1.794 
    SOX21 -1.939     TSC22D2 -1.791 
    CD164 -1.937     ULK2 -1.784 
    S100A11 -1.932     GSR -1.78 
    ZMYM2 -1.931     NPTX1 -1.78 
    PPP1R2 -1.93     GMCL1 -1.773 
    UGCG -1.928     TNFRSF1B -1.771 
    OPTN -1.926     CYLD -1.771 
    ITGAV -1.924     LIPA -1.77 
    BBS2 -1.918     CCNC -1.763 
    SFN -1.916     CDC2 -1.761 
    DCAF7 -1.914     MAP2K5 -1.755 
    APIP -1.914     APP -1.751 
    TNFAIP3 -1.913     XPC -1.75 
    CITED2 -1.909     STAP2 -1.744 
    KPNA2 -1.905     LTB -1.743 
    LRP8 -1.898     TRIM21 -1.739 
    NPC1 -1.897     UACA -1.732 
    ZNF259 -1.893     SH3RF1 -1.732 
    PRKCA -1.889     MAP4K4 -1.729 
    THOC6 -1.889     PKN2 -1.727 
    HDAC9 -1.882     PDE5A -1.718 
    MAPK1 -1.879     ULBP1 -1.717 
    KIAA0261 -1.876     CD40 -1.717 
    ITGA2 -1.873     PSME3 -1.716 
    ARHGAP1 -1.873     PTGER4 -1.712 
    DEK -1.87     SLC47A1 -1.71 
    XRCC5 -1.856     SDC1 -1.709 
    ATP2B1 -1.852     ATG16L1 -1.709 
    ASNS -1.844     TNFRSF1A -1.708 
    PPARA -1.841     F2R -1.706 
    VPS13A -1.84     ATXN3 -1.705 
    SERPINI1 -1.833     HS.371609 -1.7 
    VPS41 -1.823     HS.4988 -1.698 
    PDGFC -1.82     ALDH1A3 -1.697 
    GRB10 -1.82     FGFR4 -1.693 
    KIF14 -1.816     MBD1 -1.689 
    ANXA5 -1.814     M6PR -1.688 
    SETX -1.814     RAPGEF2 -1.688 
    SPG7 -1.812     PTPN13 -1.681 
    NAMPT -1.808     AXIN1 -1.676 
    TRIM24 -1.803     DDX3X -1.669 
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    RBM3 -1.798     APOBEC3B -1.667 
    VEGFC -1.796     PPP2CA -1.667 
    BCL2L13 -1.795     GFPT1 -1.666 
    MIR21 -1.795     TP53BP2 -1.659 
    RECQL -1.794     TNFRSF10A -1.657 
    CTNNBIP1 -1.794     ITPR1 -1.653 
    API5 -1.794     RHOB -1.651 
    HS.334831 -1.789     PAK2 -1.645 
    DHX9 -1.788     FIS1 -1.645 
    E2F7 -1.786     PRKRA -1.645 
    SON -1.782     KEAP1 -1.644 
    LEPR -1.779     MALT1 -1.643 
    NPHS1 -1.777     EBF4 -1.643 
    RGPD8 -1.776     RANBP9 -1.641 
    RFC1 -1.775     FKBP1A -1.64 
    CD46 -1.773     GNAQ -1.638 
    LASS6 -1.769     SEC23B -1.637 
    ALCAM -1.768     BARD1 -1.635 
    AHR -1.759     NLRX1 -1.631 
    POT1 -1.759     DEPDC1 -1.63 
    ATMIN -1.758     MIR302C -1.629 
    IRF2 -1.752     ARHGEF7 -1.624 
    ERCC5 -1.751     RIPK2 -1.624 
    RCAN1 -1.75     SUB1 -1.621 
    STAT5B -1.749     DDX20 -1.62 
    SLC40A1 -1.749     SRPX -1.619 
    PRKAA2 -1.745     TOP1 -1.615 
    GCLC -1.744     FYN -1.601 
    SLC9A4 -1.743     ECT2 -1.593 
    SNX7 -1.741     SAV1 -1.59 
    UBE2V1 -1.737     IFNAR2 -1.586 
    NFKB2 -1.737     CAPN2 -1.585 
    GEM -1.736     STK24 -1.583 
    FBXL5 -1.734     HIP2 -1.583 
    PLD1 -1.734     TRADD -1.582 
    PARP16 -1.732     ATP6AP2 -1.582 
    CCT6A -1.729     RAB1A -1.58 
    LASS2 -1.724     MAL -1.579 
    IL28A -1.722     FOXF2 -1.578 
    FER -1.721     STAG1 -1.578 
    USP22 -1.721     MELK -1.578 
    DUSP1 -1.72     CTNNA1 -1.576 
    PLS1 -1.718     MAPK13 -1.572 
    DPYD -1.718     RHOH -1.569 
    TANK -1.717     CSE1L -1.566 
    CERK -1.717     THOC1 -1.564 
    RNF19A -1.716     ARL8B -1.562 
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    SQSTM1 -1.716     ING3 -1.561 
    XPO1 -1.714     CCNT1 -1.558 
    NEK1 -1.714     SPATA2 -1.558 
    HMGA1 -1.711     RECK -1.555 
    TCERG1 -1.706     KLRF1 -1.555 
    TMBIM6 -1.703     TRIM13 -1.554 
    NCOA2 -1.703     SH2D4A -1.553 
    HMGCR -1.701     ARHGEF6 -1.551 
    BCL2A1 -1.7     SIK1 -1.547 
    PSMB8 -1.699     BACH2 -1.546 
    RAB28 -1.699     TAF6 -1.546 
    AURKA -1.697     AKR1C3 -1.543 
    PPP2R5C -1.695     PTPN2 -1.54 
    NDST1 -1.695     BLM -1.538 
    EFNA1 -1.684     TICAM1 -1.536 
    ERBB2 -1.683     ARHGEF3 -1.532 
    GPHN -1.681     IFT57 -1.531 
    OBFC2A -1.68     RNF144B -1.528 
    BIRC6 -1.68     DEDD -1.524 
    CDKN1A -1.678     TCF12 -1.522 
    PLCG2 -1.676     HES1 -1.522 
    FAM134B -1.676     SHQ1 -1.522 
    SERPINA3 -1.675     TRMT11 -1.521 
    CBLB -1.673     HIP1 -1.52 
    PEX11B -1.672     CASP6 -1.519 
    HAS2 -1.67     EMILIN2 -1.518 
    ZEB1 -1.67     CXCR4 -1.515 
    PROS1 -1.668     AIFM1 -1.514 
    TP53BP1 -1.667     RBM5 -1.514 
    TLR6 -1.666     ATF2 -1.513 
    PDE9A -1.666     MAPT -1.51 
    VAC14 -1.664     MCOLN3 -1.51 
    ANGPTL4 -1.663     LASS5 -1.51 
    AVEN -1.663     IL17RA -1.508 
    PRKAG1 -1.661     DNM2 -1.506 
    EGFR -1.661     REPS2 -1.506 
    MSH3 -1.657     DCUN1D3 -1.504 
    TAF9L -1.657     SPAG5 -1.503 
    CALCRL -1.656     ZNF274 -1.503 
    ST3GAL1 -1.656     ATG5 -1.503 
    FSTL1 -1.654     MAP2K4 -1.503 
    BRE -1.651     CCBL1 -1.502 
    HLA-F -1.647     ADRB1 -1.501 
    PPIA -1.636     STK38 -1.501 
    PIK3CB -1.636         
    KIF11 -1.636         
    CHMP2A -1.634         
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    GLIS3 -1.628         
    RBCK1 -1.626         
    UBA3 -1.625         
    CD59 -1.625         
    FANCL -1.625         
    MTDH -1.623         
    ZFP82 -1.623         
    IFNGR2 -1.62         
    RAD50 -1.619         
    ANXA2 -1.619         
    SEPN1 -1.619         
    DYNC1H1 -1.617         
    IREB2 -1.616         
    DLL1 -1.615         
    KLF6 -1.611         
    CPEB4 -1.611         
    RHBDD1 -1.61         
    EPB41 -1.608         
    CNOT2 -1.607         
    E2F6 -1.606         
    XRCC4 -1.606         
    BAZ1A -1.605         
    CAPRIN1 -1.6         
    ATP2B4 -1.599         
    HEXB -1.594         
    PCID2 -1.593         
    NPAS2 -1.592         
    EXOC2 -1.592         
    CCDC47 -1.592         
    CKAP5 -1.592         
    EPAS1 -1.59         
    PRCC -1.59         
    PRKD3 -1.59         
    FBXO5 -1.587         
    SFRS2B -1.587         
    AATF -1.585         
    EIF2C3 -1.584         
    MAN2A1 -1.582         
    DCTN1 -1.581         
    RNF4 -1.58         
    MAP3K7IP2 -1.579         
    PIK3R1 -1.578         
    RND3 -1.577         
    PARK2 -1.575         
    GPN1 -1.574         
    MXD1 -1.572         
    SLC2A1 -1.571         
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    PAF1 -1.57         
    SOCS2 -1.568         
    JAK2 -1.568         
    CTCF -1.566         
    NUDCD3 -1.564         
    MAP3K4 -1.563         
    STAT6 -1.561         
    SLC29A2 -1.56         
    TYMS -1.56         
    IGFBP4 -1.559         
    MUC1 -1.556         
    LIN7C -1.555         
    GJC1 -1.552         
    CDK8 -1.549         
    CERKL -1.549         
    MYO6 -1.548         
    MCPH1 -1.547         
    SPINT1 -1.545         
    HGF -1.545         
    ADA -1.544         
    RRAS2 -1.544         
    TBC1D15 -1.543         
    ABCC1 -1.541         
    TOPBP1 -1.534         
    CISD2 -1.533         
    PPID -1.532         
    MTMR2 -1.532         
    CD2AP -1.532         
    ATP11C -1.532         
    DPP8 -1.526         
    TMX1 -1.524         
    RB1CC1 -1.523         
    ARRB2 -1.519         
    IVNS1ABP -1.519         
    YEATS4 -1.519         
    FRAP1 -1.518         
    AKT2 -1.516         
    ACSL4 -1.515         
    IFIT3 -1.515         
    PLTP -1.515         
    FBLN1 -1.513         
    PALLD -1.512         
    SORBS2 -1.512         
    KRT19 -1.511         
    CTBP2 -1.508         
    WASF1 -1.507         
    AGGF1 -1.507         
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    TXNRD1 -1.506         
    ATP2C1 -1.506         
    PCNA -1.505         
    EZH2 -1.503         
    GSTA2 -1.503         
    EFEMP1 -1.502         
    MCRS1 -1.502         
 
C. 
Expected  Inversely related  
decreased migration 
 
 
 
increased migration 
 
 
 
up-genes 
(7) 
fold change down genes 
(122) 
fold 
change 
up-genes 
(22) 
fold change down 
genes (23) 
fold change 
MYH9 2.289 EGR1 -15.086 C1QBP 3.473 RNF144 -4.078 
DNAJA3 2.113 RAC1 -8.138 DPAGT1 2.397 STAT1 -4.047 
DPYSL2 1.725 IL8 -6.204 S100A4 2.256 ARRDC3 -3.535 
CMTM8 1.706 CTGF -4.591 ACTN4 1.946 LAMC2 -3.497 
BRMS1 1.548 PLAU -4.394 ARF1 1.885 SPRY2 -3.196 
LAMA5 1.54 DDX58 -4.085 DVL2 1.826 VASP -3.034 
DNAJB6 1.534 CDCP1 -4 PPFIA1 1.821 TPM3 -2.476 
    SDCBP -3.874 LGALS1 1.802 RASA1 -2.476 
    CYP2J2 -3.777 ETS1 1.787 CAT -2.164 
    ITGB1 -3.766 MAPK8IP3 1.765 EBI3 -2.121 
    E2F5 -3.714 CDC42 1.731 TIMP1 -2.002 
    F2RL1 -3.358 DYRK1B 1.716 ASNS -1.844 
    DOCK1 -3.257 LEP 1.704 ADAM9 -1.842 
    SSH1 -3.222 MTA1 1.691 FAF1 -1.798 
    NRG1 -3.129 HS.535028 1.67 SMARCB1 -1.734 
    CTNNB1 -3.028 ILF3 1.652 FAM188A -1.722 
    CD151 -2.924 DIDO1 1.63 WDR44 -1.679 
    CCL20 -2.862 VEGFB 1.627 GNAI1 -1.618 
    SERPINE1 -2.835 CD24 1.6 PARK2 -1.575 
    BMPR2 -2.784 CDC25B 1.597 IGFBP4 -1.559 
    AFAP1 -2.7 SHC1 1.58 ARHGAP2
1 
-1.519 
    SMAD3 -2.627 HES6 1.52 PALLD -1.512 
    EIF2AK2 -2.549     KRT19 -1.511 
    ACTA2 -2.542         
    CAV1 -2.515         
    CD81 -2.482         
    JAK1 -2.43         
    TNF -2.402         
    CD44 -2.382         
    HAS3 -2.356         
    HS.128753 -2.337         
    CTTN -2.309         
    MAP3K7 -2.285         
    CX3CL1 -2.264         
    NOTCH2 -2.247         
    MAP2K1 -2.213         
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    ITGA6 -2.21         
    FOSL1 -2.21         
    LIN28B -2.204         
    MERTK -2.188         
    SLC12A2 -2.114         
    CUL4A -2.051         
    RAB21 -2.018         
    PTHLH -2.018         
    VGF -2.002         
    S1PR3 -1.994         
    GAB2 -1.989         
    HNRPK -1.981         
    ADAM17 -1.975         
    ARFGEF1 -1.959         
    CYR61 -1.957         
    TNFAIP8 -1.942         
    RPS6KA3 -1.939         
    ITGAV -1.924         
    DAB2 -1.919         
    SFN -1.916         
    PRMT6 -1.908         
    KPNA2 -1.905         
    PRKCA -1.889         
    FOXQ1 -1.88         
    MAPK1 -1.879         
    ITGA2 -1.873         
    JUN -1.871         
    MAP3K8 -1.871         
    KRAS -1.824         
    SMAD4 -1.8         
    VEGFC -1.796         
    MIR21 -1.795         
    ADAM10 -1.774         
    ALCAM -1.768         
    ANKRD28 -1.757         
    FNBP1L -1.753         
    APP -1.751         
    IQGAP1 -1.751         
    WWTR1 -1.746         
    PLD1 -1.734         
    VAMP7 -1.733         
    MAP4K4 -1.729         
    FER -1.721         
    GOLPH3 -1.717         
    CD40 -1.717         
    PTGER4 -1.712         
    TRIO -1.712         
    USP9X -1.709         
    F2R -1.706         
    GNAI3 -1.699         
    HS.4988 -1.698         
    AURKA -1.697         
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    ERBB2 -1.683         
    CDKN1A -1.678         
    ZEB1 -1.67         
    HAS2 -1.67         
    EGFR -1.661         
    ITPR1 -1.653         
    RHOB -1.651         
    WASL -1.648         
    PAK2 -1.645         
    RANBP9 -1.641         
    MTDH -1.623         
    ANXA2 -1.619         
    LMO7 -1.61         
    FYN -1.601         
    ETV4 -1.6         
    ECT2 -1.593         
    CAPN2 -1.585         
    LTBP2 -1.58         
    SLC2A1 -1.571         
    JAK2 -1.568         
    CSE1L -1.566         
    MUC1 -1.556         
    AKAP11 -1.551         
    HGF -1.545         
    CTNNAL1 -1.526         
    TCF12 -1.522         
    ARRB2 -1.519         
    FRAP1 -1.518         
    CXCR4 -1.515         
    ACSL4 -1.515         
    CTBP2 -1.508         
    WASF1 -1.507         
    DNM2 -1.506         
    EZH2 -1.503         
 
Supplemental Table B3.  Sp4-regulated associated with growth inhibition, cell death and inhibition of 
migration/invasion after Sp4 knockdown: expected and inversely regulated genes.  
A. 
Expected Inversely related 
decreased cell proliferation 
 
 
increased cell proliferation 
 
 
up-genes (68) fold 
change 
down 
genes 
(447) 
fold 
change 
up-genes (131) fold 
change 
down 
genes 
(221) 
fold 
change 
TXNIP 4.646 EGR1 -13.207 LMNA 10.206 DCBLD2 -6.867 
CDCA4 3.479 RRM2 -10.183 NCOR2 3.634 STAT1 -5.293 
RNH1 3.269 FOS -5.995 HMGB1 3.379 PLOD2 -4.87 
HMOX1 3.189 PDE5A -5.765 C1QBP 3.093 LIPA -4.506 
NUMA1 2.972 CTGF -5.348 HMGB2 3.081 ARRDC3 -3.84 
EI24 2.961 BIRC3 -4.833 RCE1 3.003 EIF4G2 -3.785 
TCF3 2.595 NCSTN -4.492 H2AFX 2.91 ITGA6 -3.665 
MSX1 2.469 DKK1 -4.291 CBX7 2.91 TGFBR3 -3.607 
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MXD4 2.454 DUSP6 -4.027 SERPINH1 2.644 PNPT1 -3.293 
UCP2 2.453 LIN28B -3.856 PTPMT1 2.629 TRIB1 -3.286 
EIF1 2.369 GOLM1 -3.835 SUMO2 2.39 AKAP12 -3.279 
TIMP2 2.349 RPS6KA3 -3.8 LRPAP1 2.336 LIFR -3.193 
RALBP1 2.288 BIRC2 -3.744 NOLC1 2.264 TFPI -3.143 
GPR56 2.251 IL6ST -3.727 CDCA5 2.226 SPRY1 -3.016 
GEMIN2 2.233 AFAP1 -3.709 NOP58 2.209 EGR2 -3.01 
SH2B3 2.221 DDX58 -3.697 ARF1 2.207 CHEK2 -2.983 
DNAJA3 2.179 CCNB1 -3.663 ACIN1 2.203 B3GNT5 -2.962 
ACTN4 2.107 CXCL8 -3.59 EMP1 2.173 ABCC5 -2.869 
SREBF1 2.099 TFRC -3.539 CDC25B 2.173 ASPH -2.85 
MED25 2.021 B4GALT6 -3.49 CSF2RA 2.166 UBE2D3 -2.821 
NFKBIB 2.012 PPP3CB -3.478 ATP5G1 2.148 STX2 -2.795 
NUPR1 1.962 ADAR -3.472 DEPTOR 2.125 ATG5 -2.746 
GADD45A 1.958 FNDC3B -3.381 ANTXR1 2.124 PROS1 -2.711 
SIGIRR 1.929 IER3 -3.343 MCM8 2.087 CASP7 -2.665 
NUP62 1.926 AKIRIN1 -3.304 ETS1 2.086 CRLF3 -2.598 
HSPA1A/HSPA1
B 
1.919 AGO2 -3.198 EWSR1 2.075 SESN1 -2.596 
PCBP4 1.892 CYR61 -3.158 MED1 2.069 FRMD6 -2.595 
DAXX 1.89 PLAU -3.072 TBP 2.041 CTNNA1 -2.582 
MUL1 1.885 MCL1 -3.012 SET 2.028 TGFBR2 -2.574 
CHD5 1.876 DICER1 -2.978 RPS15A 2.014 RRAS -2.572 
ATF5 1.867 SERPINE1 -2.973 RARA 2.005 KRIT1 -2.557 
DNAJB6 1.859 LBR -2.959 YWHAG 1.998 NDFIP1 -2.509 
BCCIP 1.849 F2R -2.95 H3F3A/H3F3B 1.971 ULK2 -2.479 
TSPYL2 1.838 CTNNB1 -2.941 TBC1D8 1.968 SPRY2 -2.451 
DIABLO 1.82 VCL -2.927 NACA 1.966 SPRY4 -2.435 
DACT3 1.801 ERCC1 -2.888 MKL1 1.964 WIPF1 -2.423 
BMF 1.763 F2RL1 -2.884 ISG15 1.962 BMPR2 -2.396 
UXT 1.762 E2F5 -2.873 CREB1 1.947 WTAP -2.382 
COMMD5 1.759 CD44 -2.866 TPD52 1.936 RHOB -2.37 
MTA1 1.752 DDAH1 -2.769 CDK6 1.935 ANXA7 -2.367 
EEF1B2 1.731 ZNF451 -2.743 ULK1 1.915 PPP2R1B -2.359 
SSTR2 1.72 PRKCA -2.726 S100A4 1.906 YWHAZ -2.351 
GPS2 1.703 GCNT2 -2.721 CBS/LOC10272456
0 
1.897 PCYOX1 -2.344 
FBLN1 1.69 ERO1L -2.695 PIP4K2B 1.893 H2AFY -2.337 
STRA13 1.684 PTHLH -2.695 CORO1B 1.875 RBL2 -2.325 
ERF 1.673 GFM1 -2.678 MPRIP 1.865 KIFAP3 -2.307 
FBXO2 1.671 DOCK1 -2.674 E2F4 1.863 CTH -2.295 
BNIPL 1.653 GCH1 -2.667 TFF3 1.851 SEC23A -2.293 
HRASLS 1.646 NBN -2.657 UBE2C 1.839 TAP1 -2.289 
FKTN 1.635 ERO1LB -2.639 HNRNPA2B1 1.838 RASA1 -2.286 
ABCC3 1.625 P4HA1 -2.623 CRCP 1.833 CAT -2.286 
DNAJB2 1.616 STT3B -2.621 LEP 1.833 TBK1 -2.28 
GABPB2 1.591 CITED2 -2.617 HOXC6 1.821 NFE2L2 -2.278 
EMP3 1.587 C1GALT1 -2.611 RANBP1 1.82 PHLDA1 -2.25 
ARID1A 1.575 ARFGAP3 -2.61 FBRS 1.816 FAM188A -2.249 
PDCD4 1.573 HSPA4 -2.6 ID3 1.814 ERRFI1 -2.248 
TSPO 1.561 TXNDC5 -2.591 TXLNA 1.81 ROCK1 -2.233 
TOP3A 1.56 RAN -2.569 POLR2L 1.804 P4HA2 -2.217 
RPL26 1.555 PLK2 -2.565 PFDN5 1.804 CAPRIN1 -2.198 
CCDC85B 1.553 SGK1 -2.554 DOHH 1.788 RB1 -2.193 
LILRB1 1.548 LAMC1 -2.526 DCLRE1A 1.777 RND3 -2.173 
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SRM 1.548 JAK1 -2.514 NDEL1 1.764 PLXNA1 -2.152 
ATPIF1 1.54 NUP98 -2.507 NUDT1 1.759 RNASEL -2.147 
NRG2 1.538 PIGN -2.499 IL18 1.758 CAST -2.143 
RBM10 1.531 DDX5 -2.487 RPS9 1.749 FBXO11 -2.14 
TNFRSF25 1.529 ITGB1 -2.481 PPL 1.749 IFNL2 -2.139 
MXI1 1.525 SPTBN1 -2.478 STX3 1.739 G3BP1 -2.137 
DBI 1.501 MUC1 -2.466 CEP131 1.737 TRIM24 -2.135 
    ITGAV -2.466 NSMF 1.72 JUNB -2.12 
    STAT5B -2.464 MCM10 1.718 RBBP4 -2.111 
    TNS3 -2.454 AHNAK 1.712 GEM -2.102 
    TDG -2.451 NAA38 1.7 AKTIP -2.1 
    ICAM1 -2.449 SRC 1.692 ROCK2 -2.096 
    NFKB1 -2.435 SPTAN1 1.69 NFIB -2.09 
    PIK3CA -2.434 BASP1 1.688 SERINC3 -2.087 
    CDC16 -2.431 MCM4 1.683 B3GNT2 -2.08 
    FZD7 -2.431 DUSP12 1.67 BTG2 -2.047 
    RYK -2.422 ARHGEF1 1.658 MXD1 -2.047 
    MFN1 -2.409 DTL 1.647 BHLHE40 -2.044 
    MAP3K7 -2.4 LGALS1 1.644 PARG -2.039 
    RECK -2.393 CD320 1.643 TFPI2 -2.025 
    HIF1A -2.374 FEN1 1.635 DDX3X -2.022 
    TP53BP1 -2.37 GJC1 1.634 ASNS -2.018 
    DLGAP5 -2.37 DAPP1 1.633 RAD17 -2.016 
    NFYA -2.367 PPP1R15A 1.632 CUL2 -2.005 
    EOMES -2.36 POLR2F 1.628 SMYD2 -1.999 
    NASP -2.349 IGBP1 1.626 CASP3 -1.996 
    HMGCR -2.348 PTP4A2 1.624 RNF14 -1.995 
    CYP2J2 -2.339 THRAP3 1.622 RCHY1 -1.971 
    PHIP -2.336 MDK 1.619 ZMAT3 -1.967 
    CD2AP -2.323 SP1 1.601 ENPP1 -1.966 
    ARFGEF1 -2.293 EEF1D 1.591 PKP2 -1.924 
    EXTL3 -2.291 CDC20 1.59 PHF14 -1.919 
    KRAS -2.288 ARHGEF2 1.588 ADAMTS
1 
-1.918 
    CCPG1 -2.286 CDT1 1.582 TRIB3 -1.914 
    EPCAM -2.282 FANCD2 1.58 TOM1L1 -1.906 
    ACER3 -2.262 PSMA4 1.579 SMAD4 -1.903 
    DNM1L -2.261 SHC1 1.578 HIAT1 -1.899 
    CSNK1G3 -2.261 MXD3 1.577 PPP2CA -1.896 
    PRKAA1 -2.258 DIXDC1 1.577 PEX2 -1.883 
    NRG1 -2.255 PTMA 1.576 SMARCA
1 
-1.882 
    LGR4 -2.254 HSF1 1.576 TJP1 -1.882 
    USO1 -2.249 PTGDS 1.568 SYNJ2BP -1.879 
    PDE4D -2.248 CDK4 1.568 CCNG2 -1.87 
    ARL5A -2.235 S100A6 1.563 MAP3K2 -1.87 
    SLC20A1 -2.213 PPIB 1.563 DYRK1A -1.869 
    BTRC -2.198 RALGDS 1.553 CSE1L -1.869 
    HIF1AN -2.189 TNFSF14 1.553 NACC2 -1.866 
    MAP4K4 -2.187 PCK2 1.55 DNER -1.863 
    TOP2A -2.183 HGS 1.548 DLG1 -1.861 
    EPAS1 -2.164 PIDD1 1.546 TP53INP1 -1.847 
    DSG2 -2.162 SNX12 1.546 MERTK -1.842 
    USP47 -2.16 CYBA 1.544 KIF23 -1.839 
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    EIF5A2 -2.158 TBX1 1.542 MORC3 -1.834 
    NAMPT -2.151 mir-130 1.539 DYNC1H1 -1.833 
    USP18 -2.15 AKIRIN2 1.539 CAPRIN2 -1.826 
    TPR -2.15 CNTFR 1.537 KLF10 -1.825 
    MAPK13 -2.149 CISD1 1.537 VLDLR -1.817 
    YES1 -2.148 SLC7A5 1.533 EIF2AK2 -1.814 
    PIK3CB -2.146 SLC44A4 1.53 STARD13 -1.81 
    DDX17 -2.142 CKS1B 1.526 PTPN14 -1.791 
    FAT4 -2.128 ACACA 1.525 ARID4A -1.791 
    SLC39A6 -2.126 PIN1 1.519 IFNL3 -1.79 
    ILK -2.118 TIMELESS 1.513 TES -1.785 
    PIK3C2A -2.107 MFGE8 1.512 PTPN12 -1.782 
    CD46 -2.106 NSA2 1.512 GPNMB -1.779 
    XRCC5 -2.091 COPS2 1.511 ARID4B -1.773 
    HSPD1 -2.089 ORAI1 1.508 CSNK1A1 -1.772 
    KIF11 -2.088 SRF 1.503 USP16 -1.77 
    TNFRSF10
B 
-2.08 SH2B1 1.502 HOXA5 -1.757 
    PRPS2 -2.077 SHFM1 1.501 CTSV -1.756 
    TNFAIP8 -2.074     CPEB1 -1.755 
    ZMYM2 -2.063     CYLD -1.742 
    RGPD4 
(includes 
others) 
-2.061     NAB1 -1.733 
    RAB28 -2.06     DUSP5 -1.729 
    ANGPTL4 -2.057     RHOH -1.729 
    MYOF -2.056     PDS5B -1.72 
    RPA1 -2.034     APBB2 -1.714 
    ITGA2 -2.025     CDK8 -1.71 
    CXCL1 -2.023     MCRS1 -1.705 
    BMPR1A -2.011     LIMK1 -1.704 
    CDC14B -2.011     CAV1 -1.702 
    RALA -2.005     TOP1 -1.702 
    DIDO1 -2.004     SGPL1 -1.701 
    SUV420H1 -2.003     BACH2 -1.697 
    AMD1 -2     AJUBA -1.693 
    GAD1 -1.997     DVL1 -1.693 
    TADA3 -1.997     CD83 -1.691 
    REL -1.995     SPRED1 -1.69 
    ASCC3 -1.993     ITPR1 -1.689 
    PRKAR1A -1.993     ATG7 -1.687 
    CUL4A -1.987     RNF111 -1.684 
    ROR1 -1.987     ABLIM1 -1.683 
    PLS3 -1.983     VMP1 -1.683 
    HNRNPK -1.978     PAQR3 -1.679 
    SSR1 -1.975     PHC3 -1.672 
    TSNAX -1.971     PPM1A -1.669 
    STAT4 -1.968     RGN -1.664 
    MINA -1.96     ST7L -1.662 
    NFKBIA -1.955     FOXN3 -1.658 
    TGIF1 -1.951     CASK -1.656 
    ACVR1 -1.951     ABCC1 -1.655 
    ATP7A -1.948     NOTCH2 -1.649 
    ADAM17 -1.945     TP53BP2 -1.644 
    SDCBP -1.94     APPL1 -1.637 
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    KDM5B -1.939     IFIT3 -1.613 
    ARID3A -1.939     BAX -1.608 
    OPTN -1.936     ATP6V0A
2 
-1.606 
    KIF2A -1.931     ADIPOR1 -1.601 
    SEMA4D -1.931     TSG101 -1.595 
    VEGFC -1.925     IFNAR1 -1.595 
    OPA1 -1.923     FBXL2 -1.594 
    WWTR1 -1.923     BCAN -1.591 
    ILF3 -1.919     ZFP36 -1.591 
    CENPF -1.915     KDM3B -1.591 
    ADAM9 -1.909     KLK3 -1.59 
    C1GALT1
C1 
-1.908     RANBP9 -1.589 
    DVL3 -1.905     RAP1GA
P 
-1.588 
    NFAT5 -1.904     STEAP3 -1.586 
    MAPK1 -1.901     LATS1 -1.58 
    NAE1 -1.898     WARS -1.579 
    MEMO1 -1.896     HAS3 -1.579 
    IL13RA1 -1.895     MEN1 -1.579 
    ELMO2 -1.885     PMEPA1 -1.574 
    NEDD4L -1.883     CREG1 -1.572 
    NFIA -1.882     TANK -1.571 
    EXOC5 -1.881     CD40 -1.568 
    TEAD2 -1.88     CCNL2 -1.566 
    BPNT1 -1.878     STK3 -1.563 
    UBE2A -1.878     PLSCR1 -1.562 
    CSRP1 -1.874     LAT2 -1.561 
    MSH2 -1.867     RPS6KA2 -1.56 
    PAK2 -1.864     FGFRL1 -1.556 
    PTPN3 -1.864     PLCL2 -1.556 
    RCAN1 -1.858     TCF12 -1.551 
    KPNA2 -1.855     USP10 -1.55 
    ABI2 -1.855     HERC2 -1.55 
    MALT1 -1.853     TEX11 -1.549 
    PTPN1 -1.85     IQGAP1 -1.548 
    BMI1 -1.85     DAB2 -1.548 
    APP -1.846     RASL10A -1.543 
    GLDC -1.843     CDK11B -1.539 
    MET -1.834     IFT88 -1.535 
    WAPAL -1.832     PARK2 -1.534 
    LCN2 -1.83     SIX5 -1.533 
    CCDC88A -1.827     RBBP7 -1.531 
    API5 -1.825     OAS3 -1.528 
    LDHA -1.823     CXADR -1.527 
    FBXW11 -1.823     KCND2 -1.527 
    AHR -1.82     STRN -1.527 
    RASGRP3 -1.818     PHLDA2 -1.525 
    IMPACT -1.816     KLF13 -1.52 
    PTPN13 -1.816     CTBP2 -1.512 
    NR2C2 -1.813     FBXW7 -1.511 
    CTSB -1.812     NPDC1 -1.511 
    RUVBL1 -1.811     EEF1A1 -1.506 
    STAT3 -1.806     MIB1 -1.506 
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    KMT2C -1.792     WDR48 -1.506 
    ANXA2 -1.791     IFNGR1 -1.504 
    NPC1 -1.791     IFT74 -1.502 
    C8orf44-
SGK3/SGK
3 
-1.79     TLR6 -1.501 
    BCAT1 -1.789         
    UFL1 -1.789         
    STEAP2 -1.784         
    FUT4 -1.782         
    FOXQ1 -1.778         
    ALCAM -1.776         
    SPAST -1.775         
    NOC3L -1.773         
    PDPK1 -1.769         
    PRMT6 -1.769         
    KIAA1429 -1.766         
    STK38L -1.765         
    PFKM -1.761         
    IDE -1.76         
    WLS -1.756         
    AURKA -1.755         
    ARNTL -1.749         
    TTC5 -1.748         
    ERBB2 -1.74         
    LEPR -1.739         
    SLC12A2 -1.739         
    PPIA -1.736         
    ALDOA -1.736         
    STAM2 -1.734         
    mir-21 -1.733         
    ADM -1.732         
    IGF1R -1.729         
    MSI2 -1.729         
    MAP2K5 -1.728         
    POT1 -1.727         
    UBR5 -1.723         
    GNAQ -1.722         
    FAIM -1.72         
    EPS8 -1.716         
    FGFR1OP -1.716         
    GLB1 -1.715         
    STK39 -1.713         
    NRAS -1.713         
    CCT2 -1.711         
    CHUK -1.708         
    CTTN -1.707         
    AMACR -1.699         
    RBBP9 -1.699         
    AKR1C3 -1.698         
    YAP1 -1.696         
    CDK1 -1.693         
    HOXB3 -1.691         
    LTB -1.691         
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    PTPN11 -1.688         
    RECQL -1.687         
    FDFT1 -1.687         
    MSH3 -1.686         
    HGF -1.685         
    NFKB2 -1.685         
    HSP90B1 -1.683         
    BIRC6 -1.682         
    CDK13 -1.679         
    ACTB -1.678         
    PALLD -1.676         
    FKBP1A -1.676         
    SMC3 -1.675         
    PLD1 -1.675         
    BUB3 -1.674         
    TGIF2 -1.674         
    CD164 -1.673         
    CUL1 -1.673         
    MDM2 -1.672         
    ADNP2 -1.671         
    CCNA2 -1.67         
    NCOA2 -1.666         
    KIF3A -1.666         
    ABCB7 -1.665         
    TASP1 -1.664         
    TNF -1.663         
    TIRAP -1.662         
    FUT8 -1.661         
    NUMB -1.66         
    HDAC8 -1.659         
    RIPK1 -1.655         
    CASP8 -1.652         
    RAB1A -1.648         
    EXOC4 -1.647         
    HLA-DMB -1.646         
    PRKX -1.642         
    COPS4 -1.639         
    MAP2K1 -1.639         
    SLC30A6 -1.638         
    OSBPL1A -1.637         
    HEYL -1.637         
    CDK2 -1.635         
    DNAJA2 -1.635         
    PSMC2 -1.634         
    CD151 -1.634         
    VGF -1.633         
    EIF4A1 -1.632         
    PKM -1.63         
    RAB11A -1.629         
    EPHB2 -1.628         
    CDK5 -1.627         
    EBI3 -1.623         
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    TAF9B -1.622         
    MAPK6 -1.62         
    CCNE1 -1.619         
    PIK3R1 -1.619         
    RAD50 -1.617         
    PGK1 -1.616         
    RHOQ -1.616         
    RAB5A -1.615         
    FGF2 -1.613         
    IL11RA -1.611         
    CCND1 -1.609         
    USP1 -1.608         
    TTLL7 -1.608         
    DMTF1 -1.607         
    ARFGEF2 -1.607         
    AGO4 -1.606         
    KIF20B -1.605         
    MAP3K4 -1.604         
    SYNM -1.604         
    ALG14 -1.603         
    MYD88 -1.602         
    MAPK9 -1.601         
    SLC52A1 -1.601         
    BTN3A1 -1.601         
    KIF3C -1.6         
    EEA1 -1.599         
    GLCE -1.597         
    EXT1 -1.596         
    ECT2 -1.596         
    DDR1 -1.595         
    HUWE1 -1.594         
    TACC2 -1.593         
    SRSF5 -1.589         
    TRAF5 -1.589         
    RAP1B -1.588         
    CDH1 -1.587         
    ARHGAP2
4 
-1.587         
    SS18 -1.585         
    PRDX3 -1.584         
    PTPRA -1.583         
    SPP1 -1.581         
    ATF6 -1.579         
    LATS2 -1.579         
    CALCRL -1.578         
    TCP1 -1.577         
    MBP -1.575         
    AGGF1 -1.574         
    CNOT6 -1.572         
    FZD4 -1.571         
    NEK2 -1.57         
    FER -1.569         
    ASPM -1.567         
    METAP2 -1.567         
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    BMP6 -1.566         
    STAM -1.566         
    E2F6 -1.565         
    KCNMA1 -1.565         
    PLAG1 -1.565         
    HK2 -1.563         
    TRIB2 -1.563         
    MORF4L1 -1.561         
    TEAD4 -1.56         
    CLCN3 -1.558         
    STK17A -1.558         
    CSNK2A1 -1.557         
    CHKA -1.557         
    MAP1B -1.557         
    RALB -1.556         
    ACSL4 -1.555         
    SHMT1 -1.554         
    SMO -1.553         
    FASN -1.553         
    TNFRSF12
A 
-1.55         
    LIG4 -1.55         
    E2F3 -1.549         
    TRPC1 -1.549         
    CAPN2 -1.548         
    ITGB4 -1.547         
    PDGFC -1.546         
    ASAH1 -1.545         
    CASP6 -1.545         
    AGO3 -1.545         
    RLIM -1.544         
    MCFD2 -1.544         
    ID4 -1.543         
    PLCE1 -1.543         
    PRKD3 -1.54         
    SLC30A1 -1.539         
    HOXB4 -1.538         
    PTGER4 -1.538         
    ACER2 -1.536         
    EGFR -1.535         
    CCNE2 -1.535         
    CUL4B -1.533         
    PREP -1.532         
    DUSP10 -1.531         
    JAK2 -1.53         
    CCNDBP1 -1.53         
    GOLPH3 -1.529         
    UGCG -1.527         
    ARRB1 -1.526         
    UBE2N -1.525         
    RBM3 -1.524         
    RAC1 -1.523         
    SLC12A4 -1.522         
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    KIF18A -1.522         
    COPS6 -1.521         
    MMP25 -1.521         
    LAMB1 -1.521         
    VAPA -1.519         
    PRKCE -1.518         
    LCK -1.516         
    PRKD1 -1.515         
    TIMP1 -1.514         
    KDM2B -1.513         
    MSRA -1.512         
    CUX1 -1.51         
    PDF -1.51         
    STK24 -1.509         
    ARHGAP5 -1.508         
    TPP2 -1.505         
    AKAP13 -1.503         
    EIF4E -1.502         
 
B. 
Expected Inversely related 
increased cell death 
 
decreased cell death 
 
 
 
up-genes 
(91) 
fold 
change 
down genes 
(401) 
fold change up-genes 
(101) 
fold 
change 
down genes 
(278) 
fold 
change 
TXNIP 4.646 RRM2 -10.183 ARID3B 3.667 EGR1 -13.207 
NCOR2 3.634 SLC4A7 -5.397 HMOX1 3.189 CD69 -10.009 
SMARCC
1 
3.407 CTGF -5.348 EI24 2.961 FOS -5.995 
HMGB1 3.379 BIRC3 -4.833 RGS10 2.924 PDE5A -5.765 
HMGB2 3.081 NCSTN -4.492 STX8 2.918 STAT1 -5.293 
NUMA1 2.972 SCARB2 -4.157 MEF2D 2.859 LIPA -4.506 
H2AFX 2.91 DCAF7 -4.08 SERPINH1 2.644 DKK1 -4.291 
HS1BP3 2.75 RRM2B -3.882 PTPMT1 2.629 DUSP6 -4.027 
TCF3 2.595 RPS6KA3 -3.8 MSX1 2.469 ANTXR2 -3.813 
ITGB3BP 2.534 EIF4G2 -3.785 LMO4 2.36 AFAP1 -3.709 
BOK 2.277 NEK6 -3.76 TIMP2 2.349 DDX58 -3.697 
IL17RD 2.252 BIRC2 -3.744 NUAK1 2.346 ITGA6 -3.665 
MYH9 2.208 IL6ST -3.727 LRPAP1 2.336 CCNB1 -3.663 
ACIN1 2.203 CXCL8 -3.59 NOLC1 2.264 TGFBR3 -3.607 
DNAJA3 2.179 NEK7 -3.481 SIP1 2.233 TFRC -3.539 
EMP1 2.173 PPP3CB -3.478 CREBBP 2.207 IER3 -3.343 
CSF2RA 2.166 ADAR -3.472 DMC1 2.184 IFIH1 -3.322 
DPM3 2.15 TRIB1 -3.286 DAG1 2.155 PNPT1 -3.293 
ANTXR1 2.124 AKAP12 -3.279 DEPDC6 2.125 OLR1 -3.236 
SREBF1 2.099 AGO2 -3.198 ACO2 2.101 TFPI -3.143 
ETS1 2.086 NSF -3.186 EWSR1 2.075 GULP1 -3.08 
PPARBP 2.069 CYR61 -3.158 RPS24 2.067 CHEK2 -2.983 
SET 2.028 CCT6A -3.12 TBP 2.041 F2R -2.95 
BRMS1 2.019 PLAU -3.072 KRT8 2.034 SLC25A24 -2.885 
NFKBIB 2.012 MCL1 -3.012 NME2 2.011 F2RL1 -2.884 
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PTRH2 2.006 EGR2 -3.01 RARA 2.005 GFPT1 -2.835 
IL10 1.979 LDLR -2.978 BCL2L12 2.002 SCP2 -2.828 
ISG15 1.962 DICER1 -2.978 YWHAG 1.998 PPP2R5A -2.777 
NUPR1 1.962 SERPINE1 -2.973 PLEC1 1.99 ATG5 -2.746 
GADD45A 1.958 WEE1 -2.951 TAOK3 1.972 ZAK -2.735 
CCDC86 1.944 TBL1XR1 -2.941 INTS1 1.966 ATG4A -2.686 
CDK6 1.935 CTNNB1 -2.941 MKL1 1.964 DOCK1 -2.674 
DAXX 1.89 VCL -2.927 CREB1 1.947 GCH1 -2.667 
MPRIP 1.865 ERCC1 -2.888 TPD52 1.936 CASP7 -2.665 
PRELID1 1.864 ABCC5 -2.869 SIGIRR 1.929 ZFYVE16 -2.644 
DIABLO 1.82 CD44 -2.866 NUP62 1.926 ATP2A2 -2.641 
ID3 1.814 MTM1 -2.838 HSPA1B 1.919 ZMYND11 -2.627 
E2F2 1.782 CDCP1 -2.796 S100A4 1.906 FRMD6 -2.595 
TGFBI 1.774 APH1B -2.791 CAMK2G 1.902 CTNNA1 -2.582 
BMF 1.763 PRKCA -2.726 CBS 1.897 CTSL1 -2.581 
LAMP1 1.76 PROS1 -2.711 ATF5 1.867 DRAM1 -2.533 
MBD4 1.758 PTHLH -2.695 E2F4 1.863 JAK1 -2.514 
IL18 1.758 NBN -2.657 DNAJB6 1.859 CCNC -2.508 
RASSF6 1.755 BBS2 -2.643 TRIAP1 1.858 DDX5 -2.487 
FAU 1.747 CITED2 -2.617 TFF3 1.851 ITGB1 -2.481 
ADRM1 1.734 HSPA4 -2.6 EBAG9 1.847 ULK2 -2.479 
MRPL41 1.733 TXNDC5 -2.591 UBE2C 1.839 SPTBN1 -2.478 
UBE2L3 1.725 TGFBR2 -2.574 LEP 1.833 ICAM1 -2.449 
SSTR2 1.72 RRAS -2.572 HOXC6 1.821 PDCD6IP -2.435 
GPS2 1.703 PLK2 -2.565 NCOA6 1.814 WASPIP -2.423 
TNFAIP8L
1 
1.667 KIF14 -2.559 CDR2L 1.812 RECK -2.393 
NRGN 1.663 SGK1 -2.554 MAD2L2 1.799 WTAP -2.382 
BNIPL 1.653 FANCL -2.533 DDIT4 1.791 RHOB -2.37 
CAMLG 1.651 MUC1 -2.466 NDEL1 1.764 MX1 -2.358 
HRASLS 1.646 ITGAV -2.466 UXT 1.762 LGALS8 -2.322 
LGALS1 1.644 STAT5B -2.464 NUDT1 1.759 PRKDC -2.306 
AKAP1 1.637 APIP -2.458 HSPBP1 1.751 PDCD2 -2.3 
PPP1R15
A 
1.632 SPRY2 -2.451 TUB 1.73 CTH -2.295 
EGLN2 1.628 NCEH1 -2.44 MCM10 1.718 KRAS -2.288 
CCAR1 1.618 NFKB1 -2.435 CENPB 1.703 RASA1 -2.286 
DEDD2 1.611 PIK3CA -2.434 LSMD1 1.7 DNM1L -2.261 
SIVA1 1.605 MFN1 -2.409 SRC 1.692 HS.551128 -2.255 
STX1A 1.6 MAP3K7 -2.4 NUF2 1.692 PHLDA1 -2.25 
ATN1 1.594 LIN7C -2.395 FBLN1 1.69 XPR1 -2.241 
CDC20 1.59 VAMP3 -2.388 WDR4 1.685 MAP4K4 -2.187 
EMP3 1.587 HSD17B4 -2.386 TNRC6A 1.684 TOP2A -2.183 
CACNB3 1.582 SORL1 -2.379 SCG5 1.681 PARP14 -2.165 
CDT1 1.582 UBA3 -2.374 ERF 1.673 DSG2 -2.162 
SHC1 1.578 HIF1A -2.374 FBXO2 1.671 MAPK13 -2.149 
PDCD4 1.573 TOP2B -2.371 ARHGEF1 1.658 YES1 -2.148 
HIST1H1C 1.57 TP53BP1 -2.37 FEN1 1.635 RNASEL -2.147 
PTGDS 1.568 PLS1 -2.369 GJC1 1.634 GPR37 -2.137 
CDK4 1.568 ANXA7 -2.367 STXBP1 1.632 AP1G1 -2.128 
S100A6 1.563 NFYA -2.367 ABCC3 1.625 RFK -2.125 
PPIB 1.563 LRP8 -2.361 CHMP4B 1.625 RBBP4 -2.111 
TNFSF14 1.553 EOMES -2.36 PTP4A2 1.624 QKI -2.096 
BRCA1 1.549 PPP2R1B -2.359 MDK 1.619 ROCK2 -2.096 
LILRB1 1.548 YWHAZ -2.351 CCBE1 1.617 SERINC3 -2.087 
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LRDD 1.546 HMGCR -2.348 DNAJB2 1.616 TNFRSF10B -2.08 
BNIP3L 1.545 ABCE1 -2.342 TAF10 1.614 SEC23B -2.071 
CYBA 1.544 CYP2J2 -2.339 DAD1 1.602 AIFM1 -2.053 
MIR130A 1.539 PHIP -2.336 SP1 1.601 BPTF -2.043 
DFFA 1.538 RBL2 -2.325 EEF1D 1.591 SH3RF1 -2.042 
TNFRSF2
5 
1.529 CD2AP -2.323 ARHGEF2 1.588 PARG -2.039 
PIN1 1.519 FBXL5 -2.308 APRT 1.582 TFPI2 -2.025 
FAM162A 1.519 KIFAP3 -2.307 FANCD2 1.58 DDX3X -2.022 
NME4 1.512 CAT -2.286 PRDX5 1.58 PKN2 -2.021 
ORAI1 1.508 EPCAM -2.282 MXD3 1.577 GNA12 -2.02 
PRPS1 1.507 MBTPS1 -2.282 PTMA 1.576 SOAT1 -2.018 
MUTYH 1.506 TBK1 -2.28 UBQLN1 1.576 PSEN2 -2.009 
KIAA0831 1.505 VPS13A -2.28 HSF1 1.576 RFWD2 -2.005 
    NFE2L2 -2.278 ARID1A 1.575 CASP3 -1.996 
    CPEB4 -2.26 PCK2 1.55 WDR19 -1.995 
    PRKAA1 -2.258 NRG2 1.538 PRKAR1A -1.993 
    PEX11B -2.256 CNTFR 1.537 IL1R1 -1.993 
    TXNRD1 -2.255 FANCE 1.536 ING3 -1.992 
    LGR4 -2.254 GADD45GIP1 1.527 CCDC109A -1.978 
    PDE4D -2.248 TNPO2 1.526 STAT4 -1.968 
    STK40 -2.243 MFGE8 1.512 ZMAT3 -1.967 
    BCL2L13 -2.23 NEDD8 1.51 SP110 -1.952 
    SLC20A1 -2.213 SRF 1.503 GSR -1.919 
    SERP1 -2.21     ADAMTS1 -1.918 
    BTRC -2.198     GMFB -1.917 
    CAPRIN1 -2.198     TRIB3 -1.914 
    ATP2B4 -2.195     SMAD4 -1.903 
    SIAH2 -2.195     NAE1 -1.898 
    RB1 -2.193     PPP2CA -1.896 
    CERS6 -2.187     ALDH1A3 -1.89 
    IPPK -2.185     MCOLN3 -1.888 
    FIGNL1 -2.183     TLR1 -1.876 
    RND3 -2.173     CSE1L -1.869 
    EPAS1 -2.164     MSH2 -1.867 
    USP47 -2.16     HS.531457 -1.866 
    NAMPT -2.151     PAK2 -1.864 
    USP18 -2.15     MALT1 -1.853 
    TPM3 -2.15     PTPN1 -1.85 
    TPR -2.15     TP53INP1 -1.847 
    GRB10 -2.147     ZFAND5 -1.846 
    PIK3CB -2.146     APP -1.846 
    CAST -2.143     SNAP25 -1.843 
    TMED10 -2.141     OAS1 -1.841 
    IFNL2 -2.139     MLKL -1.84 
    TRIM24 -2.135     KIF1B -1.837 
    SUN1 -2.135     CREBL2 -1.837 
    FAT4 -2.128     IRF7 -1.831 
    BRE -2.127     LCN2 -1.83 
    MTMR6 -2.126     CCDC88A -1.827 
    JUNB -2.12     CAPRIN2 -1.826 
    ILK -2.118     LDHA -1.823 
    IREB2 -2.113     FAF1 -1.82 
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    CD46 -2.106     PTPN13 -1.816 
    GEM -2.102     EIF2AK2 -1.814 
    PDE4B -2.098     CTSB -1.812 
    CALM1 
(includes 
others) 
-2.093     TRMT11 -1.812 
    XRCC5 -2.091     HTRA1 -1.806 
    NFIB -2.09     FUT4 -1.782 
    HSPD1 -2.089     TIA1 -1.781 
    KIF11 -2.088     UACA -1.768 
    SLC2A3 -2.08     IDE -1.76 
    TNFAIP8 -2.074     HOXA5 -1.757 
    HLTF -2.069     TTC5 -1.748 
    ZMYM2 -2.063     CYLD -1.742 
    SPINT1 -2.061     SGPP1 -1.742 
    RGPD4 
(includes 
others) 
-2.061     TRPS1 -1.736 
    RAB28 -2.06     STAM2 -1.734 
    MSRB3 -2.059     TSC22D2 -1.734 
    ANGPTL4 -2.057     RHOH -1.729 
    NR2C1 -2.055     MSI2 -1.729 
    DHX9 -2.054     MAP2K5 -1.728 
    PIGA -2.048     HS.4988 -1.725 
    BTG2 -2.047     HMOX2 -1.723 
    SORBS2 -2.047     GNAQ -1.722 
    MXD1 -2.047     STAP2 -1.71 
    BHLHE40 -2.044     TOP1 -1.702 
    RPA1 -2.034     ZMYM3 -1.702 
    DPYD -2.033     SGPL1 -1.701 
    HIPK3 -2.029     PRKRA -1.699 
    MTMR2 -2.026     AKR1C3 -1.698 
    ITGA2 -2.025     BACH2 -1.697 
    SRI -2.024     USP12 -1.697 
    CXCL1 -2.023     CDC2 -1.693 
    ASNS -2.018     LTB -1.691 
    UBR2 -2.017     ITPR1 -1.689 
    CUL2 -2.005     PSMD6 -1.687 
    DIDO1 -2.004     ATG7 -1.687 
    REL -1.995     ERCC3 -1.682 
    SOX21 -1.989     NSMAF -1.68 
    GLO1 -1.987     FKBP1A -1.676 
    ROR1 -1.987     KLRF1 -1.676 
    HNRNPK -1.978     KIAA1468 -1.676 
    ADH5 -1.967     PPM1A -1.669 
    NFKBIA -1.955     TNF -1.663 
    ATP7A -1.948     TIRAP -1.662 
    SERPINI1 -1.945     NUMB -1.66 
    ADAM17 -1.945     RIPK1 -1.655 
    TAX1BP1 -1.94     ADRB1 -1.654 
    OPTN -1.936     CASP8 -1.652 
    ARF4 -1.928     NOTCH2 -1.649 
    VEGFC -1.925     RAB1A -1.648 
    OPA1 -1.923     CKAP2 -1.645 
    ILF3 -1.919     TP53BP2 -1.644 
    CD47 -1.916     APPL1 -1.637 
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    CENPF -1.915     CDK2 -1.635 
    SRXN1 -1.911     VGF -1.633 
    ATP2B1 -1.909     SPIN1 -1.633 
    NFAT5 -1.904     HIP2 -1.631 
    MAPK1 -1.901     EPHB2 -1.628 
    PAFAH2 -1.901     CDK5 -1.627 
    CES1 -1.891     WWC3 -1.623 
    SNX7 -1.883     CCNE1 -1.619 
    SMARCA1 -1.882     TMEM158 -1.616 
    TEAD2 -1.88     IL11RA -1.611 
    SMARCA5 -1.879     MAP3K8 -1.61 
    MAP3K2 -1.87     BAX -1.608 
    RCAN1 -1.858     SENP2 -1.606 
    KPNA2 -1.855     ANKRD1 -1.602 
    BMI1 -1.85     MYD88 -1.602 
    MERTK -1.842     MAPK9 -1.601 
    EXOC2 -1.841     NIF3L1 -1.597 
    MET -1.834     M6PR -1.596 
    DYNC1H1 -1.833     ECT2 -1.596 
    WAPAL -1.832     IFNAR1 -1.595 
    API5 -1.825     BID -1.594 
    AHR -1.82     FBXL2 -1.594 
    RANBP2 -1.818     HUWE1 -1.594 
    EFEMP1 -1.814     DEDD -1.592 
    NR2C2 -1.813     TBCCD1 -1.592 
    HEXB -1.808     ZFP36 -1.591 
    STAT3 -1.806     RANBP9 -1.589 
    ANXA2 -1.791     SORT1 -1.588 
    NPC1 -1.791     MAP3K9 -1.587 
    C8orf44-
SGK3/SGK3 
-1.79     STEAP3 -1.586 
    GPHN -1.79     MOAP1 -1.586 
    SON -1.786     PTPRA -1.583 
    YME1L1 -1.784     ATP1A1 -1.583 
    HDAC9 -1.783     LATS1 -1.58 
    DSP -1.776     ATF6 -1.579 
    ALCAM -1.776     HAS3 -1.579 
    HADHA -1.772     LATS2 -1.579 
    SQSTM1 -1.771     MEN1 -1.579 
    PDPK1 -1.769     PANX1 -1.578 
    PFKM -1.761     MBP -1.575 
    CTSV -1.756     MBD1 -1.574 
    LIMS1 -1.755     PMEPA1 -1.574 
    AURKA -1.755     CCNT1 -1.573 
    ERCC5 -1.755     MYO7A -1.573 
    MYO6 -1.751     TFDP2 -1.571 
    LGMN -1.748     CD40 -1.568 
    XPO1 -1.741     HOXA13 -1.567 
    ERBB2 -1.74     BMP6 -1.566 
    LEPR -1.739     CCNL2 -1.566 
    SLC12A2 -1.739     SUB1 -1.566 
    PPIA -1.736     STK3 -1.563 
    ALDOA -1.736     TRIB2 -1.563 
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    YWHAB -1.733     SCRIB -1.562 
    mir-21 -1.733     PLSCR1 -1.562 
    ADM -1.732     RPS6KA2 -1.56 
    ANXA5 -1.73     STK17A -1.558 
    IGF1R -1.729     CSNK2A1 -1.557 
    POT1 -1.727     MAP1B -1.557 
    FAIM -1.72     RALB -1.556 
    TCERG1 -1.719     TCF12 -1.551 
    BAZ1A -1.716     TNFRSF12A -1.55 
    NRAS -1.713     RNPS1 -1.55 
    CKAP5 -1.712     E2F3 -1.549 
    CDK8 -1.71     CCBL1 -1.549 
    CHUK -1.708     CAPN2 -1.548 
    CTTN -1.707     DAB2 -1.548 
    FAM134B -1.706     TRIM13 -1.548 
    MCRS1 -1.705     CASP6 -1.545 
    CAV1 -1.702     RASL10A -1.543 
    MTMR9 -1.7     PERP -1.542 
    AMACR -1.699     PTGER4 -1.538 
    YAP1 -1.696     ACER2 -1.536 
    DVL1 -1.693     CUL4B -1.533 
    PTPN11 -1.688     TAF1B -1.533 
    RECQL -1.687     ARL8B -1.532 
    FDFT1 -1.687     OAS3 -1.528 
    MSH3 -1.686     ARRB1 -1.526 
    HGF -1.685     ZNF148 -1.526 
    NFKB2 -1.685     RAC1 -1.523 
    HSP90B1 -1.683     KLF13 -1.52 
    BIRC6 -1.682     APOBEC3B -1.52 
    GCLM -1.681     NDUFAF1 -1.52 
    VCP -1.681     ATP6AP2 -1.516 
    SPG7 -1.679     CUTL1 -1.51 
    PALLD -1.676     STK24 -1.509 
    PLD1 -1.675     OMA1 -1.508 
    RELB -1.674     EEF1A1 -1.506 
    CD164 -1.673     MIB1 -1.506 
    CUL1 -1.673     WDR48 -1.506 
    PICK1 -1.672     IFNGR1 -1.504 
    MDM2 -1.672     MIR302C -1.503 
    SLC9A4 -1.672     PRMT2 -1.502 
    ADNP2 -1.671     TNFRSF10A -1.502 
    NCOA2 -1.666     ATP7B -1.502 
    KIF3A -1.666     TJP2 -1.501 
    ABCB7 -1.665         
    RGN -1.664         
    TASP1 -1.664         
    ABCC1 -1.655         
    CENPE -1.652         
    VPS41 -1.652         
    RABGGTA -1.652         
    ANXA4 -1.649         
    AFG3L2 -1.649         
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    YWHAE -1.645         
    SP3 -1.643         
    ALMS1 -1.643         
    MAP2K1 -1.639         
    HEYL -1.637         
    CYP26B1 -1.636         
    CD151 -1.634         
    PKM -1.63         
    PARP16 -1.63         
    NCAPG2 -1.628         
    SLCO1B3 -1.622         
    TAF9B -1.622         
    PIK3R1 -1.619         
    RAD50 -1.617         
    TMX1 -1.617         
    FGF2 -1.613         
    VAMP2 -1.613         
    IFIT3 -1.613         
    GORASP1 -1.611         
    RNF34 -1.609         
    CCND1 -1.609         
    AGO4 -1.606         
    MAP3K4 -1.604         
    CCT7 -1.603         
    CDC14A -1.602         
    TSG101 -1.595         
    DDR1 -1.595         
    PON2 -1.593         
    RDH10 -1.593         
    PIAS2 -1.59         
    PSMB8 -1.59         
    KLK3 -1.59         
    PPP1R2 -1.589         
    TRAF5 -1.589         
    RAP1GAP -1.588         
    RAP1B -1.588         
    IKBKAP -1.587         
    CDH1 -1.587         
    PRDX3 -1.584         
    NUPL1 -1.584         
    DPP8 -1.583         
    SLX1A/SLX
1B 
-1.582         
    SPP1 -1.581         
    OGG1 -1.58         
    CALCRL -1.578         
    TCP1 -1.577         
    CERKL -1.575         
    SELE -1.574         
    AGGF1 -1.574         
    CCT4 -1.573         
    TANK -1.571         
    NEK2 -1.57         
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    FER -1.569         
    METAP2 -1.567         
    NPHS1 -1.566         
    STAM -1.566         
    ATP2C1 -1.566         
    E2F6 -1.565         
    KCNMA1 -1.565         
    SETX -1.565         
    PDE9A -1.564         
    HK2 -1.563         
    ABCC4 -1.562         
    CLCN3 -1.558         
    CHKA -1.557         
    FGFRL1 -1.556         
    ACSL4 -1.555         
    HSPA9 -1.555         
    SMO -1.553         
    FASN -1.553         
    TMBIM4 -1.551         
    USP10 -1.55         
    LIG4 -1.55         
    TRPC1 -1.549         
    TEX11 -1.549         
    ITGB4 -1.547         
    PDGFC -1.546         
    ASAH1 -1.545         
    AGO3 -1.545         
    INTS3 -1.541         
    B4GALNT1 -1.54         
    PRKD3 -1.54         
    HOXB4 -1.538         
    ATP11C -1.538         
    EGFR -1.535         
    PARD3 -1.535         
    PARK2 -1.534         
    DUSP10 -1.531         
    JAK2 -1.53         
    UGCG -1.527         
    CXADR -1.527         
    KCND2 -1.527         
    HSF2 -1.526         
    NEK1 -1.525         
    PPID -1.524         
    RBM3 -1.524         
    PAF1 -1.523         
    ALDH2 -1.521         
    VAPA -1.519         
    PRKCE -1.518         
    ARSB -1.516         
    GLUD1 -1.515         
    PRKD1 -1.515         
    TIMP1 -1.514         
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    KDM2B -1.513         
    CTBP2 -1.512         
    PSMC1 -1.511         
    FBXW7 -1.511         
    RAD18 -1.51         
    LCMT1 -1.508         
    TPP2 -1.505         
    LYNX1 -1.504         
    KRT18 -1.503         
    EIF4E -1.502         
    TLR6 -1.501         
 
C. 
Expected Inversely related 
decreased migration 
 
 
 
increased migration 
 
 
 
up-genes (12) fold 
change 
down genes 
(123) 
fold 
change 
up-genes (19) fold 
change 
down genes 
(27) 
fold 
change 
HMOX1 3.189 EGR1 -13.207 C1QBP 3.093 STAT1 -5.293 
TIMP2 2.349 CTGF -5.348 PPFIA1 2.365 ARRDC3 -3.84 
MYH9 2.208 LIN28B -3.856 ARF1 2.207 LAMC2 -3.579 
DNAJA3 2.179 RPS6KA3 -3.8 DPAGT1 2.185 SPRY2 -2.451 
KRT8 2.034 AFAP1 -3.709 CDC25B 2.173 RASA1 -2.286 
BRMS1 2.019 DDX58 -3.697 ACTN4 2.107 CAT -2.286 
DNAJB6 1.859 ITGA6 -3.665 ETS1 2.086 FAM188A -2.249 
CMTM8 1.717 CXCL8 -3.59 S100A4 1.906 TPM3 -2.15 
SP1 1.601 AKAP11 -3.208 HNRNPA2B1 1.838 ASNS -2.018 
PDCD4 1.573 CYR61 -3.158 LEP 1.833 CD47 -1.916 
BRCA1 1.549 PLAU -3.072 MTA1 1.752 ADAM9 -1.909 
mir-130 1.539 SERPINE1 -2.973 SRC 1.692 PTPN1 -1.85 
    F2R -2.95 ARHGEF1 1.658 TP53INP1 -1.847 
    CTNNB1 -2.941 LGALS1 1.644 FAF1 -1.82 
    F2RL1 -2.884 PTP4A2 1.624 GNAI1 -1.796 
    E2F5 -2.873 MDK 1.619 SACM1L -1.725 
    CD44 -2.866 SHC1 1.578 PALLD -1.676 
    CDCP1 -2.796 MAPK8IP3 1.575 EBI3 -1.623 
    PRKCA -2.726 ORAI1 1.508 FBXL2 -1.594 
    PTHLH -2.695     WDR44 -1.592 
    DOCK1 -2.674     RAP1GAP -1.588 
    FNBP1L -2.614     CDH1 -1.587 
    JAK1 -2.514     MEN1 -1.579 
    ITGB1 -2.481     BMP6 -1.566 
    MUC1 -2.466     PARK2 -1.534 
    ITGAV -2.466     PRKD1 -1.515 
    MAP3K7 -2.4     TIMP1 -1.514 
    BMPR2 -2.396         
    HIF1A -2.374         
    RHOB -2.37         
    CYP2J2 -2.339         
    ARFGEF1 -2.293         
    KRAS -2.288         
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    NRG1 -2.255         
    MAP4K4 -2.187         
    ILK -2.118         
    NES -2.109         
    TNFAIP8 -2.074         
    ITGA2 -2.025         
    GNA12 -2.02         
    ANKRD28 -2.007         
    DIDO1 -2.004         
    CUL4A -1.987         
    ROR1 -1.987         
    HNRNPK -1.978         
    ADAM17 -1.945         
    SDCBP -1.94         
    VEGFC -1.925         
    GNAI3 -1.924         
    WWTR1 -1.923         
    ILF3 -1.919         
    USP9X -1.909         
    SMAD4 -1.903         
    MAPK1 -1.901         
    CSE1L -1.869         
    PAK2 -1.864         
    KPNA2 -1.855         
    BMI1 -1.85         
    APP -1.846         
    MERTK -1.842         
    MET -1.834         
    CCDC88A -1.827         
    EIF2AK2 -1.814         
    RUVBL1 -1.811         
    LTBP2 -1.807         
    STAT3 -1.806         
    ANXA2 -1.791         
    FOXQ1 -1.778         
    ALCAM -1.776         
    PRMT6 -1.769         
    AURKA -1.755         
    ERBB2 -1.74         
    SLC12A2 -1.739         
    mir-21 -1.733         
    IGF1R -1.729         
    MGAT5 -1.725         
    NRAS -1.713         
    CTTN -1.707         
    LIMK1 -1.704         
    CAV1 -1.702         
    ITPR1 -1.689         
    PTPN11 -1.688         
    HGF -1.685         
    VCP -1.681         
    PLD1 -1.675         
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    TNF -1.663         
    CASP8 -1.652         
    NOTCH2 -1.649         
    PODXL -1.639         
    MAP2K1 -1.639         
    CD151 -1.634         
    VGF -1.633         
    EPHB2 -1.628         
    CDK5 -1.627         
    FGF2 -1.613         
    MAP3K8 -1.61         
    SYNM -1.604         
    ECT2 -1.596         
    IFNAR1 -1.595         
    RAB21 -1.592         
    RANBP9 -1.589         
    RAP1B -1.588         
    SPP1 -1.581         
    HAS3 -1.579         
    FER -1.569         
    CD40 -1.568         
    RALB -1.556         
    ACSL4 -1.555         
    TCF12 -1.551         
    TMBIM4 -1.551         
    WASL -1.55         
    CAPN2 -1.548         
    IQGAP1 -1.548         
    DAB2 -1.548         
    PTGER4 -1.538         
    EGFR -1.535         
    JAK2 -1.53         
    GOLPH3 -1.529         
    ARRB1 -1.526         
    RAC1 -1.523         
    LCK -1.516         
    CTBP2 -1.512         
    CTNNAL1 -1.504         
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Supplemental Table B4.  A list of antibodies, primers and siRNAs that were used and their manufacturers in 
Chapter VIII. 
 
Antibodies Company 
1-Integrin Santa Cruz Biotechnology  
(Santa Cruz, CA) 
Sp3 
 
Sp4 
 
EGFR 
 
ZBTB4 
 
p300 
 
Secondary mouse IgG-HRP 
 
normal rabbit IgG 
 
Secondary goat IgG-HRP 
 
  
4-Integrin Cell Signaling Technology  
(Danvers, MA) 
5-Integrin 
 
6-Integrin 
 
FAK 
 
p-FAK 
 
c-PARP 
 
c-Caspase3 
 
survivin 
 
c-myc 
 
secondary rabbit-HRP 
 
  
Sp1 Abcam (Cambridge, MA) 
Histone H3K27 Ab 
 
Histone H3K4 Ab 
 
  
ZBTB10 Bethyl Laboratories 
 (Montgomery, TX   
RNA polymerase II Active Motif (Carlsbad, CA) 
Histone H4K16 
 
  
NR4A1 Novus Biologicals (Littleton, 
CO) 
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β-Actin Sigma-Aldrich (St. Louis, MO) 
 
Primers and 
siRNA 
 
Company 
   c-Myc ChIP primer sequences 
  c-Myc-ChIP-F GCC CTT TCC CCA GCC TTA GC 
Sigma-
Aldrich 
(St. Louis, 
MO) 
  c-Myc-ChIP-R 
AAC CGC ATC CTT GTC CTG TGA 
GTA 
 
   
6-Integrin ChIP primer sequences 
  ITGA6-ChIP-F CTCTGTGCTACTCGGCAAC 
Sigma-
Aldrich 
(St. Louis, 
MO) 
 ITGA6-ChIP-R  GTT CTCTGGAGACTCGCAGG 
 
   
  4-Integrin ChIP primer sequences 
  ITGB4-ChIP-F  
CCG GCG GCG GCA CCC AGC 
TCC T 
Sigma-
Aldrich 
(St. Louis, 
MO) 
 ITGB4-ChIP-R  
CCT CTT CCT CCT CGG GGC 
GGA 
 
   
   5-Integrin ChIP primer sequences 
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  ITGA5-ChIP-F 
 
ACAGCAAATCATTCCTACTGAGC  
Sigma-
Aldrich 
(St. Louis, 
MO) 
 ITGA5-ChIP-R  
 
CCCACTGCCCCTCTAAATGATCT 
 
   
1-Integrin ChIP primer sequences 
ITGB1-ChIP-F  TCACCACCCTTCGTGACAC 
Sigma-
Aldrich 
(St. Louis, 
MO) 
ITGB1-ChIP-R  GAGATCCTGCATCTCGGAAG 
 
 
 
 
siRNA 
sequences 
 
Company 
siSp1 SASI_Hs02_00363664 
Sigma-Aldrich (St. 
Louis, MO) 
siSp3 SASI_Hs01_00211941 
 
siSp4 SASI_Hs01_00114420 
 
siNR4A1 SASI_Hs02_00333289 
 
siGL2  
(nonspecific 
control oligomer) 
CGU ACG CGG AAU 
ACU UCG A 
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